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Abstract
It is suggested that older adults have more difficulty maintaining sleep than 
younger adults, and that sleep also becomes more fragmented with increasing age. The 
aim of this thesis was to assess sleep patterns in older adults, and to investigate some 
pharmacological agents taken by older adults as sleep aids.
A survey of 5846 older adults identified sleep complaints and methods of 
alleviation. Results supported previous findings, and pain and nocturia were found to be 
the main reasons for nocturnal awakenings. Respondents reported the use of hypnotics, 
antidepressants, over-the-counter preparations and herbal remedies as sleep aids. 
Respondents also used whisky, hot milky drinks and reading at bedtime to aid sleep.
Three placebo-controlled clinical trials were implemented to assess the effects of 
a herbal remedy (valerian), three hypnotics (loprazolam, zopiclone and zolpidem), and 
two antidepressants (dothiepin and moclobemide) on sleep and daytime performance. 
Results showed few advantageous effects o f an acute dose o f valerian. Loprazolam, 
zopiclone and zolpidem were given to younger adults to assess these treatments without 
the confounds of old age. These treatments were found to be effective hypnotics from 
the first night of use, but there were more residual sedative effects under loprazolam 
than zopiclone or zolpidem. Neither dothiepin nor moclobemide were found to be 
suitable for use as sleep aids, also using a younger population.
Findings indicate most older adults do not have sleep complaints, but those who 
do are likely to have sleep problems due to physical reasons. More research is necessary 
into the duration o f valerian use and doses for efficacy. Residual sedative effects under 
loprazolam may increase the risk of accidents, and shorter acting hypnotics, such as 
zopiclone and zolpidem, may reduce this risk. Dothiepin showed more sedative effect 
than moclobemide, but there was little evidence of improved sleep. Further research is 
necessary to establish the causes o f poor sleep in old age, and to assess the suitability of 
other sleep aids in this age group.
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Chapter 1
1.1 Abstract
This chapter introduces the definitions of sleep, describes how it has been 
historically studied, and outlines the pitfalls associated with current methodology. 
Examples o f brain activity during sleep are given, and their development, associated 
brain neurophysiology and neurochemistry are explained.
A common disorder o f sleep is insomnia, which can appear in many forms. A 
particular population which is reported to have poor sleep is the elderly, with 
approximately a fifth complaining o f disturbed sleep. This mild or intermittent insomnia 
is usually divided into a difficulty initiating sleep (DIS), a difficulty maintaining sleep 
(DMS) and early morning awakenings (EMA). Older adults have been shown to suffer 
primarily with DMS and frequent awakenings. This may be partly due to natural sleep 
fragmentation in older adults. It is also suggested to be partly due to needing the toilet in 
the night, pain, poor health and respiratory problems. Other possible triggers include 
worrying and stress. The aim of this thesis is to assess the reported sleep problems of 
older adults, and to assess some treatments which are taken to alleviate these problems.
1.2 Introduction
Sleep is a major part of everyday life. Eveiy night we descend from our ‘normal’ 
waking selves into a period of time which many o f us will have little or no memory of. 
We all experience sleep regularly; this occurs to virtually everyone once or more in a 24 
hour period. Yet this state is relatively poorly researched, and even less well understood.
The scientific study o f sleep has increased in popularity in recent years, due to 
the increase in knowledge of neurotransmitter systems, and the growth of brain research 
in general. Many sleep centres have been developed to approach the issues o f 
mechanisms, causes and effects o f sleep and its disorders, with a recent interest in 
respiratory issues. Progress is rapidly being made, but there are many issues in sleep 
research that remain unresolved.
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1.2.1 The Definition o f ‘Sleep’
To begin an overview of sleep, it is necessary to firstly consider a definition. 
Although we all have experience o f sleep, it is difficult to suitably interpret exactly what 
occurs. We think of sleep as Hartmann described in 1973, that it is a recurrent, easily 
reversible condition characterised by a relative quiescence, and by a greatly increased 
threshold for response to external stimulation. Corner et al. (1984) thought of sleep as “a 
state o f reduced orientation to environmental stimuli, such that behavioural responses 
become either poorly directed or limited to a veiy small aspect o f the total situation” 
(p.66), adding that this allowed for “internally generated sources of excitation to 
predominate within the brain” . This definition allows for more varied and complex 
responses to external stimuli, as the direction of attention is thought to be reduced, not 
responsiveness. You may wake more easily, for example, when your name is called than 
when you hear a meaningless noise (Williams et al., 1974).
1.2.2 History and Measures of Sleep Research
Research into sleep was first performed using measures such as stimulus 
threshold determinations, and physiological measures (for example body temperature, 
heart rate, respiration, metabolic rate, and galvanic skin response, as described by 
Foulkes ini 966). However, the discovery of electrical currents on the surface of monkey 
and rabbit brains by Caton in 1875 eventually lead to the invention of the 
electroencephalogram (EEG) in 1929 by Berger. By placing electrodes on certain parts 
of the scalp, corresponding to different brain areas, the electrical signals of the brain’s 
activity were recorded in the form of an EEG trace (see figures 1.1 to 1,5; from 
Carskadon and Dement, 1994).
The first EEG machines consisted o f paper rolling continuously under a pen that 
would be sensitive to, and move with, any changes in electrical activity. Nowadays most 
recordings are undertaken digitally with the aid of computers, making the recording and 
viewing of sleep records much easier. In the near future, neural network computers, 
which ‘ intelligently’ interpret these recordings, will perhaps be commonplace. The use 
of EEG to measure sleep is considered the most accurate and detailed method of 
analysis; therefore, this thesis will primarily use EEG to assess objective measures of 
sleep.
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Loomis et al. (1935) made the first classification of human sleep. They found 
five different ‘stages’ thought to represent five different stages of consciousness, which 
they labelled A to E. This classification was advanced in 1953, when Aserinsky and 
Kleitman found both fast and slow eye movements. The fast eye movements, called 
rapid eye movements (REMs), seemed to cluster together in the night. When this 
occurred, the authors woke their subjects and found they reported having dreams. This 
phase of sleep became known as rapid eye movement (REM) sleep, or dream sleep.
In the 1960’s, a committee of leading sleep experts attempted to establish a set 
of ‘normal rules’ for human sleep. This was primarily for two reasons: firstly to enable 
the detection and measurement of external influences on sleep, and secondly to enable 
the measurement o f the variation in internal systems in sleep (Williams et al., 1974). 
Over 6000 records were used to complete these ‘rules’ ; these records were of various 
sleeping conditions of various types o f subject. In 1968, Rechtshaffen and Kales 
published these rules as a manual for sleep staging. This has become the most 
commonly used method o f measuring EEG sleep.
1.2.3 The Measure of EEG Sleep: Sleep Stages According to Rechtshaffen and Kales 
(T968)
As already mentioned, sleep is divided into the two main categories of non-REM 
(NREM) and REM sleep. In addition, events in sleep also include waking and 
movement time. It is necessary to define in more detail what is meant by these 
categories in terms of EEG sleep staging. Stages refer to the type and depth of sleep 
experienced. These normally undergo a cycle o f approximately 90 minutes, from light 
sleep to deep sleep and dream sleep. The sleep record is considered in discrete parts 
(epochs) of usually 30 seconds duration. Whichever stage o f sleep accounts for over 
half the epoch, that epoch is assigned that stage. The EEG traces themselves are 
achieved using the 10-20 system of electrode placement (Jasper, 1958). This is an 
international standard for electrode placement, primarily using the C4/A1 channel for 
staging. The C4 electrode is a central electrode on the right hand side of the head, 
referenced to A l, an electrode placed on the mastoid behind the left ear. The potential 
difference between the electrical signals from these points provides the EEG trace. The 
staged epochs are then usually represented by a hypnograms, showing the path o f the 
night's sleep. Other sleep variables can be determined from the sleep EEG recording. 
Commonly used variables are time in bed, total sleep time, sleep latency (time taken to
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fall asleep), wake after sleep onset, and sleep efficiency (total sleep time divided by the 
time in bed).
Movement time (MT) is assigned to epochs where the EEG traces are obscured 
by muscle tension or artifact for more than half the epoch. Wake (stage W) corresponds 
to low voltage, mixed frequency waves and/or alpha waves (low amplitude and high 
frequency). This is usually accompanied by high tonic electromyogram (EMG) readings 
and possibly eye blinks. These are observed using an electrooculogram (EOG), using 
electrodes placed near the eyes.
NREM sleep is divided into four categories, which are said to coincide with 
depth of sleep. Stage 1 (see figure 1.1) is thought to be the lightest stage o f sleep, like 
‘drifting o ff , a transitional stage. Random thoughts are sometimes reported here, and 
stage 1 can sometimes be characterised by slow rolling eye movements on the EOG. 
The EEG is again a low voltage, mixed frequency trace, with a prominence o f activity 
in the 2-7 cycles per second (cps, also called Hz) range. Sometimes vertex sharp waves 
are present. These are distinctive ‘V ’ shaped wave forms with peaks reaching 100- 
200pV (Rechtshaffen and Kales, 1968). Stage 1 sleep usually lasts between 1-7 minutes 
during nocturnal sleep.
STAGE 1
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Figure 1.1: Stage 1 Sleep (C3/A2 channel) - Low voltage and mixed frequency.
Stage 2 (see figure 1.2) is defined by the presence o f characteristic K-complexes 
and sleep spindles. Sleep spindles are the occurrence of noticeably high frequency (12- 
14 cps) and low amplitude waves, compared to the average waves of stage 2 sleep. 
These should last for 0.5 seconds and 6 or 7 distinct waves are required within that 
period. K-complexes are EEG waveforms which have a well delineated negative sharp 
wave, which is immediately followed by a positive wave. This all should exceed a 
duration o f 0.5 seconds, and may or may not include sleep spindles. Although mostly 
generated internally, K-complexes can be produced by sudden external stimuli (Johnson 
and Karpam, 1968), indicating a degree of responsiveness.
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Figure 1.2: Stage 2 Sleep (C3/A2 channel) — The arrow indicates a characteristic K-complex, and the 
underlines show sleep spindles.
Stages 3 and 4 are very similar, and are collectively termed slow wave sleep 
(SWS) or deep sleep. Stage 3 (see figure 1.3) is assigned when 20% to 50% of an epoch 
is 2 cps or slower, with an amplitude greater than 75pV. These are delta waves, and are 
also present in stage 4. Here, there must be more than 50% delta in an epoch before the 
epoch can be classed as stage 4 (see figure 1.4).
lOGjiV
5 Sec
Figure 1.3: Stage 3 Sleep (C3/A2 channel) — 20% to 50% o f  the epoch features delta waves.
IOOju-V
5 sec
Figure 1.4: Stage 4 Sleep (C3/A2 channel) -  Over 50% o f the epoch shows delta waves.
Stage REM (see figure 1.5) is also known as desynchronised sleep or 
paradoxical sleep. Originally thought the deepest form of sleep, it is also the most 
active. With respect to EEG traces, it appears very much like wake, with low voltage 
mixed frequency waves just 1 or 2 cps slower than waking alpha (Johnson et al., 1967).
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Indeed, earlier work classed REM as a form of stage 1 sleep (Foulkes, 1966). 
Occasionally distinctive ‘saw tooth’ waves can be seen (Berger et al, 1962).
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Figure 1.5: Stage REM Sleep -  EEG waves are similar to that o f wake, but EM G is lowered, and rapid 
eve movements (REMS') are often present.
Figures 1.1-1.5 reproduced from: Carskadon, M. A. and Dement, W. C., (1994): Normal Human Sleep: 
An Overview. In: Kryger, M. N., Roth, T., and Dement, W. C., (Eds) Principles and Practice o f Sleep 
Medicine, 2nd Ed. Philadelphia: W.B. Saunders.
REM is predominantly characterised by distinctive fast eye flickers known as 
rapid eye movements (REMs) from which REM sleep obtains it name. When woken 
from sleep containing REMs, more dreams are reported than in any other stage 
(Aserinsky and Kleitman, 1955). It was originally thought that dreams only occurred in 
REM, but this was found not to be the case (Aserinsky and Kleitman, 1955). However, 
NREM dreams are reported to be more like thinking and feeling rather than vivid 
images (Foulkes, 1966).
EMG in REM is noticeably lower than wake EMG. This is due to the muscle 
atonia that occurs in this state. It is thought this paralysis may prevent the acting out of 
the vivid REM dreams (Chase et al., 1981). Lesions in cats preventing the muscle atonia 
lead to behaviour resembling waking, such as chasing and washing (Morrison et al., 
1981).
Caution is advised as these sleep variables, such as the o f amount each stage, 
latency to sleep onset and the amount o f wake, could be interpreted in different ways. A 
total sleep time of five hours, for example, may be adequate for some, but may be 
inadequate for others (Hindmarch, 1983). Some may report satisfactory sleep, but may 
actually have had many short awakenings without remembering them (Rotenberg, 
1993). However, sleep efficiency, which is the percentage of the time in bed that is 
spent asleep, has been shown to be an accurate indicator of good sleep.
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A major problem with EEG determined stages of sleep is the lack of correlation 
between these objective measures and concomitant subjective measures of sleep. For 
example, in a type o f insomnia called sleep state misperception, patients grossly 
underestimate the amount o f sleep they have each night (Coleman, 1983). In relation to 
this, Adam et al. (1986) found that self-determined good sleepers were good estimators 
of sleep, whilst self-determined poor sleepers were poor estimators of EEG sleep. 
However, a recent study by Krystal et al. (2002) found that subjective complaints of 
insomnia were correlated to non-REM spectral indices (such as delta, alpha, sigma and 
beta waves). Despite no direct correlation between subjective and objective measures of 
sleep, EEG measurements are still necessary to describe sleep. Research into 
correlations are ongoing, to assess the relationship between objective and subjective 
measures of sleep.
Finally, it is worth mentioning here that the first night from any EEG sleep 
recording is often discarded due to the ‘ first night effect’ (Agnew and Webb, 1968). 
Unfamiliar surroundings and equipment in the sleep laboratory bedrooms tends to lead 
to increased periods of stage 2 sleep, increased REM latency, reduced sleep efficiency 
and a reduction in the percentage of REM sleep (Agnew and Webb, 1968). For this 
reason, most researchers include at least one ‘adaptation’ night before the start of a 
sleep study. This hopefully limits the effects o f the first night (Oswald, 1980).
1.2.4 The Limitations o f Rechtshaffen and Kales (1968)
The scoring system outlined by Rechtshaffen and Kales (1968) has yet to be 
surpassed by a 'better' scoring system. However, this does not mean these descriptions 
of sleep stages are perfect. There are many difficulties and flaws, and users of this 
system tend to introduce their own deviations.
Sleep here is classified according to 30 second epochs, meaning it will be 
labelled according to whichever stage is present most in the epoch. This may obliterate 
more subtle differences in sleep (Martin and Marzec, 2003). Related to this is the 
example o f stage 4 sleep. This is classified by 50% or more o f an epoch filled with delta 
waves. This means epochs showing both 60% and 90% delta are both termed stage 4, 
despite obvious differences. This is especially important in drugs research, whereby the 
hypnograms of one drug may be identical to another drug (e.g. same number o f stage 4 
epochs), but they may differ in terms of number of delta waves (Borbely et al., 1991). 
Also, Hori et al. (1994) identified a 9-point continuum, relating to Rechtshaffen and
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Kales’ stages of wake, 1 and 2, which the authors suggested was a more accurate 
categorisation. In addition, the manual by Rechtshaffen and Kales (1968) is suggested 
by Martin and Marzec (2003) not to address arousals and their meaning.
Most subjects assessed to create these rules were healthy college students, and it 
has subsequently emerged that older adults and young children tend to have their own 
patterns of sleep which do not follow the descriptions outlined by Rechtshaffen and 
Kales. For example, there is no description of sleep in pathological conditions (Martin 
and Marzec, 2003). In addition, ‘normal’ elderly individuals have been found to have 
less SWS than younger adults (Reynolds et al., 1985a). Also, Webb (1982b) studied 80 
volunteers, aged either 50 to 60 years old or between 19 and 31 years old. Results 
showed significant differences between the amounts o f time spent in each sleep stage 
between the age groups. The records were then re-analysed, where stages 3 and 4 were 
staged on the criteria of frequency alone, without consideration o f amplitude. Results 
then showed no significant differences in these measures between older and younger 
participants. However, records staged in this manner cannot be compared to other 
studies which did not use this criteria. This system devised by Rechtshaffen and Kales 
(1968) is therefore a useful guide, but it must be noted that it is occasionally too rigid, 
too broad, or lacking in appropriate guidance for some situations.
1.2.5 The Necessity o f Sleep
Sleep occurs to virtually all of us, and is a natural process. When considering 
animals such as the cat family, it leads some researchers to muse upon whether sleep is 
actually the ‘normal’ state, and wake is merely a disruption for personal housekeeping 
and reproduction (Bosinelli, 1995). It is clear we need to sleep. A linear decrease in 
sleep leads to a linear decrease in alertness (Currie et al., 1992), and impairments of 
alertness and daytime performance have also been noted by Roehrs et al. (1989), 
Rosenthal et al. (1991), and others (e.g. Carskadon and Dement, 1979), which will be 
discussed later.
Sleep deprivation can have dramatic effects. Full sleep deprivation can lead to 
psychotic behaviour and hallucinations; partial deprivation can lead to unsteadiness and 
daytime sleepiness (Webb, 1982a). For example, Kamphuisen et al. (1992) deprived 5 
healthy students of sleep for 65 hours, and found reports o f loss o f memory, loss of 
contact with reality, and ataxia. Dement et al. (1960), as reported in Webb (1982a), first 
reported the importance o f REM sleep. Participants were awoken from REM sleep for
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five consecutive nights, which lead to reports of daytime irritability, nervousness, 
inability to concentrate, and hallucinations. Most importantly, when normal sleep 
patterns were resumed, an increased amount o f REM sleep was observed, termed REM 
rebound. Dement et al. postulated that this rebound occurred to compensate for lost 
REM time, and many other authors have since shown this effect (for example, Endo et 
al., 1998; Werth et al., 2002). Jouvet (1967) placed cats on a large conical island 
surrounded by water, a common technique o f the time. When they entered REM sleep, 
muscle atonia occurred and they would slip into the water and wake up. This REM 
deprivation produced abnormal behaviour, and eventually death.
Non-REM (NREM) sleep is also necessary, as Oswald (1966) theorised NREM 
was useful for the restoration of functioning, as it provides sensory deprivation. 
Alternatively, memory theories of sleep suggest SWS can aid the clearance of unusable 
memories (Ambrosini et al., 1988a/b). Lancel et al. (1992) showed there was an 
increase in the amount of NREM after a 12-hour sleep deprivation in cats. The authors 
concluded this may have been part of a recoveiy process, agreeing with the restoration 
theory (Oswald, 1966). Borbely et al. (1981) also fomid similar results after sleep 
deprivation in humans.
The amount o f sleep required by humans is subject to individual differences. 
These can include age, gender, personality, culture, location, occupation, and mental or 
physical illness. For example, Taylor and McFatter (2002) used the Eysenck Personality 
Questionnaire and tests of time estimation, delayed and immediate recall, spatial 
processing, digit span and the Stroop task to show overnight sleep deprivation affected 
extraverts more than introverts. This shows sleep alteration can affect different people 
in different ways, indicating inter-individual variation in sleep research. Also, Wehr et 
al. (1993) tested the effects of season on sleep, by subjecting 10 young volunteers to the 
light conditions of a North American winter. The amount o f baseline sleep taken by the 
volunteers averaged 7.2 hours, but under winter conditions they slept for 10 hours per 
night initially, and then slept 8.2 hours per night after 4 weeks. In addition, depression 
can disrupt and shorten sleep (Reynolds and Kupfer, 1999), and ageing can fragment 
sleep (Parrino et al., 1999a), perhaps explaining why older adults have less of a decrease 
in reaction time and alertness than younger adults do when they suffer sleep loss 
(Bomiet and Rosa, 1987).
Most consider eight hours the norm, but sleep duration is often between five and 
nine hours. Ferrara and DeGennaro (2001) suggest there is no one amount of ‘ sleep 
need’ , as it is highly individual. They found sleep restriction had negative effects on
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sleepiness, motor and cognitive performance, but 2 or 3 hours extra sleep did not have a 
positive effect on these measures. They conclude a ‘ somnotypology’ that takes account 
of age, gender, and positions in the sleep-alert and morningness-eveningness continua 
will show the sleep need of individuals.
It is daytime functioning (how well tasks during the day are performed) and 
sleepiness that dictates the amount o f sleep required by the individual. Military 
experiments of gradual shortening of sleep time (30 minutes every three weeks) show 
that daytime functioning is normal at six hours sleep, but Webb (1982a) found 
decrements in psychomotor performance after five hours sleep per night. Taub and 
Berger (1976) found a decrement of 3 horns sleep from normal (which was 9.5 hours to
10.5 hours sleep in this study o f 10 healthy male students) caused declines in vigilance 
and subjective arousal when tested the next morning.
1.2.6 Neurophvsiological Effects. Neurochemical Roles and the Developmental 
Importance of Sleep and Wake
1.2.6.1 The Neurophvsiolosv o f Sleep and Wake
This thesis is concerned with the effects of drugs on sleep parameters. Therefore, 
an explanation of the neurophysiology o f sleep is necessary to aid understanding o f the 
action of these drugs. The neurological function of sleep is very complicated, and is 
thought to involve areas such as the cortex, thalamus, hypothalamus, and the brainstem 
(Hartmann, 1973). In 1949, Moruzzi and Magoun identified the reticular activating 
system (RAS). The brainstem reticular formation (RF) was then, and still is today, 
thought to play a role in cortical and behavioural arousal through the ascending RAS 
(ARAS). Balkin et al. (2002) used a PET scan (positron emission tomography) to 
establish areas involved in alertness following sleep. They found centrencephalic 
regions (brainstem and thalamus) mediated conscious awareness, and during the first 
fifteen minutes o f awakening, cortical blood flow increased in the anterior cortical 
regions, the prefrontal cortex, the ventromedial caudate nucleus, and the mesencephalic 
reticular formation. This supports earlier work by Starzl et al. (1951) who suggested the 
ARAS is a non-specific formation, which occupies the brainstem tegmentum from the 
medulla to the rostral part of the mesencephalon. Also, Krout et al. (2002) suggested 
that the mesencephalic reticular formation in the rat had projections to the thalamus.
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The RAS may be involved in passive or active mechanisms of sleep onset. This 
reflects the distinction made by Kleitman (1963), that “to fall asleep” (active) is not the 
same as “to be unable to remain awake” (passive). The passive mechanism shows a lack 
of maintained wakefulness by the ARAS will result in sleep (Bremer, 1960). This is 
demonstrated by the phenomena of coma. Coma (Lindsley et al., 1950) and ‘ locked-in’ 
syndrome (alert coma; Maurri et al., 1989) can occur when the mesencephalic 
tegmentum is damaged, which interrupts the ascending flow of reticular impulse. Also, 
PET studies have shown a decrease in cortical activation during slow-wave sleep (SWS) 
(Maquet et al., 1997). Sleep therefore may be due to a reduction in the activation tone of 
the ARAS (Bremer, 1960). Indeed, Ganji et al. (1996) reported a case study where a 50 
year old woman suffered a defect in her ARAS after the surgical removal of a brainstem 
cholesteatoma, which resulted in hypersomnia. Twenty-four hour ambulatory 
monitoring revealed normal sleep architecture, but 62.7% of her time was spent asleep.
Other brain structures may be responsible for cortical activation and behavioural 
arousal, and cessation o f the action of these structures may lead to sleep. There is an 
extrareticular system in front o f the mesencephalon which may be responsible for 
cortical desynchronisation (Batsel, 1963). Chronic lesions o f this area can suppress 
cortical desynchronisation, yet the animal tested may be behaviourally awake (Feldman 
and Waller, 1962; Jouvet, 1962). It is thought this area may be additional to the 
behavioural arousal produced by the descending RAS (Feldman and Waller, 1962; 
Jouvet, 1962). In addition, Arpa and De Andres (1993) lesioned the central superior 
raphe nucleus in seven cats, and found it was associated in arousal mechanisms rather 
than in direct sleep promotion. Indeed, Rasmussen et al. (1984) found the firing rate o f 
the ascending raphe nuclei decreased during SWS and was silent during REM sleep. 
Similarly, the locus coeruleus also has a role in arousal, as Hobson et al. (1975) found 
maximal firing o f neurones in this region dining wake, less during SWS and virtually no 
firing during REM sleep.
The active theories of sleep, first identified by Moruzzi (1960), favour the 
existence of sleep-inducing structures. Removal o f the midpontine section from the 
lower brainstem of a cat (King and Marchiafava, 1963) resulted in a significant increase 
in fast cortical activity measured by EEG (78% compared to 37%), indicating this 
structure may be able to dampen the arousing activity o f the ARAS. However, a right­
sided tegmental pontine hematoma caused hypersomnia in a 44 year old man (Arpa et 
al., 1995). Exact location o f these structures is therefore difficult. Hodes (1964) has 
shown active sleep structures may even exist in the spinal cord, as injection of
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novocaine (an anaesthetic) to the spinal cord may in itself produce EEG cortical 
activation. The thalamus is also thought to have a role in sleep production. It is 
suggested to be necessary for the production of spindles, as sectioning of the thalamus 
abolishes cortical spindles (Cordeau et al., 1963). In addition, Ueda et al. (2000) found 
the source of 12 to 14 Hz spindles was near the thalamus. However, removal of the 
neocortex stops slow activity in the thalamus and reticular formation (Jouvet and 
Michel, 1958), indicating cortical involvement. Indeed, Ueda et al. (2000) also found 
these 12 and 14 Hz spindles were projected from the thalamus to the centro-parietal lobe 
and the frontal lobe respectively. Jouvet (1962) suggested reticular slow waves can still 
occur, as long as the gyrus orbitalis and coronalis anterior are left intact. The basal part 
of the cortex is therefore essential for slow wave sleep, found in lesion studies of the 
basal forebrain (Ray and Jackson, 1991), and in PET studies o f normal human sleep 
(Maquet, 2000).
REM sleep may have different neurological mechanisms to NREM sleep. REM 
can be neurologically identified by the cessation of EMG activity in the neck, and the 
appearance of rapid eye movements, plus subcortical monophasic pontine spikes 
(Kohyama et al., 1998). In REM sleep, there is neurochemical evidence for activation 
and disinhibition in the cortex (Rasmussen et al., 1984; Vanni-Mercier et al., 1984). 
However, REM can exist in neodecorticate animals (Jeannerod et al., 1965), so the 
cortex does not play an essential trigger role, and REM can also exist without the 
cerebellum, indicating this is also not essential (Jouvet, 1962). Rossi et al. (1963) found 
a lateral hemisection in front o f the caudal part o f the nucleus reticularis pontis oralis 
and the rostral part o f the nucleus reticularis pontis caudalis delayed the cortical 
desynchronisation during REM sleep, indicating that the behavioural and EEG signs of 
REM occurs at the level of the pons.
Indeed, the pontine structures in the brainstem may also be important for REM 
sleep (Coenen, 1998). For example, ablation of a limited area in the rostral part o f the 
mediolateral pontine tegmentum (which includes the locus coeruleus) and dorsal parts 
suppresses muscular atonia during REM (Jouvet and Delorme, 1965). Indeed, Jones
(1991) found descending projections through the caudal dorsolateral pontine tegmentum 
and into the medial medullary reticular formation may be involved in the initiation of 
atonia. Experiments o f the bilateral destruction of the medial and descending vestibular 
nuclei show these areas are necessary for the bursts o f eye movements, and the clonic 
jerks of peripheral muscles (Morrison and Pompeiano, 1965). The phasic PGO spikes 
(pons-geniculate-occipital spikes) produced in REM sleep have been found to be due to
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the lateral pontine tegmentum, as its ablation suppresses these spikes (Jouvet et al., 
1965). Jones (1991) suggests the major ascending projections into the thalamus, 
including the lateral geniculate, may provide the means by which phasic and tonic 
activation is communicated in part to the cerebral cortex. Evidence for the involvement 
of these structures also comes from central triggering techniques. High-frequency (200- 
300cps) stimulation during SWS of the pontine (Jouvet, 1962) and mesencephalic 
reticular' formation (Faure et al., 1962), and low-frequency stimulation during SWS of 
the hypothalamus (Faure, 1965) and hippocampus (Faure et al., 1962), can both induce 
REM sleep. However, because of the necessity of SWS, it is hard to tell if the 
appearance of REM is induced or coincidental (Roldan and Weiss, 1963).
1.2.6.2 The Neurochemistrv o f  Sleep and Wake
Neurotransmitters play an important role in the transfer o f information to the 
brain structures discussed above. Their mechanisms of action are complicated, and it is 
likely that sleep is due to a combination o f neurotransmitters and their interactions. 
Chemically, there are four main categories of neurotransmitter, most of which have a 
role in sleep regulation: acetylcholine, biogenic amines (serotonin, histamine, and the 
catecholamines dopamine and noradrenaline), excitatory amino acids (glutamate and 
aspartate), inhibitory amino acids (gannna-aminobutyric acid (GABA), glycine and 
taurine) and lastly, neuropeptides.
Acetylcholine has been found to have influencing effects on both serotonin and 
noradrenaline. It excites noradrenergic neurons in the locus coeruleus, and is weakly 
inhibitory on serotonergic neurons in the dorsal raphe nucleus (Guyenet and 
Aghajanian; 1979; Koyama and Kayama, 1993). Also, electrical stimulation in the basal 
forebrain favours acetylcholine release in the cortex (Kurosawa et ah, 1989). Increases 
in acetylcholine have been noted to increase the amount o f REM sleep, while decreasing 
acetylcholine decreases the amount o f REM sleep (Guilleminault and Foutz, 1983). 
Local injections o f cholinergic agonists into the pontine tegmentum trigger REM sleep 
marked by phasic PGO spikes in association with cortical activation and neck muscle 
atonia (Jones, 1991). Also, Marrosu et al. (1995) showed that levels o f acetylcholine are 
higher during REM sleep than during wake, but levels are low during SWS.
Dahlstrom and Fuxe (1964) discovered the presence o f monoaminergic neurons 
in the brain stem. They found serotonergic neurons in the raphe nucleus o f the 
brainstem, and in the spinal cord and rostral parts of the brain. Jouvet (1965) found the
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destruction of the raphe nucleus in the cat resulted in an almost permanent state of 
wakefulness, and partial ablation lead to a decrease in SWS. The locus coeruleus, 
previously mentioned as having a role in REM sleep, is also rich in monoamine oxidase 
(MAO), and may play a role in the monoaminergic system (Hashimoto et al., 1962). 
The appearance o f PGO activity in REM is suppressed by MAO inhibitors and is 
therefore mediated by monoaminergic neurotransmitters (the behavioural aspects of 
REM (e.g. muscle atonia) is dependent on the cholinergic and the catecholaminergic 
systems) (Jouvet, 1967).
In 1972, Jouvet first demonstrated the importance of serotonin, by showing that 
blocking its synthesis (by a tryptophan hydroxylase inhibitor) lead to insomnia, which 
could be counteracted by the administration o f a serotonin precursor. Jouvet (1967) 
reported that the injection o f the serotonin precursor 5-HTP provoked an increase in 
SWS for 5 to 6 hours in normal cats. Serotonin reuptake inhibitors can also affect sleep 
architecture, and can suppress REM and increase REM latency (Luthringer et al., 1996; 
Saletu et al., 1991). Also, the use of MAO inhibitors can increase SWS, indicating the 
involvement of these neurotransmitters in sleep, and the importance o f serotonin in 
SWS. More than half of the noradrenergic and serotonergic neurons are found in the 
locus coeruleus and the dorsal raphe nucleus respectively (Dahlstrom and Fuxe, 1964), 
and have been noted to fire in free moving rats and cats the most during wake, and 
decrease during SWS and REM (Trulson and Jacobs, 1979; Aston-Jones et al., 1986).
Dahlstrom and Fuxe (1964) also found catecholaminergic neurons (mostly 
noradrenergic) in the lateral part o f the medulla, pons and mesencephalon, The 
noradrenergic system is involved in the regulation of the sleep/wake cycle. Tricyclic 
antidepressants (TCAs) alter the noradrenergic system, and TCAs are potent 
suppressors o f REM sleep (Kupfer et al., 1982). In relation to this, adrenaline is 
important in the maintenance of the tone of the ARAS, as previously discussed (Jouvet, 
1967). Lin et al. (1992) found that increases in noradrenaline can increase waking. 
Dopamine, another catecholamine, also plays a role in sleep and wake. Again, the use of 
dopamine-enhancing drugs such as D-amphetamine, high doses o f L-Dopa and cocaine, 
can increase arousal and decrease the amount o f REM sleep (Gillin et al., 1978a). 
Administration o f DOPA (precursor to catecholamines) induces a wake state, which 
excludes SWS and REM sleep for 6 hours (Jouvet, 1967).
Gamma-aminobutyric acid (GABA) is primarily an inhibitory neurotransmitter, 
and can be found in a large number o f brain areas. For example, benzodiazepine drugs, 
which are hypnotics, enhance GABAergic transmission. It has been found that
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benzodiazepines decrease wakefulness and suppress SWS and REM sleep (Lloyd et al., 
1983). The introduction o f a GABAa antagonist to the dorsal raphe nucleus by Levine 
and Jacobs (1992) reverse the suppression o f activity in SWS, so it is possible that 
GABA-induced inhibition might therefore be responsible for the decrease in activity of 
monoaminergic neurons during SWS. Indeed, Nitz and Siegel (1997) found an increase 
in the amount of GAB A in the cat locus coeruleus during SWS compared to wake. The 
newer nonbenzodiazepines, such as zopiclone, zolpidem and zaleplon, also enhance 
GABAergic transmission. Zopiclone has no preferential affinity for either of the 
benzodiazepine omega-1 and omega-2 receptors in the GABAa receptor complex, 
although some research concluded a bias towards the omega-1 receptor (Nakajima et al., 
2000). Zolpidem and zaleplon have tendencies as agonists to the omega-1 receptor 
(Holm and Goa, 2000).
Histamine can also alter wakefulness, and has been found in tracts ascending 
from the reticular formation. Microinjections of histamine into the dorsal pontine 
tegmentum can result in cortical desynchronisation and periods of quiet wakefulness 
(Kliateb et al., 1990). Antagonism of histaminic activity on Hi receptors (a type of 
histamine receptor) in humans can impair vigilance and shorten sleep latency 
(Hindmarch and Kerr, 1993), and agonists of the postsynaptic Hi receptor can increase 
waking (Monti et al., 1994). Histaminergic neurons are found almost exclusively in the 
posterior hypothalamus (Yamatodani et al., 1991). This area is known for its 
associations with waking mechanisms, as lesions in this area can lead to hypersomnia 
(Lin et al., 1988). Also, an increased amount of histamine in the posterior hypothalamus 
of monkeys is observed in waking (Onoe et al., 1992). Blocking the transmission of 
histamine has been found to increase cortical slow activity and SWS, whereas 
enhancements of histaminergic activity can promote wakefulness (Lin et al., 1990).
1.2.6.3 The Development o f  Sleep and Wake
To understand sleep it may be helpful to assess its developmental process. The 
dominant characteristic of sleep in babies is periodicity. Adult sleep cycles last 
approximately 90 minutes, whereas the baby will cycle eveiy 60 minutes or so. These 
cycles are predominated by REM sleep. NREM is only characterised by low attenuation 
o f visceral and somatic activities, and so when not in REM, babies are thought to be 
‘ resting’ (Sterman, 1979). Babies sleep for a vast proportion o f the day, suggesting sleep
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may have a generative function. As babies age, Parmelee et al. (1964) suggest they 
spend longer and longer awake for motor and social learning.
Periodicity o f somatic activity lasting 40 to 60 minutes is foimd in foetuses of 
only 24 weeks old (Sterman and Hoppenbouwers, 1971), implying possibility for a 
hardwired rest-activity cycle. After birth, and with increasing age, the EEG patterns 
have been found to become more like adult patterns, as the periods of quiescence and 
wake become more defined (Sterman et al., 1977). Their circadian rhythms are weak at 
3 to 6 weeks o f age, but become strong by the age o f 23 to 26 weeks (Kleitman and 
Englemann, 1953). Lastly, the baby develops an ultradian rhythm, and will sleep more 
in the night than the day.
Sterman (1979) tested 10 babies from the age of 1 week old to 6 months old, to 
determine their EEG patterns, using T3-C3 and T4-C4 electrodes. The babies slept in a 
warm room, with arm restraints to prevent the removal of electrodes. Results showed 
babies up to 5 weeks old had EEG power almost totally in the 0-3 Hz band (delta waves 
associated with SWS), but showed periodicity in the 12-14 Hz band by 10 weeks old 
(sigma waves associated with sleep spindles). By 19 weeks, there was a clear distinction 
between the two bands, where the sigma activity represented the rest-activity cycle, and 
the delta waves represented a slower periodicity. A decrease in delta sleep was also 
found in a study of 46 neonates aged between 24 hours and 40 weeks (Nunes et al., 
1997). Sterman (1979) found mature sleep was achieved by 20 weeks old. Theta and 
alpha activity (associated with thinking and wake) did not change until 16 weeks o f age.
These age-related changes may be indicative o f the maturation process o f the 
forebrain. The apical dentrites o f the cortical pyramidal cells are the first to mature 
(Scheibel and Scheibel, 1964). It is these cells which provide the substrate for receptive 
interaction among cortical cells, and their synchronous activity is thought to be 
associated with EEG slow waves. Early delta activity may therefore be viewed as 
emerging intracortical communication (Sterman, 1979). Also, the dendritic spines and 
the basilar dentritic structures start maturing (Scheibel and Scheibel, 1971), which 
receive afferent sensory information involved in thalamocorticial interactions. This is 
thought to be the substrate for other rhythmic EEG activity, such as theta and alpha.
Neurological changes in ageing include a loss of brain volume (more white 
matter than grey matter), especially in the hippocampus and fi'ontal lobes, a loss of 
myelin, a loss of synapses and dentritic arbour, and an increase in infarcts (Anderton, 
2002). Changes in EEG may be due to the weakening of the restorative role o f sleep and 
impairment o f brain functions (Frolkis and Bezrukov, 1979), a result of either
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maturation or perhaps involution o f the central nervous system, as the functioning of the 
body declines with ageing (Zepelin and McDonald, 1987). Changes also occur to the 
sleep-wake cycle in old age, which wiil be discussed later. Crowley et al. (2002) studied 
the sleep of 14 young and 20 elderly participants. They foimd the number, density and 
durations o f sleep spindles and k-complexes were lower in the elderly than the young, 
and suggested this was due to alterations in the thalamocortical regulatory mechanisms. 
Carrier et al. (2001) studied the effects o f age on sleep EEG power density, using 100 
volunteers aged between 20 and 60 years. They found age primarily decreased slow- 
wave activity, but also decreased theta and sigma activity, and increased beta activity. 
The authors suggest that increasing age may be related to an increase in cortical 
activation during sleep.
1.3 Problems in Sleep
Almost everyone has disturbed sleep, because we restrict our sleep by the use of 
alarm clocks, and disturb our sleep by sharing our beds with others, for example. 
However, not all o f us complain o f sleep problems, as these restrictions are largely 
acceptable to us, and do not interfere with our day's functioning. Sleep complaints 
therefore often arise when daytime functioning is impaired (Webb, 1982a), and sleep 
disturbance can generally be defined as "disturbances of normal and healthy sleep 
patterns that may or may not impact waking performance" (Webb, 1982a, p.80). These 
are different to sleep disorders like narcolepsy, which are pathological and arise from a 
physiological basis. Organically based sleep disorders will not be discussed here.
1.3.1 Insomnia
The International Classification of Sleep Disorders (Diagnostic Classification 
Steering Committee o f ASDA, 1990) outlines four major categories o f 84 sleep 
problems. These categories are dyssomnias (problems initiating or maintaining sleep, or 
excessive sleepiness); parasomnias (abnormal sleep behaviours); sleep disorders 
associated with medical/psychiatric disorders; and a fourth categoiy for any unclassified 
proposed sleep disorder. Dyssomnias are further divided into extrinsic sleep disorders 
(external prompts such as poor sleeping environment or alcohol); intrinsic sleep 
disorders (internally prompted by psychological reasons, breathing problems, or restless
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legs); and circadian rhythm disorders (such as jet lag, advanced and delayed sleep phase 
syndrome).
In addition to cause, insomnia is also classified by its duration (National 
Institutes of Health Consensus Development Conference, 1991). Transient insomnia 
lasts two to three days and is associated with an acute stressor (such as examinations, 
public speaking and hospitalisation) or disruption or circadian rhythm (such as jet lag). 
Short term insomnia may last up to three weeks, and is associated with an ongoing 
stress or a traumatic event, such as loss o f employment, illness/pain, divorce or moving 
house. Long term insomnia lasts longer than three weeks and is often due to 
bereavement, or a psychiatric/medical disorder (Swift and Shapiro, 1993).
Wagner, Wagner and Hening (1998) describe insomnia as "the subjective 
complaint of poor sleep quality or inadequate quantity of sleep that adversely affects 
daily functioning" (p.680). Reported prevalence of insomnia differs greatly due to 
population, time frame and questions asked (Bliwise, 1991), which will be discussed in 
chapter 3. In a recent poll (The Gallup Organisation, 1995), 49% of American adults 
had difficulty sleeping an average o f five nights per month.
Transient or short term insomnia predominantly arises from two causes, namely 
worrying (stress or trauma) and poor sleep hygiene (Engle-Friedman et al. 1992). Stress 
and worries often lead to increased arousal and excitation o f neurons in the brain, and 
this creates a vicious circle, as the arousal and lack of sleep leads to worrying (Hobson, 
1990). Indeed, long standing sleep problems may be intrinsically linked to anxiety and 
depression, as indicated in the review of ICD-10 by Soldatos and Lugaresi (1987). 
However, is it unclear if psychopathology leads to insomnia, or the insomnia 
predisposes the sufferer to psychiatric disorder (Ford and Kamerow, 1989). Charon et 
al. (1989) noted that 56% of insomniacs seen in general medical practice also presented 
with anxiety or agitation. In a study of 51 medication-free patients with anxiety using 
the Eysenck Personality Inventory, the Beck Depression Inventory, and the Spielberger 
State-Trait Anxiety Inventory, Mathew et al. (1981) found more incidences of disturbed 
sleep compared to non-anxious controls.
Insomnia is also more prevalent among the depressed. Mellinger et al. (1985), in 
a survey of 3161 noninstitutionalised adults aged 18 to 79 years old, found 
approximately 20% of insomniacs are also depressed. In addition, Liljenberg et al. 
(1988) questioned 1687 young adults and 1870 older adults, and found insomnia was 
twice as prevalent in depressed than in non-depressed Swedish populations. There is a 
well established link between sleep disturbance and depression. Studies have shown that
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sleep deprivation can alter mood in 50% of depressed patients (Pflug and Tolle, 1971; 
van den Burg and van den Hoofdakker, 1975; Post et al., 1976; Wu and Bunney, 1990), 
REM sleep deprivation can also change mood (Vogel et al., 1975), and during major 
depression, up to 90% of patients will show some sleep disruption (Reynolds and 
Kupfer, 1999).
Poor sleep hygiene (meaning maladaptive sleep behaviour) is also suggested to 
have a causal role in insomnia. Maladaptive bedtime behaviours can include drinking 
alcohol or caffeine (which disrupts sleep and delays sleep onset respectively), or 
exercising just before retiring (because the body temperature is in a state of decline, 
instead o f warming), sleeping on an uncomfortable bed, or in light or noisy 
environments (which can all delay sleep onset). If these behaviours are perpetuated, 
they can disrupt sleep patterns in some individuals. Sleep hygiene is currently thought to 
include drinking hot milky drinks before bed, meditation, reading, and sleeping regular 
houi-s, as reviewed by Bootzin and Perlis (1992).
1.3.2 Sleep in Old Age
The population with the highest incidence and severity o f insomnia is reported to 
be the elderly, and sleep problems tend to increase with age (Webb, 1982a; Braz et al., 
1990; Habte-Gabr et al., 1991; Bliwise et al., 1992; Hoch et al., 1994; Foley et al., 1995; 
Mallon and Hetta, 1997). In a classic survey o f sleep disturbance, Karacan et al. (1976) 
questioned 1645 adults in Florida, found only 9% of those aged 20-29 reported often 
having trouble sleeping, but this complaint was reported by 21% of those aged 60-69. It 
is therefore important to understand and treat insomnia in the older adult, especially as 
the proportion o f the elderly population continues to expand (Office of National 
Statistics, 1999). Yet the study of elderly sleep has been a much neglected area in the 
past, with most population studies omitting older adults, or only including a small 
number in relation to other age groups studied (Bixler et al., 1979; Gledhill, 1985). 
Morgan et al. (1988b) thought studies looking at high numbers of older adults lacked 
the necessary detail about the elderly population (for example, focusing on prevalence 
o f the use o f sleeping pills, rather than the types taken).
Poor sleep in the elderly is associated with excessive daytime sleepiness, 
irritability and increased nocturnal activity, which increases the risk of accidents and 
falls due to daytime sleepiness (Ray et ah, 1987; Poliak and Perlick, 1991; Swift and 
Shapiro, 1993; Leger, 1994). In a Finnish study, Martikainen et al. (1992) surveyed
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1600 middle-aged people. They found daytime sleepiness was associated with disturbed 
nocturnal sleep, and also those suffering from tiredness complained of poor health more 
than other respondents. Traffic accidents and other mishaps attributable to tiredness had 
occurred in 1.3% of cases, and almost 5% of male respondents had dozed off while 
driving at least five times in their lives. Poliak et al. (1990) suggests these problems 
may even result in institutionalisation of the elderly individual. Research into insomnia 
is therefore important with respect to its daytime effects and the quality o f life of the 
sufferers. Young et al. (1998) found that accidents in the elderly had an increased risk of 
mortality and cost to society than accidents involving younger individuals. Cwikel
(1992) studied 3494 volunteers over the age of 65 years, and found 24% reported a fall 
in the last year, of which 37% went to hospital. It was also shown that advancing age 
was associated with repeated falls. Kazar et al. (1996), in a study o f 2055 injured older 
Hungarian adults (65 years and over), found the rate o f home accidents increases with 
ageing, and the elderly are particularly susceptible as pedestrians or cyclists. In this 
study, Hungarian seniors totalled half o f all fracture patients studied. Daigneault et al. 
(2002) found elderly drivers in Quebec (Canada) are prone to accidents from errors of 
judgement, and the number o f these accidents increases with age. These studies show 
the importance of reducing the potential for accidents in the elderly, both for their safety 
and for reducing the cost to society (because there will be less o f the elderly in hospital, 
for example).
Insomnia may also impact both subjective wellbeing and objective health 
(Kripke et al. 1991; Janson et al., 1995). For example, Foley et al. (1995) studied over 
9000 American participants aged over 65 years in a multicentre project. They found 
between 7% and 15% rarely or never felt rested in the morning, and that sleep 
complaints were associated with an increased number of respiratory symptoms, physical 
disabilities, depressive symptoms and poorer self-perceived health. Similar findings 
were also reported in a survey of 628 American community dwelling older adults, with 
respect to breathing problems and self-perceived health (Schmitt et al., 1996). Poor 
sleep has even been linked to an increased risk of mortality (Wingard and Berkman, 
1983; Poliak et al., 1990; Foley et al., 1995), These findings were demonstrated in a 
large cohort study o f 1.1 million participants between the ages o f 30 and 102 years 
(Kripke et al,, 2002). Results showed participants who reported less than 6 hours o f 
sleep and particularly more than 8 hours o f sleep had a higher mortality hazard ratio, 
and an increased mortality risk. For both men and women, the optimum sleep duration 
was found to be 7 hours (6.5-7.4 hours) when data was controlled for comorbidities and
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sociodemographic factors (such as age, diet, exercise, health and smoking), although 
reasons for this were unclear. A critique by Buysse and Ganguli (2002) points out the 
study was not designed to investigate the effects of sleep on mortality, as the survey was 
part of the 1982 Cancer Prevention Study. ‘ Insomnia5 in the survey was ill-defined, and 
reports of sleep duration were rounded up or down to the nearest whole hour. 
Participants were not representative o f the population as they were mainly friends and 
relatives o f volunteers for the American Cancer Society. In addition, there was no 
investigation o f sleep quality, daytime sleepiness or napping behaviour.
Despite the flaws in this large survey, a link between lack of sleep and mortality 
is suggested. Indeed, sleep problems have been linked to poorer health in various 
surveys (McGhie and Russell, 1962; Regestein, 1980; DeGraaf et al., 1983; Cirignotta 
et al., 1985; Gislason and Almqvist, 1987; Morgan et al., 1988b; Ford and Kamerow, 
1989; Monk et al., 1991; Bliwise et al., 1992; Hoch et al., 1994; Asplund, 1996). For 
example, Habte-Gabr et al. (1991) studied the self-reported sleep patterns o f 3097 
people, 1155 men with an average age o f 73.7 years, and 1942 women with an average 
age o f 74.8 years. They were participants in the Iowa 65+ Rural Health Study, which 
spanned two Iowa counties. Questions were asked regarding time to bed, time o f sleep 
onset, rising time in the morning, and how rested they felt on rising. This was assessed 
in relation to information on their physical health, psychological health, social networks, 
amount o f exercise, and religion. The authors found physical functional limitations were 
linked to an earlier bedtime, increased sleep duration, increased likelihood o f a 
prolonged sleep latency (over 30 minutes in duration), and a decreased likelihood of 
feeling rested in the morning. A histoiy of heart attack and stroke in women was 
associated with not feeling rested in the morning, and in men was associated with a 
prolonged sleep latency. Poor sleep is also associated with increases in arthritis (Morin 
and Gramling, 1989; Habte-Gabr et al., 1991), angina and hypertension (Newman et al., 
1997), and psychiatric disorders (Kales et al., 1984; Reynolds et al., 1985b; Morin and 
Gramling, 1989). Schechtman et al. (1997) studied 485 elderly individuals in three sites 
in the U.S., and found self-reported bodily pain and poor general health, and a history of 
falls, were all linked to disturbed sleep. However, it must be remembered that it is 
difficult to know whether poor health leads to poor sleep, or poor sleep leads to poor 
health, but research does suggest an association.
There are many questionnaires designed to gauge quality o f life, an example of 
which is the Short Form 36 (SF36). This asks about 8 aspects o f life, namely physical 
functioning, social functioning, physical and emotional role function, mental well being,
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vitality, pain and general health. The SF36 has been successfully used in many studies 
of diseases and conditions. For example, Kingston et al. (2001) used the SF36 to assess 
differences between living conditions for the elderly in retirement housing and the local 
neighbourhood. After assessments over a year*, they showed the retirement community 
maintained physical and mental health more successfully than those living locally. Also, 
Creed et al. (2002) used the SF36 to show impairment of health-related quality of life in 
263 patients with depression and anxiety.
Despite its utility in measuring and describing quality of life in these 
circumstances, a search o f Medline (August 2003) showed no publications relating to 
SF36 and insomnia or sleep. Although many authors such as Habte-Gabr et al. (1991) 
and Gislason et al. (1993) have questioned their participants on these matters, 
established quality o f life scales do not appeal’ to be commonplace in the assessment o f 
insomnia.
1.3.3 The Origin of Sleep Problems in Old Age
Studies in Sweden (Mallon and Hetta, 1997), the U.S. (Karacan et al., 1976), 
England (Morgan et al., 1988b), and Japan (Yamaguchi et al., 1999) show that sleep 
problems in older age appear to be global. However, a major problem when researching 
sleep problems in the elderly, and indeed in other populations, is what people perceive 
insomnia to be. For example, Weinstein et al. (1983) found 4% to 5% of those surveyed 
in San Francisco would report ‘ insomnia’ , but 13% to 16% would then admit to 
difficulty initiating or maintaining sleep, and other aspects o f ‘ insomnia’ itself. This 
may be indicative o f a possible stigma associated with ‘ insomnia’ (Friedman et al., 
1991/1992). Alternatively, older adults may experience events such as nocturnal 
awakenings or extended sleep latency (time taken to get to sleep), but may not consider 
this to be ‘ insomnia’ per se. Indeed, some may enjoy sleeplessness at the beginning of 
the night as a chance to read, for example (Hindmarch, 1984). A similar pattern of 
findings is also noted when the elderly are asked about their general health. Von Faber 
et al. (2001) questioned older adults aged 85 years, who lived freely in the community, 
and found 45% rated their health as good-to-excellent. However, objective measures of 
their physical and psychological abilities (vision, hearing, motor and cognitive function) 
and social function showed only 10% were in an optimum state of functioning. 
Chambers and Keller (1993) have suggested that insomnia will only be reported if 
daytime activities are affected by sleep problems. A change in sleep pattern may only be
Chapter 1
22
a problem if sleepiness the next day interferes with daytime activities. This must be 
considered when reviewing the literature.
The prevalence o f insomnia in the older population has been reported in many 
countries. In the U.S., 23.3% of those over 50 years old suffer insomnia in Florida 
(Karacan et al., 1976), 10.4% of those over 60 years old in Kentucky (Schmitt et al.,
1996), and 20.8% of those aged over 50 years around California (Mellinger et al., 
1985). In Italy (North East), 45% of those aged 65 years and over reported suffering 
insomnia (Maggi et al., 1998). In Sweden, 18.6% of those aged 65 to 79 years old 
reported insomnia (Mallon and Hetta, 1997). In England, Morgan et al. (1988b) found 
12.8% of those over 65 years of age reported insomnia, and Beaman (1989) found the 
prevalence to be 76% o f those aged over 60 years. This last figure is probably so high 
because the report was o f sleep problems experienced in the last week, whereas other 
percentages were based on sleep problems over longer time frames (for example, one 
month in the study by Karacan et al., 1976). Not including this last percentage, the 
average o f these percentages is 21.8%, approximately a fifth o f older adults. The 
difference between the prevalence o f insomnia differs greatly between old and young 
populations sampled. For example, Gislason et al. (1993) studied 800 volunteers from 
Reykjavik aged between 65 and 84 years o f age, and found 67.5% suffered from sleep 
disturbance. Janson et al. (1995) studied a younger age group (20-45 years), also from 
Iceland, and found only 9% complained o f sleep problems.
It is also globally found that females tend to complain o f increased frequency 
and severity o f sleep disturbance in Finland (Habte-Gabr et al., 1991), England (Morgan 
et al., 1988b) the U.S. (Schectman et al., 1997) and Japan (Yamaguchi et al., 1999). For 
example, in a Swedish study completed by Mallon and Hetta (1997) there were 876 
volunteers aged between 65 and 79 years old. They found sleep problems were reported 
by 23.8% of females, but only by 13.3% of males. It is unclear as to why, but research 
has shown that females appear to have a higher agreement between objective and 
subjective measures o f sleep than males, so females may be more likely to be 
subjectively affected by changes in sleep than males. Hoch et al. (1987) demonstrated 
this in an experiment comparing subjective and objective measurements of sleep. Both 
males and females both showed significant correlations between sleep latency and time 
taken to fall asleep, and sleep duration and total sleep time. However, only females 
showed significant correlations between wake after sleep onset and ‘restlessness5, and 
amount o f SWS with ‘ soundness’ o f sleep. It has also been suggested that females are 
more in touch with their feelings, and so are more able to talk about unpleasant
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experiences and have a more accurate perception of these experiences (Hoch et al., 
1987; Blay and Mari, 1990). Briscoe (1978) suggested females are more likely to talk 
about their feelings and emotional problems. Urponen et al. (1988) found females 
tended to be more bothered at night by thoughts of human relations, arguments and 
social worries, whereas males were more preoccupied by work-related worries (when in 
employment), stress, and may be more likely to be under the effects o f alcohol (which 
disrupts latter part o f the night and suppresses REM sleep (Moran et al., 1988)).
Depression itself in the elderly can lead to poor sleep, as was found in the 
questionnaires o f Habte-Gabr et al. (1991), Foley et al., (1995), Ohayon and Caulet 
(1996) and Maggi et al. (1998) perhaps contributing to the reasons why studies have 
found females have poorer sleep, as females are suggested to report more depressive 
symptoms (Kronholm and Hyyppa, 1985; Habte-Gabr et al., 1991). However, it is 
suggested there are more suicides in older males than females (Pearson, 2002), 
indicating the prevalence o f depressive symptoms might be similar between the genders. 
Again this shows differences in the prevalence of sleep complaints may only exist 
because females may be more willing to talk about depression and sleep problems 
(Middelkoop et al., 1996).
Females tend to have more health complaints (Habte-Gabr et al., 1991), 
especially during old age, and are prescribed more medication (Bliwise et al., 1992). 
The percentage prescription o f hypnotics is around 10.1% to 28% for females, but only 
4.3% to 16.7% for males (Karacan et al., 1976; Morgan et al. 1988a; Beaman, 1989; 
Seppala, 1993; Asplund, 1996; Middelkoop et al., 1996; Ohayon and Caulet, 1996; 
Mallon and Hetta, 1997; Seppala et al., 1997; Maggi et al., 1998). Morgan et al. (1982) 
suggests sleep medication is vastly over-prescribed to females. Unnecessary hypnotic 
use may be detrimental to health because o f issues such as adverse effects of the drugs, 
or the respiratory depression that some hypnotic medications can cause (Swift and 
Shapiro, 1993). It is the purpose o f this thesis to identify hypnotics used and to assess 
any adverse effects.
1.3.4 Physical and Psychological Health in Normal Ageing
According to Rowe and Kahn (1987), complaints of sleep problems are related 
to whether or not ‘ successful ageing’ has occurred. This is good ‘mental and physical 
health’ , ‘vitality’ (maintenance of active engagement in life), and ‘resilience’ (being 
able to ‘bounce back’ from stressors); and successful adaptation to ageing is best
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demonstrated by normal sleep efficiency (Morin and Gramling, 1989; Hoch et al.,
1997). There are two aspects o f successful ageing, namely the physical and the 
psychological.
1.3.4.1 Physical Aspects o f  Aseinz that Influence Sleep
A  high number o f  health problems are associated with increasing age and sleep 
problems, found in surveys from The Netherlands (Middelkoop et al., (1996), Iceland 
(Gislason et al., 1993), Sweden (Asplund, 1996), the U.S. (Newman et al., 1997), 
Australia (Lack et al., 1988), and England (Beaman, 1989). Pain is cited in many 
surveys as a major cause o f poor sleep (Moran et al., 1988; Beaman, 1989; Hyyppa and 
Kronholm, 1989; Waters et al., 1993; Henderson et al., 1995; Fichten et al, 1995; 
Seppala et al., 1997). Moffitt et al. (1991) completed a multiple regression analysis on 
data o f  sleeping problems from 1765 elderly Australians. They found poor sleep 
worsens the subjective experience o f  pain, and poor physical health was most associated 
with waking up in the early hours o f  the night. Pain in the night as a cause o f sleep 
problems was experienced by 23.1% o f 134 elderly sleep disturbed Australians 
(Henderson et al., 1995). In Sweden, Mallon and Hetta (1997) found 28.8% o f those 
with a sleeping difficulty complained o f  pain. Maggi et al. (1998), in a study o f  2398 
elderly volunteers in North-East Italy, found 6.5% blame pain when they have a 
difficulty initiating sleep, 4.2% when they have a difficulty maintaining sleep, and 3.8% 
when they wake too early in the morning. Gastro-esophageal reflux and general 
indigestion have also been highlighted in surveys as a disturbance to sleep (Gerard et 
al., 1978; Reynolds et al, 1985a; Mailt and Eyland, 1988). Maggi et al. (1998) also 
noted indigestion occurs in 4.9% o f the elderly when they are unable to get to sleep, in 
1.1% when they wake in the night, and in 0.9% when they wake too early in the 
morning.
Whilst some researchers have proposed that physical ailments result in poor 
sleep, Foley et al. (1995) have suggested that sleep deprivation from poor sleep can lead 
to ill health. The authors showed this in their survey o f  around 9000 elderly respondents 
from Boston, Connecticut and Iowa (all in the U.S.). Newman et al. (1997), in their 
survey o f 5201 pensioners, suggested poor sleep may even be a trigger for illnesses like 
angina. Also, Gislason et al. (1993), in their Swedish survey o f  800 elderly, suggest that 
individuals presenting with a sleep problem may have a causal underlying physical 
problem, and the complaint o f  poor sleep may distract General Practitioners (G.P.s)
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from the correct diagnosis. G.P.s receive very little training on the subject o f insomnia, 
and tend to prescribe sleeping pills without considering alternatives, or indeed what 
might really be causing the sleep problems (Moffitt et al., 1991; Moran et al., 1988). 
This may result in unnecessary hypnotics being used, which may exacerbate respiratory 
problems (Swift and Shapiro, 1993) and cause adverse effects (Clark et al., 1986). Also, 
the underlying physical illness will remain untreated.
One o f  the major contributors to sleep disturbance in the elderly is the frequent 
need to use the toilet at night, and has been identified as a cause o f wakefulness in many 
surveys across the globe (Zepelin and Morgan, 1981; Barker and Mitteness, 1988; Mant 
and Eyland, 1988; Gislason et al., 1993; Foley et al., 1995; Asplund, 1996; Seppala et 
al., 1997; Englert and Linden, 1998). Friedman et al. (1991/1992) suggests this problem 
receives little or no attention in many studies, despite a finding by Asplund (1996) that 
90.7% o f males and 90.2% o f females need to use the toilet in the night. Maggi et al.
(1998) found a frequent need to urinate during the night had virtually no effect on 
getting to sleep (1.1% o f older adults) and little effect on time o f awaking in the 
morning (11.4% o f older adults), while its main impact was on sleep maintenance. 
Overall prevalence o f needing to urinate in the night was reported to be 67.5% o f the 
elderly in The Netherlands (Middelkoop et al., 1996), 71.0% in England (Beaman, 
1989), and 65.6% in Italy (Maggi et al., 1998). Middelkoop et al. (1996) in the Dutch 
survey o f 1485 respondents found a prevalence for needing the toilet in the night o f 
62.7% for those aged 50-59, 67.3% for 60-69 year olds, 73.6% for 70-79 year olds and 
81.7% for the over 80’ s, suggesting that needing the toilet in the night increases with 
age. These authors suggest this may be due to the decrease in nocturnal anti-diuretic 
hormone with ageing, especially in men. This highlights the need to assess the causes 
behind insomnia, as the management o f changes in this anti-diuretic hormone may 
result in less waking and increased sleep continuity, perhaps negating the need for 
hypnotic medication (Vitiello and Prinz, 1988).
Other physical influences on sleep are not somatic, but are due to the effect o f 
conditions upon the body. Urponen et al. (1988) completed a comprehensive survey o f 
174 over 60 year olds in Canada. They found noise and uncomfortable environments 
can cause sleep problems, in addition to caffeine consumption, alcohol and nicotine. 
Noise at night (from dogs, neighbours etc.) has also been cited as a cause o f sleep 
disturbance from surveys in England (Beaman, 1989), the U.S. (Foley et al., 1995), 
Australia (Lack et al., 1988; Henderson et al., 1995), and Italy (Maggi et al., 1998), so is 
a global problem. Caffeine is a stimulant and can delay sleep onset (Smith, 2002), and
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alcohol can aid sleep onset, but can disrupt the latter part o f  the night and cause 
increased awakenings (Moran et al., 1988).
It is clear that health problems may affect sleep, and may increase or result in 
sleep problems. Pain, indigestion and needing to urinate have been shown to be 
influential on sleep. This demonstrates the importance o f  considering the whole sleep 
situation o f the elderly person when assessing how they sleep, and what needs to be 
done to aid poor sleep. Alleviating health problems may in turn alleviate sleep 
problems.
1.3.4.2 Psychological Aspects o f  Aseins Which Influence Sleep
Good ‘psychological adjustment’ to ageing is also important for good sleep. 
Problems occur when the elderly fail to accept that the changes in their sleep patterns 
are normal for their age. It has been suggested that some elderly have unrealistic 
expectations o f  how they should be sleeping (Kronholm and Hyyppa, 1985; Lack et al., 
1988; Liljenberg et al., 1988; Beaman, 1989; Monk et al., 1991; Hohagen et al., 1994; 
Fichten et al., 1995; Ohayon and Caulet, 1996; Englert and Linden, 1998). For example, 
Morin and Gramling (1989) surveyed 72 elderly volunteers in the U.S., on actual sleep 
and also expected sleep need. They found poor sleepers had a larger discrepancy 
between current sleep patterns, and their expected sleep requirements. Not fulfilling 
their expected sleep requirement may lead to anxiety over sleep. Libman et al. (1997), 
in a study o f  240 good and poor sleepers aged between 55 and 89 years, suggested that 
this ‘psychological distress’ may lead to increased arousal and more sleep problems. 
Worries (Urponen et al., 1988; Habte-Gabr, et al., 1991; Gislason et al., 1993; Fichten et 
al., 1995; Mayers et al., 1999), grief (Breckenridge et al., 1986; Foley et al., 1995) and 
tension (Liljenberg et al., 1988; Waters et al., 1993; Fichten et al., 1995; Mallon and 
Hetta, 1997) are mentioned in most surveys as significant causes o f sleeping problems. 
Worrying late at night has been found to affect sleep initiation rather than sleep 
maintenance or waking in the morning (Urponen et al., 1988; Mallon and Hetta, 1997; 
Seppala et al., 1997; Maggi et al., 1998). Studies in Sweden and The Netherlands have 
shown that more females tend to suffer from worries and tension than males 
(Middelkoop et al., 1996; Mallon and Hetta, 1997).
Morin and Gramling (1989) suggest unrealistic expectations may occur because 
o f erroneous beliefs held by a poor sleeper about how their peers sleep; for example, if 
they think their peers can still obtain 8 hours o f uninterrupted sleep. There are serious
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implications here, as help from G.P.s might be sought for supposed abnormalities, and 
unnecessary hypnotics may duly be supplied (Lack et ah, 1988). Fichten et al. (1995) 
surveyed 634 elderly community residents in Canada, to investigate the differences 
between good and poor sleepers in old age. These authors put forward a theory about 
the complaint o f  insomnia, rather than actual insomnia. It has been found that poor 
sleepers will only complain o f  sleeping badly if they suffer psychological distress from 
it, as Stepanski et al. (1989) demonstrated in an objective study o f 50 American 
insomniacs, Stepanski et al. measured sleep parameters, daytime functioning (by a sleep 
latency test), mood and health, and found poor sleepers who did not suffer any 
psychological distress did not complain o f  insomnia. This may explain why those in 
good health might still report sleeping badly. A measure o f  psychological distress is 
therefore suggested to be the most reliable method to distinguish between good and 
poor sleepers, as ‘poor’ sleepers without distress seem to have similar sleep to ‘ good’ 
sleepers (Libman et al., 1997).
‘Vitality’ is another aspect thought to be required for ‘ successful ageing’ . Habte- 
Gabr et al. (1991) in their survey o f  3097 American elderly respondents found that more 
active people have better sleep and less illness. The problem here is thought to be 
retirement, as the elderly become less active and more lethargic (Asplund, 1996). 
Kronholm and Hyyppa (1985), however, surveyed 213 elderly Finns and have 
suggested that sleep is worse just before retirement, due to increased effort to cope at 
work. Perhaps any poor sleep experienced due to retirement or inactivity is better than 
that experienced because o f  work stress. Fichten et al. (1995) found there is no 
difference in the amount o f activity between good and poor elderly sleepers. They 
studied 396 elderly volunteers, and showed that between individuals with and without 
insomnia, there was no difference in the diversity o f  activities engaged in, nor 
differences in how busy they perceived themselves to be. However, differences in sleep 
occurred for insomniacs and non-insomniacs when rating how pleasant they found their 
day. Sleep problems appear to arise when more subjectively adverse activities are done 
during the day than subjectively pleasant ones. Whether individuals are active or not, 
Fichten et al. (1995) suggests better sleep will occur if the perception o f the lifestyle is 
favourable.
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1.3.5 Researching Sleet) in the Elderly
1.3.5.1 Qualitative Measurements o f  Sleep
For simplicity in research and to aid reproducibility o f studies, in the young as 
well as the elderly, mild, transient, intermittent or short term insomnia is usually 
categorised into three types: a difficulty initiating sleep (DIS), a difficulty maintaining 
sleep (DMS) and early morning awakening (EMA) (e.g. Foley et al., 1995; Mallon and 
Hetta, 1997). Difficulty initiating sleep (DIS) includes a long sleep latency, and is 
consistently found to increase with age. This was demonstrated in a study by Weyerer 
and Dilling (1991) o f  1536 Upper Bavarian volunteers, aged from 15 year's old and 
upward, as the prevalence o f  DIS was 8.2% at age 15 to 19 years (similar to the 8.3% 
prevalence noted by Kim et al. (2000) in a Japanese population), compared to 49.4% o f 
those over 70 years old.
Prevalence o f  DIS in England has been found to be 51% by Beaman (1989) in 
those aged 60 to 85 years. In Florida, the prevalence o f  DIS was 52.6% o f those aged 
over 50 years (Karacan et al., 1976), and was 39.9% in the over 50’ s in the Los Angeles 
area (Bixler et al., 1979). The prevalence o f  DIS was only 5.1% when 59 adults aged 
over 70 years were questioned near Canberra, Australia (Henderson et al., 1995). 
However, this questioning was based only on sleep in the last fortnight, and other 
studies were based on longer periods. Also, there were noticeably fewer participants in 
the Australian study than most other studies.
Most researchers found elderly females complain more than elderly males about 
DIS, in questionnaires from European, Eastern and Hispanic cultures (Kronholm and 
Hyyppa, 1985; Domino, 1986; Liljenberg et al., 1988; Dodge et al., 1995; Middelkoop 
et al., 1996; Schmitt et al., 1996; Mallon and Hetta, 1997; Newman et al., 1997; 
Schectman et al., 1997; Maggi et al., 1998; Yamaguchi et al., 1999). For example, 
Gislason et al. (1993) sent questionnaires about social status, smoking habits, coffee 
consumption, health, sleep disturbances and daytime sleepiness to 400 men and 400 
women, o f which they collected 430 correctly completed questionnaires. Respondents 
also completed a chart o f  their sleep, similar to a sleep diary. The authors found 11.4% 
o f Icelandic females habitually suffered DIS, compared to only 7.8% o f Icelandic men. 
This demonstrates the bias towards increased sleep problems in females, which may 
appear in subsequent research.
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Although the incidence o f DIS is thought to increase with age, Morin and 
Gramling (1989) suggest that DIS is more o f  a problem to younger adults, and this was 
supported by a survey o f 1000 adults aged over 20 years old in Brazil (Braz et ah,
(1990). Morin and Gramling (1989) suggest a long sleep latency may be more socially 
acceptable in the older population, as it may be expected to happen. A long sleep 
latency in a young person may lead others to believe there is an underlying problem, 
perhaps anxiety or depression. This is important as it may bias future studies if middle 
aged or younger participants conceal their true sleep patterns to avoid this implication o f 
ill health.
Difficulty maintaining sleep (DMS) is also thought to increase with age, shown 
in various surveys o f  older adults from the U.S. (Karacan et al., 1976; Morin and 
Gramling, 1989), England (Beaman, 1989), Iceland (Gislason et al., 1993), Brazil (Braz 
et al., 1990), and Australia (Henderson et al., 1995). Prevalence o f DMS has been 
reported to be 29.7% o f 9000 participants aged over 65 years and 20.9% o f 1645 
participants aged over 50 years old in the U.S. (Foley et al. (1995) and Karacan et al. 
(1976) respectively), 33.4% o f 430 adults aged 65 to 84 years old in Iceland (Gislason 
et al., 1993), 34.2% o f 876 adults aged 65 to 79 years old in Sweden (Mallon and Hetta 
(1997), and 48.5% o f 102 adults aged between 60 and 85 years old in England (Beaman, 
1989). The rate o f DMS was again lower in Australia at 8.0%, but this is again probably 
due to the relatively low number surveyed (n=59) (Henderson et al., 1995). The 
prevalence o f  DMS in young adults has been found to be 15.0%, but this study was 
completed in Japan, and so may not be comparable (Kim et al., 2000).
Newman et al. (1997) completed a comprehensive study primarily to research 
cardiovascular health in ageing adults. They studied 5201 adults aged over 65 years old 
by questionnaires oil cardiopulmonary symptoms and diseases, depression, social 
support, activities o f daily living, physical activity, cognitive function, current 
medications, and also assessed sleep disturbances and ECG. The authors found 
approximately 67.2% o f the participants suffered disturbed sleep in the night, and 
proposed that increased DMS in older adults is only due to the association between 
DMS and illness, as older adults tend to have more illnesses. Indeed, many researchers 
have found that sleep problems are closely associated with health problems, in countries 
like the U.S. (Foley et al., 1995; Schechtman et al., 1997), England (Morgan et al., 
1988b), and Iceland (Gislason et al., 1993). However, Rodin et al. (1988), Kennedy et 
al. (1989) and Seppala et al. (1997) emphasise the role o f the psychological effects o f 
poor health rather than the physical illness itself, in that depressed mood due to ill health
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may be more influential in poor sleep. In a Swedish study, Asplund (1996) assessed 
questionnaires from 6262 pensioners. Primarily a survey o f  daytime sleepiness and 
napping behaviour, the questionnaire included questions about daytime sleep and 
sleepiness, nocturnal sleep, health, somatic diseases and medication. Asplund was able 
to positively correlate daytime sleepiness and cardiac diseases, diabetes, musculo­
skeletal diseases, urological symptoms, and diseases with sensory and neurological 
impairments. Gislason et al. (1993), also surveying a Swedish population, foimd DMS 
was significantly more common amongst volunteers with obstructive pulmonary 
diseases and systemic hypertension, and complaints o f DIS were associated with 
cardiovascular diseases. It is not clear as to whether males or females suffer more with 
DMS. Middelkoop et al. (1996) assessed 1692 sleep questionnaires completed by over- 
50-year-olds in The Netherlands. These authors suggest DMS increases with age more 
in males than females, primarily because o f waking due to habitual snoring, as males 
tend to snore more than females. This is supported by the Icelandic study o f Gislason et 
al. (1993) who questioned 430 adults over 65 years old, and found habitual DMS was 
reported by 37.1% o f men but only 18.5% o f the women. However, other studies 
suggest more females overall than males suffer from DMS. Beaman (1989), in an 
English study o f 102 retired elderly over the age o f 60 years, found more females 
suffered DMS than males. Also, Domino (1986) questioned 362 over-50-year-old 
Hispanics in Mexico, Spain and Venezuela about their sleep, and found similar results 
to Beaman (1989). These differences may be due to cultural reasons or the number o f 
participants assessed, as other differences between these studies are not evident.
An obvious symptom o f DMS is nocturnal awakenings. These are also thought 
to increase in number with age, found in surveys carried out in Italy (Parrino et al., 
1999a), the U.S. (Reynolds et al., 1991; Bliwise, 1993), Canada (Fichten et al. 1995), 
and Australia (Lack et al., 1988). Mallon and Hetta (1997), in their Swedish survey o f 
876 adults aged 65 to 79 years old, found the average number o f  awakenings per night 
was 1.9, whilst the Dutch survey showed the average was 2.0 awakenings per night 
(Middelkoop et al., 1996). This compares to an average o f 1.0 awakenings per night 
reported by 2202 young adults aged between 20 and 45 years old from Sweden, Iceland 
and Belgium (Janson et al., 1995). This shows the difference in remembered 
awakenings does not appear to be extensively different between old and young adults.
Lack et al. (1988) conducted a telephone survey o f 216 respondents o f all ages 
in the Adelaide area o f  Australia, and have suggested that the increase in nocturnal 
awakenings with age is due to increases in awakenings by males and not females.
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Indeed, this is supported by the Swedish study by Gislason et al. (1993), and the U.S. 
study by (Webb, 1982b), and is probably again due to more incidences o f snoring in 
males than females (Middelkoop et al., 1996).
Another significant aspect o f  insomnia is the phenomena o f early morning 
awakenings (EMA), meaning waking up too early in the morning and not being able to 
return to sleep. Kronholm and Hyyppa (1985), in a survey o f  213 retired Finns (aged 65 
years and above), found no age related increase in EMA, but an increase was noted in a 
survey by Beaman (1989) on 102 English elderly volunteers (mean age 75 years). 
Beaman’ s work was supported by other surveys in Australia (Lack et al., 1988; 
Henderson et al., 1995), Iceland (Gislason et al., 1993; Janson et al., 1994), and Canada 
(Fichten et al., 1995). Prevalence o f habitual EMA has been found to be 14.2% o f the 
over 65 year olds in the Swedish study o f  430 respondents by Gislason et al. (1993). In 
the U.S, prevalence o f  EMA in the over 65 year olds was found to be 32.9% in the 
Newman et al. (1997) cardiovascular' survey. Other prevalences were found to be 28.9% 
in a survey o f over 65 year olds in North East Italy (Maggi et al., 1998), and 25.6% o f 
over 70 year olds in Berlin (Englert and Linden, 1998). Compared to only 8.0% o f 
younger adults (Kim et al., 2000), it can be seen there is a higher number o f sufferers in 
old age. Although Mallon and Hetta (1997), in a Swedish survey, have suggested this 
increase is more dramatic for older males, other surveys in England, the U.S. and Italy 
suggest the problem o f EMA affects more older females (Beaman, 1989; Newman et al., 
1997; Maggi et al., 1998). The reason for this is unclear, but may be related to the 
increased amount o f  worrying experienced by females compared to males, as previously 
discussed. Table 1.1 shows a summary o f  these findings.
It is demonstrated here that differences between males and females, cultures, and 
ages, for example, can be detected not only within the number o f complaints o f 
insomnia, but also within the number o f  complaints o f difference types o f insomnia. For 
example, the research described previously suggests the prevalence o f  DIS, DMS and 
EMA occurs more with increasing age, but that males suffer more DMS whilst females 
tend to suffer more DIS and EMA. Dividing insomnia into these differing types o f DIS, 
DMS and EMA appear to show a more detailed picture o f  the sleep experienced under 
each condition.
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1.3.5.2 Quantitative Measurements o f Sleep
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Sleep in the elderly may bemeasured in the same way as sleep in the younger 
adult. Several variables can be considered when assessing the pattern o f sleep. These 
include time spent in bed (TIB), total sleep time (TST), and sleep efficiency (SE). A 
summary o f  some findings can be found in table 1.1. These are often measured using 
sleep electroencephalography (EEG), as previously described, and EEG can provide 
more accurate measurements o f sleep onset and wake times, for example. It is a lengthy 
and expensive process, but can provide objective measures o f  the night’ s sleep.
1.3.5.2.1 Time in Bed (TIB)
Time in bed (TIB) generally increases with age, as was suggested by surveys in 
England (Morgan et al., 1988b), Sweden (Middellcoop et al., 1996), Finland (Seppala et 
al., 1997; Seppala, 1993), and the U.S. (Habte-Gabr et al., 1991). In a Swedish study o f 
876 elderly volunteers, Mallon and Hetta (1997) found that elderly females tend to stay 
in bed for longer than males (males spend on average 6.7 hours in bed and females 
spend 7.0 hours), which is agreed by other surveys in England and Sweden (Beaman, 
1989; Middelkoop et al., 1996). Seppala et al. (1997) suggest this may be due to an 
attempt to compensate for degradation in sleep quality due to ageing (Brabbins et al., 
1993), because staying in bed may provide more opportunity for sleep. Alternatively, it 
may simply be a method o f  staying warm. Janson et al. (1995) and many others (Hayter 
et al., 1983; Morgan et al., 1988b; Prinz et al., 1990; Monk et al., 1991; Weyerer and 
Dilling, 1991; Bliwise, 1993; Fichten et al., 1995) agree that total nocturnal sleep time 
(TST) decreases with age, and Habte-Gabr et al. (1991) found this happens to both 
males and females. There is some controversy over the relationship between gender and 
the total sleep time. In an American study by Webb (1982c), the EEG o f 80 healthy 
males and females over 50 year's o f age was measured for three nights. He found older 
females tended to sleep for less time than older males. However, Liljenberg et al.
(1988), in a survey o f  2439 Swedish volunteers aged 30 to 65 years, found females 
reported sleeping for longer than males. This is perhaps demonstrating the difference 
between actual sleep and estimated sleep, described previously. Most researchers, using 
subjective methods, have suggested nocturnal sleep time is even between the sexes 
(Habte-Gabr et al., 1991; Gislason et al., 1993; Beh, 1994; Seppala et al., 1997).
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1.3.5.2.2 Sleep Efficiency (SE)
The time spent in bed (TIB) and total sleep time (TST) can be divided to give a 
measure o f sleep efficiency (SE), meaning the amount o f  time spent in bed that is used 
for sleeping. Hoch et al. (1994) completed an EEG study in the U.S. o f  50 healthy adults 
aged 60 years old and above. They found an average sleep efficiency o f  83.3% in the 
older adults aged between 60 and 75 years, and a sleep efficiency o f 78.2% in those 
over 75 years old, showing sleep efficiency may also decline with age. Riedel and 
Lichstein (1998) also measured the EEG o f older adults, but with primary insomnia. 
This U.S. study was based on 47 adults over the age o f  59 years, and their sleep was 
recorded for two nights. These authors found a sleep efficiency o f  79.5% for night 2 
(the first night was discarded due to the ‘ first night effect’ , as previously described). 
This is similar to the sleep efficiency found for healthy seniors in the study by Hoch et 
al. (1994), indicating a lack o f  difference between the sleep efficiency o f healthy and 
insomniac older adults. Subjective assessment o f  sleep efficiency has placed it at 75.0% 
in 240 participants aged 60 years and over (Libman et al., 1997), and at 72.0% in 634 
participants aged 55 years and over (Fichten et al., 1995). Compared to 88%, which is 
the cut point between good and poor young sleepers used by Coates et al. (1982b), it can 
be seen that sleep efficiency in the elderly may be poor. A study by Hoch et al. (1987) 
o f  20 healthy elderly volunteers, sleeping in a laboratory bedroom for three consecutive 
nights, found that there was no significant difference in objective sleep efficiency 
between the sexes (84.7% average for males and 84.6% for females).
1.3.5.2.3 Total Sleep Time (TST), and TST in a 24 Hour Period
Total sleep time (TST) overnight in the elderly has been foimd to be 5.7 hours in 
the U.S. (Fichten et al., 1995), 6.8 hours in Sweden (Mallon and Hetta, 1997), 7.7 hours 
in The Netherlands (Middelkoop et al., 1996) and 7.0 hours in England (Morgan et al., 
1988b) in subjective surveys. In objective studies (e.g. EEG), nocturnal TST has been 
found to be 6.5 hours and 6.0 hours in the U.S. (Riedel and Lichstein (1998) and Hoch 
et al. (1994) respectively), and 7.1 hours in Finland (Kronholm and Hyyppa, 1985). 
Sleep time measured over a 24 hour period reveals different findings. Studies have 
shown that total sleep time during a 24 hour period is approximately the same duration 
for older and younger adults (Blois et al., 1983; Gislason et al., 1993). This duration 
(which includes naps) has been found to be 7.6 hours and 7.8 hours in Finland
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(Kronholm and Hyyppa (1985) and Seppala (1993) respectively), and 6.6 hours in the 
U.S. (Morin and Gramling, 1989).
Although sleep efficiency and the amount o f TST per night declines with age, 
the amount o f  TST in the 24 horn* period does not. Indeed, Dement et al. (1982) in their 
‘white paper’ on sleep and ageing, and others (including Moran et al., 1988; Morin and 
Gramling, 1989; and Seppala, 1993), suggest there is no change in the daily sleep 
requirement, just that the sleep o f  older adults becomes more fragmented, so is more 
dispersed around the 24 hour* period. One explanation for sleep fragmentation in the 
elderly is that there is reduction in the effectiveness o f control mechanisms, including 
the sleep mechanism (Shock, 1977). Moran et al. (1988) and Morin and Gramling 
(1989) in reviews have suggested that natural circadian rhythms (for example, body 
temperature, secretion o f melatonin), which regulate sleep, become ‘out o f phase’ , 
leading to irregular and polyphasic sleep patterns. Stampi (1992) has suggested our 
‘ normal’ monophasic adult sleep/wake cycles apply only dining social or occupational 
constraints. When these are removed (in a situation such as retirement) it is natural that 
we would revert back to polyphasic patterns as seen in infants and other mammals.
1.3.5.2.4 Napping
Beh (1994) suggests that napping reduces the amount o f  complaints o f  poor 
sleep, because the naps help to alleviate daytime sleepiness and the associated decline in 
cognitive function. As previously mentioned, it is these daytime declines that lead to the 
reports o f poor sleep (Chambers and Keller, 1993). In turn, napping also reduces the 
consumption o f hypnotics because it reduces the complaints o f  poor sleep. Also, when 
naps are habitual, nocturnal sleeplessness and its alleviation become less important to 
the sufferer (Seppala, 1993). As age advances, sleep fragmentation seen in the reduced 
sleep efficiency and increased wake time seems to become more pronounced, so the 
occurrence o f napping increases. This was found in surveys o f England (Beaman,
1989), Finland (Kronholm and Hyyppa, 1985), and the U.S. (Morin and Gramling, 
1989; Hoch et al., 1997). Good and poor sleepers seem to nap equally often (Morin and 
Gramling, 1989; Fichten et al., 1995), indicating napping does not interfere with elderly 
sleep as it does in younger adults. Feinberg et al. (1985) found younger adults who nap 
during the day can increase their sleeplessness during the following night. Beaman
(1989) found that 59% o f his 102 English elderly volunteers regularly took a nap. Beh 
(1994) studied 500 Australian volunteers, aged 65 years o f age and over, and found
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19.0% napped once a day, for a duration o f approximately 15-45 minutes. Other surveys 
have found the prevalence o f  napping in the elderly to be 42.1% and 56% in Finland 
(Kronholm and Hyyppa (1985) and Seppala et al. (1997) respectively), 22.1% habitually 
nap in Sweden (Mallon and Hetta, 1997), and 24.6% o f the elderly (65 year's and over) 
nap in the U.S. (Foley et al., 1995). It seems that elderly males tend to nap more than 
elderly females (Gislason et al., 1993; Seppala, 1993; Asplimd, 1996), as 29.4% o f 
males were found to habitually nap compared to 14.7% o f females in Sweden (Mallon 
and Hetta, 1997), and 31.4% o f males compared to 20.1% o f females in The 
Netherlands (Middelkoop et al., 1996). Asplimd (1996), in a survey o f the daytime 
sleepiness and napping o f  6262 pensioners in Sweden, suggested this may be due in part 
to snoring and sleep apnoea. This is a sleep related breathing disorder that is more 
prevalent in older adults, especially males (Asplund, 1996; Newman et al, 1997). Sleep 
apnoea might go some way to explaining why males tend to nap more. Sleep apnoea 
tends to cause more DMS by increasing nocturnal awakenings, suggesting napping may 
be a result o f  poor sleep where illness is involved.
1.3.5.2.5 Daytime Sleepiness
Sleep apnoea and polyphasic sleep patterns can lead to increased daytime 
sleepiness (DS). Braz et al. (1990) surveyed 1000 residents o f  Sao Paulo in Brazil, and 
found the prevalence o f DS in the over 50 year olds was 22.0%. Other surveys have 
foimd a prevalence o f  15.3% who often have DS in Australia (Lack et al., 1988), 35.5% 
in Sweden (Asplund, 1996), and 16.3% in Iceland (Gislason et al., 1993). This 
prevalence increases with age, as Middelkoop et al. (1993) in The Netherlands and 
Newman et al. (1997) in the U.S. showed 25.2% and 25.0% o f 60-69 year olds 
respectively suffer DS, but 43.6% and 52.0% o f those over 80 years old respectively 
suffer. In disagreement, Braz et al. (1990) in Brazil and Asplund (1996) in Sweden 
found that the elderly do not have more DS than younger adults. Asplimd (1996) 
concluded excessive DS in the elderly may only be due to pain or illness experienced in 
the night (as previously described), which disturbs their sleep. Indeed, Seppala (1993), 
in a study o f  1800 Films aged over 65 years old, reversed her statistics to show around 
80% o f the elderly sleep satisfactorily (despite long sleep latencies and nocturnal 
awakenings), so the complaint o f sleep problems is not intrinsic to ageing.
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1.3.6 O b jective Changes in Sleep Associated w ith  A ge in g
Chapter 1
As previously discussed, objective measures o f sleep can show decrements with 
increasing age, and fragmentation o f sleep can occur. There are many cognitive and 
neurological changes associated with old age. There is extensive research showing the 
elderly never score more than younger groups on almost all psychometric tests. For 
example, an 89 year old person is expected to only recall 50% o f  what a 20 year old 
person does on the Wechsler delayed paragraph recall subtest (Wechsler, 1997).
There are many EEG sleep stages which have been found to change with 
increasing age. Webb (1982c) completed a follow-up study o f the EEG sleep o f  5 
participants from Florida aged in their mid-60s, and found that the amount o f  REM 
sleep decreases with age. This was also noted in an EEG study o f  22 healthy 
participants aged over 80 years old, compared to 29 young participants (Reynolds et al.,
1991). The amount o f  REM sleep in the night is reported to be 20.1% by Monk et al. 
(1991), who studied the EEG o f 34 elderly Americans, and 21.8% in those over 60 years 
old (Hoch et al., 1994). This is compared to an average o f 25% o f  the night in younger 
adults (Keenan, 1999), showing possible decreases in the elderly. The issue o f  SWS is 
more complex. EEG studies by Dement et al. (1982), Reynolds et al. (1985a) and Monk 
et al. (1991) in the U.S. have shown SWS also decreases with age. However, Reynolds 
et al. (1983) found SWS only decreases in ageing males. This reduction has been 
suggested to be due to reduced brain activity during waking, possibly due to retirement 
or quieter social lives (Feinberg et al., 1983). Percentages o f  SWS in the elderly have 
been reported to be 4.3% by Hoch et al. (1994) for those over 60 years old, 5.0% in 
those over 75 years old, (Hoch et al., 1997), and 3.7% in those over 80 years old (Monk 
et al., 1991). This compares to approximately 14% o f SWS per night in younger adults 
(Keenan, 1999), again showing a decrease. Stages 1 and 2 are often referred to as light 
sleep, and the overall percentage o f light sleep has been found to be 66.3% in an EEG 
study o f 20 elderly healthy participants (Hoch et al., 1987), 73.2% in those aged over 60 
years (Hoch et al., 1994), and 60.5% in the elderly aged approximately 65 years old 
(Webb, 1982c). This compares to approximately 55% in younger adults (Keenan, 1999), 
and other researchers in EEG studies have also noted no change in light sleep with 
increasing age (Hayashi and Endo, 1982; Morgan, 1987). However, gender differences 
in light sleep have been proposed. For example, a study by Zepelin et al. (1984) on 
awakening auditory thresholds showed females tend to be less susceptible to awakening,
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and therefore may have less light sleep than males. A  summary o f some EEG findings 
can be found in table 1.1.
1.4 Summary
It is clear that the sleep o f  the elderly does change, but this does not necessarily 
mean a decrease in sleep requirement. There are few associations between objective and 
subjective measures o f  sleep (Hoch et al., 1994), and those with objectively poor sleep 
may not complain o f  insomnia (Fichten et al., 1995). Changes in the sleep patterns o f 
the elderly can occur due to change in circumstance (e.g. retirement), fragmentation and 
phase changes, and changes in sleep architecture. Sleep architecture may be altered by 
natural ageing processes, or by psychiatric illnesses such as depression, as depression 
has been foimd to increase REM sleep (Berger et al., 1982). Increases in the frequency 
and severity o f sleep complaints may be due to levels o f  health and pain, and also 
acceptance o f changing sleep patterns, rather than increases in insomnia itself.
1.5 Research in this Thesis
When non-organic sleep problems are reported by the elderly (which are not due 
to illness or pain), it is difficult to know how to approach these problems. There are 
several methods available to the elderly, including hypnotics, sleep hygiene and 
restrictions, herbal and over-the-counter preparations, alcohol and hot drinks. Little is 
known about the sleep behaviours o f  the elderly, and which method is best for achieving 
good sleep. The following studies will investigate the use o f  some prescription and self- 
help methods o f improving sleep, and will evaluate them for suitability and efficacy in 
the elderly.
Research into the elderly is rife with problems. As already discussed, sleep in 
the elderly is disturbed by physical problems that are not commonly seen in a younger 
population, such as nocturia (needing to use the toilet frequently in the night), pain or 
respiratory problems (Middelkoop et al. 1996; Schechtman et al. 1997). In turn, these 
disturbances may mask or distort effects seen in trials o f  sleep medication. Therefore, it 
may be more useful to use a younger sample in these trials. Using younger volunteers 
may remove these confounds, to reveal the effects o f the medication, and may act as a 
‘ standardisation’ , because there are great interindividual differences in the physical 
problems o f the elderly. It may be argued that the solution to these interindividual
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differences is not to include younger volunteers, but instead to include healthy, carefully 
screened older adults. However, this may also bring drawbacks. Research has shown 
that 23.1% o f the elderly in Australia cite pain as a cause o f  their sleep problems 
(Henderson et al., 1995) and 71.0% in England cite nocturia (Beaman, 1989). This 
indicates a large proportion o f the elderly have physical problems, therefore ‘healthy’ 
older adults may not be representative o f  most elderly insomniacs either, also rendering 
the results o f  such studies incomparable to effects in the ‘normal’ elderly population.
In a similar manner, the completion o f psychometric testing, which is planned 
for this thesis, may be hampered if elderly volunteers are used. They may suffer a loss 
o f  fine manual dexterity or other disabilities which may interfere with the completion of 
the tests, thus showing deficits associated with ageing, and not the medication. Again 
the ‘healthy’ elderly may be used, but may not be representative o f  the general elderly.
The reasons for using young volunteers over the ‘healthy’ elderly are 
demonstrated in pharmacokinetic studies (meaning studies o f  the pharmacological 
effects o f medication), where measures such as elimination half life are altered by the 
slower metabolism seen in the elderly, including the ‘healthy’ elderly (Ford et al.,
1987). These measures can be subject to great interindividual variation in the elderly, so 
using young volunteers as an initial model for older adults may again help to 
‘ standardise’ the sample being tested. Future research would include the replication o f 
such studies using an elderly sample, as it may not be accurate to extrapolate effects 
from young to older adults. Also, some authors advocate the use o f  special rules to stage 
elderly sleep, as mentioned earlier. The use o f  young volunteers would remove the need 
for ‘ special’ staging, which would not be comparable to studies not using special 
staging rules. The normal staging rules for young adults will therefore be used in this 
thesis to compare chapters.
An important reason for using young volunteers as opposed to healthy elderly 
volunteers is the measure o f side effects, known as adverse events (AEs). The elderly 
are more sensitive to AEs (Hemmeter et al., 2000), so using younger volunteers as a 
model will remove the need for using reduced doses to minimise these effects. Most 
normal older adults tend to take concomitant medication (Morgan et al, 1988a), so the 
use o f younger adults as volunteers removes any safety issues regarding drug 
interactions. Additionally, there are methodological reasons for using younger 
volunteers. Beaman et al. (1986) has shown that napping is highly prevalent in the 
elderly. Unless specifically designed and standardised, clinical trials do not allow 
napping during the daytime. This may disrupt the elderly volunteers’ usual sleeping
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patterns, as sleep fragmentation is prevalent in older adults (Newman et al., 1997). 
Therefore, the inclusion o f  younger volunteers will help ensure a normal sleep/wake 
pattern is studied. However, although preferable to non-standardised sleep/wake 
patterns, it is likely that this also is not representative o f  the general elderly population.
It is therefore difficult to study the elderly, and it may be methodologically 
easier to make approximations via the use o f  younger volunteers. Indeed, Kryger et al.
(1991) and Holm and Goa (2000) have suggested that differences in sleep patterns are 
large between ‘normal’ sleepers and insomniacs or the elderly, but not between 
insomniacs and the elderly. Therefore, younger insomniacs and the elderly may produce 
similar findings when studied. Libman et al. (1997) suggest that the difference in effects 
occur between good and poor sleepers, rather than the elderly and the yotmg, per se. In 
addition, Mouret et al. (1990) tested 10 elderly volunteers for 15 days, and found 
zopiclone, a non-benzodiazepine hypnotic, had similar effects in the elderly to the 
young.
To conclude, this thesis will evaluate some medications taken by the elderly to 
aid their sleep. Where literature has indicated that AEs following this medication may 
be detrimental to the elderly (for example, when testing prescription medication rather 
than beverages), younger volunteers with mild sleep disturbance will be used to 
approximate the findings that may occur when testing the elderly. It is hoped this will 
eliminate the aspects o f  ageing which may confound the effects o f  medication on sleep, 
such as physical problems and napping, and will further elucidate the actions o f these 
medications on sleep.
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Chapter 2
2.1 Abstract
This chapter provides an outline o f  the methods used in this thesis and why. This 
includes electroencephalography (EEG), to record brain activity, which is sensitive to 
changes in sleep architecture. Also, this includes psychometric tests o f information 
processing capacity, psychomotor performance, and memory. These are used to assess 
both the effects o f  treatments on cognitive and psychomotor performance, and to assess 
any residual decrements after a night’ s sleep. Subjective measures o f  sleep and mood 
are also included, to assess how the participants feel about their sleep and morning 
performance.
2.2 Methods and Measures
2.2.1 Electroencephalography (EEG)
As described in chapter 1, many sleep variables have been defined using the 
staging rules o f  Rechtshaffen and Kales (1968). Sleep electrophysiologists typically 
examine variables such as: time in bed (TIB), total sleep time (TST), sleep efficiency 
(SE), sleep latency (SL), number o f  awakenings, percentage stage 1 and 2 sleep, stage 3 
and 4 sleep (or slow wave sleep (SWS)), and percentage o f and latency to REM sleep. 
Caution is advised as some o f these variables can be interpreted in different ways. A 
total sleep time o f  five hours, for example, may feel adequate for some, but may feel 
inadequate for others. Some may report satisfactoiy sleep, but may actually have had 
many short awakenings without remembering them (Rotenberg, 1993). However, sleep 
efficiency, which is a percentage o f  the time in bed spent asleep (time asleep divided by 
time in bed), has been shown to be an accurate indicator o f  good sleep quality (Hoch et 
al., 1987).
When recording EEG sleep, it is usual to include an ‘adaptation night’ before the 
start o f a study (Oswald, 1980), and to discard these recordings because o f the ‘ first 
night effect’ (Agnew and Webb, 1968). This is when the unfamiliar surroundings and 
equipment in the sleep laboratory bedrooms tends to lead to increased periods o f stage 2 
sleep, increased REM latency, reduced sleep efficiency and a reduction in the
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percentage o f  REM sleep (Agnew and Webb, 1968). However, Lorenzo and Barbanoj 
(2002) found only changes in REM dining the first night effect.
In this thesis when EEG was used, eight channels o f  data were recorded 
throughout the night (4 EEG channels C4-A1, C3-A2, 02-A1, 01-A2; two electro- 
occulograph (EOG) and two submental electromyograph (EMG) channels, using 
Ag/AgCl electrodes, on to a Nicolet Ultrasom digital EEG machine. The sleep variables 
that were assessed using the EEG recordings included those mentioned above. An 
experienced sleep stager assessed the stages o f each epoch o f data according to the 
standard criteria o f Rechtschaffen and Kales (1968), including the data o f older adults. 
This ensured comparability between studies. All sleep records were staged blind, 
meaning the stager had no knowledge o f  the condition under which the record was 
made. This helped ensure there was no bias in the staging, as sleep staging has 
subjective aspects open to the influence o f  the stager.
2.2.2 Behavioural Assessment
EEG is not the only method o f assessing sleep, and should be used in 
conjunction with other measures; as Hartmann (1973) suggests: “ Sleep is not an EEG 
tracing but a behavioural state” (p.21). Indeed, Karacan et al. (1976) said that the 
subjective view should be the most important aspect o f  sleep, as it is this that most 
affects how we feel about our sleep, and how we feel the day after a night’s sleep. When 
considering drug treatments in sleep, it is the patient’ s own perception o f therapeutic 
effect which is most important. Roehrs et al. (1989) suggests that behaviour following 
the night’ s sleep is also important when assessing sleep, because daytime performance 
can be indicative o f  sleep obtained the night before. Measures o f daytime performance 
were used in this thesis to assess the extent o f the effects o f  drugs on objective 
responses, such as sensory threshold, memory, and reaction time. Subjective measures, 
such as sleep questionnaires and mood scales, were also used to assess the opinion and 
experience o f  each participant. The psychometric test batteiy, outlined below, included 
both objective and subjective measures o f  cognitive and psychomotor effect.
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2.2.3.1 Critical Flicker Fusion (CFF)
The CFF task assessed the integrative capacity o f  the central nervous system 
(CNS), and more specifically, the ability to discriminate discrete 'bits' o f  sensory 
information (ITindmarch, 1975). Participants discriminated flicker from fusion, and vice 
versa, in four light emitting diodes arranged in a one centimetre square held in foveal 
fixation at a distance o f one metre. Individual thresholds were determined by the 
psychophysical method o f  limits on three ascending and three descending scales 
(Woodworth and Schlosberg, 1958), the mean o f which gave the threshold frequency in 
Hertz (Hz). CFF has been shown to be sensitive to a variety o f  psychoactive compounds 
(Hindmarch, 1982), such as milnacipran (Hindmarch et al., 2000), promethazine 
(Hindmarch et al., 1999), triazolam (Maddock et al., 1993) and antidepressants 
(Holmberg, 1981). It is also sensitive to the effects o f  ageing (Curran, 1990; 
Lachenmayr et al., 1994). Hindmarch (1980) suggests a decrease in the CFF threshold is 
indicative o f a reduction in the overall integrative activity o f the CNS. However, it has 
been noted that CFF may be a measure o f visual discrimination (Wilson, 1999).
2.2.3.2 Choice Reaction Time (CRT)
The CRT task (Hindmarch, 1975; Hindmarch, 1980) was used as an indicator o f 
sensorimotor performance, assessing the ability to attend to and respond to a critical 
stimulus (Sherwood and Kerr, 1980). Participants placed the index finger o f their 
preferred hand on a central stalling button and extinguished one o f six equidistant red 
lights, illuminated at random, by touching the response button immediately in front o f 
the light as quickly as possible. Using only one specified finger does reduce reaction 
time, however it is thought necessary to standardise the test (Andreas, 1972). The mean 
o f 20 consecutive presentations was recorded as a response measure o f three 
components o f  reaction time: recognition, motor and total reaction time. The CRT 
shows advantage over simple reaction time tests, as it can measure components o f 
reaction time. Recognition reaction time (RRT) is the time it takes for the participant to 
notice the light, being the time between stimulus onset and the subject lifting their 
finger from the start button. Motor reaction time (MRT) indexes the movement 
component o f this task, and is the time between the participant lifting their finger from
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the start button and touching the response button. Total reaction time (TRT) is the sum 
o f RRT and MRT. RRT and MRT are subject to ‘event uncertainty’ , which lengthens 
reaction time (Andreas, 1972), but if this is the same for each participant at each time 
point, it will not have an influencing effect on the results. CRT has been found to be 
sensitive to drugs such as zopiclone and triazolam (Warot et al., 1987), amitriptyline 
(Hindmarch et al. 1983), multivitamins (Benton et al. 1995), and to the effects o f ageing 
(Swift et al. 1985; Frewer and Hindmarch, 1988). Wilson et al. (1999) points out this 
test can be easily influenced by participant motivation, but this is the case for most 
psychometric tests.
2.2.3.3 Sternberg Memory Scanning Task (STM)
High speed scanning and retrieval from short-term memory were assessed using 
a technique based on a reaction time method (Sternberg, 1966). Participants memorised 
a random series o f one, three or five digits (the stimulus set) that were presented 
sequentially at a rate o f  1.2 seconds per digit. This was followed by a series o f  twelve 
single probe digits. Participants indicated whether each probe digit was contained within 
the original stimulus set or not, by pressing one o f two mouse buttons as quickly and as 
accurately as possible. During each test, two trials for each stimulus set size were 
carried out, and response time and accuracy were recorded automatically by the 
computer for each probe digit.
Although the participant can influence this test via ‘ chunking’ numbers, for 
example into odd and even numbers, or by grouping, for example when remembering 
telephone numbers (Bower and Springston, 1970), the rapid rate o f  presentation should 
minimise these techniques. The environment o f the participants during this test is 
important, as Wickelgren (1965) found acoustic information can interfere with visual 
information. To compare this test over separate time points, sound must be minimised in 
both conditions. All psychometric tests were completed in silence and away from the 
distractions o f other participants. Performance o f this task is sensitive to psychoactive 
compounds such as zolpidem and zopiclone (Isawa et al., 2000), including herbal 
supplements (Rigney et al. 1999) and to the effects o f ageing (Anders et al., 1972; 
Strayer et al., 1987).
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2.2.3.4 Dieit Symbol Substitution Task (DSST)
Chapter 2
The DSST is a subscale o f  the Wechsler Adult Intelligence Scale (WAIS; 
Wechsler, 1981). This scale measures verbal intelligence, via information handling, 
tests o f verbal similarities, vocabulary, arithmetic, comprehension and digit span. 
Performance intelligence is tested by picture completion, block design, picture 
arrangement, object assembly, and the digit symbol substitution test (DSST).
In the DSST, participants were presented with rows o f  blank squares paired with 
randomly assigned numbers. They were required to substitute each digit with a different 
nonsense symbol, the key to which is printed at the top o f  the sheet. This test has been 
described both as a measure o f  simple information processing and o f psychomotor 
performance (Parrott, 1991). The DSST is thought to exemplify the definition o f how to 
test ‘ fluid ability’ (Catterell, 1971), which is the reasoning ability o f  the brain (e.g. to 
solve problems without prior training (Woliver and Saeks, 1986)). The DSST is a test o f 
speed, as participants must substitute as many symbols as they can in 90 seconds. It has 
the highest cognitive load o f the performance intelligence tests, and has been found to 
be reliable and valid (Kline, 1993).
A  similar test is the Stanford-Binet test (Terman and Merrill, 1960). However, 
this is more verbally orientated, and lacks the emphasis required to be a test o f 
performance o f  fluid ability. This test gives more o f  a global score o f intelligence, 
whereas the WAIS is separated out into verbal and performance aspects, meaning the 
DSST can be used as a useful measure o f  cognitive processing and visuomotor 
performance, and not intelligence. The DSST has been found to be sensitive to 
medications such as zaleplon and triazolam (Rush et al., 1999b), befloxatone (a 
reversible selective MAOI) (Warot et al., 1996) and is also negatively influenced by the 
effects o f ageing (Bryan and Luszcz, 1996).
2.2.3.5 Immediate and Delaved Recall o f  Word Lists
In this test, participants were given two minutes to learn a list o f twenty words. 
This learning period was immediately followed by a two minute free recall period in 
which they wrote down as many o f  the words as they could remember. A  delayed free 
recall period took place thirty minutes later. Word lists across different time points were 
matched for concreteness, imagery, meaningfulness, frequency and number o f syllables 
(Paivio et al., 1968). Immediate recall is thought to involve short-term memory, whilst
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delayed recall performance is assumed to be a measure o f long-term memory (Baddeley 
and Hitch, 1974; Baddeley, 1986). This test is the simplest method to test recall, and is 
easy to apply.
However, it is suggested that participants can use different techniques for 
remembering, such as the narrative, which can influence recall. However, if  the same 
technique is used at every test point, this inter-subject variable will not influence the 
results. The forgetting involved in the delayed recall is not simply due to the time 
elapsed. Interference theory suggests the activities done during the delay can influence 
the amount recalled (Andreas, 1972). Retroactive inhibition occurs when other tasks are 
performed before delayed recall, and proactive inhibition can occur if  the participants 
have previously learnt other word lists (Underwood, 1957). It is therefore necessaiy to 
standardise participant behaviour during the delay before second recall, and to ensure 
identical tests are administered to each participant at the same time point. Participants in 
this test read quietly until the delayed recall was due to commence. Immediate and 
delayed recall was found to be a useful measure o f memory when assessing the effects 
o f moclobemide and lorazepam (Wesnes et al., 1997), and Borbely et al. (1988) 
successfully used this test to show detrimental effects o f  midazolam.
2.2.4 Subjective Measures o f  Sleep and Mood
2.2.4.1 Leeds Sleep Evaluation Questionnaire (LSEQ)
The LSEQ (Hindmarch, 1975) is a visual analogue scale consisting o f a series o f 
questions regarding getting to sleep, quality o f sleep, and how the participant feels on 
awakening. The scale is a 100 millimetre line with opposite answers to a question at 
either end. The participant must then mark the answer to the question on that line, with 
the mark nearest to the response they wish to give. The nearer the end o f the line, the 
more intense their answer, with the middle o f the line representing a lack o f  opinion or 
no change in response. For example, the question ‘How would you compare getting to 
sleep last night with getting to sleep normally?’ requires the responses o f either ‘ easier 
than usual’ or ‘harder than usual’ . Marking the line nearer ‘ easier than usual’ indicates 
getting to sleep was much easier than usual. Marking the line nearer the middle but on 
the side o f the ‘ easier than usual’ response indicates getting to sleep was only 
marginally easier than usual. This technique therefore elucidates direction and 
magnitude o f responses.
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The LSEQ has been shown to be a reliable assessment o f sleep and early 
morning behaviour (Parrott and Hindmarch, 1980). It is used to show what promotes 
sleep, and what disrupts sleep by measuring morning after effects (Hindmarch and 
Gudgeon, 1980), and is especially useful in assessing psychoactive compounds such as 
temazepam (Hindmarch, 1975) and zolpidem (Fairweather et al., 1992). A factor 
analysis (Parrott and Hindmarch, 1978) has shown the LSEQ to assess four sleep 
factors: the perceived ease o f  getting to sleep (GTS), the quality o f sleep (QOS), 
awakening from sleep (AFS) and the behaviour following waking (BFW). The last two 
factors (AFS and BFW) can be summed to provide an index o f early morning 
‘hangover’ effect.
The LSEQ is preferable to other similar tests because o f  the visual analogue 
style. Visual analogue scales are useful because the continuous line means the 
participant can indicate exactly what s/he feels, without restraints (Andreas, 1972). For 
example, the Pittsburgh Sleep Quality Index (Buysse et al., 1989) allows for severity 
and frequency, but is more o f a checklist than a scale o f  subjective sleep, which is the 
style o f  most sleep questionnaires (Spellman et al., 2000). The Insomnia Symptom 
Questionnaire is also visual analogue, but it is only available on request, as it is not 
published (Speilman et al., 2000). The Pittsburgh Sleep Quality Index also has 24 items, 
whereas the LSEQ only has 10, which makes the LSEQ quicker to administer.
2.2.4.2 Line Analogue Rating Scales (LARS)
The Line Analogue Rating Scale (LARS) is a visual analogue scale, first used in 
1983 by Gudgeon and Hindmarch. A factor analysis (HPRU Medical Research Centre, 
University o f  Surrey, unpublished data) has shown it to assess four factors: Anxiety 
(anxious, relaxed), Depression (happy, sad, depressed), Sedation (tired, drowsy, 
energy), and Uncoordination (dizzy, clumsy). Participants were asked to indicate on a 
100 millimetre line, in the same manner as the LSEQ, whether they felt more or less 
happy, sad, etc. compared to how they felt before the study started, or the medication 
was taken. Like the LSEQ, the LARS has the advantages o f  a visual analogue scale, 
which is preferable to scales like the POMS (Profile o f Mood States; McNair et al.,
1992), which uses a discrete rather than continuous ratings scale. The POMS is also 
widely used in sleep research (Mitler et al., 2000), and measures vigour, confusion and 
fatigue. However, it has been found that fatigue can occur independently o f sleepiness 
(Mitler et al., 2000).
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2.2.4.3 The State-Trait Depression Inventory (STD1) and the Stcite-Trait Anxiety 
Inventory (STAI)
The STDI (Spielberger et al., 1995) is composed o f  two separate self-rated ten 
item scales, and the STAI (Spielberger et al., 1970) is composed o f  two separate self- 
rated twenty item scales. Both are used to evaluate two distinct concepts: state 
depression or anxiety and trait depression or anxiety. Both state depression and anxiety 
are conceptualised as emotional states, which vary in intensity and over time, in 
response to particular events. With both the state depression and anxiety scales, 
participants rate how they feel at that moment in time. In contrast, trait depression and 
anxiety are both conceptualised as a relatively stable and permanent aspect o f 
personality. When completing these scales, participants describe how they feel 
generally.
The STAI is for adults aged 16 year's and upwards. It is reliable after test-retest 
(trait only, because state anxiety changes), and has an internal reliability consistency o f 
0.9 (Kline, 1993). The STAI correlates well with other tests o f  anxiety, such as the 
IP AT anxiety scale (Catterell and Schneier, 1963) and the Manifest Anxiety Scale 
(Taylor, 1953). However, the method used by Spielberger to show validity has been 
questioned. Kline (1993) has criticised the STAI because Spielberger et al. (1970) 
showed evidence for the efficacy o f  this test by asking participants to answer the scale 
by pretending to be taking a stressful exam. Kline (1993) suggests the state anxiety can 
be easily faked. However, the STAI has been shown to be sensitive to both insomnia 
and psychoactive compounds (e.g. Monteiro et al., 1990; Edinger et al., 2000), and 
Spielberger et al. (1975) found it sensitive to the state anxiety shown by patients before 
and after surgery. Kline (1993) also states “as a quick and easy measure o f  state and 
trait anxiety, the STAI would appear' to be about as good as you can get” (p.478).
The STDI has yet to be established as a commonly used inventory o f  depression, 
as a search o f Medline (August, 2003) for ‘ Spielberger Depression Inventory’ returned 
only 130 publications, most o f  which referred to STAI. Like the STAI, the STDI is 
quick and easy to administer. The Hamilton Rating Scale o f  Depression (Hamilton, 
1960) is more widely used, but is based on a patient interview, and requires 
administration by a clinician. The Hamilton Rating Scale o f Depression is therefore 
more time and resource consuming than the STDI. A popular self-administered test for 
depression is the Beck Depression Inventory (BDI; Beck, 1967; Beck and Beck, 1972), 
as it was used by 2318 publications in a search o f  Medline (August, 2003). This
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measures the intensity o f  depression, and is significantly related to clinical diagnoses 
(Shaver and Brennan, 1991). However, the full test contains 21 items, whereas the full 
STDI only contains 10 items. This indicates the STDI is quicker to complete. Also, the 
BDI has been criticised as essentially a checklist o f  depression, rather than a subjective 
scale (Kline, 1993). Unlike the Hamilton Rating Scale o f Depression and the Beck 
Depression Inventory, the STDI measures state and trait depression.
2.2.4A Milford-Eimorth Sleepiness Scale (MESS)
The MESS is also a 100 millimetre visual analogue rating scales, and is also 
used in the same way as the LSEQ. In the MESS, participants were required to rate the 
likelihood o f falling asleep in eight eveiyday situations, either ‘unlikely’ , or ‘very 
likely’ . The overall mean score represented the level o f sleepiness during the day. This 
scale is useful because it asks participants to make a judgement about their behaviour, 
not just express how they are feeling. This shows it is complementary to measures o f 
sedation like the LARS. The MESS rating scale was adapted from the Epworth 
Sleepiness Scale (ESS), which Johns (1991, 1992) showed successfully measured the 
difference in daytime sleepiness in sleep apnoeics before and after CPAP treatment 
(continuous positive airway pressure).
The MSLT (Multiple Sleep Latency Test) is the preferable choice when 
measuring daytime sleepiness (Carskadon et al., 1986). This is where participants are 
put to bed at specified time points, and are asked to attempt sleep. The time taken to fall 
asleep is therefore an indication o f how sleepy the participant is. However, this is 
inefficient, and too time consuming and costly. A popular alternative is the Stanford 
Sleepiness Scale (SSS; Hoddes et al., 1973), which also measures introspective 
sleepiness. From 7 statements, participants must choose the statement which describes 
their level o f  current sleepiness. This is a brief test, but is restrictive. Also, 
experimentally induced sleep deprivation was foimd not to increase SSS scores (Mitler 
et al., 2000).
The MESS is also very brief and simple, but offers the rater more flexibility than 
the SSS, and does not require the time and cost o f an MSLT. Fairweather et al. (1996) 
successfully used the MESS to show the sedative effects o f the antidepressant dothiepin.
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3.1 Abstract
Objective and subjective measures o f  sleep o f  the older adult are difficult to 
assess because o f differing levels o f  physical and psychological health, adaptation to 
change, sleep hygiene and expectations o f  sleep. It is generally thought that as age 
increases, so do the prevalence o f sleep problems. Sleep is thought to become more 
fragmented, causing daytime drowsiness and napping, and less nocturnal sleep. There 
are few scientific publications about the help that the elderly seek for their sleep 
problems, with regard to prescription medication, ‘ over-the-counter’ (OTC) 
preparations, herbal remedies, and alcoholic and non-alcoholic beverages, or to their 
appropriateness and efficacy in an older population.
A survey was produced to ask older adults about their sleep and bedtime 
behaviours. This was completed by 5846 respondents, 3557 males and 2020 females 
(269 unidentified) aged between 50 and 98 years (mean age 69 years, sd = 8.5), who 
answered an advert in a magazine for readers aged over 50. No controls were placed 
over health, location, education or status.
Results showed older adults suffered principally from difficulty maintaining 
sleep, and the main cause o f  this was arousals from pain and needing to use the toilet in 
the night. Females slept less and had more trouble sleeping than males (more difficulty 
initiating and maintaining sleep, and more early morning awakenings). Females also 
used more prescription medications and herbal preparations than males. The prevalence 
o f prescription use was 10.8%, and the most popular hypnotics were temazepam and 
nitrazepam. These may not be appropriate drugs for the elderly due to their longer half- 
lives than newer hypnotics, as residual effects may cause adverse events. OTC and 
herbal remedies were also popular (prevalence 17.7%), as well as alcoholic (prevalence
11.0%) and non-alcoholic beverages (prevalence 31.3%), and other methods used to 
improve sleep problems were also noted (prevalence 9.1%).
3.2 Introduction
It is suggested that changes in sleep pattern, either due to physical, psychological 
or situational changes, are more prevalent in the elderly (Kronholm and Hyyppa, 1985).
CHAPTER 3
51
Chapter 3
Problems with nocturnal sleep can lead to daytime sleepiness, which can increase 
susceptibility to accidents and falls during the day (Ray et ah, 1987; Martikainen et al., 
1992; Leger, 1994), and also impairments in daytime functioning, such as impaired 
memory and increased irritability (Poliak and Perlick, 1991; Bliwise et al., 1992). It is 
difficult to know if  sleep pattern changes are compromising quality o f  life o f the older 
adult because o f  limitations associated with the self reports o f sleep disturbances. For 
example, those reporting numerous visits to the toilet at night might complain o f a 
bladder problem and not a sleep disturbance, without understanding the impact the 
condition is having on their daytime performance and quality o f  life.
3.2.1 Self Reports
Self reports (interview, survey or questionnaire) can provide a viable method to 
study the frequency, nature and perception o f sleep disturbances in a large elderly 
population group, and how these sleep disturbances are treated. A  large number o f  
participants can be studied at little expense, gaining an extensive collection o f  data. 
Whilst many have used self reporting and consider it a valid tool (Karacan et al., 1976; 
Morgan et al., 1989; Rryger et al., 1991; Weyerer and Dilling, 1991; Maggi et al., 1998; 
Ersser, 1999), there is controversy as to whether self reports are reliable (Webb, 1982b). 
Carskadon et al. (1976) compared self reports o f  sleep experience to EEG findings, and 
found a lack o f correlation. Indeed, Hoch et al. (1987) found only females showed 
significant correlations between wake after sleep onset and ‘restlessness’ , and the 
amount o f  SWS with the ‘ soundness’ o f  sleep. Weiss et al. (1973) studied 14 
hospitalised patients with depressive syndromes and schizophrenia. They recorded EEG 
sleep, nurses’ observations and patients’ self ratings o f sleep for 14 consecutive nights. 
They found the nurses were only able to make valid estimations o f  sleep, according to 
the EEG traces, for one depressive patient and one schizophrenic. Also, the patients’ 
reports were only slightly more reliable. In addition, the reports by the nurses and 
patients did not correlate significantly.
The basis o f  self report is honesty, which cannot always be relied upon (Urponen 
et al., 1988). Any information requested on surveys that is o f a sensitive nature, such as 
bedroom habits or toilet use, might cause the participant to lie or omit details. Phillips 
(1971) has suggested information gathered might be the product o f censoring by social 
acceptability. However, Morgan et al. (1988b) consider self reports to be good
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indicators o f sleep because all participants will report the same inaccuracies, and so will 
not affect the statistical findings. The problem with this view is that poor sleepers tend 
to be poor estimators too, so their reports will not report the same inaccuracies as good 
sleepers. Poor sleepers have been found to overestimate sleep latency and underestimate 
the number o f nocturnal awakenings and total sleep time, whereas good sleepers are 
accurate in their estimations o f  all components o f  insomnia (Adam et al., 1986; 
Liljenberg et al., 1988; Morin and Gramling, 1989). It is due to this difference between 
poor and good sleepers that has lead Coates et al. (1982b) and Frankel et al. (1976) to 
conclude that self reports are not accurate, but do show reliability over time. This means 
self reports may be more accurate in their assessment o f changes in individuals over 
time, but not an accurate measure o f  their sleep parameters. Habte-Gabr et al. (1991) 
suggests it is difficult to determine the reliability o f self reports without extensive 
longitudinal studies. Most investigations into the sleep o f  older adults, due to practical 
and financial reasons primarily, are cross-sectional (Reynolds et al., 1991), and so there 
is very little data are available on longitudinal findings (Webb, 1982a; Hoch et al.,
1997). In addition, self reports lack ‘ cause and effect’ , as all work is correlational.
Whilst self report data may have limitations and should be interpreted with care, 
they should not be dismissed as they may have value. Sufferers o f sleep problems often 
seek help on the basis o f  their ‘ feelings’ about their problem, either medical from their 
G.P., or from their local chemist in the form o f ‘ over-the-counter’ (OTC) medication 
(Beaman, 1989; Morin and Gramling, 1989; Webb, 1989). Indeed, the subjective 
perceptions o f  sleep problems are all that G.P.s and other health-care workers have to 
use in order to understand and treat complaints (Morin and Gramling, 1989). As 
Karacan et al. (1976) wrote: “The ultimate criterion as to what constitutes a good 
night’s sleep may be a subjective one” (p.243).
Most studies o f sleep, insomnia, and medication use are based on self reports, 
and are often cross-sectional. Comparing these studies if often difficult, because o f 
differences in their focus, such as insomnia or hypnotics, and participants can differ in 
their living arrangements (such as married, single, or in a care institution (Reynolds et 
al., 1985a; Seppala, 1993)), or by occupation (working versus retired) (Middelkoop et 
al., 1996). The phrasing and context o f  questions can also affect results (Karacan et al., 
1976; Bixler et al., 1979; Braz et al, 1990; Bliwise et al., 1992). The elderly will report 
less insomnia than they will report long sleep latencies (SLs), a difficulty initiating sleep 
(DIS) and a difficulty maintaining sleep (DMS) (Mellinger et al., 1985). For example,
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napping to some might mean being fast asleep during the day, but others may include 
intense resting or dozing. ‘Resting’ might still be scored as stage 1 sleep in EEG trials 
(Beh, 1994). Scoring techniques may differ, as some researchers collect scores o f sleep 
behaviour rather than prevalence. For example Schechtman et al. (1997) and Englert 
and Linden (1998) asked their participants to rate their sleep, rather than finding the 
percentage who had insomnia. Time scales are also problematic, as questions can be 
asked in relation to the previous few months, weeks or days (Liljenberg et al., 1988; 
Weyerer and Dilling, 1991; Martikainen et al., 1992; Ohayon and Caulet, 1996). For 
example, Karacan et al. (1976) reported questions about the previous weeks sleep 
resulted in a higher prevalence o f  poor sleep than over a longer time scale. Some 
investigators do not specify time scales making comparisons even more difficult 
(Weyerer and Dilling, 1991). Different seasons and climates will also impact on 
answers given to some questions (Karacan et al., 1976). Time in bed may be longer 
during the winter as it is darker, and more alcohol, hot water bottles and warm drinks 
might be used to combat the cold. Conversely, the elderly might have more sleeping 
problems in the sticky heat o f  summer. Also, sleep medication has been found to alter 
the perception and recollection o f sleep (Silvestri, 1982; Habte-Gabr et al., 1991; 
Guilleminault and Mendelson, 1995). ‘Often’ and ‘occasional’ hypnotic users report 
more sleeping difficulties, more frequent drowsy feelings during the day and less sleep 
satisfaction than those who do not use hypnotics (Lugaresi et al., 1983; Lack et al.,
1988)
Despite problems with self reports, studies using this technique have found 
sleeping difficulties in the elderly are greater in number and severity than in younger 
adults. For example, Karacan et al. (1976) questioned 1645 adults in Florida, and found 
only 9% o f those aged 20-29 years reported often having trouble sleeping, compared to 
21% o f those aged 60-69 years. Self reports can also help identify how the elderly 
attempt to alleviate their sleep problems.
3.2.2 Use o f Hypnotics
The majority o f  studies have found a larger number o f older adults take 
hypnotics and related drugs compared to younger populations. Henderson et al. (1995) 
surveyed 59 Australians over 70 years old, and found the prevalence o f hypnotic use to 
be 14.5%. Morgan et al. (1988b) surveyed the sleeping habits o f 1023 adults aged 65 to
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74 years old, and found the prevalence to be 15.4% in England. Karacan et al. (1976) 
showed 14.8% o f those over 50 years old took medication to aid sleep, with 7.8% o f 
those aged 50 to 59 year's, 14.4% o f those aged 60-69 years, and 13.1% o f those aged 
over 70 years, taking sleeping pills ‘ often5 in Florida. Ohayon and Caulet (1996) 
conducted telephone interviews o f 5622 French and 1722 Canadian adults o f all ages. 
They found 2.4% o f  Canadians and 4.4% o f the French aged 25 to 34 used psychotropic 
drugs, compared to 15.4% o f Canadians and 27.6% o f the French aged over 65 years. 
Also, Janson et al. (1995) surveyed 2202 young (20 to 45 year olds) volunteers, and 
found the prevalence o f  hypnotic use was 1.7% in Iceland, 0.8% in Sweden and 2.0% in 
Belgium. This indicates far* fewer adults under 50 year's old use hypnotics than those 
over 50 year's. Lader (1997) suggests this is possibly due to primary health problems 
being overlooked in the elderly, leading to hypnotics being prescribed merely for a 
symptom alone. For example, with periodic leg movement disorder (PLMD), sufferers 
uncontrollably move legs or aims when in bed, which can be very disturbing to sleep. If 
this disorder goes unrecognised and hypnotics are prescribed for a sleep problem, then 
the underlying problem will not be addressed and sleep will be unlikely to improve 
(Weiss et al., 1973).
There is always a persistent demand for sleep medication (Englert and Linden,
1998). It is widely agreed that increasing age is correlated to an increasing amount o f 
hypnotic use. Research in Florida, Finland, Canada, France and Great Britain has shown 
approximately 7.8% to 14% o f 45 to 59 year olds are hypnotic users o f some description 
(Karacan et al., 1976; Kronholm and Hyyppa, 1985; Lugaresi et al., 1987; Middelkoop 
et al., 1996; Ohayon and Caulet, 1996). Also, 7.2% to 18.9% o f 60 to 69 year olds 
(Karacan et al., 1976; Morgan et al., 1988b; Klaukka and Martikainen, 1989; 
Middelkoop et al., 1996; Ohayon and Caulet, 1996), 11.8% to 53.7% o f 70 to 79 year 
olds (Karacan et al., 1976; Kronholm and Hyyppa, 1985; Lugaresi et al., 1987; Morgan 
et al., 1988b; Klaukka and Martikainen, 1989; Middelkoop et al., 1996) and 15% to 
30.4% o f the over 80 year olds (Lugaresi et al., 1987; Seppala, 1993; Middelkoop et al.,
1996) have been found to use hypnotics. A higher prescription rate is found in nursing 
homes and other care institutions (Morgan, 1990), and this is suggested to be more for 
the benefit o f staff than for the benefit o f the patients (Learman et al., 1990; Morgan, 
1990; Monane et al., 1996), so may not necessarily be due solely to the age o f the 
patients.
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Although many studies have examined the use o f  hypnotics over many time 
scales, very few have identified what types are actually used by the elderly. These may 
be very different to those used by younger adults, as the elderly have different 
pharmacokinetics and altered responses to medication (Greenblatt et al., 1982; 
Greenblatt et al., 1991). Any side effects experienced by younger adults will be 
amplified in the elderly due to increased sensitivity (Morgan, 1990) and slower 
metabolism (Massoud, 1984; Cook, 1986). There is little consensus on the medications 
used most by the elderly, probably reflecting the time when a study was completed. For 
example, in 1988, the benzodiazepines nitrazepam (Morgan et al., 1988a) and 
flurazepam (Moran et al., 1988) were the most popular hypnotics to prescribe. More 
recently, hypnotics like zopiclone and zolpidem have been suggested to be more 
suitable (Lader, 1997).
Since 1988, knowledge has expanded and more attention has been paid 
specifically to older adults (Morgan, 1990; Trewin et al., 1992). In a recent survey 
Busto et al. (2001) found approximately two-thirds o f elderly hypnotic users take a 
benzodiazepine. Many benzodiazepines have long half-lives, meaning their effects can 
still be detected the next day, and may even accumulate for greater effect, especially in 
higher doses. This is reflected in reduced doses often recommended for elderly patients 
(Joint Formulary Committee, 2002). Residual effects o f benzodiazepine use can include 
daytime sedation (Greenblatt et al., 1984), impaired psychomotor performance (Cook et 
al., 1983; Morgan, 1985; Maczaj, 1993), unsteadiness, cognitive and memory 
disturbances, and even confusional states (Evans and Jarvis, 1972). Nitrazepam lOmg 
(Castleden et al., 1977) and 5mg (Cook et al., 1983), temazepam 20mg (Cook et al.,
1983), and diazepam (Cook, 1986) have all been found to result in these impairments. 
Lader (1997) suggests these adverse effects could lead to the misdiagnosis o f dementia. 
This could lead to unnecessary admission to homes and geriatric hospitals (Williamson 
and Chopin, 1980). This is understandable when the effects o f some hypnotics on mood 
are considered. These include hostility, antagonism, irritability (Oswald et al., 1979), 
disinhibition o f aggression (Lion et al., 1975), paranoia and panic (Lader, 1997). 
Mechanisms are unclear (Morgan, 1990), but it seems these effects may be due to 
within-day withdrawal effects (Lader, 1997).
In addition, it has been suggested that the use o f some benzodiazepines can 
increase the duration o f  sleep apnoea episodes (Dement et al., 1982; Dolly and Block, 
1982; Moran et al., 1988) due to respiratory depression (Model and Berry, 1974). This
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condition is potentially dangerous as some patients may be asymptomatic o f a sleep- 
disordered breathing problem, and taking a prescribed hypnotic may worsen breathing 
and possibly lead to death (Kriplce et al., 1979; Kripke and Garfinkel, 1984; Ancoli- 
Israel et al., 1985; Morgan, 1990). Indeed, a large cohort study o f 1.1 million 
participants by Kripke et al. (2002) has shown the use o f  sleeping pills is associated 
with increased mortality. However, the types o f  hypnotics reported or the duration o f 
treatments were not identified. As the survey was completed in the 1980s, it is possible 
that the hypnotics in question were less advanced benzodiazepines or barbiturates, with 
more severe adverse health effects (Kripke et al., 2002).
Also, a link has been noted between the use o f hypnotics and the prevalence o f 
accidents and falls (Granek, 1987; Larsen et al, 1987; Ray et al., 1987). Trewin et al.
(1992) studied clinical and medication data from 2878 admissions to the Department for 
Care o f the Elderly in Exeter, and associations between the administration o f hypnotics 
and the incidence o f  falls were examined retrospectively. They found lorazepam and 
nitrazepam had a significant association with the number o f  falls, and that females fell 
more than males. However, there was no significant link between hypnotics and 
benzodiazepines and falls generally, but the authors did note that higher doses o f  
medication were associated with increased falls.
The newer hypnotics, such as zopiclone, zolpidem and zaleplon, have much 
shorter half-lives. The half-life o f  zopiclone is 6 hours in the over 65’ s and 8 hours in 
the over 80’ s. The half-life o f zolpidem is only 3 hours (Lader, 1997), and the half-life 
o f zaleplon in the elderly is as little as 1 hom* (Lader, 1997). These act like the longer- 
acting benzodiazepines described above, but are thought less likely to cause tolerance or 
impairment in performance, due to their shorter duration o f  effect. Also, very few side 
effects are seen. Zopiclone, for example, reduces sleep latency, increases sleep duration, 
sleep quality and soundness (Klimm et al., 1987), but only causes a bitter taste and a dry 
mouth (Lader, 1997). Zolpidem has been found effective at 5mg and lOmg doses in the 
elderly (Scharf et al., 1991; Shaw et al., 1992; Leger et al., 1999), reducing sleep latency 
(Scharf et al., 1991; Fairweather et al., 1992), increasing efficiency (Scharf et al., 1991) 
and quality o f  sleep (Fairweather et al., 1992), but does so with no adverse effects on 
memoiy or performance (Fairweather et al., 1992; Lader, 1997). However, due to their 
shorter duration o f  action, these newer hypnotics may only be suitable for difficulty 
initiating sleep. This may be a problem for the elderly, as their main complaint is o f  
difficulty maintaining sleep. Because o f  this short acting hypnotics may increase safety.
Chapter 3
57
The elderly require more visits to the toilet at night (Asplund, 1996), and if under 
sedative effects, will be more likely to fall (Lader, 1997). Despite the advantages of 
shorter acting hypnotics, Busto et al. (2001) found only 11% o f elderly hypnotic users 
take zopiclone. This may be a matter o f  cost. Nitrazepam (5mg), for example, is only 
59p for 20 tablets, but zopiclone (3.75mg) is £3.07 for 28 tablets (Joint Formulary 
Committee, 2002).
Although daytime sedation and accumulation can be greatly reduced or 
eliminated by the use o f  short-acting hypnotics, they also cause their own problems. 
Because long-acting hypnotics can cany-over to the next night, when the course o f the 
drug is terminated, there may be fewer withdrawal effects. However, with a lack o f 
accumulation, withdrawal effects from shorter-acting hypnotics can occur, in the form 
o f mild ‘rebound’ insomnia, where sleep is worse than before the start o f the drug 
treatment, and this may occur within the night (Lader and Lawson, 1987; Lader, 1992; 
Maczaj, 1993). Zopiclone may be an exception to this, perhaps because it has the 
longest half life o f  the shorter acting hypnotics (Goa and Heel, 1986). The elderly also 
suffer daytime anxiety, panics, perpetual hypersensitivity and weight loss (Lader, 1997), 
tinnitus, involuntary movements and nausea (Lion et al., 1975; Petursson and Lader,
1984) during withdrawal. A vast proportion o f  elderly hypnotic users are long tenn 
users, with 25% o f the community elderly using hypnotics for over 10 years (Morgan,
1990). However, most hypnotics lose their efficacy within just three to fourteen days o f 
use (Committee on the Review o f Medicines, 1980). It is likely that the elderly persist in 
their medication due to the fear or avoidance o f these unpleasant withdrawal effects 
(Morgan, 1990; Monane et al., 1996). They are in effect maintaining the risks from the 
side effects, yet gaining no benefit to their sleep (Morgan, 1990), although there is some 
evidence o f  tolerance built against these side effects (Swift et al., 1984). This could 
explain why Simen et al. (1995) found that 45% o f older adults still had a sleep problem 
despite taking regular hypnotics.
It is little surprise, then, that alternatives are sought to help the elderly with their 
sleeping problems. There has been an increase in the use o f  antidepressants (useful if 
depression is present in addition to insomnia (Mullan et al., 1994)), neuroleptics 
(Linden and Gothe, 1993; Monane et al., 1996) and also herbal preparations (Linden 
and Gothe, 1993), which are discussed below. The use o f the pineal hormone melatonin 
has also increased (Lader, 1997), and has been found to increase sleep efficiency and 
reduce the amount o f  wake time after sleep onset in insomniacs (Garfinkel et al., 1995),
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reduce sleep latency (Gilbert et al., 1999) and increase sleepiness (Arendt et al., 1984). 
Hughes et al. (1998) found melatonin shortened objective sleep latency in 14 elderly 
insomniacs, but did not change subjective measures o f sleep. Melatonin is secreted at 
nighttime (Lynch et al., 1975), and is thought to play a role in the mechanisms o f 
normal nocturnal sleep generation. Pires et al. (2001) studied six young healthy male 
volunteers who took melatonin (0.3mg or LOmg) at different points in the evening. 
Results showed a significant reduction in sleep latency, an increase in sleep efficiency, a 
reduction in the number o f awakenings, a reduction in stage 1 sleep, and an increase in 
REM latency. However, subjective ratings again were not altered, as there was no 
change in Profile o f Mood States questionnaire, or the Stanford Sleepiness Scale. 
Arendt (1994) found melatonin had side effects o f  sleepiness, headache, dizziness and 
nausea, but these were uncommon.
In an elderly population, Zhdanova et al. (2001) studied 30 men and women 
over the age o f  50 years old, some with and some without a sleep problem. They took 
0.3mg o f melatonin a night for a week, and their EEG was recorded for the last three 
nights o f that week. They found the poor sleepers had a lower level o f melatonin, and 
taking supplemental melatonin improved their sleep efficiency, but did not alter the 
sleep o f the normal elderly sleepers. However, there was no effect o f  melatonin on total 
sleep time, the number o f  awakenings, sleep latency, latency to REM sleep, or percent 
o f time spent in each sleep stage for either insomniac or normals. The authors suggest 
the two hom- delay before the onset o f polysomnography (EEG and other objective 
measures o f sleep) may have missed these effects.
Suppression o f  melatonin can also be achieved with bright light therapy to the 
upper and middle visual fields (Smith et al., 2002), to normalise levels. Sproule et al.
(1999) have found 1.1% o f their elderly sample (176 participants aged 60 to 92 years) 
use a melatonin supplement.
3.2.3 Use o f Over-The-Counter (OTC) and Herbal Preparations
There has been a distinct increase in the number o f herbal and OTC preparations 
available. Beaman (1989) surveyed 102 elderly with a mean age o f  74 years in England. 
He found that 43% o f older adults use ‘ self-help’ remedies, such as alcohol and cough 
mixture, to initiate sleep. Sproule et al. (1999) surveyed 176 elderly also with a mean 
age o f 74 years. They found 24% o f the elderly used non-prescription treatment for
Chapter 3
59
insomnia, which is a smaller percentage as it does not include remedies like alcohol and 
hot drinks. Busto et al. (2001) noted 12% used an ‘over-the-counter’ treatment in a 
survey o f  3860 Canadians aged 60 to 95 years old. Again this percentage is lower still, 
because this does not include remedies like drinks or herbals. Alcohol was a popular 
method for sleep aid, as it was used by 13% in the survey by Sproule et al. (1999) and 
by 50.7% in the Dutch survey o f  1485 over 50 year olds (Middelkoop et al., 1996). The 
high percentage in the Dutch study seems to be due to the high percentage o f  Dutch 
males using alcohol, 67.2% compared to 34.2% o f females. Alcohol does reduce sleep 
latency, but also suppresses REM towards the latter part o f  the night, fragments sleep 
(Iliffe et al., 1991), and increases the number o f  awakenings (Roth et al., 1985; Iliffe et 
al., 1991). This is more o f a problem in the elderly rather than the young as the effects 
o f  intoxication are greater, due to increased sensitivity (Iliffe et al., 1991).
The proportion o f  older adults using OTC preparations at least ‘ sometimes’ is 
15% in the U.S. (Mellinger et al., 1985), 26.4% in Australia (Lack et al., 1988), and 
20.5% in Canada (Sproule et al., 1999), with males being equally likely to use them as 
females (Mellinger et al. 1985; Martikainen et al., 1992). OTC drugs are commonly 
antihistamines, such as diphenhydramine and promethazine. Other OTC drugs include 
analgesics, and the use o f  non-prescription pain relief products was found to be 5.1% by 
Sproule et al. (1999) and 3% by Busto et al. (2001) in two Canadian studies. OTC 
sleeping pills (antihistamines) were found by Balter and Uhlenhuth (1991) to be similar 
in efficacy to temazepam for maintaining sleep and reducing the frequency o f night 
awakenings. Sproule et al. (1999) found that subjective ratings o f  sleep efficacy were 
better for those taking OTC preparations (antihistamines, analgesics, alcohol and 
herbals) than those who did not. However, Sproule et al. (1999) also found 75% o f OTC 
users reported side effects such as headache, agitation and dry mouth, and 62% said 
prescription medication was more affective than OTC medication. In addition, both 
Bliwise (1991) and Maczaj (1993) believe that OTC medication (largely antihistamines) 
should be recommended for the elderly with caution as some may be anticholinergic, 
which may result in confusion and residual daytime sedation.
Little is known about the use o f  herbal preparations. The percentage o f elderly 
who use o f  herbal medications for sleep has been found by Sproule et al. (1999) to be 
3%, and 5% by Busto et al. (2001). These include kava kava, passiflora, lettuce, and 
hops. There is some evidence that valerian (valeriana officinalis L) may be useful for 
improving sleep. Schulz et al. (1994) found valerian increased total sleep time (TST) in
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the elderly, and Leathwood and Chanffard (1983) found it decreased sleep latency in 
older adults, but not much is known about the numbers o f  elderly that actually use it.
3.2.4 Sleep Hygiene
Many medications used for sleep problems in the elderly may either be 
associated with adverse effects, or may not help at all. In view o f this, it has been 
recommended that hypnotics should be prescribed to the elderly “ for short periods, and 
only after careful consideration” (Committee on the Review o f Medicine, 1980; Lader, 
1997), ideally on an ‘ as and when needed’ basis (Lader, 1997). So what alternatives to 
medication do the elderly have?
The causes o f  insomnia can be very complex. It is due to this that many 
researchers now advocate thorough inspections o f  the sleep behaviour patterns o f those 
presenting with insomnia. Maladaptive behaviours may arise from unrealistic 
expectations or erroneous beliefs about sleep in old age, as previously described (Engle- 
Friedman and Bootzin, 1981; Lichstein and Fisher, 1985; Fichten et al., 1995). The 
model from which this is suggested can also provide relief in the form o f cognitive 
therapy (Bootzin, 1985a), to cope with sleep problems by identifying irrational 
thoughts. This introduces control, moving away from the perception by the insomniac o f 
being a victim (Bootzin, 1985b). However, some have found this ineffective (Turner 
and Ascher, 1982; Lacks et al., 1983). Bootzin and Perlis (1992) believe that something 
as simple as keeping a sleep diary can often prove useful (also Kazdin, 1974). Patients 
sometimes find their sleep problems were not as severe as they first thought, and other 
times intervention is required. Bootzin and Perlis (1992) suggest treatments should be 
tailored to the individuals’ needs. For example, an insomniac with stress might benefit 
from stress management techniques. However, this was found no more effective than 
other non-pharmacological treatments (Espie et al., 1989). Maladaptive behaviours 
include staying in bed too long, having irregular’ sleep schedules, exercising close to 
bedtime (although exercise during the day is recommended by Sproule et al., 1999), 
engaging in exciting or emotionally upsetting activities close to bedtime, taking 
products containing caffeine, nicotine or alcohol, and sleeping in an unsuitable 
environment (e.g. too bright, too cold or stuffy, too noisy etc.; Becker and Jamieson, 
1992; Bootzin and Perlis, 1992; Mullan et al., 1994). Addressing these maladaptive 
behaviours is known as ‘ sleep hygiene’ . This is just simple information about how to
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eliminate sleep-damaging behaviours and accentuate positive behaviours. It has been 
found very effective when used in counselling, but not so when in the form o f handouts 
or checklists (Hoelscher and Edinger, 1988; Engle-Friedman et al., 1992). Morin and 
Azrin (1988) and Morin et al. (1990) have both found behavioural treatments are more 
effective for intractable or chronic insomnia. Examples o f  these behavioural treatments 
include ‘ stimulus control’ (Bootzin and Nicassio, 1978). This establishes the bedroom 
as a place o f  sleep, achieved by a set o f  rules, such as getting up when not sleepy, and 
strict sleep schedules. Sleep restriction (Spielman et al., 1987), whereby the number o f 
hours spent in bed is restricted to the number o f  hours usually spent asleep. ‘Paradoxical 
intention’ is where the insomniac must try and stay awake as long as possible, and was 
devised to alleviate performance anxiety (Morin et al., 1994). Chronobiology is used 
when a shift in the sleep phase is present, and bedtimes are altered in increments until 
the desired bedtime is reached (Czeisler et al, 1981). Bright light therapy is also 
effective in these situations, to re-train diurnal rhythms and to adjust melatonin levels 
(Lewy et al., 1984; Czeisler et al., 1989; Smith et al., 2002). There is also a possible role 
for relaxation training and acupuncture (Larzelere and Wiseman, 2002), meditation and 
biofeedback (Borkovec et al., 1979; Van Oot et al., 1984), to help eliminate any anxiety 
associated with falling asleep.
However, neither psychological nor pharmacological treatments seem to provide 
the complete answer to insomnia. An intuitive step to take might be combining the two 
treatments, but this appeal’s to be problematic. Psychological treatment is found to be 
long lasting (Milby et al, 1993; Hauri, 1997), but when combined with drug treatment, 
gained improvements in sleep are lost as quickly as with drug treatment alone (Hauri,
1997). Reasons are unclear, but it seems psychological methods are learnt better without 
hypnotics (Hauri, 1997; Morin et al. 1999). This may be due to the associations made by 
patients between hypnotics and improvements in sleep, even if  the improvements may 
actually be due to the concomitant behavioural therapy. Therefore, this may strengthen 
the patients’ beliefs that pharmacological methods are reliable, and that behavioural 
methods are ineffectual (Hauri, 1997).
3.2.5 Other Solutions
Libman et al. (1997) surveyed 240 Canadians over the age o f 60 years. They 
found the top six activities used by the elderly for improving sleep were: lying quietly,
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relaxing, using the toilet, changing thoughts, reading, and tossing and turning. Both tea 
and coffee were used to sleep (Urponen et al., 1988; Morgan et ah, 1989) despite the 
disruptive effects o f  caffeine (Colton et al., 1967; Shirlow and Mathers, 1985; Foley et 
al., 1995). Other methods to aid sleep mentioned in the literature include having baths 
(Urponen et al., 1988), listening to music (Urponen et al., 1988; Libman et al., 1990; 
Libman et al., 1997), exercising (Urponen et al., 1988), eating (Urponen et al., 1988; 
Libman et al., 1990; Libman et al., 1997), sexual activity (Urponen et al., 1988), having 
a nice environment (Urponen et al., 1988) and watching television (Urponen et al., 
1988; Libman et al., 1997).
3.3 Aims
Despite the shortcomings o f  self reports, they are an ideal method o f gaining 
extensive cost-effective information about the sleep o f  older adults. This method is 
adequate as long as it involves some detail and there are a large number o f  participants 
involved (Morgan et al., 1988b). There is limited British data on the normal sleep o f  the 
elderly. This study will therefore investigate prevalences so far described, and add data 
to the growing body o f  literature. As Reynolds et al. suggested in 1991 most research is 
out-of-date, this study will also bring the research up to date in line with the current 
climate. Total sleep time (TST) per night, difficulty initiating sleep (DIS), difficulty 
maintaining sleep (DMS), early morning awakening (EMA), dissatisfaction with sleep 
and feeling tired in the morning, napping behaviour and daytime sleepiness will all be 
looked at, to try to shed light on some o f  the issues raised in this area o f research, as 
many anomalies exist.
Medication appears to be a key aspect o f sleep in the elderly, as it carries so 
many consequences when used. It seems some prescription drugs can actually be 
physically dangerous in some circumstances (Bliwise et al, 1992; Martikainen et al, 
1992; Swift and Shapiro, 1993). Information will therefore be collected revealing the 
types o f  sleeping medication currently taken by elderly patients.
An area lacking in research is sleep hygiene. Many encourage its use with 
fervour (Reynolds et al., 1985a; Lack et al., 1988; Moran et al., 1988; Beaman, 1989; 
Hoch et al., 1997), and some suggest it is unimportant (Morin and Gramling, 1989; 
Fichten et al, 1995), but few have actually investigated to see if the sleep hygiene o f  the 
elderly is poor or in need o f  improvement. Indeed, Urponen et al (1988) stated that
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factors promoting and disturbing sleep “are largely based on assumptions and beliefs 
rather than research” (p.443). Indeed, Weyerer and Dilling (1991) suggested: “ It 
is...largely unknown how the majority o f insomniacs not using psychotropic drugs cope 
with their problems...”  (p.398). Information is needed on the sleep behaviours o f  the 
elderly, plus the use o f  OTC and herbal remedies.
Therefore, sleep amongst older adults will be examined via a postal survey to 
gather statistics on the types, prevalence and severity o f sleeping problems experienced 
in this age group. Data will be collected to answer the questions o f  whether older adults 
do suffer from disturbed sleep, and if so, how widespread this problem is. Special 
consideration will be given to methods employed by older adults to remedy their 
situation, to assess if  there is a role for sleep hygiene in preference to prescription 
hypnotics. This study will show basic information about problems experienced and 
options available to alleviate these problems.
3.4 Methods
3.4.1 Design
A questiomiaire was designed to investigate the sleep habits o f  the older adult, 
with special reference to their sleep hygiene and use o f  medication. The aspects to be 
studied were: total sleep time (TST), napping, difficulty initiating sleep (DIS), difficulty 
maintaining sleep (DMS), early morning awakenings (EMA), satisfaction with sleep, 
tiredness when awoken, daytime effects o f  poor sleep, use o f  prescription medication 
for sleep, use o f 4over-the-counter’ (OTC) medication, and also use o f herbal remedies, 
alcohol, any other beverages, and any other methods used. An example o f  this 
questiomiaire can be found in appendix 1. This was not an extensive survey o f all sleep 
disorders, as there were no questions regarding apnoea, restless legs, or any 
parasomnias, for example. A  basic demographic questionnaire was also administered to 
collect details about respondents. A research team including the author o f  this thesis 
performed the mailing and collation o f  the questionnaires, but the author completed the 
categorisation and analysis o f  all data.
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A total o f 8577 questionnaires were sent out, from which there were 5895 
respondents in total (response rate 68.2%), 35.1% male and 61.8% female (3.1% 
undetermined). All but 49 respondents were between the ages o f 50 and 98 years, with 
mean age 69 (sd = 8.5), which left a sample size o f 5846 for analysis. These were 
divided into age groups o f 50-54 (n = 299), 55-59 (n = 479), 60-64 (n = 779), 65-69 (n = 
1171), 70-74 (n = 1217), 75-79 (n = 1025), 80-84 (n = 364), 85-89 (n = 108), 90-94 (n = 
19), 95-99 (n = 1) years (those aged 85 years and over, n “  128). Overall, 5% were 
single, 63.5% were married, 1.9% were living with their partner, 6.3% divorced and 
19% were widowed. Throughout the UK, 16.9% lived in North East England, 15.9% in 
the South Central region o f  England, 15.0% in the Midlands, 11.9% in the South East o f 
England, 11.6% in Anglia, 7.8% in the North West o f  England, 7.2% in the South West 
o f  England, 6.7% lived in Scotland, and 2.9% in Wales. Therefore, there were no 
controls placed over the number o f  respondents in each age group, or the number in 
each geographical location.
All participants were respondents to a SAGA (a popular club for the over 50’ s) 
magazine article inviting them to volunteer to take part in a trial. This trial was on the 
effects o f  ginkgo biloba, the results o f which will not be discussed here. However, 
initial mailings to those who responded to the article on ginkgo biloba included 
questionnaires on demographics, and sleep and sleep behaviour. This means the 
respondents were not responding to a sleep trial, and so the sample collected were 
representative o f  the older population with respect to sleep problems. Inviting older 
adults to reply to a trial on sleep may encourage a disproportionate amount o f  response 
by insomniacs. Because this was a trial on ginkgo biloba, this bias was removed. 
However, it must be noted that ginkgo biloba is often taken by people hoping to 
improve age related cognitive decline (Canter and Ernst, 2002), so those replying to the 
advert hoping to receive ginkgo biloba may have had cognitive deficits. Cognitive 
deficits have been linked to poorer sleep (Webb, 1982a), so this may have biased the 
sample.
No controls were affected over respondents with respect to economic, 
educational and social background, although SAGA magazine appeals more to the more 
affluent older adult. There were no controls over intelligence; although it was required 
that questionnaires were completed to a certain standard. Importantly, no controls were
3.4.2 Participants
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affected over health, both physical and mental, and indeed no questions were asked 
regarding this matter. Table 3.1 shows the demographic information o f the participants 
used.
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Age (years) 50-54 299 5.4
55-59 479 8.7
60-64 779 14.1
65-69 1171 21.3
70-74 1217 22.1
75-79 1025 18.6
80-84 364 6.6
85-89 108 2.0
90-95 19 0.3
95-99 1 0.0
Gender Males 2020 35.1
Females 3557 61.8
Marital Status Single 287 5.0
Married 3654 63.5
Divorced 364 6.3
Living with partner 108 1.9
Widowed 1094 19.0
Age o f  Finishing Education (years) <14 1172 20.4
15-16 2357 40.9
17-19 1153 20.0
20-24 685 11.9
25-29 75 1.3
>30 55 1.0
Geographical Location South Central 753 13.1
Scotland 386 6.7
Anglia 666 11.6
South East 687 11.9
North East 975 16.9
Midlands 865 15.0
South West 415 7.2
Wales 167 2.9
North West 450 7.8
London 159 2.8
Other 11 0.2
Smoking Habits Never 2682 46.6
Past 2465 42.8
Occasional 92 1.6
Current 294 5.1
Table 3.1: Demographics o f  volunteers
3.4.3 Procedure
Firstly, a sleep questionnaire was devised to investigate aspects o f sleep patterns
described in the literature (listed above). No pilot questionnaires were used due to
financial constraints, although care was taken to ensure the questionnaire was clear and
concise. The constructs under investigation, primarily DIS, DMS and EMA, are well
researched (see section 3.2) and show strong indications for their validity. For example,
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sleep has been successfully categorised into DIS, DMS and EMA by many previous 
authors (e.g. Foley et al., 1995; Mallon and Hetta, 1997). Also, napping is an 
established phenomenon (e.g. Beaman, 1989). Therefore the questionnaire was assumed 
to be valid. However, the questionnaire did not undergo a factor analysis, so it is 
unknown if  all questions were necessary. A questiomiaire containing questions about 
demographics was also compiled. Next, an article was published in SAGA magazine 
inviting readers to participate in a survey. Those who responded to the article were sent 
the demographic and sleep questionnaires. This mailing occurred in September 1998, 
and a total o f  8577 surveys were sent out.
The sleep questiomiaire was the focus o f  this study. A  total o f 5846 
questionnaires were returned suitable for use, giving a response rate o f  68.2%. Returned 
questionnaires were then scanned into a database using Formic software"(version 3.0). 
Closed ended questions were recorded automatically, but open ended questions were 
subject to interpretation by one rater. All responses were assigned to broad categories 
appropriate to the question asked.
3.4 Results
3.4.1 Statistical Analysis
All analyses o f  responses were completed using a cross-tabulated chi square test, 
two tailed, using SPSS for Windows v. 10.0.7. The data was o f  nominal level, and 
unrelated. Chi square provided the best comparison between the numbers o f responses 
as it compares expected and observed values for each case, therefore the unequal 
numbers o f responses provided for each question were not an issue. There is some 
debate as to the robustness o f  chi square under a large ‘n’ , especially when there are 
over 20% o f cases with calculated values lower than the expected values. However, this 
study has an extremely large ‘ if ,  and this is assumed to provide the appropriate power 
for the analysis (Coolican, 1996). Any percentages given are the percentage o f people 
who answered the question given, and so do not include those who did not respond.
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3.4.1.1 Hours Sleep
There were 5657 respondents to this question. Most responses (42.0% and 
45.6%) were given for the categories o f 5-6 hours and 7-8 hours sleep. Therefore, 
overall there is no evidence for a subjective shortening in duration o f nocturnal sleep 
with older age. A cross-tabulated chi square test revealed significant difference (x2 = 
66.85, df = 4, p<0.01) between the two genders. On inspection o f  the data, males 
seemed to sleep for longer than females, with most answers being in the 7-8 hour 
categoiy, and with more responses in the >8 hour category.
Chi square analysis o f  the eight age groups revealed significant difference (x2 = 
54.09, df = 28, p<0.01). This was further investigated using post-hoc chi square cross 
tabulation, showing significant differences between the age groups 50-54 and 75-79 (x2 
= 7.83, df = 3, p = 0.05), but no other differences were present. On further breakdown o f 
results, gender by age responses were also analysed. There were significant results here 
also (x = 194.10, df = 60, p<0.01). There were no significant differences between the 
male age groups, but when females reached the age o f  70+, the number o f hours slept 
became significantly different to the hours that 50-54 year olds slept (x2 = 12.45, df = 4, 
p<0.05). Inspection o f  the number o f responses showed that females over the age o f  70 
had more responses in the 3-4 horns and 5-6 hours categories, therefore slept for less 
time than those 50-54 years o f  age.
Comparisons between age groups for each gender showed significant differences 
between males and females in age groups 55-59 (x2 = 9.01, df = 3, p<0.05), 65-69 (x2 =
14.30, df = 4, p<0.01), 70-74 (x2 = 30.17, df = 4, jXO.Ol), 75-79 (x2 = 27.84, d f = 3, 
p<0.01), 80-84 (x2 = 26.16, df = 4, p<0.01) and 85+ (x2 = 13.47, d f = 3, p<0.01), where 
in all cases females reported sleeping for shorter durations than their male counterparts.
3.4.1.2 Time Spent Napping
There were 5619 respondents. The distribution o f responses to the categories o f  
time spent napping was skewed towards the ‘None’ and ‘Up to 30 mins’ , as they were 
the most popular answers (42.9% and 36.0% respectively). Analysis between the two 
genders showed a significant difference between male and female responses (x2 = 
249.73, df = 4, p<0.01). Inspection showed males mostly napped for ‘Up to 30 mins’ 
whilst females mostly responded ‘None’ . The number o f people napping for over 30
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mins was very similar between the genders, but males appeared to take quick naps when 
females did not. Age breakdown revealed significant differences between ages 50-54 
and age 65 upwards (%2 = 47.77, df = 4, p<0.01). Before the age o f  65 there were many 
more respondents in the ‘None’ category than in the ‘Up to 30 mins’ category. After 65, 
the responses in these two categories tended towards evening out. The data showing an 
increase in short naps did indicate a linear trend, as differences are found between the 
age groups o f 60-64 and 65-69 (x2 -  57.09, df = 4, p<0.01), 65-69 and 70-74 (x2 =
20.31, df = 4, p<0.01), and 75-79 and 80-84 (x2 = 14.06, df = 4, p<0.01) only.
Further breakdown showed napping behaviour changed after the age o f 65, for 
both males and females. For both genders, with increasing age responses were given in 
categories for increasing time spent napping. However, it was noted before that males 
napped for longer than females, and here again there was significant difference between 
males and females for each age group (p<0.01), with the exception o f  the 85+ age 
group. In these age groups, females had a tendency to nap for shorter periods.
3.4.1.3 Difficulty Initiating Sleep (DIS)
The question o f  whether or not DIS was suffered was answered by 5330 
respondents. Results are shown in Graph 3.1. Overall, 40.5% answered ‘ Yes’ , and 
59.5% answered ‘No’ as to whether they have a difficulty initiating sleep. A significant 
difference between the genders was found (x = 287.11, df = 1, p<0.01), whereby more 
females than males answered ‘Yes’ . There were no significant differences noted 
between the age groups, so there is no change in ability to get o ff to sleep with 
increasing age. However, further breakdown o f the data showed this is only the case for 
males. Females, in contrast, complained in majority o f DIS when they were over 60, and 
there is significant difference between complaints age 50-54 and ages 60-74 (x2 = 7.79, 
df =1, p<0.01) and 80-84 (x2 = 5.83, df = 1, p<0.05). This is not noted in the age group 
85+ where results fell short o f significance (x2 = 3.79, df = 1, p = 0.051). This may be 
due to a much smaller number o f  respondents in this age group (n = 76). This gender 
difference was seen again in analysis between age groups and genders, where 
differences were seen between males and female from the age o f 60 upwards (x2 = 
25.40, d f= l,p<0 .01).
There were 3390 respondents to the question o f the severity o f  DIS experienced. 
Most responded either ‘Mild’ (41.8%) or ‘Moderate’ (44.5%), and only 13.7%
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responded ‘ Severe’ . Significant differences were found between male and female 
responses (x2 = 17.56, df = 2, p<0.01), as females tended to have ‘Mild’ DIS and males 
mostly responded ‘Moderate’ . There were no significant differences between the age 
groups. Further breakdown showed significance between females ages 50-54 and 
females aged 55-59 (x2 = 9.76, df = 2, p<0.01), 70-74 (X2 = 7.54, df = 2, p<0.05), and 
75-79 (x2 = 7.81, d f= 2, p<0.05). There were also significant differences between males 
and females in the 55-59 (x2 = 8.13, df = 2, p<0.05), 70-74 (x2 = 6.01, df = 2, p = 0.05), 
and 75-79 (x2 = 11.56, df = 2, p<0.01) age groups. No overall trends were apparent, and 
significances appeared to be due to more ‘Mild’ than ‘Moderate’ complaints, which are 
present for females aged 70-79.
The question regarding the occurrence o f  DIS suffered was answered by 2669 
respondents. Most responded towards the most frequent end o f  the scale, with the 
majority (29.2%) suffering from DIS 1-3 nights per week. Males and females responded 
significantly differently (x2 = 18.93, d f = 4, p<0.01), as most females suffered 1-3 nights 
per week (31.4%), and most males suffered 4-7 nights per week (28.1%). There were no 
significant differences between the age groups, and post-hoc breakdown o f results age 
versus gender also found no significant results.
3.4.1.4 Difficulty Maintaining Sleep (DMS)
The question asking if DMS was suffered was answered by 5674 respondents. 
Results are shown in Graph 3.2. The majority responded ‘Yes’ to suffering a difficulty 
maintaining sleep (68.9%). There was significant difference between genders (£  = 
24.50, df = 1, p<0.01), with a higher number o f females responding ‘Yes’ than males 
(71.4% versus 64.7%). Analysis by age group showed significant differences, where the 
50-54 years age group contained proportionally more ‘Yes’ answers than the 55-59 age 
group (x = 3.85, df = 1, p = 0.05), and also contained proportionally more ‘No’ answers 
than the age groups 80-84 (x2 = 6.14, d f = 3, p<0.05) and 85+ (x2 = 4.15, df = 1, 
p<0.05). This suggests either adults suffered less with DMS in very old age, or that the 
80-84 and 85+ groups were too small in number to achieve true results. If less DMS is 
suffered in ‘old old’ age, then there is not a linear decline in DMS, as there were no 
differences found linearly between age groups.
Further breakdown into age versus gender showed no trends. However 
significance was achieved between females aged 50-54 and females aged 80-84 (x2 =
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4.61, df = 1, p<0.05), and also between males and females both aged 65-69 (x2 = 12.46, 
d f = 1, p<0.01).
The severity o f DMS was provided by 4377 respondents. Again, the majority o f 
answers were in the ‘Mild’ (51.3%) and ‘ Moderate5 (39.3%) categories, and fewer in 
‘ Severe’ (9.4%). There was significant difference between genders (x2 = 15.42, df = 2, 
p<0.01), with males principally answering ‘Mild’ (55.4%) and females responding in 
similar quantities to both ‘Mild’ (49.5%) and ‘Moderate’ (40.3%). This indicates that 
females may suffer slightly worse DMS than males. There was no significant difference 
found between age groups, and few results noted in the age by gender breakdown. 
Significance was noted between females aged 50-54 and 80-84 (x2 = 20.98, df = 2, 
p<0.01), males and females aged 65-69 (x2 = 13.32, df = 2, p<0.01) and also between 
males and females aged 80-84 (x2 = 15.42, df = 2, p<0.01). There were no trends present 
with increasing age.
There were 4413 respondents to the question regarding the occurrence o f DMS, 
and the majority answered in the categoiy o f  4-7 nights per week (38.6%). There was 
significant difference between the genders (x2 = 15.68, df = 4, p<0.01). Although both 
genders answered principally 4-7 nights per week, males responded more to this 
categoiy than females. One age effect was noted, as the age group 85+ contained 
answers significantly different to 50-54 (x2 = 20.20, df = 4, p<0.01) and 80-84 (x2 = 
16.27, d f = 4, p<0.01). This may indicate a difference in the occurrence o f  DMS only 
after the age o f 85+ (more respondents to the 4-7 nights per week categoiy), or again it 
could be a type I error due to proportionally fewer respondents in the 85+ category (n = 
134). Further breakdown revealed only one significant difference, between males and 
females aged 75-79 (x2 = 24.58, df = 4, p<0.01). There were no trends within the age 
groups, or by age versus gender.
3.4.1.5 Early Mornins Awakeninss (EMA)
There were 5259 respondents, and the results are shown in Graph 3.3. The 
numbers responding to ‘ Yes’ and ‘No’ were veiy similar at 49.6% and 50.4% 
respectively. There were significantly (x2 = 4.41, df = 1, p<0.05) more females than 
males responding ‘Yes’ compared to ‘N o’ . Age differences were again apparent over 
the age o f 85 (compared with age 50-54 (x2 -  6.04, df = 1, p<0.05) and 80-84 (x2 = 4.88, 
df = 1, p<0.05), with again maybe due to relatively few answers (n = 134). Also
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significance was noted between age groups 55-59 and 60-64 (x2 = 4.51, df = 1, p<0.05), 
but no trends were noted. Further analysis noted significant differences between males 
aged 50-54 and males aged 75-79 (x2 = 6.13, df = 1, p<0.05) and 85+ (x2 = 7.18, df = 1, 
p<0.01). There were also differences between males and females aged 70-74 (x2 = 
14.19, df = 1, p<0.01) and 75-79 (x2 — 19.61, df = 1, p<0.01), but there were no age by 
gender trends.
The severity o f  EMA suffered was reported by respondents, and this was mostly
thought ‘Mild’ (58.0%). Analysis o f the genders showed both responded ‘Mild’ the
• • 2most, but males gave significantly (x = 8.85, df = 2, p<0.05) more ‘Mild’ responses 
than females, and females gave more ‘Moderate’ and ‘ Severe’ responses than males. 
There was no significant effect o f  age on severity o f EMA. Further analysis revealed 
this was due to lack o f  significant age effect within females, but males showed an effect 
when comparing 50-54 year olds with 65 years and older (x2 = 7.22, df = 2, p<0.05). 
Inspection o f  data shows reports tend towards ‘Mild’ with over 65 year old males, and 
less towards ‘Moderate’ . There are also significant differences between males and 
females aged 75-79 (x2 = 9.41, df = 2, p<0.01) and 85+ (x2 = 6.67, df = 2, p<0.05).
There were 2947 respondents to this question regarding the occurrence o f EMA 
suffered, and this was mostly placed at 4-7 nights per week (44.7%). There were, 
however, no significant differences between male and female responses. With respect to 
age, there was significant difference between ages 50-54 and 70-74 (x2 = 21.50, df = 4, 
p<0.01), and also between 60-64 and 65-69 (x2 = 17.72, df = 4, p<0.01), 65-69 and 70- 
74 (x2 = 94.65, df = 4, pO .O l) and 70-74 and 75-79 (x2 = 59.79, df = 4, p<0.01) years o f 
age. 65-69 year olds mostly responded 1-3 nights per week, while 70-74 year olds 
mostly responded <1 night per week. Further analysis revealed no significant age by 
gender effects.
3.4.1.6 Getting Enonsh Sleep
There were 5316 respondents, and most answered ‘N o’ as to whether they felt 
they had enough sleep (62.0%). There was a significant difference between answers 
given by males and females (x2 = 70.04, df = 1, p<0.01), as more females felt they did 
not get enough sleep. Analysis by age shows significant differences between ages 50-54 
and 60+ (x2 -  17.32, df = 1, p<0.01), indicating those 60 years and over reported not 
getting enough sleep more than those under 59. However, the feeling that not enough
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sleep was obtained does not get more prevalent with increasing age. Although there was 
significant difference between ages 55-59 and 60-64 (x2 = 15.10, d f = 1, p<0.01) and 
between 60-64 and 65-69 (x2 = 4.82, df = 1, p<0.05), there were no other effects 
indicating there was no general linear increase in ‘No’ answers.
This age effect o f  the over 60’s was also present in both males and females, with 
significant differences between males 50-54 compared to 60+ (x2 = 7.15, df = 1, p<0.01) 
and with females 50-54 compared to 60+ (x2 = 9.53, df = 1, p<0.01). However, there 
were differences between the male and female age groups, with significant differences 
between males and females aged 60-64 (x2 = 5.31, df = 1, p<0.05), 65-69 (x2 = 29.09, df 
= 1, p<0.01), 70-74 (x2 = 19.20, df = 1, p<0.01), 75-79 (X2 = 12.08, df = 1, p<0.01) and 
85+ (x2 = 4.11, df = 1, p<0.05). Here, proportionally more females responded ‘Yes’ they 
have enough sleep than males responded.
The number o f  responses totalled 2608 for the question regarding the severity o f 
not getting enough sleep. The most frequent answers given were ‘Mild’ and ‘Moderate’ 
(41.1% and 42.2% respectively), with relatively few reporting ‘ Severe’ problems with 
not getting enough sleep (16.7%). There were no significant differences between 
answers given by males and females, and also between age groups. An age by gender 
breakdown also revealed no significant effects.
The occurrence o f  not getting enough sleep was provided by 2693 respondents, 
most frequently reporting not getting enough sleep on 4-7 nights per week (37.1%). 
There was no significant difference between the genders; however there were some 
significant effects when data was analysed by age. Differences were noted between 50- 
54 years and 65-69 years (x2 = 29.50, df = 4, p<0.01), and also between 60-64 and 65- 
69 years (x2 = 59.06, df = 4, p<0.01), 65-69 and 70-74 years (x2 = 59.47, df = 4, 
p<0.01), and 70-74 and 75-79 years (x2 = 15.61, df = 4, pcO.Ol). This does not imply a 
linear age related effect. Indeed, analysis o f age by gender revealed no significant 
effects.
3.4.1.7 Tiredness on Awakening
The question regarding being tired on awakening was answered by 5365 
respondents, and most responded ‘No’ (53.7%). There was a difference between male 
and female reports, where significantly more males said ‘Yes’ , they were tired on 
awakening (x2 = 49.40, df = 1, p<0.01). There are also significant differences between
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the 50-54 age group and all other age groups (all p<0.01), but significance between only 
60-64 versus 65-69 (x2 = 5.71, df = 1, p<0.05) and 65-69 versus 70-74 (x2 = 10.49, df = 
1, p<0.01) shows there is no linear trend with increasing age. However, further 
breakdown analysis age by gender showed males after the age o f  65 answered ‘No’ 
more often than ‘Yes’ (x2 = 21.26, df -  1, p<0.01), and females over 70 answered ‘No’ 
more often than ‘Yes’ (x = 38.31, df = 1, p<0.01). By gender, there was an age related 
trend towards less complaints o f  tiredness on awakening. Also, over the age o f  70, 
females reported a lack o f  tiredness on awakening more than males did (males versus 
females 70-74 (x2 = 15.92, df = 1, p<0.01), 75-79 (x2 = 4.74, df = 1, p<0.05) and 80-84 
(X2 = 5.72, df = 1, p<0.05)).
The severity o f being tired on awakening was provided by 2840 respondents. 
Severity was mostly judged as ‘Mild’ (54.3%), and males reported more ‘ Severe5 
complaints than females (x2 = 16.81, df = 2, p<0.01). Some significance between ages 
was noted, whilst comparing 50-54 year olds with those 65-69 (x2 = 9.08, df = 2, 
p<0.05), 70-74 (x2 = 18.01, df = 2, p<0.01) and 75-79 = 12.28, df = 2, p<0.01).
However, no effects o f  increasing age were found. Investigation into age by gender 
effects shows some significance around the ages o f  70-74 and 75-79 when compared to 
50-54. These ages were significantly different for males (both p<0.05), as more males in 
these age groups reported ‘Mild5 severity. Differences were also found for females 
between 50-54 and 70-74 (x2 = 10.84, df = 2, p<0.01) and 75-79 (x2 = 6.68, df = 2, 
p<0.05), which was also due to a proportional increase in ‘Mild5 responses. Significance 
was also noted between the genders for the ages o f  70-74 and 75-79 (both p<0.05), as 
females in the age group proportionally reported more ‘Mild5 responses than their male 
counterparts.
The occurrence o f  being tired on awakening was specified by 2724 respondents. 
The principally reported answers were 1-3 nights per week (32.3%) and 4-7 nights per 
week (36.8%). There were no statistical differences between genders, ages, and no 
effects o f gender on age.
3.4.1.8 Havins Other Sleev Complaints
There were 5388 responses to the question o f whether or not respondents have 
another sleep complaint, and results are shown in Graph 3.4. Many more responded 
‘No5 to having another sleep complaint than ‘ Yes5 (70.7% versus 29.3%), however,
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there were no gender differences in the number o f reported sleep complaints, and no age 
differences. An age by gender breakdown showed a few significant differences. These 
were between females aged 50-54 and females aged 60-64 (y2 = 21.28, df = 1, p<0.01), 
and also between males and females aged 55-59 (%2 = 7.73, df = 1, p<0.01), 60-64 (x2 =
17.74, df = 1, p<0.01) and 85+ (x2 -  5.66, d f = 1, p<0.05). There were no age by gender 
trends present.
When asked to specify these sleep complaints, 1695 respondents gave answers, 
and these results are shown in Graph 3.5. The top ten most frequently reported sleep 
complaints were: needing the toilet (29.4%); pain (10.0%); excessive or vivid dreaming 
(7.9%); unspecified or general insomnia (5.8%); snoring (5.2%); other medical 
complaints (4.9%); thoughts running through mind (4.6%); nightmares (4.1%); waking 
easily or frequently (4.0%); and cramp (3.9%). There was a significant difference 
between the type o f  problems males and females complained o f  (x2 = 207.26, df = 22, 
p<0.01). The top three male complaints were: needing the toilet (45.4%), snoring 
(8.0%), and pain (7.7%), whereas females reported: needing the toilet (20.1%), pain 
(11.2%), and excessive or vivid dreaming (9.0%) as their top three complaints.
Analysis o f age groups revealed significant differences between group 50-54 
years and 60-64 years (x = 35.56, d f = 21, p<0.05), and age groups between 65 and 85+ 
years (all p<0.01). The number o f respondents suffering from nightmares, snoring, and 
hot flushes decreased with increasing age, however, numbers needing the toilet 
significantly increased with increasing age, rising to 69.7% at age 85 and over. Age by 
gender analysis again showed gender differences were significant between male and 
female age groups 55-85+, at the 1% level. There was no difference between males and 
females aged 50-54. There was significant difference between males aged 50-54 and 
males aged 75-79 (x2 = 44.70, df = 18, p<0.01), 80-84 (x2 = 23.01, df = 10, p<0.05) and 
85+ (x2 = 26.36, df = 6, p<0.01). Older males (75+) reported needing the toilet more, 
but had fewer nightmares and snored less than their younger (50-74) counterparts. There 
was significant difference between females aged 50-54 and those aged 60-64 (x2 = 
39.88, df = 22, p<0.05), 65-69 (X2 = 37.79, df = 20, p<0.01), 70-74 (%2 = 41.62, df = 20, 
p<0.01), 75-79 (x2 = 71.37, df = 21, p<0.01), and 80-84 (X2 = 40.75, df = 20, p<0.01). 
There was no significance between females aged 50-54 and 85+, but this could again be 
due to the relatively small numbers surveyed in this eldest age group. Alternatively, the 
differences seen between the 85+ year olds and the other age groups may be due to the 
successful ageing seen in this group, by the fact that this high age was reached. This
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Graph 3.1: Showing percentage (% ) differences in DIS between males and females at the different age 
groups. As age increases, females suffer more than males. * indicates significant difference at the 5% 
level, and ** indicates significant difference at the 1% level.
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Graph 3.2: Showing percentage (%) differences in DMS between males and females at the difference age 
groups. There is little difference in prevalence between genders. * indicates significant difference at the 
5% level, and ** indicates significant difference at the 1% level.
70
Have Early Morning Awakenings (EMA)
<sLUCT>
£
3(/>Q>
05
3
□  Males 
■  Females
50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+
Age (years)
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at the 5% level, and ** indicates significant difference at the 1% level.
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years'). There is little change o f  excessive/vivid dreaming, pain, and thoughts running through the mind 
with age, but snoring decreases and needing the toilet increases dramatically.
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Graph 3.6: Showing the percentage (% ) use o f  any prescription medications for sleep problems, for males 
and females in each age group. Male usage does not increase with increasing age as female usage does. * 
indicates significant difference at the 5% level, and ** indicates significant difference at the 1% level.
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Graph 3.7: Showing the percentage (% ) o f  the types o f  prescription medications taken for sleep problems 
in each age group (see key for ages in years). Nitrazepam is taken primarily bv the oldest elderly. 
temazepam is taken at all older ages, and zopiclone is favoured by the younger elderly.
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Graph 3.8: Showing the percentage (%) use o f  ‘over-the-counter’ (OTCI and herbal remedies bv males 
and females in each age group. There is little difference between genders and age, and there were no 
significant differences.
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Graph 3.9: Showing the percentages (%) o f  the types o f ‘ over-the-counter’ (OTC) and herbal remedies 
used by each age group (see key for ages in years). Nvtol and camomile tea are most popular overall, and 
the use o f  analgesics dramatically increases with increasing age.
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may imply these respondents are different from ‘normal’ elderly who may not reach 
these ages, because they may be fitter, healthier or hardier. With increasing age, females 
showed a trend towards less snoring, increased need for the toilet and increased 
prevalence o f thoughts running through their minds.
The question o f the severity o f their sleep complaints was answered by 1964 
respondents. Most answered ‘Moderate’ (50.3%), but there were significant differences 
between male and female responses (x2 = 15.91, df = 2, p<0.01). Males tended to claim 
more ‘Mild’ severity and less ‘ Severe’ severity than females. Comparisons between age 
groups revealed no significant effects, and an age by gender breakdown showed no age 
differences within females. However, males aged 50-54 differed from males age 70-74 
(x2 = 6.71, df = 2, p<0.05), 75-79 (x2 = 7.15, d f = 2, p<0.05), 80-84 (x2 = 6.50, df = 2, 
p<0.05) and 85+ (x -  7.02, df = 2, p<0.05), where these groups reported proportionally 
less ‘ Severe’ responses. Significance was also found between males and females aged 
70-74 (%2 = 7.33, df = 2, p<0.05) and 75-79 (%2 = 8.51, df = 2, p<0.05) where these two 
female groups reported relatively more ‘Moderate’ responses than their male 
counterparts.
There were 2327 responses given to the occurrence o f  their sleep complaint. The 
most popular response was 4-7 nights per week (43.9%), and there were significant 
difference between male and female responses (y2 = 22.43, d f = 4, p<0.01), where males 
reported more 4-7 nights per week occurrences than females. However, there were no 
significant differences between the age groups, or age groups divided by gender.
3.4.1.9 Effect o f  Sleep Complaints on Daytime Activities
There were 4945 responses given to the question o f  whether they thought their 
sleep complaint affected how they carried out their daytime activities. Most said ‘No’ , 
their complaint did not affect their daily performance (77.7%), and more females than 
males replied ‘Yes’ (x2 — 34.67, df = 1, p<0.01). There are significant differences 
between the age group 50-54 and all age groups over 60 years (all p<0.01), and 
differences between ages 55-59 and 60-64 (x2 = 14.66, df = 1, p<0.01), 60-64 and 65-69 
(X2 = 9.33, df = 1, p<0.01) and 65-69 and 70-74 (%2 = 6.30, df = 1, p<0.05) show there 
was an age-related effect in 55 to 74 year olds, where less respondents felt their sleep 
complaints had an effect on daytime performance. After the age o f 74, there was a 
plateau in the disruption to daytime performance. Analysis o f  age by gender shows both
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males and females showed reduction in the numbers reporting that their complaint 
affects their day, after the age o f 60 years (p<0.01). There was also significance 
between males and females aged 65-69 (x2 = 11.88, df = 1, p<0.01), 70-74 (x2 = 17.20, 
df = 1, p<0.01) and 75-79 (x2 ~ 5.51, df = 1, p<0.05), where proportionally less females 
complained o f daytime effects than males.
The severity o f  the effects on their daytime performance was reported by 1506 
respondents, and most opted for ‘Moderate’ severity (45.8%). There were no significant 
differences between male and female responses, and no significant age differences. Age 
by gender analysis showed significance only between males and females aged 70-74 (x2 
= 7.93, df = 2, p<0.05), so there were no age related trends.
The frequency o f  sleep complaints affecting daytime activities was reported by 
1673 respondents. The principle answers given were occurrences o f  4-7 nights per week 
(34.8%) and 1-3 nights per week (28.8%). There were no significant differences 
between male and female answers. Significant differences were found between age 
groups 50-54 and 65-69 (x2 = 11.10, df = 4, p<0.05) and 75-79 = 13.48, d f = 4,
p<0.01), and also between ages 55-59 and 60-64 (% = 12.64, df = 4, p<0.05). Age by 
gender analysis revealed no significant effects.
3.4.1.10 Use o f  Prescription Medication
Here, 5575 responses were given to the question as to whether prescription 
medication was taken for sleep complaints. Results are shown in Graph 3.6. Many more 
said ‘No’ than ‘Yes’ (89.2% versus 10.8%). There was a significant difference in 
prescription use between males and females (x2 = 25.53, df = 1, p<0.01), as females 
tended to use more prescription medication than males (12.4% versus 8.0%). There was 
no age related linear increase in prescriptions used, as there was only significant 
difference between 70-74 year olds and 75-79 year olds (x2 = 5.29, df = 1, p<0.05). 
However, other comparisons showed older adults use more prescribed medication than 
younger adults, the cut-off point being 75 years and above (significant differences 
between 50-54 year olds and those 75-79 (x2 = 7.27, d f = 1, p<0.01), 80-84 (x2 -  8.59, 
df = 1, p<0.01) and 85+ (x2 = 9.93, df = 1, p<0.01)). Further analysis showed this was 
only the case for females and not males. There were no significant age by gender results 
for males, but females age 50-54 significantly differed from those aged 75-79 (x2 =
11.91, df = 1, p<0.01), 80-84 (x2 = 13.36, df = 1, p<0.01) and 85+ (x2 = 18.87, df = 1,
Chapter 3
81
p<0.01). This was also reflected in significant differences between males and females 
aged 60-64 = 4.82, d f = 1, p<0.05), 65-69 (x2 = 6.39, df = 1, p<0.05), 75-79 (x2 =
15.14, df = 1, p<0.01), 80-84 (x2 = 6.40, d f = 1, p<0.05) and 85+ (x2 = 6.21, df = 1, 
p<0.05).
The survey showed that o f  prescription users, 10.2% where long nappers, 10.7% 
were short nappers, 13.2% were tired on awakening, 7.7% were not tired on awakening, 
15.5% felt they got enough sleep, and 6.7% felt that they did not get enough sleep. Of 
hypnotic users, 5.2% took long naps and 6.5% took short naps, 8.3% were tired on 
awakening, 4.0% were not tired on awakening, 3.2% felt that they did not get enough 
sleep and 10.3% felt that they did get enough sleep.
Prescriptions taken were specified by 595 respondents, and results are shown in 
Graph 3.7. The top ten prescription medications reported were: temazepam (26.4%), 
analgesic (13.6%), other medication (13.1%) and nitrazepam (13.1%), zopiclone 
(7.6%), unspecified hypnotic (4.2%), amytriptyline (3.4%), diazepam (2.9%), 
lormetazepam (2.4%), and antihypertensives (2.2%). There was a significant difference 
between answers given by males and females (x2 = 53.36, df = 26, p<0.01), where the 
top three male’ s prescriptions were: other medication (20.5%), temazepam (19.9%), and 
analgesic (12.2%), and the top three female’ s prescriptions were: temazepam (28.7%), 
nitrazepam (14.7%), and analgesic (14.2%). Overall, there was no significant difference 
between the number o f  hypnotics and the number o f  antidepressants that were taken by 
males and females. There were no age differences between the types o f prescription 
medication taken, and no age by gender effects.
3.4.1.11 Use o f  Additional Prescrivtion Medication
Respondents also indicated if  they took more than one prescription medication, 
and results showed the majority did not use a second prescription (5.3% versus 94.7%). 
There were no gender or age differences, and no age by gender effects. This may be due 
to the small number o f  respondents.
There were 32 respondents who specified their additional prescribed medication. 
The top five additional prescriptions taken were: analgesics (34.4%), lormetazepam 
(15.6%), nitrazepam (9.4%) and antihypertensives (9.4%), and frusemide or other 
diuretic (6.3%) and diazepam (6.3%). There were no differences between males and
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females or age groups, and no age by gender effects. This may also be due to the small 
number o f respondents.
3.4.1.12 Use o f  OTC/Herbal Remedies for Sleep Complaints
There were 5530 responses to the question o f whether or not OTC or herbal 
remedies were used to aid sleep, and the results are shown in Graph 3.8. 17.7% reported 
using an ‘over-the-counter’ or herbal remedy, and 82.3% responded ‘N o’ . There were 
no differences between male and female use, and no differences between use in each 
age group. There were also no age by gender effects.
There were 1017 respondents who specified their OTC or herbal remedy, and 
the results are shown in Graph 3.9. The top ten answers given were: Nytol (14.6%), 
camomile tea (13.2%), analgesic (11.9%), herbal or fruit tea (other type or not 
specified) (10.7%), other remedy or shop’ s own brand (9.8%), Kalms (5.6%), valerian 
(5.3%), Natrasleep (5.1%), Nytol Herbal (3.0%), and lavender oils (2.7%). There was 
significant difference between the types o f preparations taken by males and females (x2 
= 45.60, df = 27, p<0.05). The top three remedies used by males were: other or shop’ s 
own brand (14.4%), analgesic (13.9%), and Nytol (12.8%), while the top three 
preparations used by females were: Nytol (15.0%), camomile tea (14.2%), and 
other/unspecified herbal or fruit tea (11.5%) and analgesic (11.5%). There were no 
differences in the type o f  OTC/herbal preparations taken by different age groups, and 
there was only one significant difference when investigating age and gender (between 
females aged 50-54 and females aged 80-84 (x2 = 30.02, df = 17, p<0.05)).
3.4.1.13 Use o f  Additional OTC/Herbal Remedies for Sleep Complaints
The use o f  more than one OTC or herbal remedy was reported by 182 
respondents, and most did not use an additional ‘ over-the-counter’ or herbal preparation 
(96,9% versus 3.1%). There was significant gender difference (x2 = 169.46, df = 1, 
p<0.01) where more females used an additional remedy than males. There were also age 
differences between 50-54 and 60-64 (x2 -  4.55, df = 1, p<0.05), 65-69 (x2 = 13.44, df = 
1, p<0.01), 70-74 (x2 = 6.17, d f = 1, p<0.05), 75-79 (x2 = 8.90, df = 1, p<0.01), 80-84 
(X2 = 7.81, df = 1, p<0.01) and 85+ (x2 = 7.00, df = 1, p<0.01). In each case, fewer 
additional remedies were used. However, this only applied to females, as further
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analysis showed no significant age differences for males, but significant differences for 
females aged 50-54 and 60-64 (/  = 3.93, df = 1, p<0.05), 65-69 = 15.93, df = 1,
pO.Ol), 70-74 (x2 = 4.32, df = 1, p<0.05), 75-79 (x2 = 10.21, d f = 1 p<0.01), 80-84 (x2 
= 9.05, df = 1, p<0.01), and 85+ (x2 = 6.71, df = 1, p<0.05). It is females over the age o f  
60 who, with increasing age, used less and less additional remedies. This is not linear as 
there was little evidence for male and female effects over increasing age; there were 
only effects found for males and females aged 60-64 (x2 = 10.32, df = 1, p<0.01) and 
70-74 (x2 = 19.05, d f= 1, p<0.01).
These additional OTC or herbal remedies were specified by 182 respondents. 
The top ten additional remedies used were: camomile tea (22.5%), Nytol Herbal 
(14.3%), other or shop’ s own brand (11.0%), other/unspecified herbal/fruit tea (10.4%), 
valerian (8.8%), Natrasleep (6.6%), Quiet Life (4.4%), lavender oils (2.8%) and 
homeopathic remedies (2.8%), and Somnus (2.2%) and Bach’ s Rescue Remedy (2.2%). 
There were gender differences between additional remedies used, where males took: 
other/unspecified herbal/fruit tea (19.2%), other or shop’ s own brand (15.4%), and 
camomile tea (11.5%) and valerian (11.5%), and females took: camomile tea (24.4%), 
Nytol Herbal (15.4%), and other or shop’ s own brand (10.3%). There were no 
significant differences between age groups, and no age by gender effects.
3.4.1.14 Use o f  Alcohol as a Sleep Aid
There were 5474 respondents to the question o f whether or not alcohol was used 
as an aid to sleep. Results showed 11.0% took alcohol and 89.0% did not take alcohol 
for sleep problems. There was significant difference between the genders (x2 “  7.53, df 
= 1, p<0.01) as more males used alcohol than females. There were age differences 
between 50-54 and 55-59 years where less people in the latter group were users (x2 = 
4.52, df = 1, p<0.05), and also between 70-74 and 75-79, where there was an increase in 
use (x2 = 5.11, df = 1, p<0.05). There were no age trends, or trends involving age and 
gender, due to significant differences only between females aged 50-54 and 55-59 (x2 = 
5.46, d f = 1, p<0.05), and also between males and females aged 55-59 (x2 = 6.02, df = 1, 
p<0.05), 60-64 (x2 = 6.13, d f= 1, p<0.05) and 85+ (x2 = 3.90, df = 1, p<0.05).
There were 590 respondents who reported the types o f alcohol they used to aid 
sleep. The top ten alcoholic drinks used were: whisky (37.3%), wine (22.2%), sherry 
(9.5%), brandy (9.0%), unspecified alcohol (6.8%), bitter (5.1%), gin (3.2%),
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unspecified spirit (2.4%), lager (1.2%), and port (0.7%) and other (0.7%). There was 
significant difference between male and female choices for alcohol (%2 = 78.71, df = 15, 
p<0.01), where males preferred: whisky (42.6%), wine (15.7%), and bitter (10.4%), and 
females preferred: whisky (33.3%), wine (27.4%), and sherry (14.0%). There were no 
significant differences between age groups, although further analysis showed 
differences between males aged 50-54 and males aged 65-69 (x2 -  21.35, df = 8, 
p<0.01), and between females aged 50-54 and 80-84 (x2 = 26.71, df = 9, p<0.01). More 
interestingly, there were more differences between male and female age groups, 
between males and females aged 55-59 (x2 -  18.08, df = 8, p<0.05), 60-64 (x2 = 26.23, 
d f = 9, pO.Ol), 65-69 (x2 = 60.92, df = 11, p<0.01), 70-74 (x2 = 19.65, df = 11, p<0.05), 
75-79 (x2 = 21.68, d f= 10, p<0.05), and 80-84 (X2 = 25.15, df = 10, p<0.01). The lack o f 
significance between the 85+ age groups may again be due to small numbers o f 
respondents. Females used more sherry and brandy with increasing age, and less bitter 
and wine. Males used more wine and more whisky with increasing age.
3.4.1.15 Use o f  Additional Alcohol as a Sleep Aid
There were 113 respondents who reported using an additional alcohol or not, 
and 19.2% used an additional alcohol, compared to 80.9% who did not. There were no 
significant differences between the genders, age groups, and there were no age by 
gender effects.
Additional alcohols used to aid sleep were identified by 113 respondents, and 
the top ten additional alcohols used were: wine (23.0%), whisky (19.5%), brandy 
(14.2%), sherry (12.4%), bitter (7.1%), gin (5.3%) and unspecified spirit (5.3%), lager 
(4.4%), and port (1.8%), vodka (1.8%), and rum (1.8%). There was a difference 
between the additional alcohols males and females use (x2 = 25.34, df = 14, p<0.05), 
males preferred: whisky (24.5%), brandy (18.4%), and wine (16.3%), whereas females 
preferred: wine (28.1%), sherry (17.2%), and whisky (15.2%). There were no 
significant age or age by gender effects.
3.4.1.16 Use o f  Other Beverages as Sleev Aids
Whether other beverages were used as sleep aids was reported by 5430 
respondents. More people did not use a beverage to improve their sleep (68.7%), and
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31.3% do use a beverage. There was significant difference between the number o f males 
and females that used a beverage (x2 = 132.22, df = 1, p<0.01), and females used more 
beverages than males. There were no significant age differences, but age by gender 
analysis revealed significant differences between females aged 50-54 and 55-59 (x2 = 
4.70, d f = 1, p<0.05), 65-69 (x2 = 8.87, d f = 1, p<0.01), 70-74 (x2 = 5.50, d f = 1, 
p<0.05), and 75-79 (x2 — 7.63, df = 1, p<0.01). These females used fewer beverages 
than their younger (50-54 year old) counterparts. There were also significant differences 
between all age groups when males were compared to their female counterparts (all 
p<0.01). Inspection reveals females o f  all ages used more beverages than males o f the 
same age.
There were 1637 respondents who identified which beverages they use. The top 
ten were: Horlicks (28.0%), hot chocolate (17.8%), hot milk (15.3%), Ovaltine (10.2%), 
tea (9.6%), milk (8.3%), cocoa (3.4%), water (1.7%), coffee (1.5%), and other (1.1%). 
There was significant difference between the beverages used by males and females (x2 =
30.74, d f = 16, p<0.05). Males drank: Horlicks (29.6%), hot chocolate (18.9%), and tea 
(12.2%), whereas females drank: Horlicks (27.5%), hot milk (17.8%) and hot chocolate 
(17.4%). There were no age differences, but some were elucidated when analysing age 
by gender. There was significant difference between females aged 50-54 and 80-84 (x2 
= 25.04, df = 15, p<0.05) and 85+ (x2 = 21.84, df = 12, p<0.05). There were also 
differences between males and females aged 70-74 (x2 = 36.23, df = 15, p<0.01) and 75- 
79 (x2 = 24.57, df = 14, p<0.01). With increased age, males drank more hot milk, and 
females drank more tea and hot milk, and less hot chocolate.
3.4.1.17 Use o f  Additional Bey erases as Sleep Aids
There were 339 respondents to the question o f  whether additional other 
beverages were used as sleep aids, and most replied ‘No’ (79.3%) with 20.7% replying 
‘Yes’ . Significantly more females used an additional beverage than males (x2 = 27.81, 
df = 1, p<0.01), but there were no differences between the age groups. However, there 
was significant difference between males and females age 70-74 (x2 = 6.58, df = 1, 
p<0.01), 75-79 (x2 = 7.39, df = 1, p<0.01), 80-84 (x2 = 6.49, df = 1, p<0.05) and 85+ (x2 
= 6.48, df = 1, p<0.05), whereby these females replied ‘Yes’ more than the males.
There were 339 respondents who identified additional beverages used to aid 
sleep. The top ten additional beverages were: hot chocolate (23.6%), Horlicks (20.4%),
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Ovaltine (17.4%), coffee (9.2%), cocoa (6.8%), hot milk (5.6%), tea (5.3%) and milk 
(5.3%), decaffeinated coffee (1.8%), and Bovril/Oxo (1/5%). There were no differences 
between the genders, and only significance between the age groups for ages 65-69 and 
70-74 (x2 = 29.18, df = 14, p = 0.01) and 75-79 and 80-84 (x2 = 26.02, df = 12, p<0.05). 
There were no significant age by gender effects.
3.4.1.18 Use o f  Other Methods as Sleep Aids
There were 4991 responses to the question of whether or not any other methods 
were employed by the respondent to aid sleep. Most people said they did not have any 
other methods for sleeping (90.9%) and 9.1% said they did use another method. There 
were gender differences between the answers to this question, as more females tended to 
use another method more than males (x2 == 34.12, df = 1, p<0.01). There were no 
differences between the age groups, but there were significant differences between 
females aged 50-54 and 75-79 (x2 = 4.77, df = 1, p<0.05), and between males and 
females aged 55-59 (x2 = 7.39, df = 1 , p<0.01), 65-69 (x2 = 9.20, df = 1, p<0.01), 75-79 
(X2 = 6.89, df = 1, p<0.01) and 80-84 (x2 = 9.88, df = 1, p<0.01). This was due to 
females using more methods than males.
There were 430 respondents who identified the other methods they used to 
improve their sleep. The top ten methods were: reading (20.5%), other (e.g. TV, eye 
mask, Magnetic Field Therapy, puzzles, hypnotherapy, sexual activity) (18.3%), 
aromatherapy (10.9%) and special bed or bedding (10.9%), heat (e.g. Hot Water Bottle, 
Electric Blanket) (9.1%), meditation/breathing (8.6%), radio (5.6%), eating (3.5%), 
music (3.3%), and exercise (2.1%). There were significant differences between male 
and female methods (x2 = 45.18, df = 16, p<0.01). Males favoured: other (e.g. TV, eye 
mask, Magnetic Field Therapy, puzzles, Hypnotherapy, sexual activity) (29.1%), special 
bed or bedding (15.5%), and reading (9.1%), whist females favoured: reading (23.7%), 
other (e.g. TV, eye mask, Magnetic Field Therapy, puzzles, Hypnotherapy, sexual 
activity) (15.7%), aromatherapy (13.2%). There were no differences between the age 
groups, but analysing age by gender showed differences between females aged 50-54 
and 65-69 (x2 = 36.50, df = 12, p<0.01), and between males and females aged 65-69 (x2 
= 36.64, df = 12, p<0.01) and 70-74 (x2 = 24.20, df = 13, p<0.05). This was due to the 
gender differences, and there were no age or age by gender trends present.
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This survey is one of the largest and most comprehensive surveys of sleep and 
sleep behaviours of older adults and the elderly. A sample size of 5846 respondents was 
used, all aged between 50 and 98 years of age (mean age 69 ± 8.5 years). When dealing 
with subjective reports, a greater the number of participants can improve the reliability 
of findings, as Kryger et al. (1991) stated “ ...the intrinsic noise of subjective 
measurement seems to be counterbalanced by the increased signal.” (p.406). Morgan et 
al. (1988b) found some questionnaires can lack necessary detail. To address this, this 
survey totalled 16 multi-part questions, exploring different aspects of common sleep 
problems (difficulty initiating and maintaining sleep) and solutions, and incorporating 
open ended questions helped ensure quality data was collected, including details of 
other sleep complaints. A  vast amount of data was processed, which offers valuable 
insight into all areas of elderly sleep.
3.5.1 The Self-Report Survey
These insights are subjective only. Self reports can prove inaccurate, such as the 
difference in reporting between good and poor sleepers of sleep latency estimation, the 
number of nocturnal awakenings, and also total sleep time (Adam et al., 1986; 
Liljenburg et al., 1988; Morin and Gramling, 1989). However, this present questionnaire 
avoids reference to ‘sleep latency’ or amount of time taken to sleep onset, and instead 
asks generally about troubles experienced with getting off to sleep. Also, there is no 
reference to nocturnal awakenings, and questions are only asked about maintenance of 
sleep. One problem with the present survey is the question about the number of hours 
slept. It is difficult to accurately judge the exact amount of sleep obtained. Response 
categories were designed so that a general picture of time spent sleeping could be 
obtained, by each category spanning several hours, rather than forcing the participants 
to choose an exact duration of sleep. However, it is possible that times reported are 
actually the times spent in bed, rather than hours slept.
There is also a difference between the accuracy of reports given by males and 
females, as it has been suggested females have a higher agreement between subjective 
and objective measures of sleep (Hoch et al., 1987). Females may be better subjective 
judges than males, and so this may lead to false conclusions about differences between
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male and female sleep and bedtime behaviour. In addition, surveys show only 
correlational effects, and care must be taken to view the data in this manner. Also, it is 
noted that this survey contains potentially embarrassing or sensitive questions, for 
example about toilet use and bedroom habits, and so may be subject to dishonesty or 
censoring in the responses given (Phillips, 1971). This was avoided by identifying the 
questionnaires by numbers only, as names were not associated with the paper 
questiomiaire in any way.
Other bias that could be introduced into these results are in the types of 
participants used. As previously explained, there are many cultural and social 
perceptions of sleep (Domino, 1986). SAGA magazine is aimed at the over-50’s, which 
ensured a good sample. It is a national magazine, so invited males and females from all 
parts of the country to participate. Also, because initial responses were to a trial of 
ginkgo biloba, and not sleep habits, the sample is thought to be representative with 
respect to sleep and sleep behaviour. However, it may be that this survey was 
distributed only to older adults who could afford to purchase the magazine, who are 
perhaps more active, better educated, and who have better physical health (e.g. getting 
to the shops, eyesight good enough for reading etc.). Also, the questions asked in the 
survey referred only to sleep and sleep behaviour in the previous month. A longer or 
shorter time frame may elucidate different findings, as suggested by Habte-Gabr et al. 
(1991). This survey was also completed over the winter, and so answers will be biased 
accordingly.
3.5.2 Sleep in the Older Adult
3.5.2.1 The Prevalence o f  Sleep Disturbance
The results of this survey agree with previous research in the U.S. and England 
(Karacan et al., 1976; Mellinger et al., 1985; Morgan et al, 1988b) that there is an 
increase in the prevalence of sleep problems with increasing age. However, this survey 
also shows these effects are selective. Over the age of 60 years, fewer males and 
females feel that they are getting enough sleep; more males and females nap as they get 
older; females over the age of 70 year sleep less than females under 70 years old, and 
with increasing age more females suffer with a difficulty initiating sleep (DIS). Also, as 
females age, they use more prescription medication for sleep complaints, but there is no
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difference in age groups among males. Conversely, some findings implied sleep could 
actually improve with increasing age. Female over the age of 60 years use less ‘over- 
the-counter’ (OTC) and herbal remedies than females under 60, males report more 
‘mild’ severities of early morning awakenings (EMA) with increasing age, and males 
over 70 years old have less ‘severe’ sleep complaints. In addition, the number of males 
and females who feel tired on awakening decreases with increasing age, those aged 55 
to 74 complain less and less of daytime effects until after the age of 74 when the 
number of complaints plateaus. Also, there are no significant differences between the 
numbers of sleep complaints reported in each age group. It is difficult to state that sleep 
problems increase with increasing age, as there are so many different sorts of 
complaints that could be classed as sleep problems, for example, waking up too early or 
feeling tired in the daytime. Hoch et al. (1997) suggested that the decline in sleep is not 
linear, but actually accelerated with increasing age. However, inspection of the 
percentage data for sleep duration (3 or 4 hours and 7 or 8 hours), difficulty initiating 
sleep (DIS), difficulty maintaining sleep (DMS), early morning awakenings (EMA), and 
having another sleep complaint showed no steady trends towards an accelerating 
increase in prevalence. Overall, sleep in old age has been found to deteriorate with 
respect to increased feelings of not getting enough sleep, more problems initiating sleep, 
more napping, and more prescription medication. However, sleep in older adults may be 
thought of as satisfactoiy due to a decrease in the use of OTC preparations, feeling less 
tired on awakening, having less severe complaints, and having fewer adverse daytime 
effects.
Sleep in older adults is generally quite good. Seppala (1993) noted that a 20% 
prevalence of sleep problems actually meant 80% of respondents had satisfactoiy sleep. 
Likewise here, although 62.0% reported not getting enough sleep, only 46.3% felt tired 
on awakening and 77.7% said their sleep problem did not affect their daytime 
performance. This implies poor sleep does not guarantee a negative effect on quality of 
life. Indeed, it is clear from this survey that ‘true’ insomnia, or primary insomnia, plays 
only a minor role in sleep problems, and is not commonly experienced. Only 10.8% of 
the respondents complained of general insomnia, and unspecified DIS, DMS, and EMA. 
Identifiable physical complaints tended to dominate the sleep complaints reported, such 
as needing the toilet (29.4%), pain (10.0%), and snoring/respiratory problems/sleep 
apnoea (7.5%). Other medical complaints totalled 4.9% of reported sleep problems. A
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notable role of psychological causes also emerged, such as excessive/vivid dreaming 
(7.9%), and thoughts running through the mind (4.6%).
This survey attempted to avoid the problem of semantics by not asking the 
question ‘do you think you are a good or a poor sleeper?’ . Instead, individual questions 
about getting to sleep, staying asleep and waking-up behaviour were applied, and an 
open ended question about additional sleep problems was provided. To gain insight into 
the participants’ view of how well they sleep, questions such as ‘do you feel that you 
get enough sleep?’ and ‘does your sleep complaint affect your daytime performance?’ 
were used to gauge the quality of sleep experienced. However, a semantic problem may 
have occurred in the question: “Do you wake up too early?”. Respondents may have 
included times when they felt like they were waking too early, for example, when their 
alarm clocks woke them up for work, or when they had to get up to tend to pets. 
Therefore, a preferable question to elucidate EMA specifically might be: “Do you wake 
before your intended time and cannot get back to sleep?”.
‘Quality’ here is assumed to be the feeling of getting enough sleep, the amount 
of tiredness on awakening, and the effects sleep has on daytime functioning. If this is so, 
findings in this survey support most previous findings. More females reported not 
getting enough sleep than males (42.3% versus 30.7%), and the reported prevalence for 
this measure increases for both males and females over the age of 60 years. More 
females also claim to be tired on awakening, but this is only true up to the age of 70 
years, when more males than females claim to be tired on awakening. Again, more 
females claim their sleep complaint affects their daytime performance than males, 
although this is only up to the age 74 years when responses plateau to an equal amount 
of responses from males and females.
Previous research has shown the number of older adults complaining of sleep 
problems to be 76% of those aged 60-85 years and 38.5% of those ages 65+ in England 
(Beaman (1989) and Morgan et al. (1988b) respectively), 55% of 50-79 year olds and 
28.5% of those aged 65+ in the U.S. (Mellinger et al. (1985) and Foley et al. (1995) 
respectively), 47.5% of those over 50 years old in Brazil (Braz et al., 1990), 34% of 
those aged over 65 years in Finland (Seppala et al., 1997), 18.9% of those aged 65-79 
years in Sweden (Mallon and Hetta, 1997), and 12.6% of those aged 70+ in Australia 
(Henderson et al., 1995). Most of these authors agree prevalence of sleep complaints 
increase with age. If the number of people reporting DIS (40.5%), DMS (68.9%), EMA 
(49.6%) and a sleep complaint (29.3%) in this survey are totalled, the percentage of
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respondents with a sleep problem averages 42.2%, implying 57.8% of older adults aged 
50 to 98 years (mean age 69 ±  8.5 years) do not suffer sleeping difficulties. This is in 
agreement with previous research (Seppala, 1993), However, the number of respondents 
suffering DIS in this current survey does not increase as their age increases, as Karacan 
et al. (1976), Bixler et al. (1979), Middelkoop et al. (1996), and Hoch et al. (1997) 
suggested in their surveys. Closer inspection revealed a lack of increase in DIS was only 
in the male population, as more females suffered DIS with advancing age. Although 
there is no linear trend for reports of increased DMS with ageing, fewer respondents 
over the age of 80 years reported DMS. Again, this may simply be due to the smaller 
number of respondents in this category. There is no evidence for any age-related trends 
of EMA and the number of sleep complaints. This again implies getting older does not 
necessarily guarantee poorer sleep.
3.5.2.1.1 Difficulty Initiating Sleep (DIS)
The reported severity of DIS was principally ‘moderate’ (44.5%), but females 
tended to report ‘mild’ problems initiating sleep. More females than males suffer DIS 
(49.3% compared to 25.6%), but to this lesser extent. Also, with increasing age, females 
tend to report significantly more problems with DIS. DIS has been found in previous 
research to be associated with worries and running thoughts (Urponen et al., 1988; 
Beaman, 1989; Middelkoop et al., 1996; Mallon and Hetta, 1997; Seppala et al, 1997; 
Maggi et al., 1998), so it may be that more females suffer anxiety at bedtime than males. 
This survey showed a prevalence of 40.5% overall suffering DIS, which is comparable 
to the studies of Beaman (1989), who found a prevalence of 51% in those aged 60-85 
years, Karacan et al., (1976) who found a prevalence of 52.6% in those aged over 50 
year's, and Bixler et al. (1979) who found a prevalence of 39.9%, also in the over 50s.
3.5.2.1.2 Difficulty Maintaining Sleep (DMS)
Difficulty maintaining sleep (DMS) was previously reported by 29.7% of those 
aged over 65 years (Foley et al., 1995) and by 20.9% of those aged over 50 years in the 
U.S. (Karacan et al., 1976), by 33.4% of respondents aged 65 to 84 years old in Iceland 
(Gislason et al., 1993), by 34.2% those aged 65 to 79 years old in Sweden (Mallon and 
Hetta (1997), and by 48.5% of those aged between 60 and 85 years old in England
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(Beaman, 1989). The prevalence found in this present survey was 68.9%, which is a 
little higher than previous findings. This may have been due to the broader age ranges 
studied in this survey, or the method of questioning. For example, Karacan et al. (1976) 
completed their survey by interview and not questionnaire.
In this present survey, DMS is most often reported as a ‘mild’ problem (51.3%), 
occurring 4-7 nights per week. This survey does not support previous findings that 
DMS worsens with age, as noted in studies from the U. S. (Webb, 1982a; Hoch et al., 
1987; Morin and Gramling, 1989), England (Beaman, 1989), Brazil (Braz et al., 1990), 
Australia (Henderson et al., 1995), and Finland (Kronholm and Hyyppa, 1985), as there 
is actually a decrease in the reporting of DMS by those over 80 years old. However, the 
trend is present up to this age, and so the lack of effect found in the over 80’s category 
may only be due to the relatively small numbers surveyed in that group. Middelkoop et 
al. (1996) suggested DMS increased with age more in males than females, but within 
studies, most found more females overall than males suffer (Kronholm and Hyyppa, 
1985; Domino, 1986; Beaman, 1989). Here, there was no evidence to support the idea 
that males suffer more of an increase in DMS with increasing age, but overall females 
did report DMS slightly more than males (71.4% of females compared to 64.7% of 
males). It is also reported by females to be more frequent and ‘moderate’ compared to 
males who reported more ‘mild’ DMS. It may be that DMS is worse for females than 
males.
3.5.2.1.3 Early Morning Awakenings (EMA)
EMA refers to ‘early morning awakenings’ , which means waking up before an 
appropriate time in the morning and not being able to return to sleep. Prevalence has 
previously been noted to be 17.1%, 18.8% and 32.9% in the U. S. (Bixler et al. (1979), 
Foley et al. (1995) and Newman et al. (1997) respectively), 25.6% in Berlin (Englert 
and Linden, 1998), 20.6% in Italy (Maggi et al., 1998), and 17.6% in Australia (Lack et 
al., 1988), but the prevalence of EMA in this present survey was placed higher than 
these at 49.6%. The reason for this is unclear, and may be due to individual differences; 
for example, EMA is associated with anxiety (Middelkoop et al., 1996; Mallon and 
Hetta, 1997). Kronholm and Hyyppa (1985) found no variation in EMA with age, and 
this survey agrees with this finding. Support is also foimd for Beaman (1989), Newman 
et al. (1997) and Maggi et al. (1998) who all found females suffer more from EMA than
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males (in this survey, there were 50.6% of females suffering EMA compared to 47.6% 
of males).
3.5.2.1.4 Sleep Duration
As previously mentioned, the question regarding the number of hours slept may 
actually elucidate time spent in bed. Despite this, it is assumed the question regarding 
hours slept represents nocturnal sleep time, and hours slept added to the amount of time 
spent napping provides indication about sleep time in the 24 hour period. Males tend to 
report sleeping longer than females, and the length of time females stay asleep declines 
with increasing age (agreeing with Beaman, 1989; Habte-Gabr et al., 1991; and Mallon 
and Hetta, 1997). There is no age related decline for males. These findings contradict 
previous research which has suggested that older and ageing males tend to sleep less, as 
found by Liljenberg et al. (1988) who surveyed 1687 adults aged 30 to 44 and 1870 
adults aged 45 to 65 years old in Sweden. This present survey also contradicts the 
findings of equality in sleep duration between the genders (Kronholm and Hyyppa, 
1985; Beh, 1994; Seppala et al., 1997). The majority of respondents claimed 7-8 hours 
sleep (45.6%), which is regarded as a full night’s sleep, indicating support for a large 
amount of 50-98 year olds actually having a normal amount of sleep. It may not be true 
that “a large proportion of the population appeal's to be chronically deprived of sleep” 
(Liljenberg et al. (1988) p.397). This survey shows most older adults report sleeping for 
5 to 8 hours during the night (87.6%).
3.5.2.1.5 Napping, Daytime Sleepiness and Causes
Whether enough nocturnal sleep is achieved or not, there is overwhelming 
evidence for napping behaviour in the elderly. A large proportion (57.1%) of 
respondents in this survey said they napped during the day, most napping on average for 
30 minutes to one hour (16.5%) per day. Those over 65 years old nap more than 50-54 
year olds, and this increases with increasing age. More males and more females nap 
with increasing age, but overall and between comparable age groups, females nap for 
shorter durations than males. These findings support previous research where napping 
has been found to increase with age (Hayter, 1985; Kronholm and Hyyppa, 1985; 
Beaman, 1989; Morin and Gramling, 1989; Hoch et al., 1997), and where males have
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been found to nap more than females (Seppala, 1993; Asplund, 1996). It is thought that 
respiratory problems, such as snoring and sleep apnoea, have a large contributory effect 
on why males nap more than females, because males suffer these problems more than 
females (Asplund, 1996; Newman et al., 1997). The present survey supports this, and 
shows males complain more than females about respiratory problems, sleep apnoea and 
snoring (11.5% versus 5.3%). The prevalence of napping has been found to be 42.1% 
and 56% in Finland (Kronliolm and Hyyppa (1985) and Seppala et al. (1997) 
respectively), 22.1% habitually nap in Sweden (Mallon and Hetta, 1997), and 24.6% of 
the elderly (65 years and over) nap in the U.S. (Foley et al., 1995), so the percentage of 
nappers found in this present survey agrees with the Finnish study by Seppala et al.
(1997).
It has been found by Seppala et al. (1997) that napping can reduce the report of 
insomnia, and also the consumption of hypnotics. Conversely, Beh (1994) found that 
napping occurs more, with respect to frequency and duration, when taking sleep 
medication, and attributed this to ‘hangover’ and residual effects found with many 
hypnotics. She suggests older adults feel ‘unrested’ when taking sleeping pills. In this 
present survey, it was found that respondents who took long naps (over 30 minutes) and 
respondents who took short naps (under 30 minutes) had a similar prevalence of sleep 
complaints (29.0% versus 27.5%). Longer napping may not reduce the complaint of 
sleep problems. It was also found that longer naps are associated with less use of 
hypnotics than shorter naps, as 5.2% of long nappers take hypnotics, compared to 6.5% 
of short nappers. This is in disagreement with Beh (1994) but provides support for 
Seppala et al. (1997), although the difference between the percentages is very small. 
The prevalence of general prescription use amongst long and short nappers is almost the 
same at 10.2% and 10.7% respectively, indicating a lack of difference. This survey also 
showed nappers do not take more hypnotics than non-nappers, as 5.4% of those who 
nap use a hypnotic, compared to 7.3% of non-nappers. Non-nappers also take slightly 
more prescriptions generally, with a prevalence of 11.2% compared to 10.1% of 
nappers.
To investigate the suggestion that older adults feel more ‘unrested’ while using 
hypnotics, the prevalences regarding hypnotic use, feeling tired on awakening and not 
getting enough sleep were examined. Those who feel tired on awakening and use 
hypnotics total 8.3%, whilst those using hypnotics but not feeling tired on awakening 
total 4.0%, meaning twice as many hypnotic users feel tired in the morning than do not
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feel tired in the morning. This supports the suggestion that hypnotics used in the elderly 
may have ‘hangover’ effects. However, further investigation shows this is the case for 
all sleep prescriptions, and not just hypnotics. Those using prescription medication and 
feeling tired on awakening totalled 13.2%, compared to those on prescription 
medication and not feeling tired on awakening, which totalled 7.7%. Tiredness in the 
morning may not be due to hypnotic use alone. Those using hypnotics and felt like they 
did not get enough sleep totalled 3.2%, however, those using hypnotics and did feel like 
they got enough sleep totalled 10.3%. It seems hypnotics may improve the subjective 
perception of sleep. However, out of those using any sleep prescription, 15.5% get 
enough sleep compared to 6.7% who do not. It may be that taking any prescription 
medication for sleep, not just hypnotics, may improve sleep. This is obvious in cases 
where pain is involved, for instance. Painkillers would alleviate night pain and would 
therefore aid sleep.
Napping occurs because of daytime sleepiness. Previous research has found the 
prevalence of daytime sleepiness to be 17.2% in the U.S. (Newman et al., 1997), 15.3% 
in Australia (Lack et al., 1988), 15.6% in The Netherlands (Middelkoop et al., 1996), 
24.9% in Finland (Kronholm and Hyyppa, 1985), 35.5% in Sweden (Asplund, 1996), 
and 11% in Brazil (Braz et al., 1990). The question in this survey regarding daytime 
effects focused on daytime performance, asking if, how much, and how often sleep 
complaints experienced affected daytime functioning. The percentage of respondents 
suffering daytime effects was found to be 33.3%, similar to the findings in previous 
literature of the prevalence of daytime sleepiness. Daytime sleepiness is thought to 
increase with age (Dement et al., 1982; Asplund, 1996; Newman et al., 1997). Results in 
this present survey suggest that daytime performance is not reduced with ageing, which 
implies that daytime sleepiness does not increase with ageing, in agreement with the 
surveys of Lack et al. (1988) and Braz et al. (1990). Reports of sleep problems affecting 
next day performance actually decrease between the ages of 55 and 74 years, after 
which the prevalence of reports reaches a plateau. Severity is mostly thought to be 
‘moderate’ (45.8%), and this remains unchanged by advancing age. The occurrence of 
adverse daytime performance is also unaffected by ageing, and mostly occurs 4-7 days 
(34.8%) and 1-3 days (28.8%) per week. A limitation of this survey is that daytime 
performance and daytime sleepiness cannot be directly compared. Future surveys 
should assess these aspects of daytime functioning separately.
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Schmitt et al. (1996) and Newman et al. (1997) have suggested that males suffer 
more daytime sleepiness than females, but in this present survey, more females reported 
their sleep complaint affecting their daytime than males. Gender did not have bearing on 
the severity or the occurrence of these daytime effects. It is likely that the lack of effect 
on daytime performance reported may be due to the increased napping. The elderly 
might report more daytime sleepiness, but performance would be unaffected if naps 
were taken to compensate. Therefore these results are to be expected.
An increase in daytime sleepiness is likely to be due to disruptions of nocturnal 
sleep, and previous research has elucidated how this might happen. Sleep disruption 
may not be because of ‘ old age’ , per se, but other problems such as needing the toilet 
(Asplund, 1996), decreased physical activity (Hays et al., 1996) and poor physical 
health or pain (Habte-Gabr et al., 1991; Moffitt et al., 1991; Weyerer and Dilling, 1991; 
Asplund, 1996) which are related to ageing. To investigate this, a question in the survey 
addressed any other sleep complaints suffered. Of all respondents, 29.3% suffered 
specific sleep complaints (30.3% of males and 28.8% of females) that were mostly 
considered ‘moderate’ overall (males tended to report more ‘mild’ severities than 
females), and decreased in severity for older adults over the age of 70 years. These 
complaints largely occurred 4 to 7 nights per week, with males suffering a higher 
frequency than females. These complaints included: needing the toilet (29.4%), pain 
(10.0%), excessive or vivid dreaming (7.9%), unspecified or general insomnia (5.8%), 
snoring (5.2%), other medical complaints (4.9%), thoughts running through mind 
(4.6%), nightmares (4.1%), waking easily or frequently (4.0%), and cramp (3.9%). 
Males tended to complain of needing the toilet (45.4%), snoring (8.0%), and pain 
(7.7%), whereas females reported needing the toilet (20.1%), pain (11.2%), and 
excessive or vivid dreaming (9.0%). Those needing to use the toilet in the night 
increased significantly between the ages of 65 and 85+ years, and this was especially 
evident in males over 75 years of age. This may be due to prostate problems in elderly 
males, or as Middelkoop et al. (1996) suggests, an age-related decrease in nocturnal 
anti-diuretic hormone foimd especially in men. Needing to use the toilet is probably the 
biggest factor in sleep disturbance (Foley et al., 1995; Seppala et al., 1997; Englert and 
Linden, 1998). Asplund (1996), Middelkoop et al. (1996) and Maggi et al. (1998) 
respectively found 73.3%, 76.6% and 90.7% of males and 57.8%, 66.1% and 90.2% of 
females had to use the toilet in the night. In this survey, 29.4% of respondents needed to 
use the toilet in the night (45.4% of males and 20.1% of females). In agreement with
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Middelkoop et al. (1996), needing the toilet at night does increase with age; in this 
survey it is needed by 14.1% of 50-54 year olds, 18.1% of 55-59 year olds, 20.0% of 
60-64 year olds, 26.9% of 65-69 year olds, 29.6% of 70-74 year olds, 36.4% of 75-79 
year olds, 40.8% of 80-84 year olds, and 69.8% of those over 85 years old. When 
assessed by DIS, DMS and EMA, needing the toilet is blamed by 10.1% of respondents 
suffering DIS (10.9% of males and 9.7% of females), 23.2% of DMS sufferers (35.0% 
of males and 16.3% of females), and 13.1% of EMA sufferers (19.7% of males and 
9.3% of females). This is indeed a major disruption to sleep maintenance, which agrees 
with the findings of Maggi et al. (1998).
3.5.2.2 Physical Health and Poor Sleep
Pain and other medical problems (including respiratory/apnoea problems and 
cramp), were also reported frequently (14.9%) in the present survey. Habte-Gabr et al. 
(1991) found females tend to have more health complaints, perhaps explaining why 
females have worse sleep than males. Supporting this, Bliwise et al. (1992) suggested 
more medication is prescribed to females than males. This survey supports these 
findings, as 12.2% of male respondents suffered either pain or a medical complaint, 
compared to 16.4% of female respondents. Pain alone has been blamed for 14.4% of 
sleep problems in the elderly (Mallon and Hetta, 1997), and here the percentage is 
slightly lower at 10.0%. When assessed by DIS, DMS and EMA, pain is blamed by 
5.3% of respondents suffering DIS (2.2% of males and 7.1% of females), 7.8% of 
respondents suffering DMS (5.6% of males and 9.2% of females), and 6.0% of 
respondents suffering EMA (4.0% of males and 7.2% of females). Here, it can be seem 
females suffer the most overall. These figures differ from the findings of Maggi et al.
(1998), who found initiating sleep to be the most affected (6.5%) followed by 
maintaining sleep (4.2%) and lastly early morning awakenings (3.8%). Here, pain 
disrupts sleep maintenance the most often. It is important, as pointed out by Morin and 
Gramling (1989) and Gislason et al. (1993), to understand the causes of individuals’ 
sleep problems. If the only causes of disturbed sleep are pain and medical complaints, 
the prescription of hypnotics should be avoided. Some hypnotics have been found to 
have a detrimental effect on health. In this survey, 32 people with medical complaints or 
pain take a sleeping pill, meaning 9.0% of hypnotic users have pain or a medical 
complaint and so therefore are taking hypnotics they possibly do not need. Hypnotics
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cannot improve sleep that is disrupted by pain, as they do not work as analgesics. 
Chronic pain will still cause awakenings (Henderson et al., 1995; Seppala et al., 1997).
3.5.2.3 Psychological Health and Poor Sleep
It is not only physical problems that disrupt sleep. Past research has suggested 
some older adults in good health still complain of insomnia (Fichten et al., 1995). 
Indeed, 13.9% of DIS sufferers, 24.7% of DMS sufferers and 16.1% of EMA sufferers 
have no physical complaints. It is likely that these complaints may have arisen from 
psychological aspects of sleep. The complaint of poor sleep may be due to unrealistic 
expectations about the quality and duration of sleep they should achieve, and erroneous 
beliefs about the quality and duration of sleep their peers achieve (Lack et al., 1988; 
Liljenberg et al., 1988; Beaman, 1989; Morin and Gramling, 1989; Fichten et al., 1995; 
Seppala et al., 1997; Englert and Linden, 1998). Erroneous beliefs about sleep may lead 
to the unnecessary prescription of hypnotic drugs.
It is suggested that reduced mobility, low income, ill health, increased sleep 
fragmentation (Wingard and Berkman, 1983), and lack of quality of life due to boredom 
(Habte-Gabr et al., 1991; Schechtman et al., 1997) can contribute to depressive 
symptoms (Monk et al., 1991), and in turn these depressive symptoms are associated 
with poor sleep (Rodin et al., 1988; Ford and Kamerow, 1989; Hoch et al., 1989; Morin 
and Gramling, 1989; Seppala, 1993; Maggi et al., 1998). Females are often reported to 
have more depressive symptoms than males, and this has been suggested to account for 
the increased sleep disturbance in females compared to males (Kronholm and Hyyppa, 
1985; Habte-Gabr et al., 1991). However, in this present survey, 5.8% of male 
prescription users take antidepressants, compared to only 4.7% of female prescription 
users. This indicates a more equal prevalence of antidepressant use between the genders. 
The link between depressive symptoms and sleep problems has also been noted with 
respect to napping (Newman et al., 1997). Beh (1994) suggested the depressed elderly 
take hypnotics because of the sleep problems they are experiencing due to their 
depressive symptoms. In this survey, 0.9% of non-nappers took antidepressants, 
compared to 0.9% of those who nap for up to 30 minutes, 0.8% of those who nap for 30 
mins to 1 hour, 0.5% of those who nap for 1 to 2 hours, and 0.0% of those who nap for 
over 2 hours. Overall, 0.8% of nappers use antidepressants, and 0.9% of non-nappers 
take antidepressants. Therefore there is no evidence to suggest that the number of older
99
adults who nap and take antidepressants is greater than the number of older adults who 
do not nap and take antidepressants.
Anxiety is also thought to be detrimental to sleep, as Mallon and Hetta (1997) 
found that 9.0% of their sample blamed their insomnia on worries. Anxious 
psychological effects (thoughts running through mind, excessive or vivid dreaming, and 
nightmares) are reported in this present survey by 11.7% of males, and 19.6% of 
females who have a sleep complaint. This is 1.9% and 6.1% of all male and female 
respondents respectively. Either females have more worries and stresses than males, as 
suggested by Urponen et al. (1988), Middlecoup et al. (1996), Mallon and Hetta (1997) 
and Maggi et al. (1998), or they are simply more willing to admit to them, as suggested 
by Briscoe (1978). In this survey, 4.6% alone had thoughts running through their minds 
(1.9% of males and 6.1% of females). Assessment by DIS, DMS, and EMA shows 2.4% 
of DIS sufferers have thoughts running through there mind (1.0% of males and 3.1% of 
females), 3.4% of DMS sufferers (1.4% of males and 4.5% of females), and 2.8% of 
EMA sufferers (1.4% of males and 3.7% of females). Thoughts running through the 
mind disrupt the maintenance of sleep slightly more than the other insomnia categories, 
and again this is worse for females. Also, this survey showed females may suffer worse 
DMS than males, and females also show more anxiety. Previous research has suggested 
that initiating sleep is most disrupted by worries (Urponen et al., 1988; Beaman et al., 
1989; Middelkoop et al., 1996; Mallon and Hetta, 1997; Seppala et al., 1997; Maggi et 
al., 1998). However, in support of the present survey, Libman et al. (1997) suggested 
waking in the night may be disturbing to sleep because it gives negative thoughts a 
chance to occur, and thus thoughts can disrupt the maintenance of sleep.
3.5.2.4 Solutions to Sleep Problems
3.5.2.4.1 Bedtime Behaviour
Good sleep hygiene can alleviate a vast number of sleep problems, as insomnia 
may simply be due to an inconducive sleep environment. The survey addressed the 
question of what older adults and the elderly do about their sleep problems. Libman et 
al. (1997) found the top six sleep-enhancing activities in their survey were: lying 
quietly, relaxing, using the toilet, changing thoughts, reading, and tossing and turning. 
Other methods found in previous literature included: bathing, listening to music,
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exercise, eating, sexual activity, creating a nice environment, and also watching 
television (Urponen et al., 1988; Libman et al., 1997). In this present survey, more 
females tended to use bedtime activities for improving sleep than males (11.0% versus 
6.1%), however there is no age-related increase in the number of respondents using an 
activity. The top ten activities reported were: reading (20.5%), other (e.g. TV, eye mask, 
Magnetic Field Therapy, puzzles, hypnotherapy, sexual activity) (18.3%), aromatherapy 
(10.9%) and special bed or bedding (10.9%), heat (e.g. hot water bottle, electric blanket) 
(9.1%), meditation/breathing (8.6%), radio (5.6%), eating (3.5%), music (3.3%), and 
exercise (2.1%). Similar activities are reported in all research. There were no reports of 
any behavioural sleep treatments in this present survey, such as sleep restriction or 
stimulus control, as previously described. This is not surprising as the elderly, or indeed 
many people with sleep problems, may not know these techniques exist. With a little 
training, general practitioners could easily advise their patients of suitable techniques to 
try. Also, using the findings of surveys such as this, general practitioners may be able to 
suggest that females should try reading to improve their sleep, as this was most 
popularly reported females (23.7%), and likewise males should try special bedding, 
reportedly used by the highest number of males (15.5%).
3.5.2.4.2 Alcoholic Drinks
Two methods of enhancing sleep not yet mentioned are the two most popular 
activities. These are drinking alcoholic and non-alcoholic drinks before bedtime. 
Alcohol is often used as a sleep aid (Sproule et al., 1999), because it effectively shortens 
sleep onset latency. However, it cannot be recommended as a sleep aid because it also 
disrupts the latter part of the night’s sleep, and suppresses REM sleep (Moran et al., 
1988). Despite this, 11.0% of respondents use alcohol to aid sleep, and males use 
significantly more alcohol than females (12.2% of males and 10.1% of females). This 
difference may be due to the limited acceptability of drinking in the older female, for 
example Royo-Bordonada et al. (1997) found males were much more likely to drink 
alcohol. Females drink more wine than males, which is a more acceptable form of 
alcohol for females than spirits such as whisky (27.4% of females use wine versus 
15.7% of males). A general increase in those using alcohol was not found in conjunction 
with increasing age alone, but results show as males get older, they tend to increase 
preference towards whisky and wine, whilst females drink less bitter and wine, and
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more sherry and brandy. The most popular choice of alcohol overall is whisky (37.3%), 
followed by wine (22.2%), sherry (9.5%), brandy (9.0%), unspecified alcohol (6.8%), 
bitter (5.1%), gin (3.2%), unspecified spirit (2.4%), lager (1.2%), port (0.7%) and other 
alcohols (0.7%). Wine is the second most popular choice for both males and females, 
with percentage use of 15.7% (1.9% of all respondents) and 27.4% (2.6% of 
respondents) respectively. Previous research has shown great differences between the 
prevalence found of alcohol use. Beaman (1989) noted 43% of English older adults use 
‘ self-help’ drugs such as alcohol and cough mixture, and Middlecoup et al. (1996) 
found a prevalence of 50.7% in Sweden. These are all much larger percentages than 
those noted in this survey, and may be due to the method of questioning. Sproule et al.
(1999) reported a much more similar prevalence of 13% in Canada.
3.5.2.4.3 Non-Alcoholic Beverages
Non-alcoholic drinks taken at bedtime are very popular, with 31.3% of 
respondents reporting their use. Significantly more females than males use a non­
alcoholic beverage (21.8% of males and 36.8% of females), and this is true for all age 
groups. There is 110 age-related increase in the number of respondents using a beverage. 
The top ten beverages reported were: Horlicks (28.0%), hot chocolate (17.8%), hot milk 
(15.3%), Ovaltine (10.2%), tea (9.6%), milk (8.3%), cocoa (3.4%), water (1.7%), coffee 
(1.5%), and other beverages (1.1%). Horlicks was the most popular amongst both males 
and females, and also amongst all age groups except the first (50-54 year* olds) and last 
(85+ years), where hot chocolate and hot milk are preferred respectively. Indeed, six out 
of the top ten beverages reported were milk-based drinks. This could indeed mean the 
L-tryptophan found in milky drinks could have a beneficial effect, as suggested by 
Brezinova et al. (1972). L-tryptophan is a precursor to serotonin; so increased levels of 
tryptophan can lead to an increase in the levels of serotonin in the brain. As previously 
discussed, this is associated with an increased amount of SWS (which may be 
associated with ‘soundness’ of sleep (Hoch et al., 1987)), a shorter sleep latency, and 
the suppression of REM sleep (Jouvet, 1967; Saletu et al., 1991; Luthringer et al,
1996). Tryptophan was once available as a supplement, but it was recalled by the Food 
and Drug Administration (FDA) in 1989 because of reported neuromuscular side 
effects. Although these effects were later traced to a bacterial contaminant from a single
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manufacturer, the FDA has not withdrawn its ban of over-the-counter L-tryptophan 
sales.
3.5.2.4.4 Hypnotics, Antidepressants and Other Prescription Medication
Previous research has found there is a persistent demand for sleep medication 
(Cook et al., 1983). Seppala et al. (1997) in a survey of 600 Finnish elderly adults aged 
over 65 found a prevalence of hypnotic use of 33%. Similarly, in a survey of 1023 
elderly English adults aged over 65 years, Morgan et al. (1988b) found prevalence of 
23.8%. In a survey of 2398 over 65 year olds in Italy, Maggi et al. (1998) found a 
prevalence of only 9%. Similarly, an Australian survey of 874 Australian elderly adults 
aged over 70 years found a prevalence of 14.5%. In this study, the percentage of 
respondents taking prescription medication is 10.8% overall, 8.0% of males and 12.4% 
of females. This present survey supports previous findings, as significantly more 
females take prescription medication than males. Middelkoop et al. (1996) surveyed 
1692 over 50 year olds in The Netherlands, and found 25.4% of females use a hypnotic 
compared to 14.9% of males. Also, Mallon and Hetta (1997) surveyed 876 elderly 
adults aged 65 to 79 years old in Sweden, and found 14.7% of females use a hypnotic 
compared to 5.5% of males. With respect to ageing, significantly more older elderly 
females take prescription medication for sleep complaints than younger elderly females. 
However, the prevalence of male use of prescriptions does not increase with age.
Many previous studies have found an increasing amount of hypnotic use with 
increasing age, in England, the U.S., Australia, and Finland (Mellinger et al., 1985; 
Morgan et al., 1988b; Beaman, 1989; Henderson et al., 1995; Newman et al., 1997; 
Seppala et al., 1997). Other studies have noted 7.8% to 14% of 45-59 year olds use a 
hypnotic (Karacan et al., 1976; Kronholm and Hyyppa, 1985; Lugaresi et al., 1987; 
Middelkoop et al., 1996; Ohayon and Caulet, 1996), 7.2% to 18.9% of 60-69 year olds 
(Karacan et al., 1976; Morgan et al., 1988b; Klaukka and Martikainen, 1989; 
Middelkoop et al., 1996; Ohayon and Caulet, 1996), 11.8% to 53.7% of 70-79 year olds 
(Karacan et al., 1976; Kronholm and Hyyppa, 1985; Lugaresi et al., 1987; Morgan et 
al., 1988b; Klaukka and Martikainen, 1989; Middelkoop et al., 1996) and 15% to 30.4% 
of the over 80 year olds (Lugaresi et al., 1987; Seppala, 1993; Middelkoop et al., 1996). 
In the present survey, it was found hypnotic use increased with age only after the age of 
65 years old. Out of all respondents, those who use prescriptions or not, percentage uses
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of hypnotics were: 3.4% of males, 7.2% of females, 4.2% of 50-54 year olds, 3.2% of 
55-59 year olds, 3.5% of 60-64 year olds, 5.0% of 65-69 year olds, 6.7% of 70-74 year 
olds, 8.9% of 75-79 year* olds, 9.5% of 80-84 year olds, and 20.9% of those over 85 
years. The last figure of hypnotics taken by 85 year olds and over is much higher than 
figure for other ages. This may be due to the relatively small number of respondents in 
this category (n=134) and the small number of respondents in this category who took a 
prescription medication (n=25). Although percentages generally increase with 
increasing age, these differences were not significant (between the ages of 50 and 84 
years old).
Temazepam was the most popular hypnotic (29.4% of prescriptions taken, 2.7% 
of all elderly), and this was also the most popular prescription. Nitrazepam was the 
second most popular hypnotic (13.1% of prescriptions taken and 1.3% of all 
respondents), followed by zopiclone (7.6% of prescriptions taken and 0.8% of all 
respondents), diazepam (2.9% of prescriptions taken and 0.3% of all respondents), 
lormetazepam (2.4% of prescriptions taken and 0.2% of all respondents), and 
loprazolam (1.7% of prescriptions taken and 0.2% of all respondents). Males and 
females were both prescribed temazepam (19.9% and 28.7% of prescriptions taken 
respectively) above all other hypnotics.
Hypnotic use overall contributes 59.5% of all prescription use, males using 
29.8% and females using 37.3%. By age, 50-54 year olds use 52.4%, 55-59 year olds 
use 55.6%, 60-64 year* olds use 50.0%, 65-69 year olds use 58.6%, 70-74 year olds use 
62.1%, 75-79 year olds use 62.3%, 80-84 year olds use 61.9%, and those over 85 years 
use 82.4%. These percentages represent the proportion of people using hypnotics that 
use a prescription to help sleep, so 59.5% of any prescriptions taken for sleep problems 
are hypnotics. This is surprising, as there are 40.5% of prescriptions used to aid sleep 
that are not sleeping pills. However, some respondents may have misread the survey 
and may have reported the use of drugs which were not prescribed to aid sleep.
Other prescriptions for the alleviation of sleep problems included other 
medication (such as antihypertensives and antidiuretics; 13.1% of prescriptions taken 
and 1.3% of all respondents) and analgesics (13.6% of prescriptions taken and 1.4% of 
all respondents), which are used by respondents to combat pain and any other physical 
illness that may impede sleep. However, there is another aspect to alleviating sleep 
problems, and that is linked to the idea that psychiatric illness may impair good sleep. 
Many respondents (8.2% of prescriptions taken and 0.8% of all respondents) reported
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using an antidepressant to aid sleep problems. This is twice as many as the 4%  
prevalence noted by Busto et al. (2001) in their survey of 3860 elderly Canadian 
volunteers.
The most prescribed antidepressant was amitryptyline (3.4% of prescriptions 
taken and 0.3% of all respondents), followed by dothiepin (1.7% of prescriptions taken 
and 0.2% of all respondents), and finally paroxetine (0.3% of prescriptions taken and 
0.03% of all respondents). Males were prescribed amitryptyline the most (3.2% of 
prescriptions taken and 0.2% of all respondents), whilst most females took dothiepin 
(1.4% of prescriptions taken and 0.2% of all respondents). However there was no 
significant difference of antidepressant use between the age groups. The questionnaire 
asked for the names of medications the respondents took for their sleep problems, so it 
is assumed these antidepressants are taken as sleeping pills. However, it may be the case 
that the question was misunderstood, and these antidepressants are being taken for 
depression, but no depression or anxiety scales were completed with this questionnaire. 
For a more comprehensive view of the use of antidepressants in the elderly, a specific 
question about antidepressant use in insomnia should be used in future surveys.
A major effect of most antidepressants is the inhibition of reuptake in the 
monoaminergic system (Paes de Sousa and Tropa, 1986; Hobson et al., 1998). Vogel et 
al. (1990) reviewed 251 studies on antidepressants between 1962 and 1989, and found 
almost all antidepressants decrease REM sleep time and will lead to REM rebound on 
discontinuation. They are also suggested to affect the serotonin system, which is 
responsible for many sleep mechanisms, and as discussed in chapter 1, serotonin may 
play a role in decreasing sleep latency and the enhancement of SWS (Jouvet, 1967; 
Saletu et al., 1991; Luthringer et al., 1996).
It is important to gain understanding of hypnotics (and other prescriptions taken 
to alleviate sleep problems), because misuse can lead to health risks in the elderly. It 
was noted previously that someone complaining of poor sleep may be given a hypnotic, 
without realising the sleep problems are due to an underlying illness. Hypnotics can 
exacerbate respiratory problems (Dement et al., 1982; Dolly and Block, 1982; Moran et 
al., 1988), and so may be dangerous to those with sleep apnoea. Also a hypnotic may be 
unnecessary and ineffective if it is prescribed for physical problems such as ‘restless 
legs’ (Weiss et al, 1973). Indeed, 1.8% of those who had a sleep complaint suffered 
from respiratory or sleep apnoea problems, and 3.3% had restless legs in bed. One 
respondent in this survey was using nitrazepam whilst complaining of sleep apnoea.
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However, the precise nature of these reports cannot be determined as the survey was not 
detailed enough to provide this information.
This could be a contributing factor as to why Morin and Gramling (1989) found 
no difference between good and poor sleepers with respect to hypnotic use, as the sleep 
problems of some poor sleepers may be physical only. However, in this survey, it seems 
those using hypnotics have poorer sleep. Of those taking hypnotics, 11.0% had DIS 
(compared to 2.8% without DIS), 7.5% had DMS (compared to 2.9% without DMS), 
8.1% had EMA (compared to 3.5% without EMA), and 9.0% had a different sleep 
complaint (compared to 4.7% without a sleep complaint). It is possible that those taking 
hypnotics may be taking them incorrectly, or perhaps those with veiy poor sleep have 
been prescribed the hypnotics, but not all the symptoms have been alleviated. This 
pattern agrees with Simen et al. (1995) who found almost half of their interviewees 
complained of sleep problems despite regular hypnotic use. However, it is possible that 
the respondents were describing their sleep before administration of hypnotics, and this 
survey was not detailed enough to draw any conclusions.
Reynolds et al. (1991) suggested that most research in the area of elderly sleep is 
now out-dated, but in 1988 a popular hypnotic to prescribe to older adults was 
nitrazepam, and today nitrazepam is still the second most popular hypnotic to prescribe. 
This is surprising as this hypnotic, and also the most popular hypnotic, temazepam, 
have intermediate duration half lives, and it has been suggested they are unsuitable for 
the elderly on this basis (Lader, 1997). Cook (1986) found the elderly have a 2 or 3 fold 
greater response to these benzodiazepines than the young, due to increased sensitivity. 
A longer elimination half-life means there may be an accumulative effect with regular 
daily dosing (Cook, 1986). As drug concentrations fall more slowly in the elderly 
(Massoud, 1984), sedative effects may still be present the day after dose. The sedative 
effects of nitrazepam in particular are more pronounced in the elderly than the young 
(Cook, 1986). This can lead to the ‘hangover’ effects of daytime sedation (Greenblatt et 
al., 1984), of impaired psychomotor performance (Morgan, 1985; Maczaj, 1993), 
unsteadiness, cognitive and memory disturbances, and even confusional states (Evans 
and Jarvis, 1972). A controlled trial of one week’s dosing with nitrazepam 5mg and 
temazepam 20mg in elderly inpatients showed impairment of psychomotor performance 
the next morning after dosing (Cook, 1986). These effects may only be mild on the 
morning after dose with healthy elderly individuals, but may be detrimental to safety if 
the elderly person gets up in the night to use the toilet, for example. Indeed, research has
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shown a link between hypnotic use and the number of falls in the elderly (Granek et al., 
1987; Ray et al., 1987; Trewin et al., 1992). This present survey showed that 
respondents using hypnotics complained of their sleep problem affecting their daytime 
activities more often than not. 12.3% of hypnotic users said their complaint affected 
their day, compared to under half as many that did not say their complaint affected their 
day (5.3%). This supports the suggestion that hypnotics currently used by the elderly 
may have a detrimental effect on daytime performance. Alternatively, again it is 
possible that the hypnotics prescribed are not alleviating the sleep problems adequately, 
and so the daytime effects could be from poor sleep the night before. Future surveys 
should include questions regarding the doses of hypnotics used, and the length of time 
respondents have been using their hypnotics. This was not included in this survey, 
which has limited the interpretation of the data.
Only one respondent in the survey was still using barbiturates, which are seldom 
used for the elderly these days due to their addictiveness (Mullan et al., 1994), 
association with respiratory problems (Moran et al., 1988) and heavy residual effects 
(Pishkin et al., 1980). This survey also showed chloral hydrate is also infrequently used, 
again reported by only one respondent.
Many researchers now feel that the elderly should use the newer hypnotics on 
the market. These work in similar ways to the benzodiazepines, but have differences, 
which have a big effect on the action of the drug. Zopiclone and zolpidem have much 
shorter half-lives, as previously outlined, and so are much less likely to accumulate and 
cause morning ‘hangover’ effects. In this survey, 7.6% (0.8% of all respondents) 
reported using zopiclone, and 0.7% (0.1% of all respondents) reported using zolpidem. 
This, and the low numbers of users, is quite surprising considering the benefits of using 
short acting hypnotics over intermediate length ones. It may be that the high number of 
elderly suffering DMS (68.9%) need a slightly longer duration hypnotic to last through 
the night. However, when waking up in the night, and using the toilet (a common 
example, 29.4%), there may be a greater risk of accident or falls with intermediate 
duration hypnotics compared to short duration. One possible beneficial treatment 
regime would be taking a short acting hypnotic before retiring, and then again if 
necessary if they wake in the night and cannot get back to sleep. This would ensure lack 
of sedation when getting up in the night, but the additional middle-of-the-night dose 
would enable better sleep for the rest of the night.
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3.5.2.4.5 ‘Over-the-Counter ’ (OTC) and Herbal Preparations
Chapter 3
Due to the adverse effects often experienced by the elderly on prescription 
medication, it is not surprising that this survey found a large number of respondents 
chose to self-medicate with ‘over-the-counter’ (OTC) and herbal remedies. Sproule et 
al. (1999) foimd 24% of their elderly sample used non-prescription treatments for 
insomnia. Also, Mellinger et al. (1985), Lack et al. (1988), Sproule et al. (1999) and 
Busto et al. (2001) found between 2.8% and 12.0% use OTC preparations. Here, the 
present survey found 17.7% of adults aged 50-98 years, almost twice as many as 
prescription users, used either an OTC or herbal remedy to help alleviate sleep 
problems. There were no differences between genders (agreeing with the surveys of 
Mellinger et al. (1985) and Bliwise et al. (1992)), and also no change in the number of 
people taking OTC or herbal remedies with increasing age.
The most popular preparation was Nytol (14.6% of OTC/herbals taken and 2.5% 
of all respondents), which contains diphenhydramine hydrochloride. This, and Sominex 
(containing promethazine hydrochloride; taken by 1.0% of non-prescription takers) are 
antihistamines, which are also popular as a sleep aid, as some can cause initial 
drowsiness. However, prescription antihistamines can result in delirium (Moran et al.
1988) and residual sedation (Caranasos, 1987), and these were taken by 1.0% of those 
taking prescriptions. Some OTC antihistamines can cause residual daytime drowsiness 
(Caranasos, 1987), although attempts have been made to eliminate this in newer 
antihistamines. Indeed, the elderly sample in this present survey taking an antihistamine 
principally did not think their sleep complaint affected their daytime activities (23.5% 
of OTC antihistamine users who were affected compared to 70.6% who were not). OTC 
antihistamines were taken by 1.7% of those taking a non-prescription remedy.
The second most popular non-prescription remedy was camomile tea (13.2% of 
OTC/herbals taken and 2.3% of all respondents), followed by OTC analgesics (11.9% 
of OTC/herbals taken and 2.1% of all respondents), and other/not specified herbal or 
fruit teas (10.7% of OTC/herbals taken and 1.9% of all respondents). Sproule et al.
(1999) found the prevalence of the use of non-prescription analgesics was 5.1%, which 
is almost half the prevalence noted in this study. More females used Nytol than males 
(15.0% versus 12.8% of those using an OTC or herbal remedy), and more females 
tended to use more than one OTC or herbal remedy than males. There are no trends 
suggested regarding the type of OTC/herbal used and increasing age.
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Some doubt always exists as to whether non-prescription medication can 
actually alleviate sleep problems. Investigation into OTC and herbal remedy users with 
respect to DIS, DMS, EMA, the number of respondent with sleep complaints, and those 
with daytime effects should show if non-prescription medications can help sleep 
problems. On all measures, approximately twice as many respondents using a non­
prescription preparation had problems with DIS (25.2% versus 11.2%), DMS (20.7% 
versus 8.5%), EMA (21.3% versus 12.7%), prevalence of sleep complaints (21.9% 
versus 14.8%), and prevalence of sleep complaints affecting daytime activities (28.5% 
versus 15.9%) than those not using a preparation. Therefore, non-prescription 
medication may have no effect on these sleep measures, or respondents are not using 
their non-prescription medication properly (e.g. intermittently instead of habitually). 
However, the survey does not provide enough detail to support such suggestions. The 
use of herbal remedies has rapidly increased over recent years, which Furnham and 
Bhagrath (1993) have postulated to be linked to discontentment with the medical 
establishment. Sproule et al. (1999) found the use of herbal preparations (such as herbal 
teas and tablets) to be 3% of their sample, and Busto et al. (2001) noted a prevalence of 
use of 5%. Two of the most popular herbs for sleep aid are valerian and passiflora. 
Valerian was used by 5.3% of those who took an OTC/herbal remedy (0.9% of all 
respondents) in the current survey, but this figure rose to 23.5% (4.1% of all 
respondents) when all the remedies containing a valerian extract were considered. 
Passiflora is also commonly found in many herbal preparations. Alone, it is used by 
0.6% of OTC/herbal users (0.1% of all respondents), but this figure rises to 9.8% (1.7% 
of all respondents) when preparations containing passiflora are included. It can be seen 
that valerian is by far the most popular herbal remedy for the elderly to use when they 
have a sleep problem. Despite this, 55.7% of valerian users suffer DIS (compared to 
37.1% who do not), 74.3 %  also suffer DMS (12.9% do not), 62.9% also suffer EMA 
(27.1% do not) and 25.7% also suffer a different sleep complaint (62.9% do not). More 
respondents taking valerian products complain of DIS, DMS and EMA than valerian 
users who do not, and a quarter of valerian users still have a sleep problem. Although 
the survey and analysis was not detailed enough to support these associations, the 
efficacy of these herbal preparations needs further investigation.
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This survey was completed to provide a more accurate representation of the 
sleep and sleep behaviour of older and elderly adults. More insight is now gained into 
prevalence of different sleep problems, as well as providing support or contradiction to 
previous research about elderly sleep (Urponen et al., 1988).
Of the 5846 participants in this survey, most respondents slept for 7-8 hours, did 
not nap, had no difficulty initiating sleep, but did suffer a difficulty maintaining sleep 
(as previously shown by Liljenberg et al., 1988; Morin and Gramling, 1989; Braz et al., 
1990; and Mallon and Hetta, 1997). DMS was mostly considered a ‘mild’ problem, as 
were problems with early morning awakenings. Most felt they did not get enough sleep, 
and the severity of this was mostly reported as ‘moderate’ . Most respondents were not 
tired upon awakening (those who were reported their problem as ‘mild’), felt no 
daytime effects, and most did not have an additional sleep complaint. The major 
additional sleep complaint was a need to use the toilet in the night, which was 
moderately-severe problem in nature. Most respondents did not use a prescription, but 
those who did favoured temazepam. Secondary prescriptions taken were principally 
analgesics. The most popular OTC or herbal remedies, alcohol and non-alcoholic 
beverages were Nytol and camomile tea, whisky (secondly wine) and Horlicks 
(secondly hot chocolate). Reading was found to be the most popular activity at bedtime.
Males reported a longer sleep time than females, and also had less DIS, DMS, 
and EMA. The prevalence of males was higher than the prevalence of females for 
feeling they have enough sleep, but fewer males than females: are tired on awakening, 
have severe sleep complaints, are affected by sleep complaints during the day, use 
prescriptions for sleep complaints, use beverages for sleep complaints, and males also 
use fewer alternative methods for improving sleep. This list may lead to the assumption 
that males, in general, have better subjective sleep than females. However, males: have 
more severe and more frequent DIS, nap longer, have more severe tiredness on 
awakening when it occurs, have more occurrences of sleep complaints, and use more 
alcohol for sleep complaints than females.
There were no significantly increasing trends with increasing age for the number 
of hours slept, prevalence of EMA, having an additional sleep complaint, severity of 
DIS, DMS, not getting enough sleep and severity of sleep complaint affecting daytime 
performance, occurrence of DIS, EMA, not getting enough sleep, being tired on
3.6 Summary, Conclusions and Future Research
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awakening, having an additional sleep complaint and the occurrence of sleep complaints 
affecting daytime performance. There are no significant effects of age on the types of 
prescriptions used, and prevalence and types of OTC/Herbals, alcohols, non-alcoholic 
beverages, and other methods for sleep enhancement used. However, older elderly 
females have subjectively less sleep than younger elderly females, the over 65’s nap 
more than those under 65 years of age, more females complain of DIS with increasing 
age, there is less DMS reported by those 80-84 years of age, but reports increase over 
the age of 85, males report milder EMA with increasing age, the numbers reporting not 
getting enough sleep increase over the age of 60, more over 55 year olds are tired on 
awakening than those aged 50-54, but with increasing age more people report they are 
not tired on awakening. The severity of being tired on awakening gets milder during the 
ages 70-79 years, and the severity of sleep complaints also gets milder for males over 70 
years olds. Reports of sleep complaints affecting daytime performance decreased 
between the ages of 55 and 74 years, and over the age of 74 years reports plateau. 
Lastly, older elderly females use more prescriptions than younger elderly females.
For whatever reason, sleep does change with age in certain ways, and these 
changes must be noted to explain to older adults how they should expect to sleep and 
view their sleep in old age. Some sleep problems will still need the prescription of 
hypnotic drugs, and other medication to aid sleep. Benzodiazepines can have long half 
lives in the elderly, so the drug may accumulate leading to daytime sedation (Greenblatt 
et al., 1984. Adverse effects could increase the number of accidents or falls, as 
suggested by Granek (1987), Ray et al. (1987) and Trewin et al. (1992). There are also 
risks if the elderly adult suffers from respiratory problems, as some benzodiazepines are 
thought to increase the duration of sleep apnoea episodes (Dement et al., 1982; Dolly 
and Block, 1982; Moran et al., 1988) due to respiratory depression (Model and Berry, 
1974). A solution may be to prescribe a shorter acting hypnotic. However, with a lack of 
accumulation, shorter acting hypnotics can result in mild ‘rebound’ insomnia from 
withdrawal effects, where sleep is worse than before the start of the drug treatment, and 
this may occur within the night (Lader and Lawson, 1987; Lader, 1992; Maczaj, 1993). 
The elderly can also suffer daytime anxiety, panics, perpetual hypersensitivity and 
weight loss (Lader, 1997), tinnitus, involuntary movements and nausea (Lion et al., 
1975; Petursson and Lader, 1984) during withdrawal. Also, because these hypnotics are 
short acting, their effect may wear off before the end of the night. This is a problem 
because the most common insomnia in the elderly was found to be a difficulty
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maintaining sleep, and so a single evening dose of a shorter acting hypnotic would not 
help this problem. However, lack of sedation during the night may reduce the number of 
falls in the night. It may be that several doses could be taken in one night, so it must be 
determined how many and how close to waking it is safe to administer. In addition, 
antidepressants have also been reported for use with sleep problems (Anderson, 2001), 
and the action of these drugs as hypnotics need to be evaluated. The use prescription of 
hypnotics to the elderly, and their effects, is problematic and needs further research to 
assess the best use of hypnotics in this age group.
This survey also indicated a large proportion of respondents used non­
prescription preparations to aid their sleep. Many elderly take herbal remedies, such as 
valerian and passiflora, without any evidence of their efficacy (Houghton, 1999). Their 
suitability and clinical effect needs evaluation.
In addition to these suggested studies, this survey leads on to several avenues of 
further investigation. The sample used in this survey was very large, but it may have 
been self-selecting and therefore biased. Those who read SAGA magazine might be 
more active, more affluent and better educated. A  replication of this survey in a random 
population of the elderly would be useful to corroborate results. Also, this survey was 
only based on behaviour over the last month. A longitudinal study may provide 
additional and more reliable information. Further alterations may include changes to the 
questions asked. There are no indications about what daytime effects of poor sleep are 
suffered by the respondents. They may experience very different effects, perhaps a poor 
memory, increased napping, or confusion. The elderly need to be asked what effects 
they have from their different sorts of sleep complaints. Another point regards 
subjective perception of sleep problems. For a good sleeper, a sleep latency of 15 
minutes may constitute a problem, but for a poor sleeper this might seem like a short 
duration. Again, a sleep problem is only a problem if it is perceived as one (Stepanski et 
al., 1989). It is difficult to judge these parameters, but perhaps duration of sleep latency 
and the number and duration of nocturnal awakenings should be requested in a survey. 
To make this easier, the use of a concomitant sleep diaiy with surveys would help 
elucidate these finer details, as used by Gislason et al. (1993). Also, respondents should 
be asked their perceptions of sleep. This can be achieved by asking for their actual 
answers, the answers they think they should be giving, plus the answers they think their 
peers might give. Lastly, and ideally, survey responses should be compared and 
contrasted to objective measures of sleep, such as EEG (electroencephalography).
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However, this would be an extremely time consuming and expensive with a large 
number of participants. EEG or similar would provide actual measures of elderly sleep, 
and in conjunction with subjective reports would attempt to provide the complete 
picture of elderly sleep.
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4.1 Abstract
One of the most popular herbal remedies for the alleviation of sleep problems is 
valerian. However, research into valerian is sparse, and studies differ greatly with 
respect to design, measures, and preparations used. This clinical study used standardized 
sleep EEG and psychometric tests to evaluate the clinical efficacy of a valerian 
preparation (Li 156).
A placebo-controlled three way crossover clinical trial was completed using 16 
(5 male and 11 female) sleep-disturbed participants (aged 50 to 64 years, mean age 55.9, 
sd 4.68). Participants slept overnight in a sleep laboratory, following a 21:00 dose of 
valerian 300mg, valerian 600mg, or placebo (double-blind). EEG sleep was recorded for 
each participant at 23:00 until 07:00, when a psychometric evaluation was performed 
the morning after dose. Test periods were separated by six days washout period.
Results showed no significant effect between valerian 300mg, valerian 600mg or 
placebo on any EEG parameter or psychometric measure. This suggests valerian at these 
doses is ineffective as an acute dose for sleep problems. However, valerian is widely 
used, and is traditionally sedative. Therefore, more research is required into therapeutic 
dose, types of valerian preparation, and the optimum period of use for therapeutic effect.
4.2 Introduction
Valerian is one of the oldest known medicinal herbs, dating back to the Ancient 
Greeks, and was first documented by Hippocrates in the 5th century B.C. (Willey et al., 
1995). Its name was derived from the Latin ‘valere’ meaning ‘to be in health5 
(Heiligenstein and Guenther, 1998), and has been used since the middle ages (then 
called ‘All-heal’) as a sedative and an antispasmodic. In the 16th century, learned 
medicine increased in popularity, by the study of works by Hippocrates and other 
Ancient Greek physicians. Thomas Elyot, a supporter of lay-medicine, stalled to write 
medical literature in English rather than Latin in 1580. During the Renaissance, literacy 
increased and medical knowledge was shared by doctors and patients alike. ‘Folk’ 
remedies were still widely used and trusted at this time (Nutton, 1985). Changes in 
medicine were brought about by the plague in the 17th century, as officially appointed
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(by the civil magistrates and the church governments) doctors and nurses visited the 
poor and sick, and inspected apothecaries, chemist shops and food markets (Cook,
1997). Hospitals, however, were still the place of the rich, and most of the time ordinary 
people still relied on local wisemen or women, who used potions and spells.
Medicine was advancing, but it was difficult to convince unlearned people that 
new chemically prepared remedies (made from mercury or spirits like gin, for example, 
or the new imports of tea, coffee and chocolate) would be safe and effective, as they 
were keen to rely on traditional procedures such as bleeding or purging. Many itinerants 
sold their new remedies by providing entertainment, such as jugglers and musicians, and 
were known as ‘quacks’ . As itinerants settled, and postal services spread, third parties 
became able sell these medicines. Doctors, surgeons and apothecaries alike met for 
debates in coffee houses, and continued to publish work. In the early 18th century, a 
medical school was opened in Edinburgh which taught both the anatomy and chemistry 
of medicine. Clinics and medical courses increased rapidly in number. Impoverished 
patients had little say in treatments, and were used and mistreated in the development 
medical knowledge.
In the late 18lh century, Withering published ‘Account of the Foxglove’ (1785) 
after finding that foxglove improved ‘dropsy’ (congestive heart failure). Many new 
medicines were then discovered by the probing and reforming of folk customs. The 
Government became involved in medicines, and adopted a ‘medical policy’ for public 
hygiene. The end of the 18th century saw the industrial revolution, and with it the 
founding of new medical societies. The Apothecaries Act of 1815 stated the London 
Society of Apothecaries had responsibility for educational standards in medical 
practitioners. Following this, The Lancet was published in 1832, and the BMA was also 
founded. Health professionals began to re-assess the chemistry of medicine, and focused 
on reducing all organic processes to a chemical process. The late 19th century and early 
20th century was spent identifying micro-organisms and preparing vaccines and 
antitoxins for diseases, all from biological sources (made from animals). The search for 
synthetic chemical treatments increased, leading to mass-produced and mass-marketed 
medicines. Funding soon became an issue, resulting in practitioners having to persuade 
universities or wealthy organisations to support them. With such mass-production, 
concern soon grew over impurities in the treatments, especially those obtained from 
quacks and pill peddlers. So, in 1906, the U.S. set up the Food and Drug Administration
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(FDA). Here in the U.K., the Medical Research Council (MRC) formed in 1913, and the 
Therapeutic Substances Act was introduced in 1926.
There were obvious advantages to modem medicine, including the discoveiy of 
insulin and penicillin, contraception, surgery, transplantation, and communication about 
diseases and conditions (Cook, 1997). However, disadvantages have been emerging 
over the last century. Increasing costs of health care are a pressing issue, with many 
patients feeling unsatisfied with the treatment in hospitals (Cook, 1997). Cook (1997) 
also suggests little attention is given to the prevention of illnesses, and too much is spent 
on coping with illnesses. He also suggests that medical research has become a vehicle 
for self-advancement for some professionals, rather than solely for the bettering of the 
patients’ conditions. Furnham and Smith (1988) and Furnham and Bhagrath (1993) have 
found increased disillusionment in the public of the health professionals, as they are 
thought to be no longer being interested in their patients as people, but only as diseases. 
Because of this, Mischoulon and Rosenbaum (1999) suggest individuals feel deprived of 
the responsibility of their own well-being, and wish to again have control over their own 
medication. Most recently, the thalidomide tragedy in the 1960’s was a blow to public 
confidence. Hailed as a ‘wonder drug’ for morning sickness, thalidomide caused the 
deformities of tens of thousands of babies (Cook, 1997). These reasons are examples of 
why the public are now turning back to ‘unorthodox’ therapies.
4.2.1 Classification and Recognition of Valerian
4.2.1.1 In the U. S.
In the nineteenth century, valerian was given as an anxiolytic for nervous 
afflictions in women (Willey et al., 1995), and gained the description “the valium of the 
19th century” (Hobbs, 1989). It was even used as a treatment for shell shock during 
World War I (Wolman, 1972). Despite this, valerian was removed from the U. S. and 
British pharmacopoeias in the early twentieth centmy due to the advent of synthetic 
drugs, particularly barbiturates (Hobbs, 1989; Willey et al., 1995; Houghton, 1999). 
Recently, due to the disillusionment in the medical system described above, patients are 
reviewing herbal remedies as a viable supplement or even alternative to conventional 
medicine. Currently, pressure mounts for the FDA (Food and Drugs Administration) to 
recognise valerian as a medicinal drug (Cott, 1995a). The FDAs definition of a drug is
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any product that is used for the “prevention, treatment, mitigation or cure of any disease 
condition” (Cott, 1995a), but drug approval costs in the U. S. are very high. Herbals are 
complex and are not patentable, and funding is lacking to overcome regulatory 
obstacles. It is not economically viable for drugs companies to fund research, testing and 
promotion of herbal preparations. Indeed, no complex natural product has been 
approved as a new drug since the 1962 Kefauver-Harris amendments to the FDA 
guidelines for increasing assurance of drug safety and efficacy were enforced (Cott, 
1995a). In these times, where regulation of a medicinal product is paramount to the 
safety of patients, a substance cannot be considered a drug on the basis of tradition alone 
(O’Hara et al., 1998).
However, valerian continues to sell due to the U. S. Dietary Supplement Health 
and Education Act (1994), but without regulation from the FDA. Manufacturers are not 
required to provide any data concerning the safety, purity or efficacy of their product 
(Wagner et al., 1998), and the FDA must prove a herbal is unsafe or ineffective before it 
can be removed from the shelves (O’Hara et al., 1998). Manufacturers cannot claim 
efficacy, but unfortunately there is no legislation preventing third parties from 
advertising possible therapeutic benefits of the product (Williamson and Wyandt, 1997).
These circumstances are likely to change in the near future in America. The 
World Heath Organisation (WHO) have issued Guidelines for the Assessment of Herbal 
Medicines (Akerele, 1992), declaring that historical use of a substance is a valid form of 
safety and efficacy information, in the absence of scientific documentation to the 
contrary. Subsequently, the National Institutes of Health (NIH) has set up an Office of 
Alternative Medicine, and the European-American Phytomedicines Coalition has 
petitioned the FDA for the inclusion of valerian in the OTC (over-the-counter) 
monograph for sleep disorders.
4.2.1.2 In Germany and Europe
In contrast, attitudes towards herbal remedies in European countries such as 
Germany are very different. After World War II, German pharmaceutical companies 
invested in scientific research into herbals, searching for standardisation and high 
quality. The stringent criteria of quality, efficacy and safety of synthetic drugs 
stimulated the search for active constituents, standardisation methods and clinical trials. 
Toxicology studies were completed between 1970 and 1985, after which clinical trials
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began (Wagner, 1999). Unlike the U. S., there are no extensive regulatory guidelines in 
Germany, and private research organisations have been making progress. Valerian has 
been recognised in the German Commission E monographs (Cott, 1995a; Blumenthal,
1998), and is currently used for excitability, restlessness, trembling (Hobbs, 1989), 
anxiety, and sleeping problems (Bisset, 1994). European research has been vital to the 
continuation of interest in herbal remedies. Many drugs in use today have originated in 
plant or animal sources. For example, aspirin, a salicylate, was obtained from willow 
bark, as it contains salicin (Vane, 2000). Morphine is an opiate and was derived from 
poppy seeds (Grove et al., 1976), atropine was derived from Atropa belladonna (Mitra, 
1972), caffeine was derived from tea and coffee (Marks and Kelly, 1973), and quinine 
was derived from cinchona bark (Dobson, 1998). Findings from research into valerian 
might therefore be useful for enhancing our knowledge of conventional medicines 
(Houghton, 1999). Research into natural products can often enhance our scientific 
knowledge of conventional medicines (Cott, 1995a). For example, the use of anti-cancer 
drugs like methotrexate, triptorelin and cisplatin can be enhanced by co-administration 
of substances like selenium (for the reduction of kidney damage; Hu et al., 1997) and 
melatonin (to reduce side effects; Lissoni et al., 1997). Cott (1995a) suggests that by 
limiting the search for new drugs to only predictable synthetic chemical methods will 
mean “truly unique medications are unlikely to emerge” (p. 132).
In 1989, ESCOP was formed, the European Scientific Co-operation on 
Phytotherapy. This was founded by Belgium, France, the Netherlands, Switzerland and 
the U.K., and joined by Greece, Ireland, Italy, Sweden and Turkey. The objectives of 
ESCOP included co-ordinating a framework for assessment of phytomedicines (defined 
as: “ ...medicinal products containing as active ingredients only plants, pails of plants or 
plant materials, or combinations thereof, whether in the crude or processed state”, 
similar to the WHO guidelines (ESCOP, 1996), initiating and supporting experimental 
and clinical research, and ensuring the safety of phytomedicines (ESCOP, 1996). In 
1992, ESCOP submitted 15 monographs to the CPMP (Committee of Proprietary 
Medicinal Products), and by 1996, there were two publications each containing ten 
ESCOP monographs.
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Here in the U. K., the attitude to herbal remedies is similar to that of the U.S., 
despite being a founder member of ESCOP. In 1964, the British Herbal medicine 
Association (BHMA) was founded to advance the science and practice of herbal 
medicine in the U.K. However, the Medicines Act (1968) suppressed this by introducing 
more legislation for herbal remedies (BHMA, 2000). By the 1980’s, the EC Review of 
Medicines had stated that all U.K. manufacturers had to complete rigorous technical 
appraisal of their products, providing evidence of quality, safety and efficacy to the 
MCA (Medicines Control Agency). The BHMA hope to meet these criteria; to stand for 
the public right to use herbals, the encouragement of wider knowledge of the value of 
herbals, and the advancement of scientific research with respect to quality and safety 
(BHMA, 2000). Today, valerian can still only be obtained over-the-counter (Houghton,
1999) in health food shops or similar.
4.2.2 Using Herbal Remedies and Valerian
Despite problems with testing and marketing herbal remedies, there are an 
exceptionally large number available for purchase, even in the U.S. and U.K. 
Farnsworth et al. (1985) found that a quarter of all prescriptions in North America are 
for plant products or derivatives, and 75% of these were originally used in native 
cultures. In 1985, Mellinger et al. noted 3.1% of American adults used non-prescription 
hypnotics, but in the same time frame, only 2.6% used prescription hypnotics. In 1993, 
between 20% and 30% of Americans have been found to use alternative or 
complementary medicines (Berger, 1993; Eisenberg et al., 1993), and herbals alone 
account for around 3% to 12% of this figure (Berger, 1993).
The increase in usage can clearly be seen in the amount spent on herbal 
remedies. In 1992, North America spent around £633 million (compared to £981 million 
spent in the considerably smaller country of Germany) (Cott, 1995b), but £7 billion in 
1997 (Anonymous, 1997a). In the U. K., £20.3 million was spent on herbals in 1992 
(Cott, 1995b), rising to £38 million in 1996 (Anonymous, 1997b). U. S. valerian sales 
alone reached approximately £4 million in 1997 (Fugh-Berman and Cott, 1999). 
However, no figures are readily available on the prevalence of valerian consumption 
alone.
4.2.13 In the U.K.
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This indeed shows a strong demand for alternative medicines. However, the lack 
of regulation or control gives cause for concern. For example, herbals can differ greatly 
in formulation between batches with respect to genes, growing conditions, plant parts 
used, time of harvesting, storage, and preparation procedures (O’Hara et ah, 1998). 
Method of consumption can also differ (tea, tincture, capsule, tablet etc.) leading to 
differences in absorption and effect (Wagner et al., 1998). Lack of regulation may lead 
to the contamination of the herbs during packaging (O’Hara et al., 1998; Ernst, 1999), 
and so may result in the sale of poor quality goods (Ernst, 1999). Pye et al. (1992) 
reported that autoimmune thrombocytopenia was associated with the use of kelp, as 
1.3mg of arsenic were found in the capsules.
The lack of research into alternative remedies can result in uncertainty of their 
efficacy and possible side effects. Whilst it is widely assumed that there is little chance 
of any side effects with herbal products (Newall et al., 1996; Ernst, 1998; Schulz et al,
1998), adverse events have been reported. Barnes et al. (1998) conducted face-to-face 
interviews with 515 volunteers in six pharmacy stores and six health food stores across 
the U.K. They found that 4.3% had suffered an adverse event as a result of a herbal. 
Perharic et al. (1993) found royal jelly had been repeatedly linked with severe 
bronchospasm, and yohimbine (Sandler and Aronson, 1993) and camphor (Marguery et 
al., 1996) have been associated with allergic reactions. A  herbal tea containing valerian 
root, skullcap and chaparral may be toxic to the liver, and has been associated with acute 
hepatitis (Caldwell et al., 1994).
Veiy few people who take a herbal remedy, and experience side effects, will 
inform their G.P. (Barnes et al., 1998). Eisenberg et al. (1993) found as many as 72% 
would not even tell their G.P. that they were talcing herbal remedies. Barnes et al. (1998) 
found a lack of information about the side effects of herbals was attributable to patients 
not realising they should tell their G.P. about herbal use, as the remedy was not 
prescribed. Also, patients are suggested to have an unwillingness to admit to herbal use, 
and lastly, patients felt that informing a herbal practitioner was more appropriate. Fugh- 
Berman and Cott (1999) consider not informing G.P.s of herbal use to be dangerous. It 
is suggested that the act of self-medication alone could be detrimental as it may be 
inappropriate or symptoms may be misattributed (Newall et al., 1996; Mischoulon and 
Rosenbaum, 1999). There is also a lack of information on any interactions valerian may 
have with other medications. The elderly are prescribed more medication than younger 
adults (Janson et al., 1995). If herbal use is not disclosed to the G.P., the elderly may
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increase the risk of adverse effects occurring from these interactions. In addition, 
Mischoulon and Rosenbaimi (1999) warned that those who need real help (such as 
prescription medication for serious illnesses) might delay effective treatment by taking 
herbals instead.
Even when G.P.s are informed of herbal use, Bames et al. (1998) found 
practitioners were unlikely to be aware of the effects of herbals, and were often 
unprepared to answer their patients’ questions. However, one paper was published 
demonstrating withdrawal effects following long term use of valerian, namely tremor 
and delirium (Garges et al., 1998), which were found to be similar to the withdrawal 
effects seen with benzodiazepines. In addition, MacGregor et al. (1989) found evidence 
for liver damage in four females after taking valerian with skullcap, and studies in mice 
have indicated a possible cytotoxicity (Bounthanh et al., 1981; Braun et al., 1982). It is 
not advised that valerian is used dining pregnancy until further research has been 
completed (Berglund et al., 1984; Committee ADE, 1989; Tufik et al., 1994; O’Hara et 
al., 1998).
The majority of clinical studies using acute doses have shown that valerian is 
well tolerated, with only 9.1% of volunteers feeling they tolerated their dose moderately 
or poorly (Donath, 1997; Kuhlmann et al., 1999), and 82.8% of 202 outpatients assessed 
valerian as ‘very good’ (Ziegler et al., 2002). Lindahl and Lindwall (1989) studied the 
effects of 400mg of valerian on the sleep EEG of 27 young adults, but found no adverse 
effects. However, Kuhlmann et al. (1999) studied the effects of 14 days administration 
on the psychometric effects of valerian 600mg on 102 young volunteers. They showed 
valerian was associated with nausea, dry mouth and dizziness. Other adverse events 
associated with valerian include headache (Orland and Schenk, 1990; Berger, 1993; 
Donath, 1997), sweating, tremor (Dorn, 1996), and paradoxically, anxiety (Dorn, 1996).
The pharmacodymanic effects of valerian are poorly researched. However, 
Kuhlmann et al. (1999) found no effects on reaction time, alertness and concentration 
the morning after ingestion compared to placebo. Herberg (1991) completed a 
randomised study of 48 healthy volunteers on valerian 300mg or placebo for 8 days. The 
study included tests of visual orientation, long term concentration, simple and choice 
reaction tasks, stress tolerance, vigilance and motor skills. The first dose was found to 
result in minor deteriorations of motor skill and vigilance, but this was not found with 
repeated doses. These studies imply valerian has relatively little effect on psychometric 
tasks.
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There are over 170 varieties of valerianaceae, but common valerian (valeriana 
officinalis L.) is the most widely used preparation (Leathwood and Chauffard, 1983). 
For this reason, only valeriana officinalis L. will be reviewed here, and will be referred 
to from this point forward as simply ‘valerian’ . It grows mostly in North America, 
Europe and Asia (Leathwood et al., 1982), and is cultivated for medicinal use in 
Holland, Belgium, France, Germany, Eastern Europe, Japan and the U.S. (Bisset, 1994). 
The market for valerian is therefore global.
Differences can be found with respect to genes and growing conditions, but it is 
assumed that most valerian tends to contain the same constituents. This may not be the 
case, however, as it is possible that many lesser, and even major constituents remain 
unidentified (Houghton, 1999). This in itself makes research into valerian difficult. 
Balderer and Borbely (1985) claim that before valerian can be considered as a 
pharmacotherapy for insomnia, pharmacokinetic studies need to be completed (Schulz 
et al., 1998). This progress in research is hampered by a lack of knowledge of 
constituents. Over fifteen years on, this is still largely the case.
Despite this, the identified constituents can be divided into two main categories 
of active substances, namely sesquiterpenes and valepotriates.
4.2.3.1 Sesquiterpenes
The sesquiterpenes are the most important part of the volatile oil, often known as 
the ‘essential oil’ . This part gives valerian its distinctively unpleasant odour and taste 
(Houghton, 1999). In fact, a study using rats by Macht and Giu Ching Ting (1921) 
concluded that the fumes of valerian alone (via olfactory receptors) were enough to lead 
to sedation. Approximately 0.3% to 0.8% of volatile oil can be found in powdered root 
extract (Schulz et al., 1998). A  high content of volatile oil is found mainly in aqueous 
solutions of valerian (Bisset, 1994).
Sesquiterpenes can be divided into three main constituents: valerenic acid, 
kessyl glycol (kessane sesquiterpenes), and valeranone. Monoterpenes, mostly bomeol, 
are also present, but have received very little attention in research (Houghton, 1999).
Valerenic acid is unique to valerian, and is considered the most active of the 
sesquiterpenes in central nervous system (CNS) sedation. For example, 50mg/kg in
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mice significantly reduced motility (Hendriks et al., 1981), and increased pentobarbital- 
induced sleep time in mice (Hendriks et al., 1985). It was concluded that valerenic acid 
has a central (CNS) rather than a peripheral (muscular) effect. Riedel et al. (1982) 
studied the effects of valerenic acid in the mouse brain, and proposed a mechanism 
whereby an enzyme system which breaks gamma-aminobutyric acid (GABA) is 
inhibited by valerenic acid, which results in sedation and reduced CNS activity due the 
increased amounts of GABA.
The kessane sesquiterpenes also appear' to reduce motility and increase 
hexobarbital induced sleep time in rats (Takamura et al,, 1973). Likewise, the 
valeranone sesquiterpenes, of lesser importance, also reduce motility and increase 
barbitone-induced sleep time in mice (Arora and Arora, 1963), but this is at very high 
doses. Arora and Arora (1963) suggest this is due to a decrease in levels of 5-HT and 
noradrenaline, as this was observed during post-mortem. Hazelhoff et al. (1982), via in- 
vivo and in-vitro tests on the guinea pig ileiun, suggested valeranone acts primarily on 
the muscles rather than on the CNS, reducing motility.
4.2.3.2 Valevotricites
Valepotriates (valeriana epoxy-triesters) were discovered in 1966 by Thies and 
also Mannenstatter et al. (1966), and their discovery helped to explain why valerian 
extracts with a low volatile oil content still displayed active effects (Houghton, 1999). 
Valepotriates are water soluble and are therefore not usually present in aqueous 
solutions of valerian extract, but are relatively abundant in alcoholic preparations 
(Houghton, 1999). The content of valepotriates in valerian can range from 0.5% to 8% 
(Bos et al., 1998b).
In 1969, Von Eickstedt (1969) and Von Eickstedt and Rahman (1969) 
discovered that valepotriates also decreased motility in mice, but not to the extent of 
sesquiterpenes. They also found that valepotriates lessened the effects of alcohol on 
mice. In addition, experiments on cats showed no decrease in reactivity, but instead a 
decrease in restlessness, ‘anxiety’ , and aggressiveness (see Houghton, 1999). It is 
therefore suggested that valepotriates may have more of a tranquillizing (reducing 
anxiety without causing drowsiness (Houghton, 1999)) effect, rather than a sedating 
effect, although Kohnen and Oswald (1988) disagree. They tested lOOmg valerian under 
stressful conditions in 48 young adults, namely a public test of arithmetic. These authors
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found no change in the ratings of ‘anxiety’ or ‘tiredness’ , but did note decreases in the 
feelings of somatic arousal.
The mechanisms of a tranquillizing effect are unclear. Wagner and Jurcic (1979) 
suggest valepotriates exert a strong spasmolytic effect, which would go some way to 
explain their secondary uses for gastrointestinal problems. Godau (1991) suggests 
valepotriates bind to dopamine receptors, therefore inhibiting the stimulatory effects of 
dopamine in the CNS. Both Wagner et al. (1980) and Schneider and Willems (1982) 
implicate a derivative of valepotriates in the mechanisms of action, as they found 
homobaldrinal to be more effective than the parent valepotriates themselves.
However, there are many problems with the efficacy of valepotriates. There is 
some doubt over the oral bioavailability of homobaldrinal (Houghton, 1999). Also, 
valepotriates hydrolyse and degenerate quickly over time. This rapid degradation could 
result in a low concentration of valepotriates, and so would reduce the possibility of 
significant pharmacological effect. Houghton (1999) suggests this could account for 
problems showing efficacy in past research. Also, there is some evidence for possible 
cytotoxicity (Bounthanh et al., 1981; Braun et al., 1982; Tortarolo et al, 1982) and 
potential carcinogenicity (Bounthanh et al., 1981; Braun et al., 1982). Valtrate may 
inhibit the incorporation of thymidine and leucine into deoxyribonucleic acid (DNA) 
(Bounthanh et al, 1983). Therefore Houghton (1999) concludes that the use of 
valepotriates in commercial valerian may be undesirable. Bos et al. (1998a) advocate a 
move towards valepotriate-free preparations. However, some products on the market in 
Germany only contain isolated valepotriates, rather than valerian itself, such as 
‘Valmane’ and ‘Baldrisedone’ . These are used more as psychostimulants than 
tranquillizers (Bisset, 1994). It is clear more research is vital.
4.2.3.3 Other Constituents
Other constituents of valerian have received very little attention from the 
scientific community, as they are present in relatively small quantities. It is generally 
assumed the amounts present in valerian are too small to have a significantly 
contributory effect (Houghton, 1999). Other constituents so far identified include: 
monoterpene alkaloids (Torsell and Wahlberg, 1967) (such as bomeol), free amino acids 
in aqueous solutions (including GABA, tyrosine, arginine and glutamine), and 
furanofuran ligands (Bodesheim and Holzl, 1997).
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Animal studies have shown the alkaloids and amino acids appear to reduce 
levels of acetylcholine in the CNS, leading to stupor (Torsell and Wahlberg, 1967). The 
GABA and glutamine (which metabolises to GABA) present has been found to result in 
sedation in rodents (Santos et al., 1994a; Cavadas et al., 1995). Indeed, extracts of 
valerian have a high content of GABA (Cavadas et al., 1995; Bodesheim and Holzl, 
1997), and seem to have an affinity for GABAa receptors (Holzl and Godau, 1989; 
Mennini et al., 1993). It is suggested that valerian may induce the release of GABA in 
the synaptosomes (Mennini et al., 1993; Santos et al., 1994a/b/c; Cavadas et al., 1995), 
and may also inhibit GABA re-uptake (Santos et al., 1994a/c). However, Wong et al. 
(1998) points out this explanation may be questionable due to GABA not being able to 
easily cross the blood-brain barrier (Rosenstein, 1996). However, if other constituents 
can pass the blood-brain barrier, than this could lead to an increase in GABA in the 
CNS. Research into the ligands has shown that 1-hydroxypinoresinal inhibits 5-HT 
binding to its receptor, but has little effect on the benzodiazepine receptor. More 
research is necessary into these smaller components of valerian.
4.2.4 Experimental Effects of Valerian
The animal studies previously mentioned show that sesquiterpenes, valepotriates 
and even the smaller constituents of valerian might all have a possible contributory role 
in the cognitive and/or behavioural effects of valerian. There have been many studies 
performed on animals, most showing evidence of some effect of valerian. In fact, 
Houghton (1999) concluded: “the evidence for the efficacy of valerian is fairly strong 
and it would appeal' to be a relatively safe substitute for drugs such as the 
benzodiazepines as a mild tranquillizer and to aid onset of sleep...” (p.511). However, 
the evidence for efficacy in human trials is not so conclusive. Although animal studies 
may argue whether the effects of valerian are sedating, tranquillizing, anxiolytic or even 
antidepressant (Torrent et al., 1972; Petkov et al., 1974; Holm et al., 1980; Hendriks et 
al, 1981; Hendriks et al., 1985; Sakamoto et al., 1992; Oshima et al., 1995; Hiller and 
Zetler, 1996; Holzl, 1996), it is mostly agreed that valerian is effective. However, it 
seems a definite effect of any kind has not been sufficiently substantiated by human 
clinical trials, reported in English. Trials are mainly completed in Europe and published 
in associated languages such as German. Therefore a large proportion of trial data is 
unfortunately inaccessible to British researchers (O’Hara et al., 1998). This review will
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therefore mostly include the literature made accessible to the English speaking 
community.
Most valerian research, as with research into hypnotics, uses a comparison of the 
active treatment to placebo. However, Lindahl and Lindwall (1989) compared their dose 
of valerian to a very small dose of valerian in their study, as early researchers 
experienced difficulty in masking the distinctive odour and taste of valerian. It was 
presumed a small dose of valerian would have no experimental effect.
Very few studies into valerian have been published, and those that have tend to 
neglect the more objective measures of sleep. Drawing any conclusions about valerian is 
therefore difficult. The current research below implies valerian may have some effects 
on sleep and performance.
4.2.4J  Influencing Factors in Valerian Research
Human experimental research into valerian has yielded inconclusive trends 
regarding the effects of valerian. However, specific areas within the investigation of 
valerian may add insight to the overall picture. Most areas are poorly under-researched, 
with some gaining no attention whatsoever. Studies differ greatly with respect to design 
and method; therefore it may be of use to consider the literature in these terms. Past 
research has elucidated key areas which may be most influential on the findings of 
valerian research. These are methods used (objective or subjective), types of participant 
used (‘normals’ , the sleep disturbed or older adults) and most importantly, the type of 
valerian used (aqueous or alcoholic preparations, dose, and treatment duration).
4.2.4.1.1 Methods Used
In the literature, three distinctive methods have emerged, which are also the 
three main methods of ail sleep research. These are EEG, questionnaires and other 
psychometric tests, and activity meters (usually wrist worn). Each measures specific 
aspects of the effects of valerian, and so differences are elucidated.
The advantage of laboratory based studies are clear. They are well controlled, 
ensuring confidence to assume any effects found are due to the valerian alone, and no 
other factors. The problem is contradiction between subjective and objective measures. 
Balderer and Borbely (1985) found the effects they produced in their questionnaire
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home study could not be replicated in their laboratory based EEG study. Whilst being 
partially attributed to different volunteer age groups, partial attribution was also made to 
the artificial sleep laboratory surroundings. This was also the case for Leathwood and 
Chauffard (1983) as an additional factor to a small number of volunteers. Balderer and 
Borbely (1985) suggests a “stressful sleep environment” may be responsible for 
“obscuring the mild hypnotic action” of valerian (p.409). Indeed, Leathwood and 
Chauffard (1983) described the experience as being required to sleep “festooned with 
wires, in a strange bed” (p,121). These unnatural sleep scenarios lead Leathwood et al.
(1982) to conclude that subjective ratings are the “final arbiters of utility” (p.69). In over 
40 years of electrophysiological sleep research, very little evidence for the correlation 
between EEG and sleep quality has been found (Leathwood et al., 1982; Hoch et al., 
1987), although research still continues.
4.2.4.1.1.1 Subjective Measures
Table 4.1 below outlines the major studies which have investigated subjective 
aspects of the effect of valerian on sleep. Donath et al. (2000) administered valerian 
600mg for either 1 day or 14 days to 16 insomniac patients. The dose was given one 
hour before bedtime (22:00), and visual analogue scales were completed by the patients 
before sleep and after waking in the morning (06:00). Donath et al. (2000) found 600mg 
of valerian reduced subjective sleep latency, but showed no change in the subjective 
number of awakenings or morning sleepiness, and also no increase in sleep quality, all 
compared to placebo. Leathwood and Chauffard (1983) gave 400mg of valerian to 128 
yoimg healthy volunteers to take each night at home, an hom* before bedtime, for one 
night. The results of a sleep questionnaire showed valerian decreased subjective sleep 
latency, an increase in sleep quality, a decrease in the subjective number of awakenings, 
and a decrease in subjective motor activity, compared to placebo. Another study by 
Leathwood and Chauffard in 1985 primarily investigated the effects of valerian on EEG 
sleep in 8 patients with a long sleep latency, but sleep questionnaires were also 
completed the morning after dose. The doses were 450mg and 900mg, and Leathwood 
and Chauffard found valerian (compared to placebo) decreased sleep latency, increase 
sleep quality, and decreased subjective motor activity. However, these authors also 
found valerian produced a dose-dependent increase in morning sleepiness. Balderer and 
Borbely (1985) conducted a study in the volunteers’ homes, and a study in a laboratory.
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The 10 participants sleeping at home took 450mg or 900mg valerian thirty minutes 
before bedtime. Sleep questionnaires completed the next morning revealed valerian 
(compared to placebo) subjectively decreased sleep latency, and decreased the 
subjective number of awakenings. However, the authors also found no effect of valerian 
on sleep quality, and there was no significant reduction in subjective motor activity. 
Ziegler et al. (2002) gave 600mg of valerian (Li 156) to 202 outpatients, aged 18 to 73 
years old with non-organic insomnia, for 6 weeks. They found valerian to have similar 
effects to oxazepam lOmg, with increases in sleep quality, refreshment after sleep, and 
subjective duration of sleep.
Other studies that have also noted a significant decrease in subjective sleep 
latency include Kamm-Kohl et al. (1984), who studied elderly insomniacs taking 45mg 
of valerian 3 to 9 times per day (135mg to 405mg) for 14 and 30 days, but Kuhlmann et 
al. (1999) found no effect on sleep latency, and Donath (1997) even showed an increase 
in sleep latency. Donath (1997) explained this as a removal of the misperceptions about 
sleep latency. It is unclear if this is due to valerian per se, or simply a re-examination by 
study volunteers of their sleep patterns due to participation in a sleep trial. An increase 
in subjective sleep quality was also found in the studies of Lindahl and Lindwall, 
(1989), Vorbach et al. (1996), Donath (1997), and Kuhlmann et al. (1999). Dominguez 
et al. (2000) also found increases in sleep quality by the administration of 470mg of 
valerian to 23 Hispanic outpatients for 2 weeks, as did Wheatley (2001), who gave 
600mg of valerian to 19 stress-induced insomniacs for 6 weeks. Kulhmann et al. (1999) 
also foimd a decrease in the subjective duration of wakefulness in the night. Other 
studies agree that there is no increase in morning sleepiness (Orland and Schenk, 1990; 
Kuhlmann et al., 1999), and Donath (1997) noted a significant decrease in morning 
sleepiness.
The literature, although sparse, implies that valerian may be beneficial from a 
subjective point of view. Most studies show a decrease in sleep latency, an increase in 
sleep quality, a decrease in subjective number or duration of awakenings, and a lack of 
morning sleepiness.
4.2.4.1.1.2 Objective Effects
Few studies have assessed the effects of valerian on objective measures of sleep, 
and so results are ambiguous (see table 4.2). Donath (1997) completed a crossover study
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of 8 insomniacs over 6 weeks taking valerian 600mg or placebo. Results showed there 
was no significant effect of valerian on objective sleep latency, no difference in the 
number of awakenings, no change in sleep efficiency, and no change in the amount of 
REM (rapid eye movement) sleep. However, after this study, Donath tested valerian 
600mg (and placebo) for either 1 day or 14 days, given to 16 insomniac patients (Donath 
et al., 2000). Sleep EEG showed a significant decrease in the objective number of 
awakenings, an increase in sleep latency, and an increase in the amount of REM sleep, 
all of which disagreed with the authors’ earlier work. Reasons for this are unclear. 
Objective time in bed (TIB) and total sleep time (TST) seem largely unaffected by 
valerian (Leathwood and Chauffard, 1983/1985; Balderer and Borbely, 1985). This also 
appears to be the case for objective sleep latency (Leathwood and Chauffard, 1983; 
Balderer and Borbely, 1985; Kuhlmann et al., 1999), but Leathwood and Chauffard 
(1985) noted a decrease in sleep latency after three weeks administration of 450mg 
valerian. However, in this study, participation criteria included having a long sleep 
latency, and as before, improvements may be due to increased awareness of sleep 
patterns.
The studies by Donath (1997) and Donath et al. (2000) both showed no change 
in latency to slow-wave sleep (SWS; stages 3 and 4), although after prolonged use 
resulted in a decrease in this latency (Donath et al., 2000). Donath (1997) and Donath et 
al. (2000) also foimd there was no effect of valerian on latency to REM sleep, and this 
was also supported by Leathwood and Chauffard (1983). Results have also shown a lack 
of change in the percentage of stage 1 and 2 sleep (light sleep) after valerian use 
(Donath, 1997; Donath et al., 2000). However, Schulz et al. (1994) noted a decrease in 
stage 1 sleep and an increase in stage 2 sleep. In this study, Schulz et al. (1994) 
administered 405mg of valerian to 14 elderly insomniacs for one day and seven days. It 
is possible the age group studied lead to these effects, as the elderly are more sensitive 
to the effect of medications than young adults (Massoud, 1984; Cook, 1986). Results 
showed using valerian lead to a significant increase in total sleep time, an increase in the 
percentage of stage 3, and also stage 4 sleep, but there was no effect on sleep latency, 
sleep efficiency (also found by Leathwood and Chauffard, 1983) or the amount of REM 
sleep.
Intuitively, a desirable sleep medication for mild insomnia will affect variables 
such as sleep latency, total sleep time and the number of awakenings, but will not 
seriously alter the distribution of sleep stages. This means it will not radically alter
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‘normal’ sleep architecture, and therefore is assumed not to cause further disruption to 
sleep. However, with a lack of correlation between objective and subjective measures of 
sleep, it is unknown if changes in sleep architecture are clinically relevant in insomnia.
Although there is little evidence of changes in architecture due to valerian, there 
is also little evidence to support a change in objective sleep latency, time in bed, total 
sleep time and sleep efficiency. The exception here is possibly the objective number of 
awakenings, where some evidence is noted.
4.2.4.1.2 Type o f  Participants Used
The effects of valerian will depend very much on the types of people it is 
administered to. Those with long sleep latencies, for example, may yield different 
results than those who do not. Inspection of the current literature reveals three major 
categories of volunteers that may produce different effects: ‘normals’ (meaning no 
complaints or evidence of poor sleep), the sleep disturbed, and older adults.
In a study of ‘normal’ adults, Kuhlmann et al. (1999) found no change to 
morning sleepiness (supported by Leathwood and Chauffard (1983) using 400mg of 
valerian) or subjective sleep latency, on 600mg of valerian for a fortnight. Balderer and 
Borbely (1985) also found support for a lack of effect of 900mg on sleep latency, but 
only on objective sleep latency, and found a decrease in subjective sleep latency. 
Leathwood and Chauffard (1983), in a home study, also supported a decrease in 
subjective sleep latency. Balderer and Borbely (1985) also found no change in the 
amount of time spent in bed, and a decrease in the subjective number of awakenings 
(supported by Leathwood and Chauffard, 1983), and also a reduction in motor activity.
In research involving sleep-disturbed adults, evidence has been found for a 
significant increase in sleep quality with valerian doses of 400mg for 1 night (Lindahl 
and Lindwall, 1989), 400mg for 9 nights (Leathwood and Chauffard, 1983), 600mg for 
6 weeks (Donath, 1997), and 900mg for 3 weeks (Leathwood and Chauffard, 1985). 
However, there is no support for changes in subjective total sleep time (TST) (Donath, 
1997; Donath et al., 2000) or objective TST (Leathwood and Chauffard, 1985; Donath, 
1997; Donath et al., 2000). Donath (1997) and Donath et al. (2000) also note a lack of 
changes to percentage stage 1, percentage stage 2, percentage deep sleep, latency to deep 
sleep and sleep efficiency. In addition, Leathwood and Chauffard (1985) foimd no 
changes to motor activity.
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There are veiy few available studies on the use of valerian in older adults. Two 
of these studies include Leathwood and Chauffard (1983) and Schulz et al. (1994). As 
with the other areas, this lack of research makes drawing conclusions very difficult. 
However, Schulz et al. (1994) found an increase in objective total sleep time (TST) over 
one dose (405mg) and over seven days of dosing. This is an important result as a decline 
in nocturnal TST is a common problem amongst the elderly (Morin and Gramling,
1989), and causes much concern among sufferers (Riedel and Lichstein, 1998). A  herbal 
capable of lengthening nocturnal sleep time would be most beneficial to the wellbeing 
of elderly sufferers. Results of the study by Schulz et al. (1994) have also shown an 
indication of an increase in percentage stage 3 and no significant change in sleep 
efficiency.
The effect of valerian on each category of volunteer appears to be different, but 
most studies imply that valerian could be beneficial. Although subjective sleep latency 
was shortened for ‘normals’ , this was not the case for the sleep disturbed or the elderly. 
However, sleep quality seems to improve for the sleep-disturbed, and objective TST 
may improve for the elderly. These are both highly desirable, so all groups may benefit 
in some way from using valerian.
4.2.4.1.3 Type o f  Valerian
Bos et al. (1998b) and Houghton (1999) have suggested that the type of valerian 
investigated may hold the key to conflicting findings in the literature. It is possible that 
constituents such as the valepotriates (found in alcoholic preparations, but not in 
aqueous preparations) will produce different effects depending on the preparation used. 
This will be discussed later. It is therefore vital to view the literature in light of this. 
Preparations used tend to be either aqueous or alcoholic, but occasionally, especially in 
older research, the preparation type, or method of preparation used is not detailed.
4.2.4.1.3.1 Aqueous Valerian Preparations
Most studies investigating valerian tend to use an aqueous solution as their test 
material. Lindahl and Lindwall (1989) used aqueous valerian in a questionnaire study of 
27 volunteers with sleeping problems aged between 25 and 68 years. With a dose of 
400mg, they found subjective sleep quality increased. This was also found at the same
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dose by Leathwood and Chauffard (1983), who used a postal questionnaire of 128 
participants over nine nights. Sleep quality improved overall, but this was seen 
specifically in younger (less than 40 years of age) and poorer sleepers, but not in good 
sleepers. Poorer sleepers also subjectively reported less awakenings after sleep onset. A 
lower perceived number of awakenings was also found by Balderer and Borbely in 
1985. Their study looked at 450mg and 900mg doses of aqueous valerian in young 
adults, 10 participating in a home trial, arid 8 in a sleep laboratory. Leathwood and 
Chauffard (1985) also noted an increase in sleep quality at a 450mg dose but not 900mg 
dose, using 8 volunteers aged 33 to 59 years with long sleep latencies. However, 
Balderer and Borbely (1985) did not find this subjective effect in either their laboratory 
or home studies. Leathwood and Chauffard in both 1983 and 1985 also noted a decrease 
in subjective sleep latency, which was supported in the findings of Kamm-Kohl et al. 
(1984) and Balderer and Borbely (1985).
Objective findings show a decrease in sleep latency (Leathwood and Chauffard, 
1985). Schulz et al (1994), in a study of 14 elderly females at a dose of 405mg over one 
and seven nights, found an increase in percentage stage 3 sleep with aqueous valerian. 
However, they also found a lack of significant effect with respect to sleep efficiency.
4.2.4.1.3.2 Alcoholic Valerian Preparations
Kuhlmann et al. (1999), using 99 and 91 healthy volunteers, and Donath et al.
(2000) using 16 sleep disordered participants dosed at 600mg, both studies of acute and 
subchronic duration, disagreed with the finding of aqueous valerian studies that 
subjective sleep latency (SL) is reduced with valerian. This indicates there may be an 
experimental difference between the different preparations of valerian. However, a 
decrease in subjective SL was noted by one study, but only after 6 weeks of dosing at 
600mg in 8 sleep-disordered volunteers (Donath, 1997). Also, Kuhlmann et al. (1999) 
did note an improvement in the subjective number of awakenings, which is in agreement 
with results from aqueous preparations. Sleep quality was again found to improve in 
most studies (Vorbach et al., 1996; Donath, 1997; Kuhlmann et al., 1999), but not in all 
(Donath et al., 2000). It seems that both aqueous and alcoholic valerian preparations 
may improve the ‘feel’ of sleep.
Donath (1997) and Donath et al. (2000) found no significant changes to 
subjective and objective TST, percentage stage 1, 2, 3 and 4, and also sleep efficiency,
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the latter of which was also the case for aqueous valerian. Morning sleepiness was also 
found not to change under alcoholic valerian (Kuhlmann et al., 1999; Donath et al., 
2000).
4.2.4.1.3.3 Valerian with Hops
Valerian is popularly teamed with hops as a sleep aid and calming agent. Many 
of these varieties can be purchased in health food shops as an alternative to preparations 
of valerian alone. Although these preparations will not be given consideration here, 
Leathwood and Chauffard (1983) suggest a valerian and hops remedy may actually 
increase morning sleepiness, especially in younger or poorer sleepers. Fussel et al.
(2000) gave 30 insomniacs 250mg of valerian plus 60mg of hops per evening. They 
found after 2 weeks of dosing sleep efficiency increased, stage 1 sleep decreased and 
SWS increased.
4.2.4.1.3.4 Summary o f  Valerian Type
Each preparation seems to achieve different effects. Aqueous solutions seem to 
reduce subjective SL (Leathwood and Chauffard, 1983/1995; Kamm-Kohl et al., 1984; 
Balderer and Borbely, 1985), possibly the subjective number of awakenings (Balderer 
and Borbely, 1985) and improves sleep quality (Leathwood and Chauffard, 1983/1985; 
Lindahl and Lindwall, 1989), whereas alcoholic preparations may only increase sleep 
quality (Vorbach et al., 1996; Donath, 1997; Kuhlmann et al., 1999), and perhaps also 
decrease awakenings (Kuhlmann et al., 1999). Both indicate possible desirable effects, 
but for different aspects of sleep. This provides some evidence to suggest the type of 
valerian used may produce different outcomes.
One notable outcome from Leathwood and Chauffard’s home study (1983) is 
that hops preparations should possibly be avoided due to indications of morning 
sleepiness. This is especially relevant to the elderly who may be unsteady in the 
mornings anyway. Falls and accidents in the daytime are already highly prevalent 
amongst this age group (Dargent-Molina and Breart, 1995).
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A  note must be made that the findings of the types of valerian may be 
confounded by the dosage of valerian given. Several studies (for example, Balderer and 
Borbely, 1985; and Leathwood and Chauffard, 1985) have found differing results 
between low and high doses of the same preparation of valerian. Indeed, Kohnen and 
Oswald (1988) concluded that a low dose of valerian was more efficacious as an 
antidepressant and sedative, whilst a high dose of valerian was considered 
anticonvulsive and spasmolytic. A  typical dose ranges from 450mg to 600mg, but most 
experimental work has been completed at 400mg, 450mg, 600mg and 900mg.
Generally, aqueous solutions at 400mg or 405mg showed an increase in sleep 
quality, but there are only three studies at these doses (Leathwood and Chauffard, 1983; 
Lindahl and Lindwall, 1989; Schulz et al., 1994). Aqueous solutions at 450mg have 
been studied by Leathwood and Chauffard (1985) and Balderer and Borbely (1985) in 
their home study, finding a decrease in subjective SL. Leathwood and Chauffard (1985) 
also noted an increase in sleep quality and a decrease in objective SL, but this was not 
confirmed by Balderer and Borbely (1985). Leathwood and Chauffard (1985) 
investigated a 900mg dose, and again found a decrease in subjective and objective SL. 
At this dose, Balderer and Borbely (1985) noted a nonsignificant decrease in SL and the 
number of awakenings.
Alcoholic valerian preparations have mainly be tested at a 600mg dose. Vorbach 
et al (1996), using 121 participants over 28 days, noted an increase in sleep quality, 
which was also found by Donath (1997) after 2 and 6 weeks, and Ziegler et al. (2002) 
after 6 weeks. Little effect was found with respect to sleep latency (Donath, 1997; 
Kuhlmann et al., 1999), and most other variables. However, Ziegler et al. (2002), who 
tested 600mg alcoholically prepared valerian on 202 outpatients with insomnia, also 
noted an increase in the subjective duration of sleep, and feeling refreshed after sleep.
Patterns seem to emerge within each type of valerian, and these seem to be 
present within the differing doses. It therefore appears that the dose of valerian taken 
may be relatively unimportant compared to the type of valerian taken. The outcome of 
valerian ingestion may be more influenced by the preparation rather than dose.
4.2.4.1.4 Doses
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The most noticeable aspect of valerian research is the lack of it. Few researchers 
have invested funding into valerian and other herbals due to the lack of recognition from 
the regulatory bodies. Mischoulon and Rosenbaum (1999) suggest that manufacturers 
and suppliers traditionally tend not to fund herbal clinical trials. However, research is 
now expanding in this area due to the huge demand made by consumers. Large 
pharmaceutical companies are tending to acquire smaller herbal medicine companies, 
rather than furthering their own expertise. Cott (1995a) suggests this may be a reflection 
of this enormous demand, and the urgency to take advantage of it. However, the current 
lack of knowledge makes the search for possible effects of valerian veiy difficult, and 
meta-analyses of the data are impossible at this stage of investigation (Ernst, 1999). All 
studies differ greatly with respect to size, length, participants and design. It is clear study 
replication is necessary to support and confirm results.
As previously mentioned, this is not a complete examination of all valerian 
literature. A great deal of research has been published in a language other than English, 
making access by English speaking researchers problematic. However, many general 
conclusions can be drawn from the current literature. It is indicated that the number of 
volunteers used in studies may be of importance. Smaller studies reached different 
conclusions from those with larger numbers of participants. This must be acknowledged 
when considering results. The type of volunteer is also very important to the findings of 
a study. It emerged that different aspects of sleep improved for different populations. 
Therefore, if possible, studies should include representative samples from each of the 
main population groups of normals and sleep disturbed, both the young and older adults.
The choice of methodology is also influential. EEG studies will examine aspects 
of sleep that questionnaires cannot (such as sleep architecture) and vice versa (for 
example, sleep quality). A  lack of correlation between objective and subjective 
measures has also emerged. This has been found in most sleep studies, not just herbal 
studies (Weiss et al., 1973; Carskadon et al., 1976; Coates et al., 1982a). There is a 
certain difficulty in relating subjective and objective experiences of sleep. Poor sleepers 
have been shown to be poor estimators, overestimating sleep latency and 
underestimating the number of nocturnal awakenings and total sleep time (TST), 
whereas good sleepers estimate accurately when compared to objective sleep measures 
(Adam et al., 1986; Morin and Gramling, 1989). Despite this, many researchers such as 
Morgan et al. (1988b) believe self reports are useful and valuable tools. In this review,
4.2.5 Conclusions
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EEG and questionnaire studies agreed with respect to no significant changes in TST 
with valerian (Leathwood and Chauffard, 1983; Kuhlmann et al., 1999; Donath et al.,
2000), and some questionnaire studies agreed with a lack of change to SL (Leathwood 
and Chauffard, 1983; Balderer and Borbely, 1985; Kuhlmann et al., 1999; Donath et al., 
2000).
The results of most studies implied that the amount of dose given and length of 
study (or number of doses given) were actually relatively unimportant compared to the 
type of valerian used in each study. Different types of valerian preparation seemed to 
produce different improvements in different sleep areas. For example, aqueous extracts 
tended to reduce subjective sleep latency (Leathwood and Chauffard, 1983/1985; 
Kamm-Kohl et al., 1984; Balderer and Borbely, 1985), and the number or duration of 
awakenings (Leathwood and Chauffard, 1983; Balderer and Borbely, 1985), whereas 
alcoholic preparations tended to increase sleep quality (Vorbach et al., 1996; Donath, 
1997; Kuhlmann et al., 1999). It was also suggested that valerian preparations with hops 
were linked to increased morning sleepiness (Leathwood and Chauffard, 1983).
It is difficult to know what exactly each test material really is. Most researchers 
have come as far as stating whether their valerian is aqueous or alcoholic, but it seems 
this approach may be too simplistic. Constituents of valerian, such as valepotriates, can 
be reduced by 50% from samples by drying at room temperature as opposed to drying by 
heat at 50°C. This is due to the increased opportunity for valepotriates to decompose 
during the slower drying rate (Bos et al., 1998b). Conversely, volatile oil is lost by 50% 
when drying at 50°C rather than at room temperature (Bos et al., 1998b). The method of 
preparation is therefore vital to the composition. In addition, research has shown 
valerian is best harvested in September-November time for the highest concentration of 
some constituents, but in February-March time for others (Bos et al., 1998b). Herbals 
differ greatly between batches, and this is should be a concern for the consumer. 
Standardisation of some description is therefore necessary. These differences occur with 
respect to genes, growing conditions, plant parts used (root, stem or flowers), time of 
harvesting, storage, and method of preparation (O’Hara et al., 1998). All these factors 
can significantly alter the content of the valerian, and so may alter the effects the 
valerian remedy will have.
This would not be an issue if an exact and accurate list of all the constituents of 
valerian could be compiled, but so far this has not been achieved (Houghton, 1999), It
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may be that currently unidentified constituents actually have experimental effects, and 
this is why confusion occurs in the literature. It is simply not known yet.
Despite this, researchers still attempt to classify the different valerian 
preparations according to current knowledge. It is suggested that the standardisation of 
valerian should be based on the content of volatile oil (Bisset, 1994; Fugh-Berman and 
Cott, 1999), although others favour the valepotriates (Lindahl and Lindwall, 1989). 
However, from all these differences in types and preparations of valerian, and the fact 
that all parts of valerian may have a role in the activity of valerian, it is likely 
standardising using only one constituent may be misleading and unsuitable (Houghton,
1999).
A major advocate of standardisation is Houghton (1999). He believes all authors 
should at least explain the type of valerian they use in their studies, plus the preparation 
methods. Better still, Houghton (1999) calls for a list of the amounts of each identified 
constituent of valerian. This would give other researchers a clear idea of the expected 
results, and also may allow for the completion of meta-analyses.
4.3 Aims
It is clear that more research into valerian is necessary, from the point of view of 
the regulatory authorities, pharmaceutical companies, and most importantly, the 
consumer. More studies are needed to add to the growing body of research, as the likely 
effects of valerian are unclear. The consumer can currently purchase valerian over-the- 
counter as an aid to sleep or as a calming agent, but it seems there is no guarantee of the 
quality of preparation, no indication of constituents, and most alarmingly, no guarantee 
of any positive effects at all.
This study will therefore investigate a preparation of valerian which is currently 
available over-the-counter. This is an alcoholic preparation, and the constituents will be 
listed where possible, and when not, details of preparation procedure will be outlined. 
The valerian product studied (Li 156, brand name Sedonium®) is manufactured in sugar 
coated tablets, eliminating the unpleasant taste, and useful for avoiding volunteer 
recognition of the test substance, as this will be a placebo controlled study. The tablets 
are in doses of 300mg per tablet, and the recommended dose given by the manufacturer 
is one to two tablets. Therefore test doses will be 300mg and 600mg, to maintain a level 
of real-life relevance. Due to financial and time constraints, each of the three test doses
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(300mg, 600mg and placebo) will be given for one night each, with a one week washout 
period in between doses.
Due to the importance of both subjective and objective measures (Leathwood 
and Chauffard, 1983; Morgan et al., 1988b), methods of EEG, sleep and mood 
questionnaires, and psychometric tests will be applied to gain insight into the effects of 
this valerian preparation. Similarities and differences to the previous literature will be 
noted. The inclusion of mood scales and questionnaires reflects the differing opinion of 
what valerian actually is, possibly sedative, tranquillizer, anti-anxiety or antidepressant. 
Different studies have come to different conclusions about the nature of valerian. 
Although primarily taken as a sleep aid and calming agent, it is said that valerian may 
exhibit anti-convulsive and antidepressant effects as well as sedative, hypnotic, anti­
anxiety and tranquillizing effects. Overall, in human studies, twelve authors have 
concluded that valerian has sedative properties (Crete, 1968; Hansel and Schulz, 1982; 
Leathwood et al., 1982; Leathwood and Chauffard, 1983; Houghton, 1988; Lindahl and 
Lindwall, 1989; Bisset, 1994; Tyler, 1994; Cott, 1995a; Donath, 1996; Heiligenstein and 
Guenther, 1998; Houghton, 1999), whilst only two have disagreed with this (Kohnen 
and Oswald, 1988; Schulz et al., 1994). Two authors have concluded hypnotic effects 
(Balderer and Borbely, 1985; Ziegler et al., 2002), and six have suggested a 
tranquillizing effect (Houghton, 1988; Bisset, 1994; Schulz et al., 1994; Cott, 1995a; 
Wagner et al., 1998; Houghton, 1999). One concludes anxiolytic effects (Donath, 1996; 
both anxiolytic and sedative properties), but Kuhlmann et al. (1999) disagrees, and 
Kohnen and Oswald (1988) have favoured antidepressant effects of valerian. It therefore 
seems that valerian is mostly seen primarily as a sedative, and if not, a tranquillizer. Of 
course, due to the varying types and doses of valerian, any of these, or perhaps a 
combination of these may be possible. Lower doses of aqueous valerian may be 
sedative, whilst higher doses are suggested to be hypnotic. However, there seems to be 
no difference between high and low doses of valerian overall. Chronic dosing does not 
seem to have a hypnotic effect, and there appeal's to be little difference between the 
results of the different methods used in each study. Lastly, using ‘normal’ volunteers 
seems to lead to the conclusion that valerian is sedative, whilst using sleep disturbed 
volunteers seems to imply valerian is either hypnotic or tranquillizing.
To comply with the real-life self-medication of valerian, type and number of 
participants must be carefully considered. There is very little about valerian in the
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research literature, but a power calculation based on similar studies shows that sixteen 
participants will be sufficient to show effects, if present.
The type of participant will affect the outcome results. Surveys have shown that 
the largest consumers of non-prescription sleep remedies are the middle-aged (Mellinger 
et al., 1985), and Ernst (1999) believes that the number of elderly users will soon 
increase due to the inviting lack of adverse side effects. Also, Leathwood and Chauffard
(1983) suggested that the “typical consumer of mild sedatives is female, middle-aged 
and mildly insomniac” (p. 121). Therefore, it is most appropriate to include middle-aged 
to elderly participants, who have a mild sleep disturbance, particularly as adverse events 
are not reported to be problematic for older adults. This should hopefully provide usefiil 
information, especially for the consumer, on the effectiveness of valerian in a realistic 
environment, and hopefully encourage further research into valerian.
4.4 Methods
4.4.1 Design
This study was a single centre, randomised, double blind, placebo controlled, 
three way crossover design using sixteen volunteers with a subjective complaint of mild 
sleep disturbance. The independent variable was the medication under investigation, 
namely valerian 300mg, valerian 600mg or placebo. Each volunteer received all of the 
test doses of medication and placebo. The dependent variables are the objective 
measures of sleep EEG and psychometric tests (Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), and the Sternberg Memory Test (SMT)), and also subjective 
measures by questionnaires (Spielberger Trait Anxiety Inventory (STAI), Spielberger 
Trait Depression Inventory (STDI), Line Analogue Ratings Scale (LARS), and the 
Leeds Sleep Evaluation Questionnaire (LSEQ)). Each treatment night was separated by 
a six day washout period. The schedules of assessments are shown in table 4.3.
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Test Period Pre-
Screening
Screening Treatment Days Post
Study
Alcohol Screen X
Consent X (X) (X) (X)
Adverse events, 
concurrent illness/ 
medication
X X X
Test training X
Drug administration X
Psychometric testing X
Sleep EEG X
Sleep Adaptation X
Table 4.3 - Scheduling of Assessments
To ensure the dependent variable was directly affected by the independent 
variable, other variables had to be controlled. All participants slept in the same identical 
bedrooms at the same time each study night, and a strict schedule was adhered to. All 
adverse events or unusual circumstances were documented to take account for any 
possible causes of any effects found. All participants gave full medical histories 
(corroborated by their general practitioners) and completed health and sleep 
questionnaires to ensure suitability for inclusion. All psychometric and questionnaire 
tests were standardised, as were instructions for completion. Participants were required 
to complete all psychometric tests six times before entering the study. This allowed the 
assumption of being practised to a plateau, so experience would not influence the 
findings of these tests. A  double blind technique was used to ensure the participants did 
not know, nor infer via experimenter effects, the dose of valerian taken. The valerian 
tablets were matched to placebo, and sugar coated to avoid recognition by taste or smell. 
However, valerian is widely available in health food shops as an aid to sleep. It was 
therefore assumed that the participants were aware that the test medication might 
improve their sleep, although it was not directly stated by the experimenter. All food 
provided on the study nights was standardised, and low in fat. Caffeine was not 
permitted on study nights, or 24 hours before attending the Unit. This criterion was used 
to avoid any alerting effects of caffeine which may confound the treatment effects. 
However, it is possible that withdrawal of caffeine may have adverse effects, such as 
headache and sedation (Greden et al., 1980). Tea and coffee provided on study nights 
was de-caffeinated. No alcohol was permitted on study nights or 24 hours beforehand. 
However, no other control was affected over food and drink consumption out of study 
hours. The use of medication other than oral contraceptives and non-steroidal painkillers 
throughout the duration of the study was discouraged. However, a study by Zacny et al. 
(1996) has shown that a non-steroidal painkiller can produce feelings of sedation.
142
Perhaps non-steroidal medications should also be avoided in future, and more research 
is necessary into this area. All participants were local volunteers replying to mailings 
from a volunteer database, leaflet drops and advertisements in supermarkets local to 
Guildford. No other controls were used over social, educational, cultural and economic 
status, background or personality, although average scores on the Spielberger Trait 
Anxiety Inventory (STAI) and the Spielberger Trait Depression Inventory (STDI) were 
preferable but not essential before the inclusion of a participant. In this study, all 
participants scored around a ‘normal5 value in these tests. The author of this thesis 
completed all work involved in this study, including preparation, recruitment, 
implementation, and analysis.
4.4.2 Participants
The participants were all aged between 50 and 64 years of age (mean age 55.9, 
sd 4.68), and all lived within 24 miles of Guildford. Sixteen volunteers were tested in 
total, five male and eleven female. Response to the study was predominately by females. 
Two males suffered with a difficulty initiating sleep (DIS), two with a difficulty 
maintaining sleep (DMS), and one with early morning awakenings (EMA). Six females 
had DIS, two suffered DMS, one had EMA, one had DMS and EMA, and one 
complained of all three. Volunteers were assigned a study number which randomly 
allocated them to a test pattern group. This determined the order in which the test 
medication was administered. All were judged to be within normal ranges of the 
Spielberger Trait Anxiety and Depression Inventories.
Strict inclusion and exclusion criteria were used to select participants in this 
study, shown in table 4.4.
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The inclusion criteria were as follows:
• Males and females aged between 50 - 65 years inclusive.
• A body mass index greater than or equal to 18 and less than or equal to 30.
• Subjective complaint of mild sleep disturbance.
• In good health as determined by a health questionnaire and Rose’s angina questionnaire.
• Able and willing to give informed consent.
• Having the consent of the volunteer’s general practitioner.
The exclusion criteria were as follows:
• Pre-menopausal females who have not been sterilised and are not taking adequate contraception. 
Females on HRT who have not been established for at least 3 months.
• Volunteers who habitually smoke more than 5 cigarettes (or one cigar) per day.
• Current participation in another clinical trial, or participation in a clinical trial within the last 90 days.
• Concomitant psychotropic medication.
• Clinically significant (as judged by the investigating clinician) use of psychotropic medication in the 
last three months before the start of the study. For example, this would include the prolonged use of 
antidepressants, antipsychotics, or antihistamines, but would exclude the occasional use of cold and flu 
remedies (which often contain antihistamines and/or opiates).
• The use of any other medications in the last two weeks before the start of the study (including herbal 
supplements) with the exception of non-steroidal analgesics including paracetamol.
• Significant history of mental illness, significant drug allergy, malignancy or chronic drug abuse 
(including alcohol).
• Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological or 
haematological disease or abnormality.
• Abnormal or imstageable EEG.
• A sleep/wake cycle (e.g. shiftwork), liable to prejudice the results of the study.
• Any subject that the physician or investigator judges to be unsuitable.
Table 4.4: Inclusion and Exclusion Criteria
4.4.3 Materials and Measures
Materials used included laptops with psychometrics software, all questionnaires, 
Case Report Forms (CRFs), breath alcohol tester, height measure and weighing scales, 
EEG electrodes and application materials (tape measure, chinograph pencil, collodian 
glue, acetone, and chlorhexidine as a de-greaser), Nicolet Ultrasom digital EEG sleep 
recording equipment, test medication (see Dosing), sleep bedrooms with nurse call 
button and CCTV cameras, and psychometric test rooms.
Objective EEG was recorded with 4 EEG (C4-A1, C3-A2, 02-A1, 01-A2), 2 
EOG (electroocculograph) and 4 EMG (electromyograph) leads and Ag/AgCl electrodes 
onto a Nicolet Ultrasom digital EEG machine. Sleep stages were visually scored by one 
experienced rater according to the criteria of Rechtshaffen and Kales (1968). Although 
the participants studied in this trial were older adults, the normal rules of Rechtshaffen 
and Kales were implemented to allow comparisons with other studies.
Subjective and psychometric assessments were achieved using Critical Flicker 
Fusion (CFF), Choice Reaction Time (CRT), Sternberg Memoiy Test, Line Analogue
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Rating Scale (LARS), Leeds Sleep Evaluation Questionnaire (LSEQ) and State-Trait 
Anxiety and Depression Inventories (STAI and STDI).
4.4.4 Dosing
Volunteers received each test dose for one night. There was a six day washout 
period between each of the test doses. Each of the doses was taken orally with 150 ml of 
water, and volunteers received two tablets at 22:00 hours. The valerian tablets were 
placebo matched, and were sugar coated to avoid recognition via taste or smell. The 
dose was active treatment (valerian 300mg or valerian 600mg) or placebo, according to 
the double blind technique.
The valerian contained the root of European valeriana officinalis L., harvested in 
autumn, and washed, chopped and dried. Each tablet contained 300mg of dry root 
extract (drug extract ratio 3-6:1). This is an alcoholic extract, by use of 70% ethanol 
(V/V).
4.4.5 Procedure
Prior to the start of the study, overnight sleep EEG was recorded on an 
adaptation night, which also acted as a screening procedure. The adaptation night served 
to familiarise the participants with the instrumentation used, and also sleeping in the 
laboratory bedrooms. Within a week of the adaptation night, there was a baseline night 
of sleep recorded. Within a week of the baseline night, the treatment phase began.
4.4.5.1 Baseline Night
The procedure for the baseline night was as follows: Participants arrived at the 
unit at approximately 19:00hrs. There was a breath alcohol test and assessment of any 
adverse events or concomitant medication taken. Throughout the evening until bedtime, 
participants had EEG electrodes attached to their face and scalp in accordance with the 
10-20 electrode placement system (Jasper, 1958). A snack of sandwiches and a yoghurt 
or a piece of fruit was provided at 20:30hrs. No medication was administered on this 
night. Participants went to bed in the sleep bedrooms at 23:00hrs (lights out time), and 
their EEG traces were recorded from this time until 07:00hrs. CCTV cameras were used
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to monitor the participants while they slept. This was for their safety only and no video 
recordings were made. Participants each had a nurse call button to alert a muse if they 
needed to (for example, if they felt ill or needed the toilet) during the night. Participants 
were awoken at 07:00hrs the next morning. The test battery measuring mood, and 
cognitive and psychomotor function was then administered at 07:05hrs. Electrodes were 
then removed and participants were provided with breakfast (approximately 08:00hrs). 
Participants were then free to leave the Unit at approximately 08:30hrs.
4.4.5.2 Treatment Nishts
For each treatment phase, sleep EEG was recorded for one night. The procedure 
for each treatment phase was as follows: Participants arrived at the unit at 
approximately 19:00hrs by taxi. There was a breath alcohol test and assessment of any 
adverse events and concomitant medication taken. Throughout the evening imtil 
bedtime, participants had EEG electrodes attached to their face and scalp in accordance 
with the 10-20 electrode placement system (Jasper, 1958). A  snack of sandwiches and a 
yoghurt or a piece of fruit was provided at 20:30hrs. Test medication was administered 
at exactly 22:00hrs with 150ml of water. Participants went to bed in the sleep bedrooms 
at 23:00hrs (lights out time), and their EEG traces were recorded from this time until 
07:00hrs. CCTV cameras and nurse call buttons were used for the participants’ safety as 
before. Participants were awoken at 07:00hrs the next morning. The test battery 
measuring mood, and cognitive and psychomotor function was then administered at 
07:05hrs. Electrodes were then removed and participants were provided with breakfast 
(approximately 08:00hrs). Participants left the Unit at approximately 08:30hrs by taxi. 
They returned in the evening of the same day the following week at 19:00hrs as before. 
This procedure is summarised in table 4.5.
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Real Time Study Time (hrs) Event
19:00 -3.0 Participants arrive and are breathalysed, EEG 
electrodes attached throughout evening
19:30 -2.5 Baseline psychometric testing
20:00 -2.0 Light snack
22:00 0.0 Drug administration
23:00 +1.0 Lights out
07:00 +9.0 Participants awoken, electrodes removed 
throughout morning
07:05 +9.5 Psychometric testing
08:00 +10.0 Breakfast
08:30 +10.5 Participants depart
Table 4.5 - Study Timetable for Each Treatment Period 
4.5 Results
4.5.1 Descriptive Statistics
One outlier was noted in the data, in the test of correct responses to CRT. It was 
decided this outlier should be removed, as it clearly indicated a lack of understanding of 
the test, in that it would unfairly influence other data. This should have been avoided in 
the first instance by training, yet still occurred. However, the statistical analysis was 
unaffected by the removal of the outlier, and the same outcome (i.e. the significance) 
was shown with or without the outlier. Therefore the outlier can be removed without 
consequence.
Initial observations of the means and standard deviations show that there is little 
difference between any of the variables tested. No trends were noted within the CRT 
task, or the four categories of the LARS (except for a small trend towards increasing 
sedation with dose) or the LSEQ, although the 600mg dose score for quality of sleep is 
higher than the scores for 300mg or placebo (indicating worse quality of sleep under the 
higher dose). No trends were foimd for the state-trait questionnaire for depression, 
however there was a small trend towards decreased anxiety with increasing dose of 
valerian. Objective sleep latency is on average shorter under the 600mg dose, and sleep 
efficiency and total sleep time higher. REM latency is shorter under the 600mg dose, 
and there appeal's to be more stage 1, and stage 2 sleep present under this higher dose, 
whilst the largest amount of SWS is seen under valerian 300mg. There are no noticeable 
differences between the means for total REM time and slow wave sleep. Statistical 
analysis was performed to determine any significant differences between the means of 
each variable tested. Graphs 4.1 to 4.8 show the results for STAI, LSEQ (getting to 
sleep), sleep latency, total sleep time, sleep efficiency, latency to REM sleep, amount of
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stage 2 sleep and SWS. The measure of variation is one standard deviation above and 
below the mean.
4.5.2 Statistical Analysis
A one factor repeated measures ANOVA (using SPSS version 10.0.7) was 
completed for each of the variables under investigation. No significant effects were 
found for CFF, CRT (motor, recognition and total reaction time), LARS, LSEQ, STAI, 
STDI, sleep latency (SL), total sleep time (TST), sleep efficiency (SE), the number of 
awakenings under and over a minute in duration, the number of stage transitions, wake 
time, REM time, REM latency, percentage of REM in the first, second and third periods 
of the night, stage 1, 2, 3 and 4 time, latency to stages 1, 2, 3 and 4, SWS time, SWS 
latency, and the percentage of SWS in the first, second and third periods of the night.
4.5.3 Adverse Events
All participants reported an adverse event at some point throughout the study, 
except one. Interestingly, 12 participants reported events under placebo, 11 under 
valerian 300mg, but only 7 under valerian 600mg. Again, the least number of adverse 
events were reported under the 600mg dose (8), whilst 21 were reported at 300mg and 
16 under placebo. These figures also include adverse events that were considered 
‘unlikely’ to be related to the study drugs. The number of adverse events considered at 
least ‘possible’ were 8 in the placebo condition (9 participants), 11 in the 300mg 
valerian condition (11 participants) and 4 under 600mg valerian (7 participants). There 
appeal's to be no dose related effect on the number or frequency of adverse events. 
Indeed, there appears to be fewer under the higher dose condition.
Most of the adverse events were considered ‘mild’ under the placebo and 300mg 
dose conditions, but ‘moderate’ under the 600mg condition. This may indicate that 
although there were fewer events reported under the higher dose of valerian, they were 
actually of greater intensity.
All adverse events were resolved without sequel, and none were reported as 
serious. It was decided which adverse events were thought ‘not related’ , ‘unlikely’ , 
‘possible’, ‘probably’ or ‘definitely related’ . The adverse events in this study that were
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not considered ‘unlikely’ were all otherwise considered ‘possible’ . Only these will be 
discuss from here onwards, and their frequency is summarised in Table 4.6.
Chapter 4
Valerian 600mg Valerian 300mg Placebo
Preferred Term Group
Drowsiness 4(4) 4(4) KD
Headache KD 4(4) 2(2)
Exaggerated Feelings of Well- 
Being
1(1) 2(1) 0
Mental Dullness KD 1(1) 0
Sleep Difficult 0 2(2) 5(4)
Depression 0 KD KD
Irritability 0 1(1) 1(1)
Light Headed Feeling 0 HD 0
Feeling Remote 0 KD 0
Nausea 0 1(1) 0
Sweating Increased 0 1(1) 0
Confusion 0 0 1(1)
Dehydration 0 0 1(1)
Tiredness 0 0 1(1)
Table 4.6: The nature and number of adverse events reported under each test condition (not including 
‘unlikely’ adverse events'). Number of participants reporting each event is given in parenthesis.
The most common adverse event reported was drowsiness (9 instances). 
Valerian 600mg tended to cause drowsiness before bedtime, whilst 300mg and placebo 
caused drowsiness more often just after waking. Drowsiness was reported as mostly 
‘mild’ under the 300mg dose, but ‘moderate’ after 600mg. It is therefore possible that 
the 600mg dose is preferable to a lower dose, in terms o f amount and time o f sleepiness. 
There is some indication here o f  a dose related effect, and that 600mg o f  valerian may 
aid sleep onset.
The next two most commonly reported adverse events were a difficulty in 
sleeping and headaches. These were both reported 7 times. Most difficulty sleeping was 
reported in the form o f difficulty initiating sleep, but early morning awakenings were 
also reported on two occasions. No difficulty sleeping was reported under the 600mg 
dose, and the majority were reported on placebo. This also indicates than the higher 
dose o f valerian may improve sleep. Headaches were either present on waking or 
developed during the morning after dose, and were mostly considered mild. Other 
adverse events included exaggerated feelings o f well-being, irritability, depression, 
mental dullness, feeling remote, nausea, dehydration, tiredness, increased sweating, 
confusion, and lightheadedness.
149
Ti
m
e 
(m
in
s)
 
Me
an
 
Sc
or
es
Chapter 4
STAI Scores (State) LSEQ - Quality of Sleep
Valerian
600mg
Valerian
300mg
Treatment
Placebo
Graph 4.1 showing STAI (Anxiety) under 
valerian 600mg. 300mg. and placebo.
Anxiety is shown to be higher under 
placebo than valerian 300mg. which 
higher than valerian 600mg. There appears to 
be a dose-dependent effect where anxiety is 
reduced under the higher doses of valerian. 
There were no significant differences. Error 
bars denote one standard deviation.
Valerian Valerian Placebo
600mg 300mg
Treatment
Graph 4.2 showing LSEQ Quality of Sleep 
under valerian 600mg. 300mg, and placebo. 
The quality of sleep is shown to be slightly 
worse under valerian 600mg than both 
valerian 300mg and placebo, which are 
similar. The higher dose of valerian therefore 
appears to non-significantlv reduce the quality 
of sleep. There were no significant differences. 
Error bars denote one standard deviation.
Sleep Latency (SL)
50
Valerian Valerian Placebo
600mg 300mg
T reatment
Graph 4.3 showing Objective Sleep 
Latency under valerian 600mg, 300mg. 
and placebo. Sleep latency is appears 
longer under valerian 300mg than 
placebo, but the higher 600mg dose of 
valerian appears to reduce sleep latency and 
variation in sleep latency. There were no 
significant differences. Error bars denote one 
standard deviation.
Total Sleep Time (TST)
Valerian Valerian Placebo
600mg 300mg
T reatment
Graph 4.4 showing Total Sleep Time 
under valerian 600mg. 300mg. and 
placebo. Total sleep time appears 
to be less under valerian 300mg than 
placebo, but the higher dose of 
valerian 600mg appears to increase 
total sleep time. There were no significant 
differences. Error bars denote one 
standard deviation.
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Sleep Efficiency (SE)
Valerian Valerian Placebo
600mg 300mg
Treatment
Graph 4.5 showing sleep efficiency 
under valerian 600mg. 300mg, and 
placebo. The sleep efficiencies under 
each condition appear similar, with 
a slight increase in efficiency seen 
under the higher 600mg dose of 
valerian. There were no significant 
differences. Error bars denote one 
standard deviation.
Total Amount of Stage 2 Sleep
240 
220 -
Valerian Valerian Placebo
600mg 300mg
Treatment
Graph 4.7 showing amount of Stage 2 
Sleep under valerian 600mg. 300mg, 
and placebo. The amount of stage 2 
sleep is reduced under the 300mg 
dose of valerian, but the 600mg dose 
of valerian results in similar amounts 
of stage 2 to placebo. There were no 
significant differences. Error bars denote 
one standard deviation.
Latency to REM Sleep
Valerian Valerian Placebo
600mg 300mg
T reatment
Graph 4.6 showing REM sleep latency under 
valerian 600mg. 300mg. and placebo. This 
demonstrates a dose-dependent effect of 
valerian on latency to REM sleep. Although 
the latency is similar under valerian 300mg to 
placebo, it is less under 600mg. There were no 
significant differences. Error bars denote one 
standard deviation.
Total Amount of Stage 3 and 
Stage 4 Sleep (SWS)
140
120
Valerian Valerian Placebo
600mg 300mg
Treatment
Graph 4.8 showing amount of SWS 
under valerian 600mg. 300mg. and 
placebo. The amount of SWS is 
increased by both doses of valerian 
compared to placebo, but more so 
by the 300mg dose. There were no 
significant differences. Error bars 
denote one standard deviation.
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The aim o f this study was to investigate the effects o f  a preparation o f  valerian 
on sleep EEG, mood and psychometric performance. None o f  the variables tested were 
significant in this study. This indicates there was no significant effect o f  either dose o f 
valerian on any aspect o f  EEG sleep. Sleep architecture was therefore unaffected by the 
dosing. As mentioned previously, this in itself is thought o f  as a desirable quality in a 
hypnotic. However, aspects o f sleep such as sleep latency and the number o f awakenings 
were also unaffected, meaning the valerian also did not improve objective sleep. 
Similarly there were also no significant detrimental effects on sleep EEG.
In addition, neither the 300mg nor the 600mg dose o f  valerian aided the 
subjective experience o f  the night’ s sleep. No significant differences were found for the 
LSEQ scale, although there was a trend towards a worse quality o f  sleep under the 
600mg dose. This valerian preparation also had no significant effects on mood the 
following morning, as no significant differences were found in any mood scales. 
However, there was a non-significant trend towards increased 'sedation' with higher 
doses o f  valerian, as shown by the LARS. Also, the State Anxiety Inventory revealed a 
non-significant decrease in anxiety with increasing dose. No morning after effects were 
demonstrated using the psychometric evaluation, as Critical Flicker Fusion (CFF) and 
Choice Reaction Time (CRT) performance remained unchanged.
However, the adverse events noted in this study are o f  interest. This preparation 
o f valerian was shown to be well tolerated and safe to use. Seven participants noted 
adverse events under the 600mg dose, eleven participants reported adverse events at 
300mg, and the highest number o f  participants with adverse events was twelve under 
placebo. Therefore there is little difference in the number o f people affected by valerian 
compared to placebo. Likewise, the least number o f  adverse events were reported under 
the 600mg dose, the most at 300mg and a similar amount under placebo. Severe adverse 
events were only reported twice, and most events were considered mild. All were 
resolved without sequel, and all those not considered ‘unlikely’ were thought ‘possibly’ 
related to the study drug. None were considered ‘probably’ or ‘definitely’ related. There 
were no serious adverse events, deaths or withdrawals from the study.
Adverse events reported included exaggerated feelings o f  well-being, irritability, 
depression, mental dullness, feeling remote, nausea, dehydration, tiredness and 
increased sweating. More frequently reported adverse events included headache and
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difficulty sleeping (mostly difficulty initiating sleep). Headaches are commonly reported 
in clinical studies (Donath et al., 2000), and may be related to the circumstances o f the 
study rather than the test medication itself. Stress and tension may arise from sleeping in 
strange bedrooms, for example. The reports o f problems sleeping mostly occurred under 
placebo, but there were two reports under the 300mg dose o f  valerian. This is not a 
desirable effect, as previous reports had indicated that valerian would improve sleep 
(Kulhmann et al., 1999).
However, the most commonly reported adverse event was drowsiness. This 
compensates for the difficulty sleeping noted by some, and may imply an effect o f 
valerian on sleepiness. Four events o f  drowsiness were noted under both the valerian 
600mg and 300mg dose, but only one instance was noted under placebo. Interestingly, 
the higher dose seemed to enhance drowsiness before bedtime, whereas the lower dose 
and placebo lead to reports o f  drowsiness mostly just after waking. It is therefore 
possible that drowsiness at appropriate times may be achieved using the 600mg dose. 
Following this, it may be that a higher dose o f  valerian (for example, 900mg or 1200mg) 
could result in changes to objective and subjective measures, which remained 
unchanged at the relatively medium dose o f  600mg.
Despite encouraging adverse event data and a non-significant trend towards 
sedation, the results o f  this study still show a lack o f significant effect o f  this preparation 
o f valerian. This is contrary to the historical and folklore use o f  valerian (Willey et al.,
1995). It may be that the feelings o f  effects are more potent than the valerian itself. This 
‘placebo’ effect could explain the reports o f  drowsiness. The WHO guidelines stating 
that historical use is proof o f  safety and efficacy may not be justified. Perhaps it is 
necessaiy for the FDA to be cautious in their approach to the regulation o f this and other 
herbals. Research into valerian is indeed sparse, and without all investigations showing 
marked effects, it is difficult to be confident in its efficacy.
While caution is advised, it is also possible that a Type II error has occurred in 
this study, and in fact valerian has an effect on sleep and mood that was not shown here. 
There are many reasons as to why this could occur. Firstly, only sixteen participants 
were used which may have not been enough to elucidate effects. A power calculation 
was completed for the number o f  participants required, which was based on previous 
studies. This may have been flawed as there are relatively very few studies completed 
using valerian, and these all differ.
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In addition to this, the valerian extract was only tested over one night per dose. It 
may be that this product needs a longer time in which to build up and take effect, such 
as days, or possibly weeks. Therefore a longer study might show some improvement in 
sleep or mood. Houghton (1999) suggests that effects take approximately a fortnight to 
emerge. Kuhlmann et al. (1999) found an increased sleep quality after fourteen days but 
not after one night. Also, Donath et al. (2000) noted shorter latencies to slow wave sleep 
after fourteen nights, but shorter latencies to REM and general sleep onset after only one 
night. This shows that differences in the action o f  valerian can be seen in different study 
durations. It is therefore possible that the study completed here was not o f sufficient 
length for any significant effects to be present.
Oswald (1980) assumes that one night’ s adaptation would be sufficient for the 
participant to become accustomed to their test environment. One adaptation night was 
used by Balderer and Borbely (1985), Kulhmann et al. (1999), and Donath et al. (2000), 
but Lindahl and Lindwall (1989) did not report the inclusion o f  any adaptation nights. 
Despite this, it is possible that the short duration o f  the present study meant that 
insufficient adaptation occurred to the sleeping surroundings. The study took place in 
individual bedrooms, which were designed to be sound and light proof. Although ideal 
1 for sleep studies, it is not the normal sleeping environment for most participants. This,
combined with wearing EEG electrodes, could possibly adversely affect the 
participants’ night sleep. If valerian has a mild effect, it is possible that any conflicting 
disturbance to sleep would override this effect and therefore confound results.
Another problem with this study is the type o f participant used. The inclusion 
criteria (which needed to be met for inclusion in this study) stated that participants 
should have a mild sleep disturbance. This was judged by an experienced sleep 
researcher. However, this was still a subjective opinion on each participant, and may not 
j  have been accurate. Certainly, each participant did not have identical sleep problems.
I Although all had mild sleep complaints, these manifested themselves in different ways.
These included difficulty initiating sleep (56.2%), difficulty maintaining sleep (31.3%), 
and early morning awakenings (12.5%). It is possible that valerian could have effects on 
only one o f these sleep complaints. This means a lack o f effect on the other sleep 
complaints may confound the results. It is advisable in the future to include sufficient 
numbers o f  participants in each category o f  sleep complaint. However, this will always 
be a difficult task due to the diverse and complex nature o f  insomnia.
   ---------
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It is possible that the age o f the participants confounded the results in this study. 
It was assumed that a middle-age group would demonstrate the effects o f valerian more 
clearly. This was based on a generalised assumption that their sleep would be more 
sensitive to change due to their nocturnal sleep becoming poorer with increasing age 
(Anderson, 2001). However, this assumption may be false, and so age group may not be 
influential on the effects o f valerian. Therefore any effects expected due to age would 
not be present.
Another problem with the participants used in this study are their attitudes 
towards valerian. Some participants were convinced that valerian was a useful drug for 
aiding sleep, and were generally positive towards the use o f  herbal remedies. However, 
other participants were adamant valerian would have no effect. The viewpoints o f the 
participants may have lead to bias in their psychometric tests and mood scales. As the 
participants were blind and drug administration was randomised, no participant knew 
when they were receiving placebo and when they were receiving the active drug. It is 
therefore possible that the volunteers rated all their scores similar in anticipation that 
they might have taken some valerian. This means those in favour o f  herbals would 
always respond favourably, and those against would always respond negatively. These 
scores combined would cancel any true effects present. This is especially likely if the 
effects o f  valerian are so mild that volunteers would not be able to confidently assess if 
they had taken placebo or not. This would go some way to explain the lack o f  effect o f 
valerian as compared to placebo. However, this cannot explain the lack o f effect in the 
objective measures o f  EEG sleep, as these are not open to the participants’ subjective 
views. However, it is possible that expectation may alter objective sleep latency.
The dose o f  valerian is also important. In this study, only a minimum and 
medium dose were used. It is possible that a higher dose was required to show effects on 
the tests used. This may be especially so given the short time frame o f the study. 
Perhaps a higher dose o f  900mg or even 1200mg would demonstrate useful effects o f 
this herbal remedy. However, studies comparing low and high doses o f  valerian have 
not shown any dose-related effects (Balderer and Borbely, 1985; Leathwood and 
Chauffard, 1985), implying the dose o f valerian may be inconsequential.
An issue is also present involving the time when the valerian was taken. This 
was, as other studies (Becker, 1986; Kohnen and Oswald, 1988; Dorn, 1996; Donath et 
al., 2000), an hour before bedtime. It is widely considered that this time frame adequate 
for effects on EEG sleep, but it is possible that any effects were no longer present an
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hour later at the doses used in this study. Therefore a dose nearer to bedtime may be 
necessary to show some effects, for example, if valerian helps difficulty initiating sleep, 
but only within thirty minutes o f  dose. Also, the effects o f  valerian may be so slight or 
short-lived, that they are no longer present the morning after dose. This would explain 
the lack o f sedative or tranquillising effect in the psychometric testing or mood scales. 
Lack o f  residual effect in the morning is desirable, as the consumer would not be left 
with unwanted hangover effects. However, this coupled with a lack o f effect on EEG 
sleep means a total lack o f  effect o f  valerian, rather than improved sleep and no 
hangover, which is the aim o f a good hypnotic. Therefore this study cannot support the 
suggestion that valerian is a hypnotic, as concluded by Balderer and Borbely (1985).
Lastly, and probably the most important factor, is the valerian used in this study. 
As discussed in the literature review, the most important influence on the effectiveness 
o f  valerian appears to be the type o f  valerian used. In this study the extract was an 
alcoholic solution, so may have contained valepotriates rather than sesquiterpenes. 
These are supposedly more tranquillising, whilst sesquiterpenes are associated more 
with sedation. This may be the reason why no effects were shown in the EEG sleep, as a 
very mild tranquilliser may not affect EEG sleep. Mood scales administered in the 
morning might detect a calming effect, but if these were administered too long after 
dose (eight hours post-dose in this study) then the valerian would not have been 
effective. Therefore no results would be significant.
Due to the reported differences between alcoholic and aqueous preparations o f 
valerian, the results o f  this study should only be compared to other studies using 
alcoholic extracts. Unfortunately these are fewer in number, and are often carried out 
over longer periods o f  time. A study by Donath et al. (2000) completed over 14 nights 
showed a decrease in latency to slow wave sleep. However, this was the only change 
observed in EEG sleep. Donath (1997) in studies lasting two and six weeks, only found 
and increase in REM sleep and a decrease in the number o f  awakenings (the latter in six 
week trial only). It therefore appears that even in longer studies, objective EEG effects 
o f  valerian are not numerous. However, this in itself could be due to a small number o f 
participants used in these trials.
Subjective effects o f  alcoholic valerian are also infrequently reported. Only two 
main studies inspecting the subjective effects o f alcoholic valerian were found, 
completed by Vorbach et al. (1996) and Donath et al. (2000). After a month o f valerian 
consumption, in a study using 121 participants, Vorbach et al. (1996) only showed
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subjective increases in sleep quality at 600mg. Donath et al. (2000) after 14 days failed 
to show any subjective effects.
In the trial completed by Donath et al. (2000), effects o f an increase in sleep 
latency and a decrease in latency to REM were noted after only one night o f  valerian 
consumption. It is therefore possible that alcoholic extracts o f  valerian can have 
immediate effects which were not found in this study. Both studies tested sixteen sleep- 
disordered participants, and used 600mg o f valerian extract. The time o f dose was 
identical at one hour before bedtime, although participants slept 10 pm until 6 am in the 
study by Donath et al. (2000), and 11 pm until 7 am in this study. However, possible 
differences in results could have arisen from differences between the studies. For 
example, there was a greater age range between participants in the Donath et al. study. 
Their participants ranged from 22 years to 56 years old. In this present study, however, 
only older participants were used, ranging from 50 years to 64 years o f  age. It is possible 
that this may have been an influencing factor, in that valerian may actually have a 
greater effect on younger people. However, Schulz et al. (1994) found valerian increased 
objective TST in the elderly.
A  major difference between studies is that Donath et al. (2000) placed controls 
over breathing abnormalities and movement disorders such as restless leg syndrome. 
Although questions were asked about snoring and jerking in bed, and volunteers were 
excluded from the trial on this basis, no objective checks were made into these issues. It 
is difficult to detect sleep apnoea or leg movements from an EEG trace, as any 
movement can obliterate the trace and will be marked as movement time. It is possible, 
then, that participants in this study may have had such disorders. This may explain the 
lack o f effect o f the valerian. Valerian is reported to be a sleep aid, but it is unlikely to 
be effective against disorders like sleep apnoea or restless legs.
It is difficult to compare any findings from investigations in herbal remedies. 
Although some o f  these studies used the same preparation as this study, differences can 
be found within batches o f  preparations. In some studies, the method o f  ingestion could 
be different, such as tablets, capsules, tincture or teas (Wagner et al., 1998). The lack o f 
regulation previously mentioned may lead to poor quality o f (or at least significant 
differences in) the product (Ernst, 1999). Due to the lack o f  knowledge about the 
individual constituents o f valerian (Houghton, 1999), it is hard to determine what effects 
subtle differences between batches may have on efficacy. This present extract is 
harvested in the autumn, when valepotriate content is lowest, and essential oil
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(sesquiterpenes) content is highest (Bos et al., 1998b). This in itself may be problematic. 
The alcoholic method o f  preparation tends to remove essential oil constituents, and 
leave valepotriates (Houghton, 1999). It may well be that this extract o f valerian 
contains too small an amount o f  both essential oil and valepotriates to show major 
effects on sleep, psychometric performance, and mood.
4.7 Conclusions
In summary, no significant improvements in objective or subjective sleep 
measures were found in this study, and no change in cognitive function or psychomotor 
performance was seen. However, the adverse event data supported a sedative action o f 
valerian, although a difficulty sleeping was also reported. The numbers o f  participants 
reporting adverse events, and also the number o f  adverse events reported, were not 
related to dose. This indicates a possible beneficial advantage to taking valerian, but this 
is not statistically supported.
Based on current research findings, caution should be exercised by the FDA 
when approving the use o f  valerian as a sleep aid. More research is needed to investigate 
the pharmacokinetics and pharmacodynamic effects o f valerian preparations with 
respect to types o f valerian, doses, and discrete patient populations. It is then possible 
that valerian may be used with efficacy, and may be a worthwhile compliment, or 
indeed alternative, to conventional sleep medicines.
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Chapter 5
5.1 Abstract
As we age, our sleep patterns deteriorate, leading to a substantial proportion o f 
older adults using hypnotics (6.1% found in the survey o f the elderly). Many hypnotic 
medications can lead to sedative ‘hangover’ effects the next morning, which are 
particularly detrimental to the elderly due to increased pharmacokinetic and 
pharmacodynamic sensitivity in this age group. This study aimed to investigate three 
different types o f hypnotic used by older adults, to assess sleep effects, daytime effects, 
and the suitablility o f the hypnotics for elderly use.
Loprazolam lmg, zopiclone 7.5mg, zolpidem lOmg and placebo were taken by 
16 (10 male and 6 female) young (aged 20 to 39 years old, mean age 27.5, sd 6.07) 
volunteers with a mild sleep disturbance, for three nights, followed by a two-night 
discontinuation period on placebo. Overnight sleep EEG was recorded, and tests o f 
cognition, psychomotor performance and mood were completed before drug ingestion at 
21:00, and also the next morning.
Results showed loprazolam was associated with more cognitive and 
psychomotor hangover effects than zopiclone, zolpidem and placebo. Loprazolam 
decreased slow-wave sleep (SWS) and REM sleep, and increased stage 2 sleep. 
Zopiclone increased SWS, had no effect on REM sleep, but still increased stage 2 sleep. 
Zolpidem showed some evidence o f  increasing SWS in the begimiing o f the night, but 
there was no effect on REM sleep, and no effect on stage 2 sleep. The adverse events 
noted for all drugs were commonly noted in other clinical trials, and none were serious. 
To conclude, the results suggest that all three active mediations appear to be suitable for 
use in the elderly, and the choice between these drugs may be financial, or will depend 
on the type o f insomnia experienced.
5.2 Introduction
Chapter 3 discussed the lack o f  efficacy o f  an acute dose o f  the herbal valerian,
as it did not display hypnotic effects in older adults. It may be that sleep improvement
should be sought from chemically produced, and perhaps more potent, hypnotic drugs.
From the survey o f  sleep behaviour in the elderly, it can be seen that prevalence o f
hypnotic use is 6.1%, and the prevalence o f  benzodiazepine use (nitrazepam,
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temazepam, lormetazepam, oxazepam, clorazepate, loprazolam, flurazepam, 
flunitrazepam, and triazolam) is 4.8% in older adults. The dangers o f  hypnotic use in the 
elderly have already been highlighted in previous chapters. In particular, the elderly 
have been suggested to be more vulnerable to falls, especially in the night (Trewin et al., 
1992). Hypnotics are suggested to be widely used amongst the elderly (Morgan et al., 
1988b; Ohayon and Caulet; 1996), but debate remains whether the older population gain 
benefit from these prescribed hypnotics. There is a need to produce a safe, potent 
hypnotic that is suitable for use in the elderly.
One o f the main problems when researching hypnotics is how to define sleep 
problems, and this may lead to inter-individual variations in their report. Some 
researchers may define a problem as taking a long time to get to sleep, or waking up a 
lot in the night, or feeling sleepy in the daytime. Criteria for a sleep disturbance can 
encompass one or many different aspects o f  sleep. Many researchers tiy and use the 
same criteria, where each participant has a sleep latency greater than 30 minutes, a 
nocturnal sleep time less than six hours, and at least three awakenings in the night 
(Bourin and Malinge, 1996; Holm and Goa, 2000). Defining insomnia as a single entity 
is impossible. Introducing the factor o f  ageing into the problem enhances the 
complication with these studies. As previously discussed, sleep problems in the elderly 
not only include problems with initiation and maintenance o f  sleep, but also waking due 
to pain, illness, needing the toilet etc.; factors which are not ‘ insomnia’ per se. These 
additional factors may bias or confuse results. Because this present chapter will assess 
the effects o f  commonly used hypnotics on sleep, the factor o f  ageing will be removed. 
This will ensure the volunteers in this study have non-organic insomnia, allow the 
assessment o f  the drugs alone, and will avoid confounding the results with these 
additional elderly nighttime problems that hypnotics cannot help.
Three hypnotics (loprazolam, zopiclone and zolpidem) will be assessed using 
young participants reporting a mild sleep disturbance, to elucidate the action o f  the 
drugs alone, without the confounds o f  old age (for example, needing the toilet in he 
night, pain, or altered sleep EEG due to ageing). These three hypnotics (and placebo) 
will be compared using sleep EEG variables and daytime performance tasks, and results 
will be discussed in relation to suitablility in the older adult population. Effects o f  the 
hypnotics on young volunteers will show how these drugs may also alter sleep in an 
older population.
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5.2.1 The Origins of Benzodiazepines
Chapter 5
The main class o f  hypnotic mediation was barbiturates until the 1960’ s, when 
flurazepam (the first benzodiazepine specifically recommended for sleep) entered the 
U.S. market. First derived from barbituric acid in the early 1900’ s, barbiturates were 
used in the treatment o f  anxiety, insomnia and seizure disorders, and as muscle 
relaxants and anaesthetic agents. Today, there are over 2000 known types, although 
only a dozen or so are suitable for human use. The agents most commonly used as 
hypnotics are the short- to intermediate-acting compounds such as amobarbital, 
pentobarbital and secobarbital, which have half-lives o f  10-15 hours to 40-50 hours 
(Harrison et al., 2000). These long durations o f  effects may be due to secondary effects 
o f active metabolites.
The main action o f  barbiturates is similar to that o f benzodiazepines, as both 
block GABAa receptors and increase the amount o f  GABA. Nicoll et al. (1975) and 
Scholfield (1980) both found hippocampal postsynaptic inhibition was prolonged by 
pentobarbital. Although effective as a sedative, barbiturates were found to have many 
unwanted side effects, such as severe hangover effects in the morning, and were unsafe 
in overdose, due to their toxicity (Byerley and Gillin, 1984). Barbiturates have similar 
effects to alcohol, and became favoured as recreational drugs. A  combination o f 
barbiturates and alcohol can prove fatal, and antihistamines taken in combination with 
barbiturates can lead to respiratory arrest. For the first 15 hours after ingestion, 
barbiturates tend to relieve tension and anxiety, but cause sleepiness, feelings o f 
drunkenness/intoxication, slurred speech, an inability to control simple bodily functions 
(walking, balancing, etc.), memory impairment, and emotional instability. Roache and 
Griffiths (1985) foimd an acute dose o f pentobarbital decreased anxiety, but increased 
feelings o f fatigue, dizziness, lightheadedness and lethargy. These authors also noted 
impairments o f  performance on standard tests o f eye-hand coordination, such as choice 
reaction time and the digit symbol substitution tests (DSST), and also decreases in the 
number o f  items recalled in memory recognition tests. However, Roache and Griffiths 
(1985) also found triazolam has more pronounced effects on memory than 
pentobarbital, at doses that produced comparable subjective feelings o f  sedation.
The effects o f barbiturates on sleep parameters include shortened sleep latency, 
increased total sleep time, and often a decrease in waking time during the night. 
Barbiturates have been found to have inconsistent effects on slow-wave sleep (SWS),
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but they consistently and potently depress rapid eye movement (REM) sleep 
(Mendelson, 1987; Mendelson and Rich, 1993).
Hypnotic benzodiazepines, however, generally have a much shorter half-life 
than most barbiturates used as hypnotics, and there is relatively reduced hangover effect 
in the morning compared to most barbiturates. Benzodiazepines are also safer to 
prescribe to depressives with suicidal tendencies, due to their safety in overdose. They 
have little or no effect on the brainstem, so intoxication carries little risk o f  fatality 
(Gaillard, 1994). In addition, many benzodiazepines have anxiolytic and sedative 
effects, and have a low potential for interaction with other drugs (Parrino et al., 1997), 
unlike barbiturates.
5.2.2 Loprazolam
Loprazolam is a water soluble 1,4-benzodiazepine, first synthesised in the 
Roussel laboratories in 1977 (Ager et al., 1977). It binds to the benzodiazepine 
receptors omega-1 (associated with sedation) and omega-2 (associated with cognitive 
and psychomotor effects) in the GABAa receptor complex, found in several locations 
across the brain, but principally in the cerebral cortex (Blanchard, 1988). It is 
considered a useful drug for acute or chronic insomnia, due to its hypnotic effects.
5.2.2.1 Pharmacokinetic Profile ofLoyrazolam
Pharmacokinetic research into loprazolam has shown that it has an effective
absorption rate with plasma peak occurring 0.5 to 3 hours after a morning dose with
fasted subjects (Stevens et al., 1985; Jochemson et al., 1983a), and 2 to 5 hours in night
time dosed fed subjects (Mclmies et al., 1985). It is eliminated from the body with a
half-life o f  approximately 6 to 12 hours in young healthy adults (Nicholson and Stone,
1983; Bourin et al., 1995; Mclnnes et al., 1985), which categorises it as an intermediate
acting hypnotic (an intermediate acting hypnotic has a half-life between 6 and 17
hours). Elimination half-life has been found to increase with increasing age (Greenblatt
and Shader, 1980; Fulton et al., 1981), and slow elimination benzodiazepines, or those
with active metabolites which lengthen the duration o f  action, can be present as much as
36 horns post dose in older adults (Jochemson et al., 1983a/b). For example, Ford et al.
(1987) studied five male and five female young (21-25 years) and elderly (63-86 years)
volunteers, after evening doses o f  0.5mg or lmg loprazolam. They found no age
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differences in absorption rate, but a longer elimination half-life in the elderly group. 
Wagner (1967) found accumulation o f a daily dose would occur if elimination half-life 
exceeds 16.6 hours. Half-lives in the elderly ranged from 9.2 to 23.4 hours, indicating 
firstly, there is a large amount o f inter-individual variation, and secondly, the elderly 
may experience residual effects.
5.2.2.2 Pharmacodynamic Profile ofLovrazolam
Most research into loprazolam was completed in the 1980’s. This is not to say 
the initial research was comprehensive. Pharmacodynamic research into loprazolam is 
necessary for two main reasons. Firstly, to assess any sedative effects o f the drug, and 
secondly to measure any cognitive hangover effects that may be present the morning 
after administration. These may occur due to the slow development o f peak serum 
levels, which may delay the elimination o f the drug (Mclnnes et al., 1985).
Hindmarch and Clyde (1980) completed the first, and arguably the most 
comprehensive, psychometric evaluations o f  loprazolam, on ten volunteers (six male 
and foui* female) mean age 21.8 + 0.97 years old. There were two-nights placebo run-in, 
four nights on medication, and three nights o f a placebo discontinuation period. This 
experimental design is a commonly used procedure for the assessment o f  a hypnotic, 
due to the inclusion o f all aspects o f  hypnotic effect (namely baseline measurements, 
drug effect both night and day, and withdrawal effects). The study found no effects o f  
loprazolam 0.5mg, lmg, and 2mg on next day performance, o f  choice reaction time 
(CRT), critical flicker fusion (CFF), letter cancellation, tests o f short-term memory, and 
mood (anxiety). However, with repeated doses o f  lmg, or an acute dose o f  2mg, 
participants reported increasing tiredness the next morning. The Leeds Sleep Evaluation 
Questionnaire (LSEQ) showed an increase in the ease o f  getting to sleep, and also the 
quality o f  sleep. In agreement, Hindmarch and Gudgeon (1982) and Salkind and 
Silverstone (1983) showed no significant residual effects o f  loprazolam the morning 
after dose, and also there was no morning-after effect noted in the elderly by Bayer and 
Pathy (1986). In addition to a lack o f residual effect, McAlpine et al. (1984) noted the 
insomniac patients used in their study reported improved balance and co-ordination with 
loprazolam. However, it must be remembered insomniacs report less hangover effects 
than ‘normal’ (no sleep complaints) participants do, because insomniacs will already 
suffer more effects the next morning due to poor sleep the night before (Malpas et al., 
1974).
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Bayer et al. (1983) studied 7 nights treatment o f loprazolam lmg (n = 20) and 
nitrazepam 5mg (n = 20) in sleep disturbed older adults (65+ year's old), and found 
loprazolam had no effects on early morning coordination, and improvements in 
alertness after waking. Also, Bareggi et al. (1991) found no impairment o f vigilance, 
attention, short-term memory or learning 3.5 hours after an evening dose o f  loprazolam 
lmg and 2mg. There was only a dose-related impairment o f  a long-term complex 
memory task. The authors believe their sample size o f 12 was too small to make firm 
conclusions, although this seems to be an average number o f  participants in most 
studies o f  this nature. A similar number o f  participants were also used by Hindmarch 
and Clyde (1980), Nicholson and Stone (1983), Morgan et al. (1984), and Grobler et al. 
(2000).
Conversely, many studies have found residual or hangover effects after the 
administration o f  loprazolam. For example, Grobler et al. (2000) found healthy 
participants were drowsier in the morning after a dose the night before (22:00) o f 
loprazolam 2mg, compared to placebo and zopiclone. There were also more missed 
responses on a hand-eye coordination test. However, the authors did emphasis they had 
found a large inter-individual variation. A  study by Morgan et al. (1984) showed no 
next morning effects o f  loprazolam 0.5mg and lmg on auditoiy vigilance or the Digit 
Symbol Substitution Task (DSST), but there was impairment o f  the lmg dose in tests o f 
manual dexterity and card sorting indicating selective dose related effects. However, 
Morgan et al. (1984) also noted a decrease in morning anxiety, measured by visual 
analogue scales.
Studies have also been completed using doses during the day, to assess when the
peak decrement in performance is, and when residual effects wear off. Swift et al.
(1985), in a study comparing young (n =10, aged 23-39 years old) and old (n = 9, aged
67-83 years old) participants, found 0.5mg produced post-dose postural sway in the
young for up to 2 hours, and for up to 6 hours in the old. This dose also decreased CFF
in the young after 6 hours, and in the old after 2 hours. There was no effect o f 0.5mg o f
loprazolam at any time for the yoimg and old groups on CRT. lmg produced postural
sway after 2 hours in the young, but this was still present in the older age group for up
to 11 hours post dose. CFF was reduced with lmg loprazolam after 4 hours in the young
and 2 hours in the old, and CRT was increased after 2 hours for both groups. No
sedation was noted in either group before 2 hours post dose, and only the old age group
complained o f  sedation at the 0.5mg dose. Also, Stevens et al. (1985) found their
participants (n = 6, aged 22-40 years old) reported ‘ leaden’ effects in their aims and
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legs, and were sleepy at both lmg and 2mg doses. As soon as 30 minutes post dose, 
they found a dose-related effect for sedation, plus a dose-related effect o f increased 
clumsiness at 4 hours post dose. They also noted increased reaction times, and found 
maximum psychodynamic effect at 3 hours post dose. Elie et al. (1983) found more 
hangover at the 2mg dose than lmg, however, Botter (1983) suggests this is due to 
increased efficacy. Indeed, most o f  the findings presented in Table 5.1 show few effects 
o f using lmg o f loprazolam, and increased decrement when using 2mg.
According to Nicholson and Stone (1983), loprazolam is appropriate for use if 
residual effects are acceptable to the user. This means loprazolam may not be suitable 
for the elderly, as residual effects may affect quality o f life and increase the numbers o f 
accidents (Trewin et al., 1992). Bayer and Pathy (1986) suggest even in the elderly, 
loprazolam is unlikely produce hangover effects up to the lmg dose. They maintain 
0.5mg o f loprazolam is a good hypnotic for the elderly. To conclude, Bayer et al. (1983) 
and Bayer and Pathy (1986) found no detrimental morning after effects o f loprazolam in 
sleep disturbed older adults, and Swift et al. (1985) found no effects in the elderly after 
a 0.5mg dose. Further research in an elderly population is necessaiy.
5.2.2.3 Objective and Subjective Effects ofLovrazolam on Sleep
Uncontrolled trials o f  loprazolam have shown an increase in sleep quality, and
confirm a lack o f  hangover the next morning (Hubinon, 1983). Objective (Costa de
Silva and Borges, 1983) and subjective (Hindmarch and Gudgeon, 1982; Elie et al.,
1983; Salldnd and Silverstone, 1983; Gringras et al., 1984; Bayer and Pathy, 1986)
sleep onset latency appears to decrease, as do the objective (Costa de Silva and Borges,
1983; and Adam et al., 1984 at lmg) and subjective (Costa de Silva and Borges, 1983;
Elie et al., 1983; Gringras et al., 1984; McAlpine et al., 1984; Bayer and Pathy, 1986)
number o f  nocturnal awakenings. Controlled trials, by placebo, have shown an increase
in the perceived quality o f  sleep (Morgan et al., 1984), which is not lost after repeated
doses (Mclmies et al., 1985). A lack o f  hangover effect was also shown by Gray et al.
(1983), however these authors found no significant differences in sleep latency. A  study
by Goldenberg (1985) revealed loprazolam decreased both REM (rapid eye movement)
sleep and SWS (slow-wave sleep), and increased stage 2 sleep. The meaning and
consistency o f  these findings in relation to the relief o f  insomnia has yet to be
explained, as a sedative hypnotic should ideally induce sleep rapidly without affecting
sleep architecture in healthy subjects (Danjou et al., 1999). It is not clear as to the
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relationship between sleep architecture and quality o f  sleep (Hoch et al, 1994), 
although it is suggested that an increase in stage 4 sleep improves the ‘ soundness’ o f 
sleep (Hoch et al., 1987), and an increase in stage 1 and 2 sleep can Tighten’ sleep. 
These changes may not affect the quality o f sleep, per se (Hoch et al., 1994).
Adam et al. (1984) completed a study using 9 sleep-disturbed participants (mean 
age 61 years) undergoing a 1 week placebo run-in, 3 weeks under test medication 
(including 0.5mg and lmg loprazolam), and a final week placebo run-out to assess 
withdrawal effects. 0.5mg o f  loprazolam produced no significant effect on any sleep 
variable. The lmg dose, however, showed an increase in total sleep time (TST), a 
decrease in wakefulness, and a decrease in slow-wave sleep (SWS) after extended 
intake. Some tolerance was noted, and withdrawal effect o f  rebound insomnia was seen 
after the third placebo withdrawal night. Rebound insomnia on the withdrawal o f 
loprazolam was also found by Goldenberg (1985), but not by Kesson et al. (1984). 
Differences in rebound insomnia have been found between the doses o f 0.5mg and lmg, 
in that lmg shows rebound insomnia, and 0.5mg does not. Morgan et al. (1984) tested 
12 participants aged between 43 and 62 years on loprazolam 0.5mg and lmg. Average 
sleep quality ratings (out o f  5) at baseline were 1.29 before loprazolam 0.5mg, and 2.13 
before the lmg dose was given. After three weeks dosing, this rose to 1.90 on 0.5mg 
and 3.08 on lmg. However, on the following withdrawal week, average sleep quality 
scores were 1.65 and 1.78 on 0.5mg and lmg o f loprazolam respectively. Ratings o f 
sleep quality therefore were worse on lmg o f  loprazolam than before the start o f  the 
study, but this effect was not noted for 0.5mg. Bayer and Pathy (1986) did not find these 
rebound differences in dose in an elderly sample, as both doses were found to be 
equally disrupting. This again indicates how the elderly might be more sensitive to 
benzodiazepine effect, as the lower and higher dose had the same rebound effect in this 
age group.
To summarise, loprazolam is suggested to decrease stage 1 sleep at the lmg
dose and over (Krieger et al., 1983; Nicholson and Stone, 1983; Adam et al., 1984), but
not at 0.5mg (Adam et al., 1984), and there is little evidence for an increase in stage 2
sleep (Nicholson and Stone, 1983; Adam et al., 1984; Goldenberg, 1985). There is a
decrease noted in SWS in insomniacs (Smirne et al., 1983), but this was found by Adam
et al. (1984) at lmg and not 0.5mg, where there is no effect on SWS. Nicholson and
Stone (1983) found no effect o f  loprazolam on the SWS o f ‘normal’ participants. There
also a decrease in REM in insomniacs (Smirne et al., 1983), but again, this is not found
in ‘normals’ (Krieger et al., 1983). It has been suggested that decreases in REM are not
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suppressive mechanisms, but are due purely to a reduction in REM density (Feinberg et 
al., 2000). Loprazolam has been foimd to increase TST in insomniacs (Adam et al., 
1984) but not in ‘normals’ (Declerek et al., 1983; Krieger et al., 1983; Nicholson and 
Stone, 1983). It is possible this is due to the differences between good and poor 
sleepers, in that it is difficult to show improvements in sleep if sleep is already good. 
Overnight sleep recordings lasting 8 hours will show no increase in TST if  the good 
sleeper is already sleeping 8 hours at baseline. Therefore only poor sleepers, who sleep 
for less than 8 hours at baseline, will show improvements. A summary o f  a selection o f 
literature findings o f  the effects o f loprazolam on sleep can be found in Table 5.2.
5.2.2.4 Safety and Toler ability o f  Loprazolam
Loprazolam appears to be well tolerated without haematological or biochemical 
changes, even in the elderly (Hugonot, 1980; Costa de Silva and Borges, 1983; Kesson 
et al., 1984). However, some side effects include headache, dizziness, ataxia, 
nightmares, dry mouth, depression, nausea and gastro-intestinal disturbances (Clark et 
al., 1986). Morgan et al. (1984), studying middle-aged participants (mean age 52 years), 
noted one fall on lmg o f  loprazolam, and reported 8 adverse events (AEs) under 0.5mg 
and 11 AEs under lmg. Bourin and Malinge (1996) found one o f each o f  the following 
AEs at a lmg dose: an ebrious sensation, fantastic and unpleasant dreams, diyness o f 
mouth, post-prandial somnolence, fatigue, feeling clumsy, memoiy disorders, and 
nausea in the morning. Elie et al. (1983) found significantly more AEs with the 2mg 
dose than with 0.5mg and lmg. However, Botter (1983), Salkind and Silverstone 
(1983), and McAlpine et al. (1984) had no occurrence o f AEs in their studies. It seems 
loprazolam is adequately tolerable in both yoimg and older adults.
5.2.2.5 Summary o f  Loprazolam
Loprazolam has dose-dependent effects on both subjective and objective sleep
measures, and also on psychomotor and cognitive performance tests. Few residual
effects are seen the morning after dose, although effects may last longer in the elderly.
For this reason, Bayer and Pathy (1986) recommend a dose o f 0.5mg in the elderly,
rather than the usual recommended adult dose o f lmg per night. There is some evidence
for the characteristic benzodiazepine effects on sleep variables, namely a reduction o f
SWS and REM sleep, and an increase in stage 2 sleep (Smirne et al, 1983). However,
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there is great inter-individual variation, as Grobler et al. (2000) noted, making firm 
conclusions about the effects o f  loprazolam difficult to show. For example, differences 
in finding have been found between good and poor sleepers. The decreases in SWS and 
REM sleep, plus increases in TST, have been observed in poor sleepers, but not good 
sleepers (Nicholson and Stone, 1983; Smirne et al., 1983; Adam et al., 1984). This 
shows loprazolam may ‘normalise’ poor sleep.
5.2.3 Zopiclone
Zopiclone is one o f the newer classes o f  hypnotic medication, which is thought 
to have no preferential affinity for either o f  the benzodiazepine omega-1 and omega-2 
receptors in the GABAa receptor complex. However recent research suggests that 
zopiclone may have a higher affinity for the omega-1 receptor (Nakajima et al., 2000). 
It is structurally distinct to benzodiazepines, and belongs to the chemical class o f 
cyclopyiTolones. Despite these chemical dissimilarities, zopiclone exhibits many o f the 
pharmacological effects o f  benzodiazepines, making it an effective hypnotic. Indeed, 
Jonas et al. (1992) found there were no differences in clinical and pharmacologic 
activity between benzodiazepines (including loprazolam) and zopiclone. In addition, 
Rettig et al. (1990), in a study o f  60 patients dosed the night before elective surgery, 
found zopiclone had similar hypnotic effects to lormetazepam and midazolam. Also, 
Van der Kleijn (1989) found 7.5mg o f zopiclone was as effective as temazepam 20mg 
with respect to sleep quality, sleep latency, and status after waking. Many researchers 
regard zopiclone as a ‘ safer’ hypnotic due to its reduced affinity for the omega-2 
receptors compared with loprazolam, and therefore it has fewer unwanted cognitive and 
psychomotor effects (Goa and Heel, 1991). However, Gorenstein et al. (1990) studied 
14 healthy male volunteers aged 20 to 25 years old, with assessments at 1.5 hours and
4.5 hours after dose. Results showed lOmg o f zopiclone was found to be similar to 
0.5mg triazolam with respect to their effects on memory and the digit-symbol 
substitution task (DSST).
5.2.3.1 Pharmacokinetic Profile o f  Zopiclone
Zopiclone is rapidly absorbed after oral administration, with peak plasma
concentration being reached after approximately 0.5 to 1.5 hours (Goa and Heel, 1991;
Wad worth and McTavish, 1993). The elimination half-life is approximately 5 hours
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(Goa and Heel, 1991; Wadworth and McTavish, 1993), much shorter than loprazolam, 
and therefore zopiclone is classed as a short acting hypnotic (a short-acting hypnotic is 
suggested to have a half-life less than 6 hours). Elimination half-life is increased in the 
elderly, and so zopiclone may be more detrimental to the older population than the 
younger population (Greenblatt and Shader, 1980; Fulton et al., 1981). Hemmeter et al.
(2000) suggests that the elderly have less functional capacity to compensate for 
impairments caused by hypnotics. These authors suggest cognitive functioning is 
already impaired due to ageing; so additional decrements in performance might be 
magnified compared to the same effects in younger adults.
5.23.2 Pharmacodynamic Profile ofZoviclone
In a study by Lader and Denney (1982), 10 healthy young males were given 
single doses o f  2.5mg, 5mg, 7.5mg and lOmg o f zopiclone. Next day tests administered 
10 hours and 13 hours post dose consisted o f auditory reaction time, tapping rate, 
DSST, mood rating scales and subjective assessments. These revealed 2.5mg had no 
effects. The 5mg dose also had no residual effects, but also only marginal effects on 
improvement o f sleep latency, and no effects on sleep quality. The 7.5mg dose showed 
effects on sleep EEG, with minimal residual effects. The lOmg dose, however, showed 
significant daytime impairment. For these reasons, Lader and Denney (1982) 
recommend that the standard dose o f  zopiclone should be 7.5mg.
A study by Nicholson and Stone (1983) found that both 7.5mg and lOmg o f 
zopiclone impaired DSST up to 9 hours after ingestion. They therefore recommended a 
dose o f  5mg, not 7.5mg, may be more appropriate where skilled tasks are to be 
performed the day after ingestion. In addition, Warot et al. (1987) found 7.5mg can 
impair short-term and long-term memory for up to 6 hours post dose. Since it has been 
shown that the half-life o f  hypnotics is increased in the elderly compared to the young 
(Castleden et al., 1977; Greenblatt et al., 1977; Greenblatt and Allen, 1978), a dose o f 
7.5mg may not be appropriate for this population.
To investigate zopiclone in an older population, Hemmeter et al. (2000) tested 
12 older adults (60-70 years old) with single doses o f  7.5mg zopiclone, 20mg 
temazepam, and placebo. After an adaptation night, each participant took each o f  the 
test medication for one night at 21:30, separated by a week washout period. 
Psychometric tests o f OFF, CRT, letter cancellation and short-term memory were
administered at 02:00 (participants were woken in the night), 07:30 and 09:00.
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Hemmeter et al. (2000) noted CRT was still impaired under zopiclone at 07:00 (9.5 
hours post dose), but there was no residual impairment by 09:00 (11.5 hours post dose). 
There was no impairment o f CFF, but letter cancellation tasks were impaired by 
zopiclone at 02:00 (4.5 hours post dose). In addition, they found no significant effect on 
short-term memoiy, showing that 7.5mg o f zopiclone may selectively impair 
performance in elderly users.
A comprehensive parallel study by Stip et al. (1999), including 50 insomniacs 
(29 males and 21 females) aged 20-64 years (mean age 42.6 ±1 .6  years), tested 7.5mg 
zopiclone, 30mg temazepam and placebo over a 3 week period. They found 
nonsignificant progressive reductions in anxiety with all treatments, and a significant 
increase in sleep quality with zopiclone and temazepam, which decreased during a 
withdrawal phase. Zopiclone also improved auditory and visual span, but the authors 
found no differences in tests o f explicit and implicit memoiy, wakefulness and 
alertness, and sustained and divided attention between the three treatments. They 
suggest that zopiclone had no detrimental effect on working memoiy and attention.
It has been suggested that zopiclone is the ideal choice for patients who need full 
alertness for daytime activities, which includes the elderly, due to its short half life and 
the lack o f  sedation reported in many studies (Ponciano et al., 1990). In the majority o f  
studies, many researchers could not find evidence for residual morning effects. Van der 
Kleijn (1989) found 7.5mg had no effect on mood and daytime behaviour, and Tafti et 
al. (1992) found no morning effects o f  7.5mg on CFF, CRT, hand-eye coordination, a 
standing jump test, a running test, and the Stanford Sleepiness Scale.
Overall, most researchers found no residual morning-after effects o f zopiclone. 
However, some studies did suggest a significant effect o f  zopiclone on short-term and 
long-term memoiy (Mattila et al., 1998), coordination (Mattila et al., 1998), DSST 
(Lader and Denney, 1983), and driving tests (Mattila et al., 1998; Bocca et al., 1999). 
Differences in results may depend on how close the test was to dose, and the size o f the 
dose, as some findings are dose-dependent. Tests completed closer to the time o f 
dosing, and tests under higher doses, produced more impairment than smaller doses or 
test points more distant to the time o f dose. Table 5.3 shows a summary o f these effects.
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5.2.3.3 Objective and Subjective Effects o f  Zopiclone on Sleep
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One o f  the largest studies into zopiclone (7.5mg) was completed by Hajak et al. 
(1994), using 1315 insomniacs aged between 18 and 71 years old for a duration o f  28 
days. They found increases in sleep quality and daytime wellbeing, but no effects on 
subjective sleep latency, TST and time spent awake. However, Rettig et al. (1990) 
tested 7.5mg o f  zopiclone on 20 inpatients the night before elective surgery, and found 
reductions in subjective sleep latency and increased subjective TST. This may have 
been due to alleviations in anxiety, but similar results were found by Tsutsui et al. 
(2001) in a study o f 45 primary insomniacs over 14 days.
Objective sleep effects were found by Nicholson and Stone (1983), who 
completed an extensive study on four doses o f  zopiclone (2.5mg, 5mg, 7.5mg and 
lOmg). Six healthy male adults aged between 21 and 33 years old took each dose for 
one night. The 5mg and lOmg doses reduced the amount o f  stage 1 sleep, but this only 
lasted 6 hours under the lower dose, whereas lOmg reduced the amount o f stage 1 sleep 
throughout the whole night. The durations o f  stage 2, 3 and 4 sleep were increased by 
7.5mg and lOmg. 7.5mg increased REM latency, and lOmg reduced the amount o f 
REM in the first 6 horns o f  the night’ s sleep. This showed zopiclone primarily has a 
REM suppressant effect, but also increased the depth o f sleep (by reducing stage 1 
sleep).
In a study o f  12 healthy male participants, each taking lOmg o f zopiclone or 
placebo for one night, Yamadera et al. (1997) found similar effects to Nicholson and 
Stone (1983). Yamadera et al. (1997) found lOmg reduced the amount o f stage 1, and 
increased stage 2, TST, and SWS in first two sleep cycles. Interesting, on completion o f 
daytime EEGs using 7.5mg o f zopiclone, these authors found the changes in SWS 
positively correlated with amplitude changes in daytime resting delta-activity, and 
suggested a relationship between these two parameters.
Mann et al. (1996) studied 11 healthy young males talcing 7.5mg o f zopiclone 
for 12 days, plus 4 days placebo run-in and 4 days placebo run-out. Mann et al. (1996) 
found increases in stage 2 sleep plus, contrary to the research o f  Nicholson and Stone 
(1983), decreases in SWS. However, these findings are supported by Shirakawa et al.
(1988) and Aeschbach et al. (1994). Mann et al. (1996) also noted an increase in TST 
and a decrease in wake after sleep onset, and nonsignificant trends towards reduced 
sleep latency and increased REM latency. These findings show zopiclone may improve
sleep. There was no change in the amount o f  REM sleep recorded.
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Studies o f  older adults showed zopiclone increased sleep time and sleep 
efficiency, whilst wake time was reduced and sleep latency remained unaffected. The 
amount o f stage 2 sleep increased, and there was a slight increase in SWS. There were 
no changes to REM latency or amount o f  REM recorded (Hemmeter et al., 2000). These 
findings are o f  a similar pattern to the results o f the studies using young, healthy 
participants. It is likely the changes to sleep in older adults by zopiclone are the same 
changes that zopiclone makes to the sleep o f  younger adults, at least with respect to the 
amount o f  stage 2 sleep, SWS and REM sleep.
Overall, most researchers suggest zopiclone increases objective TST (Mann et 
al., 1996; Yamadera et al., 1997; Hemmeter et al., 2000), reduces objective amounts o f 
wake (Mann et al., 1996; Parrino et al., 1997; Hemmeter et al., 2000), and has no effect 
on objective sleep latency (Maim et al., 1996; Hemmeter et al., 2000; Nakajima et al., 
2000). Stage 1 sleep appears to be reduced at higher doses (Nicholson and Stone, 1983), 
and there is evidence for increases in stage 2 sleep (Nicholson and Stone, 1983; Mann et 
al., 1996; Nakajima et al., 2000). The effect on SWS appeal's inconclusive. The main 
effect o f zopiclone is suggested to be an increase in latency to REM sleep (Nicholson 
and Stone, 1983; Mann et al., 1996; Nakajima et al., 2000). Table 5.4 summarises these 
effects.
During the withdrawal phase in the study by Mann et al. (1996), several 
discontinuation effects were noted. These included nonsignificant trends towards 
reduced sleep time, increased time spent awake and latency to sleep. The amount o f 
stage 2 sleep and SWS returned to baseline values, and there was a significant increase 
in the amount o f  REM recorded. Nakajima et al. (2000) also noted an increase in stage 1 
sleep during withdrawal o f  zopiclone. However, a lack o f  rebound insomnia was found 
after 14 nights at 7.5mg (Jovanovic and Dreyfus, 1983) and after 4 weeks (Voderholzer 
et al., 2001). A lack o f  withdrawal effect was also noted by Mamelak et al. (1982) and 
Hajak et al. (1994). Lader (1992) attributes the diminished rebound effect to the shorter 
elimination half-life o f zopiclone.
5 .2 .3 .4  S a fe ty  a n d  T o le r  a b ili ty  o f  Z o p ic lo n e
Research suggests that zopiclone is well tolerated and safe for the use in most
patient populations. However, there is some evidence that zopiclone can induce adverse
events (AEs) which are similar to those seen with benzodiazepines. For example, Warot
et al. (1987) found that at 2 hours after a dose o f 7.5mg, participants felt more drowsy,
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dizzy, clumsy and tired, and less alert and energetic. Billiard et al. (1987), after studying 
6 participants taking 7.5mg o f zopiclone for 3 nights, noted three main AEs o f a bitter 
taste, jitteriness, and a difficulty in concentrating. Hajak et al. (1994) studied 1315 
insomniacs over 28 days, and recorded AEs including dizziness (27.6%), headache 
(25.7%), nausea (24.8%), vertigo (23.9%), feelings o f weakness (21.1%), weakness in 
the legs (14.1%), vomiting (8.8%), and a bitter metallic taste (6.7%). Tsutsui et al.
(2001) studied 20 insomniacs using 7.5mg o f zopiclone for 14 days. They recorded 173 
AEs in total, namely (in order o f  prevalence) a bitter taste, sleepiness, headache, 
lightheadedness, nausea/vomiting, malaise, and thirst. The AEs reported were not 
considered ‘ severe’ , and there were no reports o f ‘ serious’ AEs. Therefore, taking 
zopiclone appeal's safe; indeed, some researchers found no AEs reported at all (Lader 
and Denney, 1982; Mamelak et al., 1982; van der Kleijn, 1989; Rettig et al., 1990; Stip 
et al., 1999).
5.2.3.5 Summary o f  Zopiclone
In summary, zopiclone appeal's to be a safe and well tolerated 
nonbenzodiazepine hypnotic. It has a shorter elimination half-life than loprazolam and a 
shorter time to peak concentration, implying a shorter duration o f effect compared to 
loprazolam. There is evidence that the elderly have increased sensitivity to the effects o f 
zopiclone, leading to extended residual effects and greater sedation. Therefore, 
Nicholson and Stone (1983) recommended a lower dose o f 5mg should be prescribed to 
older adults. However, the Joint Formulary Committee (2002) recommends a bedtime 
dose o f  3.75mg in the elderly, to be increased as necessary.
Zopiclone shows little sign o f  residual effects the morning after dose, but some 
decrement to performance in the first few hours post dose. This may be o f concern to 
the elderly who may need to get up in the night. Zopiclone appeal's to have a different 
effect to benzodiazepines on sleep architecture. SWS is mostly increased, not reduced, 
and REM is unchanged, not reduced, but there is still the characteristic increase in stage 
2 sleep, also seen in benzodiazepines. Zopiclone has been found to improve sleep onset 
latency, sleep efficiency and increases total sleep time.
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Zolpidem is also one o f  the newer types o f nonbenzodiazepine hypnotic, classed 
as an imidazopyridine. It also has action upon the GABAa receptor complex with high 
affinity for the benzodiazepine omega-1 receptor (Holm and Goa, 2000). This lack o f 
binding to the omega-2 receptors would be expected to reduce unwanted 
psychodynamic effects. However, Abadie et al. (1996) found this selectivity was greatly 
reduced with a 20mg dose o f  zolpidem. The recommended dose is lOmg in adults (Roth 
etal., 1995).
Research has shown zolpidem has similar effects to flunitrazepam, flurazepam, 
nitrazepam, triazolam and zopiclone, and may even have better efficacy than 
temazepam (Holm and Goa, 2000). Jonas et al. (1992) again found no difference in 
clinical and pharmacologic activity compared to other benzodiazepines, also including 
loprazolam. Efficacy in the elderly is suggested to be similar to flunitrazepam, 
temazepam and triazolam (Holm and Goa, 2000).
5 .2 .4 .1  P h a r m a c o k in e t ic  P r o f i l e  o f Z o l v i d e m
Zolpidem is rapidly absorbed with maximum plasma concentration being 
reached approximately 1.6 hours after a lOmg dose (Holm and Goa, 2000). There is no 
evidence for accumulation after multiple doses, and the elimination half-life o f 
zolpidem is approximately 2.6 hours after 5mg, and 2.5 horns after lOmg (Hunt, 1989). 
This categorises zolpidem as an ultra short acting hypnotic (as it has a half-life o f less 
than 6 hours). Its shorter half life than loprazolam and zopiclone may make it an ideal 
hypnotic in the elderly. However, because the main problem with sleep in older adults is 
its maintenance (Gislason et al, 1993; Mallon and Hetta, 1997), such a short acting 
hypnotic may not be helpful in these circumstances.
5 .2 .4 .2  P h a r m a c o d y n a m ic  P r o f i l e  o f Z o l v i d e m
Most researchers maintain that there are no morning-after residual effects o f
zolpidem (Jackson et al., 1992; Berlin et al., 1993; Richens et al., 1993; Roehrs et al.,
1994; Allain et al., 1995; Vermeeren et al., 1995; Dujardin et al., 1998), even in elderly
(Fairweather et al., 1992), due to its short duration o f  action. However, some
impairments o f psychomotor and cognitive function after ingestion o f  zolpidem have
178
5.2.4 Zolpidem
been reported, although there appears to be a large inter-individual variation in response 
to zolpidem (Danjou et al., 1999). These impairments usually occur’ within a few hours 
o f  administration (Allain et al., 1995; Westensten et al., 1995). Zolpidem is suggested to 
be more detrimental to daytime performance than zaleplon, another new generation 
hypnotic (Danjou et al., 1999), with respect to DSST, immediate and delayed free recall, 
CRT, CFF, and short-term memoiy using the Sternberg memory scanning test. Most 
effects are not detectable by 6 hours post dose (Holm and Goa, 2000). Indeed, studies 
by Danjou et al. (1999) and Drover et al. (2000) have shown that lOmg and 20mg o f 
zolpidem impairs DSST and word recall for up to 5 hours post dose. Memory 
(immediate and delayed recall) was also found to be impaired (Mattila et al., 1998). 
Mintzer and Griffiths (1999) produced a more detailed analysis o f the effects o f 
zolpidem on memory, and found evidence for 15mg causing impairment o f acquisition 
(and encoding), but not retrieval in explicit and contextual memory. There was no 
impairment in semantic or implicit memory, in fact priming was facilitated in the latter. 
The authors suggest this is due to the lack o f affinity for the omega-2 receptor displayed 
by zolpidem.
In a study o f  142 insomniacs, Fleming et al. (1995) found zolpidem (lOmg) 
caused significantly less impairment than flurazepam (30mg) on DSST, but 
performance on CRT, auditory vigilance, divided attention and simple reaction time 
were equivalent for the two drugs. In addition, a study by Bocca et al. (1999) foimd that 
lateral driving position and latency o f ocular saccades were impaired in healthy young 
adults at 09:00 following an evening dose o f  zolpidem lOmg. No impairment was found 
at 11:00, suggesting that early morning driving should be avoided in affected patients. 
However, Vermeeren et al. (1995) found no impairment in driving ability the morning 
after an evening dose o f  zolpidem lOmg.
The differences between these studies are likely to be due to detrimental effects 
o f zolpidem only being found at higher doses, or at test points within 5 hours o f 
ingestion (Rush and Griffiths, 1996; Wilkinson, 1995; Troy et al., 2000; Mattila et al., 
1998). This suggests zolpidem will show no residual effect the morning after ingestion. 
There was also little effect o f  zolpidem on mood (Richens et al., 1993; Mattila et al., 
1998; Drover et al., 2000; Saletu-Zyhlarz et al., 2000). Table 5.5 shows the findings o f 
seven studies.
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Zolpidem has been found to reduce sleep latency and increase sleep duration in 
healthy volunteers (Uchiumi et al., 1994; Erman et al., 1995; Gengo et al, 1995; Roth et 
al., 1995) and in insomniacs (Walsh et al., 1999; Uchiumi et al., 1994; Erman et al., 
1995; Roth et al., 1995). It has also been found to benefit those at a simulated altitude o f 
4000m (Beaumont et al., 1996), heavy snorers (Quera-Salva et al., 1994), hospitalised 
patients before surgery (Morgan et al., 1997) and those with jet lag (Jamieson et al., 
1998). In the elderly, sleep parameters including sleep duration, sleep latency and sleep 
quality were improved (Scharf et al., 1991; Leppik et al., 1997).
Sleep architecture under zolpidem remains relatively unaffected in normal 
healthy adults (Brunner et al., 1991; Kanno et al., 1993; Patat et al., 1994), but different 
effects can be seen in insomniacs and the elderly. Blois et al. (1993) have found 
increases in SWS, which is contrary to typical benzodiazepine action (Scharf et al., 
1994; Parrino et al., 1999b). There are two implications: firstly, that zolpidem may 
indeed have different action to benzodiazepines (Holm and Goa, 2000) and secondly, 
that there maybe therapeutic differences between good and poor sleepers, with respect 
to hypnotics (Morgan et al., 1988b).
Leger et al. (1999) investigated the subjective effects o f  5mg and lOmg o f 
zolpidem on 769 elderly insomniacs (mean age 72.9 years), and found a decrease in 
sleep latency, and increase in TST, and a reduction in the number o f  awakenings. There 
was also improvement in sleep quality, less complaints o f  waking too early in the 
morning, and increased morning alertness. The number o f  naps taken decreased and 
there was improvement in mood. These are all positive effects which can improve sleep. 
Similar findings have also been found in the elderly by Scharf et al. (1991).
Monti et al. (2000) studied 12 female insomniacs (aged 27 to 59 years) over 15 
nights taking lOmg o f zolpidem. Overall, zolpidem was foimd to decrease latency to 
stage 2 sleep, increase TST and sleep quality, increase the amount o f  stage 1 and stage 2 
sleep (but not SWS), and nonsignificant trends were also found towards increases in 
REM. The number o f awakenings actually increased on recording nights 3 and 4, 
however on all other nights no change was recorded. Subjectively, there were no 
differences in alertness, but there was improvement in the ease o f  getting to sleep.
Nalcajima et al. (2000) tested 9 young healthy males for 3 treatment nights and
foimd zolpidem lOmg did not affect the percentage o f  wake, stage 1 or stage 2 sleep,
time in bed, TST, sleep efficiency, sleep latency, latency to SWS and REM sleep, but
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increased the percentage o f  SWS. A  decrease in stage 2 was noted 011 the third 
withdrawal night. There was also a trend towards an increase in REM in the last third o f 
the nocturnal recordings, possibly indicating a within-night rebound effect. These 
results agree with an experiment on lOmg zolpidem completed by Kanno et al. (2000).
As well as favourable sleep effects in patients with insomnia, there is also little 
evidence for rebound insomnia 01* withdrawal effects with zolpidem (Monti et al., 1996; 
Leppik et al., 1997; Ware et al., 1997; Elie et al., 1999; Monti et al., 2000). Walsh et al. 
(1999) also found no rebound effects after use o f  zolpidem on an ‘ as needed’ basis. 
However, there is some evidence for within-night rebound, but this is not thought to be 
clinically significant (Nakajima et al., 2000).
Overall, LSEQ ease o f  getting to sleep and quality o f  sleep were improved by 
zolpidem (Fairweather et al., 1992; Monti et al., 2000; Tsutsui et al., 2001). Zolpidem 
has been found to reduce subjective and objective sleep latency (Kryger et al., 1991; 
Scharf et al., 1991; Dockhorn and Dockhorn, 1996; Tsutsui et al., 2001) and increase 
subjective and objective TST (Scharf et al., 1991; Mendelson, 1995; Dockhorn and 
Dockhorn, 1996; Tsutsui et al., 2001). Sleep efficiency was improved by zolpidem 
(Kryger et al., 1991; Herrmann et al., 1993; Monti et al., 2000), and there was mostly no 
effect on the amount o f  stage 1 sleep (Kryger et al., 1991; Mendelson, 1995; Nakajima 
et al., 2000), and the amount o f  stage 2 sleep (Merlotti et al., 1989; Mendelson, 1995; 
Nakajima et al., 2000), although some researchers found increases in the latter (Kryger 
et al., 1991; Monti et al., 1996; Monti et al., 2000). There were no significant effects on 
stage 3 sleep (Mendelson, 1995; Monti et al., 1996), but some researchers noted 
changes in stage 4 sleep (Bentoit et al., 1994; Parrino et al, 1997; Saletu-Zyhlarz et al., 
2000) while others did not (Blois et al., 1993; Mendelson, 1995). There was some 
disagreement as whether or not zolpidem increases SWS, as some researchers found no 
effects (Merlotti et al., 1989; Mendelson, 1995; Monti et al., 2000), while others 
detected an increase, particularly at the beginning o f the night (Kryger et al., 1991; 
Herrmann et al., 1993; Nakajima et al., 2000). There was little evidence for an effect on 
REM sleep (Kryger et al., 1991; Mendelson, 1995; Monti et al., 1996). Most research 
indicated there was no rebound insomnia associated with the use o f  zolpidem 
(Herrmann et al,, 1993; Monti et al., 1996; Monti et al., 2000). The findings o f 12 
studies are shown in full in Table 5.6.
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5.2.4.4 Safety and Toler ability o f  Zolpidem
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Zolpidem is generally well tolerated (Roger et al., 1993; Leppik et al., 1997), and has a 
low risk o f abuse and dependence (Evans et al., 1990; Rush et al., 1999a). There are less 
adverse events (AEs) with zolpidem than zopiclone (Tsutsui et al., 1999). AEs 
experienced are mostly dose-related, and are especially prevalent in the elderly 
(McEvoy, 1999). In a study by Hajak and Bandelow (1998) using lOmg o f zolpidem, 
182 out o f 16944 patients (1.1%) experienced 268 AEs. In order o f prevalence, these 
were nausea, dizziness, malaise, nightmares, agitation, headache, vomiting, somnolence, 
confusion, and paranoia. Ahrens (1993) found 629 o f  30043 patients (2.1%) 
experienced 1174 AEs at the lOmg dose, namely dizziness, hypotension, headache, and 
nausea, and similar- effects were noted by Dockhorn and Dockhorn (1996) (headache, 
drowsiness, diarrhoea, dizziness, myalgia, and nausea). Tsutsui et al. (2001) 
investigated the effects o f  lOmg o f zolpidem on 422 volunteers, and found occurrence 
o f 104 AEs, including sleepiness, headache, nausea/vomiting, lightheadedness, thirst, 
bitter taste, and malaise. Drover et al. (2000) studied 10 participants, and lOmg 
produced 10 AEs (diplopia (double vision), headache, visual hallucinations, hiccups, 
and constipation), and 20mg produced 21 AEs (diplopia (double vision), hiccups, 
headache, visual hallucinations, nausea, auditory hallucinations, lightheadedness, and 
urinary incontinence). Whilst some researchers have found no AEs in their studies 
(Emeriau et al., 1988), the majority suggest AEs are common with zolpidem, even if 
prevalence is less than with zopiclone or loprazolam. Langer et al. (1999) and Hajak et 
al. (2002) have therefore suggested that the use o f zolpidem should be on an ‘as needed’ 
basis may be a better prescription strategy. Indeed, studies have shown lOmg on an ‘as 
needed’ basis is still as effective as continuous use. Arbus et al. (1999) found results 
similar to other clinical studies when they gave 245 patients four tablets o f  either lOmg 
zolpidem or placebo, two tablets to be taken on the first two nights o f  the week, and the 
other two to be taken as needed. Cluydts et al. (1998) studied 160 patients talcing lOmg 
continuously or intermittently for a fortnight. They found the efficacy and tolerability o f  
zolpidem was comparable between the two schedules.
5.2.4.5 Summary ofZolvidem
Zolpidem is a safe and well tolerated drug. AEs found with zolpidem use are
similar in nature, but less prevalent, compared to AEs found dining treatment with
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benzodiazepines. Zolpidem does display some dose-dependent effects on psychomotor 
and cognitive tasks (Rush and Griffiths, 1996; Troy et al., 2000), but all effects are 
barely detectable 4 to 6 hours post dose. There is also little evidence for residual effects 
o f  zolpidem impairing next morning performance.
Parrino et al. (1997) maintains zolpidem improves sleep synchronisation and 
prevents shallow sleep (so is protective o f  stage 4 sleep). Indeed, Declerck and Smits 
(1999) found zolpidem increased stage 4 sleep in 22 chronic insomniac patients after 3 
and 4 weeks o f intake, suggesting that zolpidem may restore physiological sleep in 
insomnia. Indeed, Declerck et al. (1992) also suggested zolpidem might return the sleep 
in insomniacs into sleep resembling ‘normal’ sleep. Zolpidem has been found to 
improve sleep latency, efficiency and quality. There are few effects on the amoimt o f  
stage 1 and 2 sleep, although there is some evidence for increases in the latter. There is 
little evidence for an effect o f  zolpidem on SWS, but some researchers have found 
increases during the beginning o f the night. There appears to be no effect on REM, and 
little evidence for significant rebound insomnia or withdrawal effects.
5.2.5 Conclusions
The three hypnotics discussed have been found to be safe and well tolerated. 
There is little evidence for detrimental rebound insomnia or severe withdrawal effects. 
There has been concern, however, that zopiclone and zolpidem may cause within-night 
rebound insomnia, due to their short duration o f  action (Lader, 1998). Within-night 
rebound insomnia may be a problem for some older adults, as this population tends to 
experience problems with sleep maintenance (Gislason et al., 1993; Mallon and Hetta, 
1997).
Loprazolam, zopiclone and zolpidem all displayed beneficial effects on
objective and subjective sleep, with little effect on daytime performance. Impairments
in cognitive function and psychomotor performance tended to occur with higher doses,
and/or at test points which were nearer in time to drug ingestion. Loprazolam decreased
SWS and REM sleep, and increased stage 2 sleep. Zopiclone, however, increased SWS,
had no effect on REM, but still increased stage 2 sleep. Zolpidem showed some
evidence o f  increasing SWS in the beginning o f  the night, but there was no effect on
REM, and no effect on stage 2 sleep. Nakajima et al. (2000) put forward a model
explaining these differences, and also explaining differences between effects on
psychomotor and cognitive tasks. Figure 5.1 shows the preference o f  each drug for
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binding sites, and the main brain areas these binding sites are found. Preference for 
binding to sites in the cortex is associated with increases in SWS, but binding to sites in 
the hippocampus and thalamus is associated with increases in stage 2 sleep. Therefore, 
it can be seen that zolpidem should increase SWS with little effect on stage 2, zopiclone 
should affect both SWS and stage 2 sleep, and the benzodiazepine loprazolam should 
increase stage 2 sleep, without much effect on SWS. This is largely echoed in the 
literature. In addition, the thalamus has close connections with the limbic system, which 
is associated with emotion and mood. The nonbenzodiazepines have less effect in this 
area (due to the high number o f  omega-2 receptors), and so this may help explain the 
weaker effects on mood o f  the nonbenzodiazepines.
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Figure 5.1: Suggested Action of Zolpidem. Zopiclone and Benzodiazepines (Including Loprazolam) on 
GABAa receptors and Sleep Architecture (Nakajima et al.. 20001. This shows zolpidem has greater 
preference for the co-1 receptor, zopiclone has slight preference for the co-1 receptor, and benzodiazepines 
('including loprazolam') bind similarly to both the co-1 and co-2 receptors.
5.3 Aims
The aim o f this study is to compare and contrast loprazolam, zopiclone and 
zolpidem in a placebo-controlled, crossover study investigating sleep variables, and 
measures o f psychomotor performance and cognitive function (the morning after 
ingestion). Each will be assessed for efficacy, and discussed in relation to the 
appropriateness o f  their use in the elderly.
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One feature o f  the past literature on loprazolam, zopiclone and zolpidem is the 
difference in results between healthy normal and insomniac or elderly volunteers 
(Kryger et al., 1991; Holm and Goa, 2000). The differences with respect to elderly 
volunteers may be due to the reasons previously described, such as differences in 
metabolism, or sleep may be more consistent in the young. The reasons for differences 
between normals and insomniacs are unclear, and may simply be due to differences in 
the perception o f  sleep (Mendelson, 1995). It is important to research the effects o f 
hypnotics in healthy normal volunteers, to gauge the effect the drugs alone have, 
without the influence o f  physical illness or problematic sleep. However, if the effects o f 
hypnotics are influenced by sleep problems, then volunteers with sleep disturbance 
should also be investigated, as they will be the target population. Investigations into the 
elderly are more complex. Their insomnia can be masked or distracted from by physical 
or psychological effects (Moffitt et al., 1991; Asplund, 1996). As previously mentioned, 
this investigation into loprazolam, zopiclone and zolpidem will use young volunteers 
with a sleep disturbance. This will assess the effects o f  the hypnotics on patients with 
insomnia, without the added confounds o f  old age. It is difficult to show changes in the 
sleep o f  a good sleeper, because sleep may already be optimum. Therefore, poor 
sleepers will demonstrate any changes or improvements resulting from administration 
o f these three hypnotics.
5.4 Methods
5.4.1 Design
This study was a single centre, randomised, double blind, placebo controlled, 
four way crossover study using twelve completing volunteers out o f  the 16 recruited 
with a subjective complaint o f  mild sleep disturbance. The independent variable was the 
treatment under investigation, either loprazolam lmg, zopiclone 7.5mg, zolpidem lOmg 
or placebo. In accordance with a within-subject design, each volunteer received all o f 
the test doses during different periods throughout the study. The dependent variables 
were the objective measures o f  sleep EEG, subjective reports, and psychometric tests 
(see Procedure). Each treatment period was separated by a week washout period. The 
schedule o f  assessment is shown in table 5.7.
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Test Period Pre-Screening Screening Treatment Days Post
Study
Alcohol screen X
Consent X (X) (X) (X)
Medical examination X X
Laboratory screens 
(haematology and 
biochemistry)
X X
Sleep adaptation X
Adverse events, 
concurrent illness/ 
medication
X X X
Test training X
Drug administration X
Psychometric testing X
Sleep EEG X
Table 5.7 - Scheduling of Assessments
Most variables were controlled to avoid bias in the dependent variables.
Participants slept in identical sleep bedrooms, which were sound and light attenuated.
All lights out, wake times, dose times and other schedule markers were identical in all
study nights. Adverse events (AEs) or problems were documented in CRFs (Case
Report Forms) for reference during analysis. Participants gave full medical histories,
corroborated by their general practitioners (GPs), and consent for participation in the
study was also obtained by their GPs. All participants underwent a medical
examination, and were screened for abnormal ECG, laboratory, biochemical or
haematological values. All psychometric tests and mood scales were standardised, as
were instructions for completion. Participants were practised on all psychometric tests
until they reached a learning plateau, to remove any possibility o f  practise effects
confounding results. A double blind technique was used to ensure that participants did
not know, nor infer via experimenter effects, the treatment taken. All medication was in
tablet form, and matched to placebo. Because the study required volunteers with a mild
sleep complaint, participants were aware they would be taking hypnotics, and the names
o f the hypnotics they would be taking, although they were naive as to the order o f
administration. All food provided on the study nights was standardised and low in fat,
although there was no control placed over food eaten when not in the Unit. Caffeine was
not permitted during the study nights, or 24 hour's before attending the Unit. This
criterion was used to avoid any alerting effects o f  caffeine which may confound the
treatment effects. However, it is possible that withdrawal o f caffeine may have adverse
effects, such as headache and sedation (Greden et al, 1980). The use o f  medication
other than oral contraceptives and non-steroidal painkillers throughout the duration o f
the study was forbidden. However, as mentioned in the previous chapter, some research
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shows some non-steroidal treatments can produce feelings o f sedation (Zacny et al.,
1996), so more research is necessary into the implications o f  allowing this concomitant 
medication in these trials.
This study was commissioned by a pharmaceutical company, and so some 
design aspects are controlled by the requirements o f the company. For example, the 
choice o f  the comparator benzodiazepine loprazolam was decided by the sponsoring 
company, as was time o f  dosing and testing. Using clinical trials to investigate 
medication does remove flexibility in the study design, due to strict guidelines o f ICH 
GCP (Good Clinical Practice). However, these guidelines have many merits, as they 
also ensure studies are scientifically sound, ethical, necessary, and respect volunteers’ 
rights and confidentiality. There is great emphasis on quality o f  data, record keeping 
and standardisation, all o f  which encourages the production o f good research. The 
author o f  this thesis contributed towards the implementation o f  the study, assisted in the 
running o f  the study, and analysed all data.
5.4.2 Participants
The participants were all volunteers aged between 20 and 39 years old (mean 
age 27.5 years, sd 6.07), selected from responses to the mailings o f  the HPRU Medical 
Research Centre volunteer database. There were 16 volunteers in total, 10 male and 6 
female, all healthy, but with a subjective complaint o f a mild sleep disturbance. This is 
defined as a subjectively long sleep onset latency (over 30 mins), a subjectively short 
total sleep time (less than 6 hours), and/or a subjectively frequent amount o f 
awakenings in the night (more than 3 awakenings). Volunteers were assigned a study 
number that randomly allocated them to a test pattern group, determining the order in 
which the test medication was administered.
Strict inclusion and exclusion criteria were used to select participants in this 
study, shown in table 5.8.
Chapter 5
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• Males and females aged between 18-40 years inclusive.
• A body mass index greater than or equal to 18 and less than or equal to 30.
• Subjective complaint of mild sleep disturbance (primarily a sleep latency greater than 30 mins).
• In good health as determined by a medical history, ECG, haematology, blood and urine biochemistry, 
and physical examination by the doctor.
• Able and willing to give informed consent.
• Having the consent of the volunteer's general practitioner.
The exclusion criteria were as follows:
• Pregnant or lactating females, or females of child bearing potential not using adequate contraception.
• Current and past (in the last six months) use of tobacco or products containing nicotine.
• Current participation in another clinical trial, or participation in a clinical trial within the last 90 days.
• Concomitant psychotropic medication.
• Clinically significant (as judged by the investigating clinician) use of psychotropic medication in the
last six months before the start of the study. For example, this would include the prolonged use of
antidepressants, antipsychotics, or antihistamines.
• The use of any other medications in the last four weeks before the start of the study with the exception 
of non-steroidal analgesics including paracetamol and contraceptives.
• Significant history of mental illness, significant drug allergy, malignancy or chronic drug abuse 
(including alcohol).
• Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological or 
haematological disease or abnormality.
• Marked laboratory, biochemical, or haematological abnormalities not including isolated abnormalities 
which are considered to be clinically insignificant by the medical supervisor.
• Abnormal or unstageable EEG.
• A sleep/wake cycle (e.g. shiftwork), liable to prejudice the results of the study.
• Any subject that the physician or investigator judges to be unsuitable._________________
Table 5.8: Inclusion and Exclusion Criteria
5.4.3 Materials and Measures
The inclusion criteria were as follows:
These included psychometrics software and computers, all questionnaires, Case 
Report Forms (CRFs), breath alcohol tester, height measure and weighing scales, ECG 
and medical examination equipment, EEG electrodes and application materials (tape 
measure, chinograph pencil, collodian glue, acetone, and chlorhexidine as a de-greaser), 
Nicolet Ultrasom digital EEG sleep recording equipment, test medication (see Dosing), 
sleep bedrooms with nurse call button and CCTV cameras, and psychometric test 
rooms.
Objective EEG was recorded with 4 EEG (C4-A1, C3-A2, 02-A1, 01-A2), 2 
EOG (electroocculograph) and 4 submental EMG (electromyograph) leads and 
Ag/AgCl electrodes on to a Nicolet Ultrasom digital EEG machine. Sleep stages were 
visually scored by one experienced rater according to the criteria o f  Rechtschaffen and 
Kales (1968).
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Subjective and psychometric assessments were achieved using Critical Flicker 
Fusion (CFF), Choice Reaction Time (CRT), Sternberg Memory Test, Immediate and 
Delayed Recall o f  word lists, Digit-Symbol Substitution Task (DSST) from the 
Wechsler Adult Intelligence Scale (Revised — 1981), Line Analogue Rating Scale 
(LARS), Leeds Sleep Evaluation Questionnaire (LSEQ), the State-Trait Anxiety 
Inventory (STAI), and the Milford-Epworth Sleepiness Scale (MESS).
5.4.4 Dosing
Each test period lasted 7 nights, and volunteers received each o f the three test 
medications for a period o f 3 nights, each period separated by a one week washout 
period. After an adaptation night, placebo was given on the first study night (to act as a 
baseline recording), medication was given on nights 2, 3, and 4, and placebo was given 
again on nights 5 and 6 to analyse any withdrawal effects. Each o f  the doses was taken 
orally as a capsule with 150 ml o f  water. Volunteers received one tablet at 21:00 (as 
specified by the sponsoring company) and all the active medication was placebo 
matched and dispensed double blind. The doses used were loprazolam lmg, zopiclone 
7.5mg, zolpidem lOmg (and placebo).
5.4.5 Procedure
Before the start o f  the study, all participants were trained on the psychometric 
tests to a learning plateau, and all were required to attend the Unit for a one night 
adaptation period. Here, overnight EEG was recorded to serve as part o f a screening 
procedure, to check for anomalies in the participants trace, but also to familiarise the 
participants with the instrumentation used, and also the sleep laboratory bedrooms. This 
is because o f  the first night effect (Agnew and Webb, 1968), whereby an initial night’ s 
recording is usually discarded because o f the poor sleep suffered by volunteers on this 
night. Within a week o f the adaptation night, the treatment phases began.
For each study period, the following assessments were made: Sleep 
Electroencephalograph (EEG), Critical Flicker Fusion (CFF), Choice Reaction Time 
(CRT), Short Term Memoiy Test (SMT), Immediate and Delayed Recall, Digit Symbol 
Substitution Test (DSST), Line Analogue Rating Scales (LARS), Leeds Sleep 
Evaluation Questionnaire (LSEQ). State Trait Anxiety Inventory (STAI), and the
Milford-Epworth Sleepiness Scale (MESS).
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On Day 1, participants arrived at the Unit at 19:30, were breathalysed, and 
underwent the baseline psychometric tests. Assessment o f  AEs and concomitant 
medication was made. Dinner was eaten at 20:00. Placebo medication was administered 
at 21:00 and went to bed in time for lights out at 23:00. Throughout the evening the 
participants had EEG electrodes attached to their face and scalp for the EEG recording, 
in accordance with the 10-20 electrode placement system (Jasper, 1958). CCTV 
cameras and nurse call buttons were used for the participants’ safety (if they felt unwell, 
or needed the toilet, for example).
On Days 2, 3, and 4, the sleep EEG recordings were terminated at 07:00 when 
the participants were awoken. They then completed the psychometric test battery at 
07:30. After breakfast, participants were transported home by taxi, and returned the 
following at 19:00 to follow the same procedure as Day 1. Active medication was 
administered at 21:00.
On Days 5 and 6, the participants followed the same procedures, except placebo 
was again taken as the medication to assess withdrawal effects. On the morning o f Day 
7, participants were transported home after their final completion o f  the test battery. 
This procedure is summarised in Table 5.9.
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Real Time Study Time (hrs) Event
19:00 -2.0 Participants arrive and are breathalysed, EEG 
electrodes attached throughout evening
19:30 -1.5 Psychometric testing
20:00 -1.0 Dinner
21:00 0.0 Drug administration (placebo on nights 1, 5, 
and 6)
23:00 +2.0 Lights out
07:00 +10.0 Participants awoken, electrodes removed 
throughout morning
07:30 +10.5 Psychometric testing
08:30 +11.0 Breakfast and participants depart
Table 5.9 - Study Timetable for Each Treatment Period
5.5 Results
5.5.1 Statistical Analyses
There were 16 participants in total included in the study, but not all were used in 
the analysis. One participant dropped out o f  the study due to personal reasons, and 
therefore had a large amount o f  missing data, so the data from this participant were 
excluded. In other cases, data sets from participants were excluded from analysis
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because o f missing data points. Missing data were due to computer error and participant 
mistakes.
For all variables, a repeated measures ANOVA was used, due to the within- 
subjects design and ratio level data. Where test points were included in the analysis, this 
was three-way (Day, Drug and Test point), otherwise it was two-way (Day by Drug). 
An epsilon correction (Greenhouse and Geisser, 1959) was enforced with these 
ANOVA. This correction factor works to reduce the degrees o f freedom, thus 
introducing more stringent criteria for significance. This was done because o f the large 
amount o f  data for analysis, as a guard against inclusion o f spurious significant effects.
Initial post-hoc analysis o f  significant interactions was completed using simple 
main effects, and significances further elucidated using orthogonal pairings in t-tests. 
This was chosen as the simplest method to compare means o f  two data sets. Tukey’ s 
(HSD) test was used with more than two data sets, when a significant factor in the 
ANOVA analysis had two or more levels. Tukey’s is thought to be a conservative 
method o f  analysis, and can sometimes reject true effects. However, it is a thorough test 
and reduces in conservatism with large numbers o f data groups, or data sets. As the 
amount o f  data in this study is large, it is thought to be the most appropriate test, to 
avoid inclusion o f spurious significant effects.
All analyses were computerised, using CLR ANOVA 2.0 (Clear Lake Research 
Inc.) on an Apple Macintosh.
5.5.2 Psychometric Analyses
5.5.2.1 Critical Flicker Fusion (CFF)
Fourteen participants were included in this analysis. A  three-way repeated 
measures ANOVA with epsilon correction revealed a significant two-way interaction o f 
Day x Drug (F(5.55, 195)=2.181, p<0.05). Post-hoc analysis by simple main effects 
showed a significant effect o f  Drug collapsed at treatment day 1 (F(3,39)=3.188, 
p<0.05), and further analysis by t-test showed the mean o f zopiclone was higher than 
the mean o f loprazolam (t=2.818, p<0.05). This means on the first dose, loprazolam had 
a lower mean CFF value (Hz), and therefore impaired information processing more than 
zolpidem (test point collapsed), but not on the other treatment nights. There were no 
significant differences between the three test medications and placebo on any night.
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Graph 5.1 shows these effects. The error bars used as ail indication o f variance show 
one standard deviation above and below the mean.
There were significant simple main effects for Drug on discontinuation day 1 
(F(3,39)=3.805, p<0.05). Further analysis by t-test showed the mean CFF value (Hz) for 
zopiclone was higher than the mean CFF value (Hz) for loprazolam (t=3.225, p<0.05), 
meaning information processing was more impaired on loprazolam compared to 
zopiclone on initial discontinuation. Analysis o f simple main effects also found 
significant difference between Drug on discontinuation day 2, and further analysis by t- 
test revealed the mean CFF (Hz) was higher for zopiclone than zolpidem (t=2.171, 
p<0.05). This means on the second discontinuation day, information processing was 
worse under zolpidem compared to zopiclone. There were no significant differences 
between the three test medications and placebo on any night.
Collapsing Day at zopiclone by simple main effects showed a difference 
between Day on zopiclone. T-test analysis showed the mean CFF (Hz) was higher for 
treatment day 1 (t=2.853, p<0.05) and the discontinuation days (t=2.193, p<0.05; and 
t=2.523, p<0.05 respectively) than the placebo baseline day at the start o f the study. 
Also, the mean CFF (Hz) was higher for treatment day 1 than treatment day 2 (t=2.251, 
p<0.05), and higher for discontinuation day 2 than treatment day 2 and 3 (t=2.329, 
p<0.05; and t=2.701, p<0.05 respectively). This means that on zopiclone only, 
information processing was better on treatment day 1 and discontinuation days than on 
treatment day 2 and the baseline day, indicating initial arousal and a progressive 
sedative effect which was lifted on discontinuation.
5.5.2.2 Choice Reaction Time. Recognition Reaction Time (RRT)
There were 14 participants included in this analysis. A  three-way analysis with 
ANOVA revealed no interaction, only a significant effect o f  Test (with Drug and Day 
collapsed) (F(l,13)=17.002, p<0.01). Post-hoc analysis by Tukey’s (HSD) test showed a 
significant difference (p<0.01) between test points 1 (evening) and 2 (morning), 
whereby the mean recognition reaction time (msec) in the CRT was slower during test 
point 2 (morning) compared to test point 1 (evening).
Recognition reaction time on the CRT task was longer in the morning tasks than 
the evening tasks. There are significant differences in recognition reaction time between 
loprazolam, zopiclone, zolpidem and placebo.
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53.2.3 Choice Reaction Time. Motor Reaction Time (MRT)
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There were 14 participants included in this analysis. A  three-way ANOVA with 
epsilon correction showed a significant effect o f Test (F(l,13)=98.100, p<0.01), and a 
significant interaction o f  Drug by Test (F(2.58,33.54)=4.452, p<0.05). Post-hoc analysis 
o f Test (with Drug and Day collapsed) with Tukey’ s (HSD) test revealed a significant 
(p<0.01) effect between the means o f  test points 1 (evening) and 2 (morning). 
Inspection o f  the means showed the motor reaction time (msec) in the CRT to be 
increased at test point 2 (morning) compared to test point 1 (evening). Post-hoc analysis 
o f the Drug by Test effect by simple main effects found motor reaction time at test point 
2 (morning) was significantly slower than at test point 1 (evening) for all medication: 
loprazolam (F(l,13)=40.275, p<0.001), zolpidem (F(l,13)=25.565, pO.OOl), zopiclone 
(F(l,13)=11.113, pO .O l) and placebo (F(l,13)=7.043, p<0.05). This means in the CRT 
test, motor reaction time was slower in the morning than the evening, irrespective o f 
drugs taken, or days tested. Impairments o f MRT were due to time o f  day only as there 
was no significant difference between test medication and placebo.
5.5.2.4 Choice Reaction Time. Total Reaction Time (TRT)
The data for 14 participants were analysed for this variable. A  three-way 
ANOVA with epsilon correction revealed an effect o f Day (F(3.6, 46.8)=3.278, 
p<0.05), Test (F(l,13)=46.437, p<0.01), and Drug by Test (F(2.25,29.25)=6.147, 
p<0.01). The significant effect o f  Day was examined with Tukey’ s (HSD) test, showing 
the total reaction time (msec) was faster on discontinuation day 2 than the baseline day 
(p<0.05) and treatment day 1 (p<0.05). This means that irrespective o f drug, CRT was 
generally faster on the second discontinuation day compared to baseline and the first 
treatment day. This may be indicative o f  a recovery from the sleep disturbance, and the 
effects o f  the drugs. The significant effect o f  Test was also examined by Tukey’ s, and 
found total reaction time (msec) during test point 2 (morning) was significantly 
(p<0.01) slower than during test point 1 (evening). TRT was therefore slower in the 
morning tasks compared to the evening tasks, irrespective o f  day or drug.
The significant two-way interaction o f  Drug by Test was examined by simple
main effects, showing that total reaction time during test point 2 (morning) was
significantly slower than during test point 1 (evening) for loprazolam (F(l,13)=50.758,
pO.OOl), zolpidem (F(l,13)=12.020, pO.Ol), zopiclone (F (l,13)02.857, pO.OOl),
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and placebo (F(l,13)=9.791, p<0.01). There was no significant difference between test 
medication and placebo, and so none o f  the treatments impaired TRT.
5. J.2.5 Sternberg's Memory Test (STM)
There were 15 participants included in this analysis. A  three-way ANOVA 
revealed a significant effect o f  Day (F(5,70)=5.647, pO.OOl), and Test 
(F(l,14)=41.785, pO.OOl), but no interactions. Analysis o f  the factor Day by Tukey’ s 
(HSD) test showed significant differences between the baseline day and treatment day 2 
(p<0.05), between the baseline day and treatment day 3 (p<0.01), between the baseline 
day and discontinuation day 1 (p<0.05), and between the baseline day and 
discontinuation day 2 (p<0.01). Inspection o f  the means revealed the reaction time 
(msec) in the memory test STM was significantly slower during baseline compared all 
days except treatment day 1. Analysis o f the factor Test, using Tukey’s, showed a 
significant (p<0.01) difference between test points 1 (evening) and 2 (morning), where 
test point 2 (morning) was significantly slower than test point 1 (evening).
To summarise, the Sternberg memory task was worse at baseline than during the 
second and third test days and both discontinuation days, and worse in the morning 
compared to the evening. There was no significant impairment o f memory by 
loprazolam, zopiclone or zolpidem compared to placebo.
5.5.2.6 Immediate Word Recall
There were 14 participants included in this analysis. A three-way ANOVA with
epsilon correction revealed a significant effect o f  Test (F(l,13)=14.556, p<0.01), and
Day by Test (F(3.55,46.15)=4.636, p<0.01). Post-hoc analysis using Tukey’ s (HSD) test
o f the effect o f  the factor Test showed significantly more words were correctly
remembered during test point 1 (evening) compared to test point 2 (morning) (p<0.01).
The significant interaction o f  Day by Test was examined using simple main effects.
This showed a significant effect between days at test point 2 (morning) (F(5, 65)=4.626,
p<0.01). T-test analysis showed more correct words were remembered on treatment day
2 than treatment day 1 (t=3.377, p<0.05), on treatment day 2 than treatment day 3, on
discontinuation day 1 than baseline (t=2.233, p<0.05), on discontinuation day 1 than
treatment day 1 (t=3.743, p<0.05), on discontinuation day 1 than treatment day 3
(t=3.354, p<0.05), on discontinuation day 1 than discontinuation day 2 (t=2.290,
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p<0.05), and on discontinuation day 2 than treatment day 1 (t=3.294, p<0.05). This 
shows no treatment or discontinuation effects o f immediate recall in the. mornings. 
There were no impairments o f  loprazolam, zopiclone and zolpidem compared to 
placebo. Graph 5.2 shows these effects.
Simple main effects also showed an effect o f Test at baseline (F(l,13)=8.187, 
p<0.05). Inspection o f the means showed there were more words remembered correctly 
on test point 1 (evening) than test point 2 (morning) on the baseline day. There was an 
effect o f Test on treatment day 1 (F(l,13)=23.273, p<0.001), where the means show 
there were more words remembered correctly on test point 1 (evening) than test point 2 
(morning) on day 2. Lastly, there was an effect o f Test on treatment day 3 
(F(l,13)=6.790, p<0.05), where the means indicate there were again more words 
remembered correctly on test point 1 (evening) than test point 2 (morning).
5.5.2.7 Delayed Word Recall
There were 14 participants analysed for this variable. A three-way ANOVA with
epsilon correction showed an effect o f  Test (F(l,13)=18.569, p<0.01), Drug by Test
(F(2.19,28.47)=3.423, p<0.05), and Day by Test (F(3.55,46.15)=l 1.001, p<0.01). The
effect o f  Test was examined using Tukey’ s (HSD) test, and results showed the mean
number o f  correctly recalled words was higher during test points 1 (evening) than test
points 2 (morning) (p<0.01).
The Drug by Test effect was broken down by the use o f  simple main effects.
This foimd a significant difference between drugs at test point 2 (morning)
(F(3,39)=3.917, p<0.05). T-tests revealed at test point 2 (morning), participants on
zolpidem scored higher than those on loprazolam (t=2.164, p<0.05), and participants on
placebo also scored higher than those on loprazolam (t=2.400, p<0.05). A  significance
was also found using simple main effect o f  test point on loprazolam (F(l,13)=6.626,
p<0.05), zolpidem (F(l,13)=5.789, p<0.05), and zopiclone (F(l, 13)=11.010, p<0.01).
Inspection o f  the means showed on loprazolam, zolpidem, and zopiclone, more words
were remembered correctly at test point 1 (evening) compared to test point 2 (morning).
Therefore, there were no significant differences between zopiclone or zolpidem and
placebo, but delayed word recall was worse under loprazolam compared to placebo, but
only in the mornings. Graph 5.3 shows these effects.
The Day by Test effect was also elucidated using simple main effects. This
showed there was an effect o f  day at test point 2 (morning) (F(5,65)=8.583, p<0.001),
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and t-tests showed there were more correctly remembered words on treatment day 2 
than baseline (t=2.302, p<0.05), on treatment day 2 than treatment day 1 (t=2.521, 
p<0.05), on discontinuation day 1 than baseline (t=4.753, p<0.05), on discontinuation 
day 1 than treatment day 1 (t=6.019, p<0.05), on discontinuation day 1 than treatment 
day 2 (t=3.462, p<0.05), on discontinuation day 1 than treatment day 3 (t=5.508, 
p<0.05), on discontinuation day 1 than discontinuation day 2 (t=4.155, p<0.05), on 
discontinuation day 2 than baseline (t=3.607, p<0.05), on discontinuation day 2 than 
treatment day 1 (t=3.414, p<0.05), and on discontinuation day 2 than treatment day 3 
(t=2.516, p<0.05). Therefore more words are correctly remembered on the 
discontinuations days and mid-treatments compared to initial treatments. This may 
reflect a practice effect.
An effect was also shown here o f  Test at baseline (F(l,13)=27.268, pO.OOl), 
treatment day 1 (F(l,13)=24.716, pO.OOl), treatment day 3 (F(l,13)=8.716, pO.05), 
and discontinuation day 1 (F(1.13)=14.736, pO.Ol), where means show the scores for 
test point 1 (evening) are all higher than the scores for test point 2 (morning). 
Participants therefore performed better in the evenings than the mornings.
5.5.2.8 Disit-Svmbol Substitution Task
There were 15 participants included in this analysis. A  three-way ANOVA with 
epsilon correction revealed a significant effect o f Day (F(2.85,39.9)=4.846, pO.Ol), 
and a significant effect o f  Test (F(l, 14)= 39.741, pO.Ol). Analysis o f  the factor o f  Day 
using Tukey’ s (HSD) test showed there were significantly more correct responses on 
discontinuation day 1 compared to baseline (p<0.01), on discontinuation day 1 
compared to treatment day 1 (p<0.05), and on discontinuation day 2 compared to 
baseline (p<0.01). This may again be indicative o f practice effects, or a lack o f 
withdrawal effects measured by DSST. There were no significant differences between 
loprazolam, zopiclone, zolpidem or placebo. Graph 5.4 shows these effects.
The significant factor o f Test (pO.Ol) needed only an inspection o f means, 
which revealed there were more correct responses during test points 1 (evening) than 
test points 2 (morning). DSST performance was therefore worse in the morning than the 
evening.
Chapter 5
198
5 .5 .2 .9  L in e  A n a lo g u e  R a t in g s  S c a le  fo r  A n x ie ty  (L A R S )
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There were 15 participants in this analysis, and a three-way ANOVA with 
epsilon correction revealed no significant effects. There was no significant difference 
between test medications and placebo.
5 .5 .2 .1 0  L in e  A n a lo s u e  R a t in g s  S c a le  f o r  D e p r e s s io n  (L A R S )
There were 15 participants included in this analysis, and a three-way ANOVA 
with epsilon correction revealed a significant effect o f  Drug (F(2.43,34.02)=4.512, 
p<0.05). Post-hoc analysis by Tukey’ s (HSD) test showed the measure o f  depression 
was higher on zolpidem (p<0.05) and placebo (p<0.05) than on loprazolam. This means 
loprazolam significantly reduced the LARS measure o f  depression compared to 
placebo.
5 .5 .2 .1 1  L in e  A n a lo s u e  R a t in s s  S c a le  f o r  S e d a tio n  (L A R S )
There were 15 participants in this three-way ANOVA with epsilon correction. 
There was a significant effect o f  Drug (F(2.7, 37.8)=3.691, p<0.05). Post-hoc analysis 
by Tukey’s (HSD) test showed there was an increased measure o f  sedation on zolpidem 
compared to loprazolam (p<0.05). Zolpidem therefore may be more subjectively 
sedating than loprazolam, but there were no significant differences between loprazolam, 
zopiclone, zolpidem and placebo.
5 .5 .2 .1 2  L in e  A n a lo s u e  R a t in s s  S c a le  fo r  U n c o o r d in a t io n  (L A R S )
There were 15 participants in this analysis, and a three-way ANOVA with 
epsilon correction revealed no significant effects. There was no significant difference 
between test medications and placebo.
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Critical Flicker Fusion (CFF)
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Graph 5.1: Showing CFF under all test medications. Tl, T2 and T3 are treatment days 1. 2. and 3. and D1 
and D2 are discontinuation days 1 and 2. It can be seen that the threshold of loprazolam was significantly 
lower than that of zolpidem indicating increased sedation, but only on the first treatment night. Sedative 
discontinuation effects can be seen on Dl. where the CFF threshold for loprazolam is lower than that of 
zopiclone. indicating increased sedation under loprazolam. Error bars denote one standard deviation. * 
indicates significant difference at the 5 %  level, and ** denotes significant difference at the 1% level.
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Graph 5.2: Showing Immediate Word Recall under all test medications. Tl. T2 and T3 are treatment days
1. 2. and 3. and Dl and D2 are discontinuation days 1 and 2. It can be seen that there is significant 
difference between the words correctly remembered in the morning compared to the evening, and 
performance is worse in the mornings. Error bars denote one standard deviation. There was no significant 
interaction between drug and day.
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Graph 5.3: Showing Delayed Word Recall under all test medications. Tl. T2 and T3 are treatment days 1. 
2. and 3. and Dl and D2 are discontinuation days 1 and 2. It can be seen that recall is again worse in the 
mornings compared to the evenings. Initial discontinuation effects are shown under loprazolam. Error 
bars denote one standard deviation. There was no significant interaction between drug and day.
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Digit Symbol Substitution Task (DSST)
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Graph 5.4: Showing DSST under all test medications. Tl. T2 and T3 are treatment days 1. 2. and 3. and 
PI and D2 are discontinuation days 1 and 2. Again it can be seen that performance is worse in the 
mornings than the evenings for all treatments. Error bars denote one standard deviation. There was no 
significant interaction between drug and day.
LSEQ - Getting to Sleep
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Graph 5.5: Showing LSEQ ‘getting to sleep’ under all test medications. An increase in score indicates 
getting to sleep is harder. TL T2 and T3 are treatment days 1. 2. and 3. and D1 and D2 are 
discontinuation days 1 and 2. It can be seen that, on average, getting to sleep was harder on the 
discontinuation days than during the treatment days. Error bars denote one standard deviation. There was 
no significant interaction between drug and day.
LSEQ - Quality of Sleep
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Graph 5.6: Showing LSEQ ‘quality of sleep’ under all test medications. An increase in score indicates a 
poorer quality of sleep. TL T2 and T3 are treatment days 1. 2. and 3. and D1 and D2 are discontinuation 
days 1 and 2. It can be seen that patterns are similar to 'getting to sleep’. On average, the quality of sleep 
was worse on the first discontinuation day than during the initial treatment day, for all treatments 
including placebo. Error bars denote one standard deviation. There was no significant interaction between 
drug and day.
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5.5.2.13 Spielberser Anxiety Inventory (STAI)
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There were 15 participants in this analysis. A  three-way ANOVA with epsilon 
correction revealed a significant effect o f  Test (F(l,14)=8.605, p<0.05). Tukey’ s (HSD) 
test showed there was significantly more anxiety under test point 2 (morning) than test 
point 1 (evening) (pO.Ol). There was no significant difference between days or drugs. 
Therefore, a higher score o f anxiety was found during the morning test compared to the 
evening test. There was no significant difference between test medications and placebo.
5.5.2.14 Leeds Sleep Evaluation Questionnaire -  Gettim to Sleep (LSEQ)
There were 15 participants included in this analysis. A  two-way ANOVA with 
epsilon correction showed a significant effect o f  Day (F(3.15, 44.1)=18.676, p<0.01). 
Tukey’s (HSD) test showed getting to sleep was more difficult on the discontinuation 
days than baseline (p<0.01), treatment day 1 (pO.Ol), treatment day 2 (pO.Ol), and 
treatment day 3 (p<0.01). The LSEQ shows getting to sleep was reported as more 
difficult on the discontinuation days than the other days. This indicates withdrawal 
effects, but there was no significant difference loprazolam, zopiclone, zolpidem or 
placebo. Graph 5.5 shows these effects.
5.5.2.15 Leeds Sleep Evaluation Questionnaire -  Quality o f Sleep (LSEQ)
There were 14 participants in this two-way ANOVA test, which showed a 
significant effect o f  Day (F(3.05,39.65)=4.505, p<0.01). Tukey’s (HSD) test showed 
quality o f sleep was worse on the discontinuation day 5 compared to baseline (p<0.05), 
and treatment day 1 (p<0.05). This indicates withdrawal effects, but there was no 
significant difference loprazolam, zopiclone, zolpidem or placebo. Graph 5.6 shows 
these effects.
5.5.2.16 Leeds Sleep Evaluation Questionnaire -  Alertness Followins Sleep (LSEQ)
There were 15 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
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5 .5 .2 .1 7  L e e d s  S le e p  E v a lu a t io n  Q u e s t io n n a ir e  - B e h a v io u r  F o l l o w i n g  A w a k e n in g  
( L S E Q )
There were 15 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5 .5 .2 .1 8  M i l f o r d -E v w o r t h  S le e p in e s s  S c a le  f M E S S )
There were 15 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5.5.3 Sleep Variable Analyses
5 .5 .3 .1  S le e p  L a te n c y  (S L )
There were 10 participants included in this analysis. A  two-way repeated
measures ANOVA with epsilon correction showed a significant effect o f  Drug
(F(2.34,23.4)=6.091, p<0.01), Day (F(1.65,16.5)=9.960, p<0.01) and Drug by Day
interaction (F(3.3,33)=3.901, p<0.05). Post-hoc analysis o f the Drug effect using
Tukey’s (HSD) test revealed the mean sleep latency on placebo was significantly longer
than that o f  zolpidem (p<0.01). Zolpidem significantly reduced sleep latency compared
to placebo, but there were no differences between loprazolam and zopiclone and
placebo. Graph 5.7 shows these effects.
The effect o f Day under Tukey’s (HSD) test showed sleep latency was
significantly longer on discontinuation day 2 than baseline (p<0.01), treatment day 1
(p<0.01), treatment day 2 (p<0.01) and treatment day 3 (p<0.01). Also, the sleep latency
on day discontinuation day 1 was significantly longer than at baseline (p<0.05) and
treatment day 1 (p<0.05). This indicates withdrawal effects.
Simple main effects were used to investigate the Drug by Day interaction. A
significant difference was found between drugs at baseline (F(3,30)=3.640, p<0.05).
This is unexpected, as all drugs are placebo on the baseline day. Simple main effects
showed a difference between drugs on treatment day 1 (F(3,30)=10.082, p<0.001). T-
test showed again that placebo was associated with a longer sleep latency than
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loprazolam (t=3.417, p<0.05), zolpidem (t=3.163, pO.05), and zopiclone (t=3.613, 
p<0.05). The same pattern was also shown by an effect o f  drugs on treatment day 3 
(F(3,30)=6.448, pO .O l), as again placebo was associated with a longer sleep latency 
than loprazolam (t=2.731, pO.05), zolpidem (t=2.536, p<0.05), and zopiclone (t=2.516, 
pO.05). This shows loprazolam, zopiclone and zolpidem reduce sleep latency on the 
first and third days o f  administration, compared to placebo. However, on 
discontinuation day 1, a significance o f effect (F(3,30)=3.829, p<0.05) was found, but a 
different pattern o f  t-test results. Here, on discontinuation day 1, zopiclone was 
associated with a longer sleep latency than loprazolam (t=3.595, pO.05) and placebo 
(t=2.659, p<0.05). There was also a significant main effect o f  Drug collapsed on 
discontinuation day 2 (F(3,30)=3.234, p<0.05), but t-tests showed no significant effects. 
This shows zopiclone has a significant withdrawal effect o f  increased sleep latency 
compared to placebo, and so zopiclone may lead to rebound insomnia on withdrawal. 
There were no sleep latency withdrawal effects o f loprazolam or zolpidem compared to 
placebo.
There was a significant effect o f  Day on loprazolam (F(5,50)=6.940, pO.OOl), 
and t-tests showed that whilst on loprazolam, there was a longer sleep latency during 
discontinuation day 1 than treatment day 1 (t=4.370, pO .05) and treatment day 3 
(t=4.568, pO.05). Also, discontinuation day 2 showed a longer sleep latency than 
baseline (t=2.509, pO.05), treatment day 1 (3.374, pO.05), treatment day 2 (t=2.600, 
pO.05), and treatment day 3 (t=3.312, pO.05). On zolpidem, there was also a 
significant effect o f  Day (F(5,50)=7.314, pO.OOl). T-tests showed discontinuation day 
1 showed a longer sleep latency than baseline (t=2.351, pO.05), treatment day 1 
(t=2.869, pO.05), treatment day 2 (t=2.694, pO.05), and treatment day 3 (t=2.760, 
pO.05). Also, discontinuation day 2 also showed a longer sleep latency than baseline 
(t=3.663, pO.05), treatment day 1 (t=3.188, pO.05), treatment day 2 (t=3.065, pO.05), 
and treatment day 3 (t=4.048, pO.05). Lastly, there was also an effect o f  Day on 
zopiclone (F(5,50)=13.169, pO.OOl), which followed the same pattern as zolpidem. 
Discontinuation day 1 showed a longer sleep latency than baseline (t=4.305, pO.05), 
treatment day 1 (t=5.199, pO.05), treatment day 2 (t=3.564, pO.05), and treatment day 
3 (t=4.508, pO.05). Also, discontinuation day 2 showed a longer sleep latency than 
baseline (t=4.242, pO.05), treatment day 1 (t=4.341, pO.05), treatment day 2 (t=3.933, 
pO.05), and treatment day 3 (t=3.492, pO.05). This shows there are withdrawal effects 
o f  a longer sleep latency after taking all three test medications.
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5 .5 .3 .2  T o t a lS l e e v  T im e  (T S T )
There were 10 participants included in this analysis. A two-way ANOVA with 
epsilon correction showed a significant effect o f Day (F(2.6,23.4)=5.203, p<0.01). 
Tukey’s (HSD) test showed mean total sleep time (TST) was longer at baseline than 
discontinuation day 2 (p<0.05). Mean TST was increased on treatment day 1 compared 
to discontinuation day 1 (p<0.05) and discontinuation day 2 (p<0.01), and mean TST 
was longer on treatment day 2 compared to discontinuation day 2 (p<0.05). These 
findings are indicative o f  withdrawal effects. There was no significant difference 
between loprazolam, zopiclone, zolpidem or placebo.
5 .5 .3 .3  S le e p  E f f ic ie n c y  (S E )
There were 10 participants included in this two-way ANOVA with epsilon 
correction. Results showed only a significant effect o f Day (F(2.6,23.4)=5.107, p<0.05). 
Tukey’ s (HSD) post-hoc tests showed mean sleep efficiency was higher at baseline than 
on discontinuation day 2 (p<0.05), higher on treatment day 1 than discontinuation day 1 
(p<0.05) and discontinuation day 2 (p<0.01), and higher on treatment day 2 than 
discontinuation day 2 (p<0.05). This again indicates withdrawal effects. There was no 
significant difference between loprazolam, zopiclone, zolpidem or placebo.
5 .5 .3 .4  A w a k e n in g s  L a s t in g  L e s s  T h a n  O n e  M in u t e
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5 .5 .3 .5  A w a k e n in g s  L a s t in s  M o r e  T h a n  O n e  M in u t e
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
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5 .5 .3 .6  A m o u n t  o f  W ak e T im e
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo,
5 .5 .3 .7  A m o u n t  o f  S ta g e  1 T im e
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5 .5 .3 .8  A m o u n t  o f  S ta g e  2  T im e
There were 10 participants analysed for this variable. A  two-way ANOVA with 
epsilon correction revealed significant main effects o f  Drug (F(2.19,19.71)=T0.709, 
p<0.01), Day (F(3.4,30.6)=8.284, p<0.01) and an interaction o f  Drug by Day (F(5.4, 
48.6)=3.024, p<0.05).
The effect o f  Drug was analysed by Tukey’ s (HSD) test, showing stage 2 time 
was longer in duration on loprazolam compared to zolpidem (p<0.01) and placebo 
(p<0.01), and zopiclone showed longer stage 2 time than placebo (p<0.05). This shows 
there was an increase in stage 2 sleep time under loprazolam than zolpidem. Also, there 
was significantly longer stage 2 time under loprazolam and zopiclone compared to 
placebo, but not zolpidem compared to placebo. Graph 5.8 shows these effects.
The effect o f  Day (Drug collapsed) was also analysed by Tukey’s, and showed 
stage 2 time was longer at baseline compared to discontinuation day 2 (p<0.01), longer 
on treatment day 1 than discontinuation day 1 (p<0.01) and discontinuation day 2 
(p<0.01), longer on treatment day 2 than discontinuation day 1 (p<0.05) and 
discontinuation day 2 (p<0.01), and longer on treatment day 3 than discontinuation day 
2 (p<0.05).
The interaction o f  Drug by Day was investigated using simple main effects. This
showed there was an effect o f  Drug on day 1 (F(3,27)=3.665, p<0.05), despite all drugs
being placebo on this day. T-tests showed this effect was longer mean stage 2 time with
the group o f  participants about to take loprazolam compared to the group o f  participants
about to take placebo (t=3.285, p<0.05). There was also an effect o f  Drug on treatment
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day 1 (F(3,27)=8.489, pO.OOl), where t-tests showed stage 2 time was longer for 
loprazolam than zolpidem (t=2.987, pO .05) and placebo (t=3.571, p<0.05), and longer 
for zopiclone than zolpidem (t=3.584, p<0.05) and placebo (t=3.995, p<0.05). This 
means that on the first treatment day, stage 2 sleep time was increased under loprazolam 
compared to placebo, and increased under zopiclone compared to placebo. There was no 
significant difference between zolpidem and placebo. There was a significant effect o f 
Drug on treatment day 2 (F(3,27)=5.791, p<0.01), where loprazolam, zolpidem and 
zopiclone all had longer mean stage 2 times than placebo (t=3.572, p<0.05; t=2.938, 
p<0.05; and t=2.601, p<0.05 respectively). All three treatments lengthened stage 2 sleep 
on the second dose. Lastly, there was also a significant effect o f Drug on treatment day 
3 (F(3,27)=7.733, p<0.01), and t-tests revealed stage 2 time was longer on loprazolam 
than zolpidem (t=4.066, p<0.05), zopiclone (t=2.372, p<0.05), and placebo (t=3.305, 
p<0.05), and also longer on zopiclone than zolpidem (t=3.744, p<0.05) and placebo 
(t=2.529, p<0.05). As treatment day 1, loprazolam and zopiclone produced significantly 
longer stage 2 sleep time than placebo. There was no significant difference between 
zolpidem and placebo.
Simple main effects also showed an effect o f  Day on loprazolam 
(F(5,45)=7.629, pO.OOl). T-test show that on baseline, treatment day 1, treatment day 2 
and treatment day 3, stage 2 time was longer than on discontinuation days (baseline vs. 
discontinuation day 1, t=2.302, p<0.05; baseline vs. discontinuation day 2, t=3.868, 
p<0.05; treatment day 1 vs. discontinuation day 1, t=2.665, p<0.05; treatment day 1 vs. 
discontinuation day 2, t=4.774, p<0.05; treatment day 2 vs. discontinuation day 1, 
t=2.922, p<0.05; treatment day 2 vs. discontinuation day 2, t=4.479, p<0.05; treatment 
day 3 vs. discontinuation day 1, t=3.078, p<0.05; and treatment day 3 vs. 
discontinuation day 2, t=4.778, p<0.05). The same pattern is found with the simple main 
effect o f  Day on zopiclone (F(5,45)=10.748, pO.OOl). While on zopiclone, t-tests show 
that on baseline, treatment day 1, treatment day 2 and treatment day 3, stage 2 time is 
longer than on discontinuation days (baseline vs. discontinuation day 1, t=2.630, 
p<0.05; baseline vs. discontinuation day 2, t=3.147, p<0.05; treatment day 1 vs. 
discontinuation day 1, t=4.586, p<0.05; treatment day 1 vs. discontinuation day 2, 
t=5.295, p<0.05; treatment day 2 vs. discontinuation day 1, t=3.728, p<0.05; treatment 
day 2 vs. discontinuation day 2, t=3.898, p<0.05; treatment day 3 vs. discontinuation 
day 1, t=4.418, p<0.05; and treatment day 3 vs. discontinuation day 2, t=4.206, p<0.05). 
This shows withdrawal effects under loprazolam and zopiclone with respect to amount
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o f stage 2 time, where stage 2 time is reduced on discontinuation. There were no 
significant withdrawal effects o f  zolpidem.
5.5.3.9 Amount o f Stage 3 Time
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5.5.3.10 Amount o f Stage 4 Time
There were 10 participants included in this analysis, and a two-way ANOVA 
with epsilon correction showed only a significant effect o f  Day (F(3,27)=3.483, 
p<0.05). Tukey’ s (HSD) test revealed stage 4 time was significantly longer at baseline 
than discontinuation day 1 (p<0.01) and discontinuation day 2 (p<0.05). There was no 
significant difference between loprazolam, zopiclone, zolpidem and placebo.
5.5.3.11 Amount o f SWS Time
The data o f  10 participants was analysed for this variable. A  two-way ANOVA 
with epsilon correction revealed only one significant effect o f  Drug 
(F(1.77,17.7)=4.093, p<0.05). Tukey’ s (HSD) test showed a longer SWS time on 
zolpidem (p<0.05) and placebo (p<0.05) than on loprazolam. Therefore loprazolam 
significantly reduced SWS time compared to placebo, but there were no significant 
effects o f  zopiclone and zolpidem compared to placebo. Graph 5.9 shows these patterns.
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Sleep Latency
■  Placebo
□  Zolpidem
■  Zopiclone
□  Loprazolam
Baseline
Graph 5.7: Showing sleep latency (SL) under all test medications. Tl. T2 and T3 are treatment days 1. 2. 
and 3. and D1 and D2 are discontinuation days 1 and 2. It can be seen that all three active drugs have a 
shorter SL than placebo, although these differences are also seen at baseline. The SL of zolpidem returns 
to placebo level upon discontinuation, but SL is worse for zopiclone and loprazolam upon 
discontinuation, compared to placebo. Error bars denote one standard deviation. * indicates significant 
difference at the 5 %  level, and ** denotes significant difference at the 1% level.
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Graph 5.8: Showing the amount of stage 2 sleep under each test medication. TL T2 and T3 are treatment 
days 1. 2. and 3. and D1 and D2 are discontinuation days 1 and 2. There is more stage 2 sleep than 
placebo during treatment with loprazolam and zopiclone. but the amount under zolpidem is not 
statistically significant. These amounts reduced on discontinuation. Error bars denote one standard 
deviation. * indicates significant difference at the 5 %  level, and ** denotes significant difference at the 
1% level.
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Graph 5.9: Showing the amount of SWS under each test medication. TL T2 and T3 are treatment days 1.
2. and 3. and D1 and D2 are discontinuation days 1 and 2. There is a reduction in SWS under loprazolam 
and zopiclone compared to placebo, and the largest reduction is seen under loprazolam. Error bars denote 
one standard deviation. There was no significant interaction between drug and day.
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Amount of REM Sleep
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Graph 5.10: Showing the amount of REM sleep under each test medication. Tl. T2 and T3 are treatment 
days 1. 2. and 3. and D1 and D2 are discontinuation days 1 and 2. There is no clear effect of test 
medication on the amount of REM sleep. Error bars denote one standard deviation. There was no 
significant interaction between drug and day.
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Graph 5.11: Showing latency to SWS under each test medication. Tl. T2 and T3 are treatment days 1. 2. 
and 3. and D1 and D2 are discontinuation days 1 and 2. Loprazolam. zopiclone and zolpidem all have a 
reduced latency to SWS during treatment phase, until discontinuation starts. SWS latency under zolpidem 
returns to placebo levels during discontinuation, and SWS latency is longer under loprazolam and 
zopiclone compared to placebo during discontinuation. Error bars denote one standard deviation. * 
indicates significant difference at the 5 %  level, and ** denotes significant difference at the 1% level.
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Graph 5.12: Showing latency to REM sleep under each test medication. Tl. T2 and T3 are treatment days 
1. 2. and 3. and D1 and D2 are discontinuation days 1 and 2. Loprazolam and zopiclone. but not 
zolpidem. showed a longer latency to REM than placebo, until discontinuation when latency returned to 
placebo levels. Error bars denote one standard deviation. * indicates significant difference at the 5 %  
level, and ** denotes significant difference at the 1% level.
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5.5.3.12 Amount o f  REM Time
There were 10 participants included in this analysis. A  two-way ANOVA with 
epsilon correction revealed only a significant effect o f Day (F(3.45,31.05)=4.634, 
p<0.01). Tukey’ s (HSD) tests showed REM time was less on baseline than 
discontinuation day 1 (pO .Ol) and discontinuation day 2 (pO.05), and less on 
treatment day 3 than discontinuation day 1 (p<0.05). There were no significant 
differences between loprazolam, zopiclone, zolpidem and placebo. Graph 5.10 shows 
these patterns.
5.5.3.13 Latency to SWS
There were 10 participants included in this analysis. A two-way ANOVA with 
epsilon correction revealed significant effects o f  Drug (F(2.34,23.4)=6.400, p<0.01), 
Day (F(1.95,19.5)=9.767, p<0.01), and Drug by Day (F(3,30)=4.391, p<0.05). The 
significant effect o f Drug was investigated by Tukey’s (HSD) test, and showed mean 
SWS latency was significantly longer on placebo than zolpidem (p<0.01) and zopiclone 
(p<0.05). Therefore zolpidem and zopiclone significantly reduced latency to SWS 
compared to placebo, but loprazolam did not. Graph 5.11 shows these effects.
The effect o f  Day was also analysed post-hoc by Tukey’ s, and revealed mean 
SWS latency was significantly longer on discontinuation day 1 compared to baseline 
(p<0.05), treatment day 1 (p<0.05) and treatment day 2 (p<0.05). Also, latency was 
longer on discontinuation day 2 than baseline (p<0.01), treatment day 1 (p<0.01), 
treatment day 2 (p<0.01) and treatment day 3 (p<0.01). This shows a withdrawal effect 
o f  a lengthening o f  the latency to SWS.
Simple main effects testing examined the interaction between Drug and Day.
There was a significant effect o f  Drug at baseline (F(3,30)=7.075, p<0.01), and t-tests
showed that mean SWS latency was longer for participants about to take zolpidem than
zopiclone (t=2.636, p<0.05), and longer for participants about to take placebo than
loprazolam (t=2.794, p<0.05), zolpidem (t=3.246, p<0.05) and zopiclone (t=3.779,
p<0.05). This is again unexpected as all drugs at baseline were placebo. Simple main
effects also showed an effect o f  Drug on treatment day 1 (F(3,30)=9.286, pO.OOl), and
t-tests revealed that on treatment day 1, the SWS latency was longer on placebo than on
loprazolam (t=4.267, pO .05), zolpidem (t=3.308, pO.05), and zopiclone (t=3.498,
p<0.05). Acute doses o f  all the active medication reduce latency to SWS compared to
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placebo. There was also an effect o f  Drug on treatment day 3 (F(3,30)=4.254, p<0.05), 
but t-tests revealed no significant effects. Drug collapsed on discontinuation day 1 was 
also significant (F(3,30)=5.409, p<0.01), with t-tests showing mean SWS latency was 
longer on loprazolam than placebo (t=2.391, pO.05), and longer on zopiclone than 
loprazolam (t=2.625, pO.05), zolpidem (t=2.509, pO.05), and placebo (t=3.304, 
p<0.05). Therefore the withdrawal effect o f  an increase in SWS was significantly 
different to placebo for loprazolam and zopiclone, but not zolpidem. The effect o f  Drug 
on discontinuation day 2 was also significant (F(3,30)=4.078, p<0.05), and t-tests 
showed loprazolam was associated with a longer mean SWS latency than zolpidem 
(t=2.426, p<0.05) and placebo (t=2.433, p<0.05). This shows that there are no SWS 
latency withdrawal effects o f zopiclone by the second discontinuation night, but the 
withdrawal effects o f  loprazolam are still present.
Simple main effects also showed a significant effect o f  Day on loprazolam 
(F(5,50)=8.950, pO.OOl). T-tests show mean SWS latency was longer on treatment day 
2 than treatment day 1 (t=2.421, pO.05), longer on discontinuation day 1 than treatment 
day 1 (+=5.716, pO .05) and treatment day 3 (t=4.587, pO.05), and longer on 
discontinuation day 2 than baseline (+=2.722, pO.05), treatment day 1 (t=3.961, 
pO.05), treatment day 2 (t=2.751, pO.05), and treatment day 3 (t=3.769, pO.05). This 
again shows withdrawal effects o f  loprazolam, with respect to SWS latency. There was 
also a significant effect o f Day on zopiclone (F(5,50)=12.312, pO.OOl). T-tests show 
that with zopiclone, there is a significantly shorter mean SWS latency at baseline than 
on treatment day 2 (t=2.950, pO.05), treatment day 3 (+=2.264, pO.05), 
discontinuation day 1 (t=4.773, pO.05), and discontinuation day 2 (+=4.447, pO.05). 
Also, the discontinuation days have significantly longer SWS latency than the treatment 
days (treatment day 1 vs. discontinuation day 1, t=5.631, pO .05; treatment day 1 vs. 
discontinuation day 2, t=3.942, pO .05; treatment day 2 vs. discontinuation day 1, 
+=3.281, pO .05; treatment day 2 vs. discontinuation day 2, +=3.360, pO .05; treatment 
day 3 vs. discontinuation day 1, t=4.800, p<0.05; and treatment day 3 vs. 
discontinuation day 2, +=3.084, p<0.05). This shows the withdrawal effects o f  
zopiclone. Lastly, there was also a significant effect o f  Day on zolpidem 
(F(5,50)=10.433, pO.OOl), and t-tests showed mean SWS latency is longer on the 
discontinuation days compared to baseline and treatment days (baseline vs. 
discontinuation day 1, t=3.663, pO .05; baseline vs. discontinuation day 2, t=4.427, 
pO .05; treatment day 1 vs. discontinuation day 1, t=4.061, pO .05; treatment day 1 vs.
discontinuation day 2, +=3.591, pO .05; treatment day 2 vs. discontinuation day 1,
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t=2.901, p<0.05; treatment day 2 vs. discontinuation day 2, t=3.927, p<0.05; treatment 
day 3 vs. discontinuation day 1, +=3.509, p<0.05; treatment day 3 vs. discontinuation 
day 2, t=4.522, p<0.05). This shows some withdrawal effects o f  zolpidem with respect 
to SWS latency.
5.5.3.14 Percentage o f  SWS in the First Period o f  the Night
There were 10 participants analysed for this variable. A two-way ANOVA with 
epsilon correction revealed effects o f  Day (F(3.1,27.9)=4.789, p<0.01) and Drug by Day 
(F(5.85,52.65)=2.676, p<0.05). Tukey’ s (HSD) test was used to analyse the Day effect, 
and showed the percentage o f  SWS in period 1 was higher at baseline than on 
discontinuation day 1 (pO .Ol) and discontinuation day 2 (p<0.05). This shows the 
amount o f  SWS in the first period o f  the night is affected by withdrawal o f  medication, 
which agrees with the findings on SWS latency above. There was no significant effect 
o f  Drug, indicating no significant differences between loprazolam, zopiclone and 
zolpidem and placebo.
The Drug by Day interaction was analysed by simple main effect, and showed 
an effect o f Drug on treatment day 3 (F(3,27)=3.725, p<0.05). T-tests showed the 
percentage o f  SWS in period 1 was greater on zolpidem than placebo (t=2.761, p<0.05). 
Therefore, on the third treatment night, zolpidem significantly increased SWS in the 
first period o f the night compared to placebo. There was also an effect o f  Drug on 
discontinuation day 1 (F(3,27)=3.264, p<0.05), where t-tests revealed the percentage o f  
SWS in period 1 was greater for placebo then for loprazolam (t=3.011, p<0.05). On the 
first discontinuation night, loprazolam significantly reduced SWS in the first period o f 
the night compared to placebo. Lastly, simple main effects showed there was a 
difference between days on zolpidem (F(5,45)=6.551, pO.OOl). T-tests revealed there 
was a lesser percentage o f  SWS in period 1 for discontinuation day 1 compared to 
baseline (t=3.144, pO.05), treatment day 1 (t=2.314, pO.05), and treatment day 3 
(t=3.854, p<0.05), and a lesser percentage o f  SWS in period 1 for discontinuation day 2 
compared to baseline (t=3.684, pO.05), treatment day 1 (t=2.674, pO.05), treatment 
day 2 (t=2.661, pO.05), and treatment day 3 (t=4.612, pO.05). This means 
discontinuation o f  zolpidem resulted in reduced SWS in the first period o f the night.
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5.5.3.15 Percentage o f  SWS in the Second Period o f the Night
Chapter 5
There were 10 participants included in this analysis. A  two-way ANOVA with 
epsilon correction showed a significant effect o f  Drug (F(2.1,18.9)=5.612, p<0.05), and 
Day (F(3.2,28.8)=3.429, p<0.05), but no interaction. The effect o f  Drug was analysed 
using Tukey’ s (HSD) test, and showed there was more percentage SWS in period 2 
under placebo than loprazolam (p<0.01) and zopiclone (p<0.05). This shows loprazolam 
and zopiclone reduce the amount o f  SWS in the middle o f  the night compared to 
placebo, but zolpidem did not. Tukey’ s was also used to analyse the Day effect, and 
showed there was more percentage SWS in period 2 on discontinuation day 2 than 
baseline (p<0.05) and treatment day 1 (p<0.05).
5.5.3.16 Percentage o f  SWS in the Third Period o f  the Night
The data o f  10 participants was included in this analysis. A two-way ANOVA 
with epsilon correction showed only a significant effect o f  Day (F(3.05,27.45)=2.984, 
p<0.05). Tukey’s (HSD) test revealed a smaller percentage o f  SWS in period 3 on 
treatment day 2 than baseline (p<0.05) and discontinuation day 1 (p<0.05). There was 
no significant difference between test medications and placebo.
5.5.3.17 Latency to REM Sleep
There were 10 participants used in this analysis. A two-way ANOVA with 
epsilon correction showed significant effects o f  Drug (F(2.07,20.7)=18.102, p<0.01), 
Day (F(2.75,27.5)=l 1.632, p<0.01) and Drug by Day interaction (F(5.55,55.5)=3.456,
p<0.01).
The effect o f  Drug was analysed by Tukey’s (HSD) test, finding REM latency 
was longer on loprazolam compared to zolpidem (p<0.01) and placebo (p<0.01), and 
longer for zopiclone compared to zolpidem (p<0.05) and placebo (p<0.01). This means 
REM latency was extended by loprazolam and zopiclone compared to placebo, but was 
not extended by zolpidem. Graph 5.12 shows these effects.
The main effect o f  Day was again analysed by Tukey’s, showing REM latency 
was shorter for discontinuation day 1 compared to baseline (p<0.01), treatment day 2 
(p<0.05), and treatment day 3 (p<0,01), and shorter for discontinuation day 2 compared
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to baseline (p<0.01), treatment day 1 (p<0.01), treatment day 2 (p<0.01), and treatment 
day 3 (p<0.01). This shows a reduction in REM latency is a withdrawal effect.
The interaction o f  Drug by Day was analysed using simple main effects. These 
revealed a significant difference between drugs at baseline (F(3,30)=8.577, pO.OOl), 
despite all the drugs at baseline were placebo. T-tests revealed mean REM latency was 
longer for participants about to take loprazolam than those about to take zolpidem 
(t=5.579, pO.05) and placebo (t=4.408, pO.05), and longer for participants about to 
take zopiclone than placebo (t=3.134, pO.05). There was also a significant effect o f 
Drug on treatment day 1 (F(3,30)=14.591, pO.OOl), and t-tests showed mean REM 
latency was longer under loprazolam than zolpidem (t=5.073, pO.05), zopiclone 
(+=2.415, pO.05), and placebo (t=5.731, pO.05), and longer on zopiclone than 
zolpidem (+=2.765, pO .05) and placebo (+=2.469, pO.05). Therefore, an acute dose o f 
loprazolam and zopiclone significantly lengthened REM latency compared to placebo, 
but zolpidem did not. There was also a significant effect o f  Drug on treatment day 3 
(F(3,30)=9.771, pO.OOl), and t-test showed that mean REM latency was shorter under 
placebo than all the other drugs (loprazolam vs. placebo, +=5.100, p<0.05; zolpidem vs. 
placebo, +=2.721, p<0.05; zopiclone vs. placebo, t=5.109, p<0.05). This shows that all 
three hypnotics lengthened REM latency by the third night o f  administration.
Simple main effects also revealed a significant difference between Day on 
loprazolam (F(5,50)=9.896, pO.OOl). T-tests showed mean REM latency was shorter 
on treatment day 2 than baseline (+=2.953, pO.05) and treatment day 1 (+=3.240, 
pO.05), shorter on discontinuation day 1 than baseline (t=4.398, pO.05), treatment day 
1 (t=3.683, pO.05), and treatment day 3 (+=2.538, pO.05), and shorter on 
discontinuation day 2 than baseline (+=6.318, pO.05), treatment day 1 (t=5.829, 
pO.05), treatment day 2 (t=2.813, pO.05), and treatment day 3 (t=5.788, pO.05). This 
shows the withdrawal effect o f  loprazolam is a reduction in REM latency. Also, there 
was an effect o f  Day on zopiclone (F(5,50)=8.910, pO.OOl). T-tests showed the 
discontinuation days had significantly shorter mean REM latencies than baseline and 
treatment days (baseline vs. discontinuation day 1, +=5.271, pO .05; baseline vs. 
discontinuation day 2, +=5.024, pO.05; treatment day 1 vs. discontinuation day 1, 
+=3.575, pO .05; treatment day 1 vs. discontinuation day 2, t=2.776, pO.05; treatment 
day 2 vs. discontinuation day 1, +=3.628, pO.05; treatment day 2 vs. discontinuation 
day 2, t=3.275, pO .05; treatment day 3 vs. discontinuation day 1, +=5.680, pO.05; and 
treatment day 3 vs. discontinuation day 2, t=5.217, pO.05). This shows a reduction in
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REM latency is also a withdrawal effect o f  zopiclone. There was no significant Day 
effect on zolpidem.
5.5.3.18 Percentage o f  REM sleep in the First Period o f  the Night
There were 10 participants included in this analysis. A two-way ANOVA with 
epsilon correction revealed an effect o f  Drug (F(2.19,19.71)= 6.466, p<0.01) and Day 
(F(2.85,25.65)=6.742, p<0.01), but no interaction. The effect o f  Drug was investigated 
using Tukey’ s (HSD) test, which showed there was a higher percentage o f  REM in 
period 1 with placebo compared to loprazolam (p<0.01) and zopiclone (p<0.05). This 
shows loprazolam and zopiclone reduced the amount o f  REM in the first period o f  the 
night compared to placebo, but zolpidem did not.
The effect o f  Day was also analysed using Tukey’ s, and showed the percentage 
o f  REM in period 1 was higher on discontinuation day 1 than baseline (p<0.01), 
treatment day 1 (p<0.05), treatment day 2 (p<0.01), and treatment day 3 (p<0.01), and 
higher on discontinuation day 2 than baseline (p<0.05), treatment day 2 (p<0.05), and 
treatment day 3 (p<0.05). This shows an increase in REM sleep in the first period o f  the 
night is a withdrawal effect (REM rebound).
5.5.3.19 Percentage o f  REM sleep in the Second Period o f  the Night
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5.5.3.20 Percentage o f  REM sleep in the Third Period o f  the Night
There were 10 participants in this analysis, and a two-way ANOVA with epsilon 
correction revealed no significant effects. There was no significant difference between 
test medications and placebo.
5.5.4 Adverse Events (AEs)
Table 5.10 shows all adverse events (AEs) recorded duiing the study. The
highest number o f AEs occurred under zopiclone 7.5mg, and the largest number o f
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volunteers reported these. AEs under zolpidem were also reported more often than 
under loprazolam. Compared to all other drugs, the least number o f AEs were reported 
under placebo.
Adverse Event -  Preferred Term Loprazolam
lm g
Zopiclone
7.5mg
Zolpidem
lOmg
Placebo
No. o f  Participants with AEs 13 15 14 10
Abdominal Pain 1 1
Agitation 2 1 1
Amnesia 1 2
Anxiety I 1 3
Appetite Increased 1
Asthenia 1
Ataxia 1 2
Autonomic Nervous System Disorder 2
Concentration Impaired 1
Confusion 4 4 1
Coordination Abnormal 3 8
Dehydration 1
Dermatitis 1
Diarrhoea 1 1 2
Diplopia 3
Dizziness 3 6 9 4
Dreaming Abnormal 2 2
Drowsiness 7 9 4
D iy  Eyes 1
Dry Mouth 1
Ear Ache 1
Emotional 1 1 1
Eye Pain 1 1
Fatigue 4 7 2 3
Hallucination 1 1
Headache 4 7 5 3
Hiccup 1
Insomnia 2 5 2 1
Nausea 1 1 2 1
Nightmare 1 3 2
Pain 2
Pruritus 1
Rash 3 2
Cold Clammy Skin 1 1
Sweating Increased 1
Tachycardia 1 1
Taste Distortion 6 1
Tremor 1 1 1 1
Vision Abnormal 1 1 7
Vomiting 1
Total N o. o f  AEs Reported 39 72 60 27
Table 5.10 - Number o f  participants with at least one incidence o f  adverse event, possibly, probably or 
definitely related to treatment drug.
The top five AEs under loprazolam were: drowsiness, fatigue and headache,
dizziness and rashes. Under zopiclone, the AEs most reported were: drowsiness, fatigue
and headache, taste distortion and dizziness. Under zolpidem, the majority o f reports
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were: dizziness, abnormal coordination, abnormal vision, headache and drowsiness and 
confusion. Under placebo, the AEs most reported were: dizziness, fatigue, headache, 
nightmares, rashes, and diarrhoea. The types o f  AEs reported under the drugs are similar 
to those reported under placebo. The types (and the numbers) o f AEs o f loprazolam 
were almost identical to placebo, whilst zopiclone showed the characteristic bitter 
metallic taste, and zolpidem seemed to impair vision and movement. Due to the general 
similarity between all AEs, this shows that all three active treatments are well tolerated.
5.6 Discussion
The aim o f this study was to assess the effects o f  three hypnotics, loprazolam, 
zopiclone and zolpidem, and placebo, during three nights o f  administration, and also on 
two nights o f  withdrawal. This was completed using overnight sleep EEG recording, 
and psychometric tests administered the evening before dose and the morning after 
dose.
5.6.1 Loprazolam
5.6.1.1 Effects o f  Loprazolam on Sleep
Subjective sleep latency and quality o f sleep, as measured by the LSEQ, were 
significantly improved by loprazolam, agreeing with Hindmarch and Clyde (1980). In 
addition, objective sleep latency (SL) under loprazolam was shorter compared to 
placebo on treatment days 1 and 3. This agrees with the suggestion o f Costa de Silva 
and Borges (1983) that loprazolam is an effective hypnotic due to its sleep-inducing 
effects, as it enhances sedation by binding to the omega-1 receptor in the GABAa 
complex (Blanchard, 1988). However, there were no changes in wake time, contrary to 
to the research o f  Adam et al. (1984) using lmg, and the suggestions o f  Costa de Silva 
and Borges (1983). There were also no effects on stage 1 sleep, contrary to Krieger et 
al. (1983), Nicholson and Stone (1983), Smirne et al. (1983), and Adam et al. (1984). 
Reasons for these differences to previous research are unclear, but may simply be due to 
different methods o f  staging the sleep recordings. Staging is subjective to the stager, and 
so anomalies can occur. Also, it is not stated in these studies whether staging was 
achieved using visual or computerised methods. There was also no effect o f  loprazolam
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on TST, but this agreed with the findings o f  Declerck et al. (1983), Krieger et al. (1983), 
and Nicholson and Stone (1983).
There was significantly more stage 2 sleep under loprazolam compared to 
zolpidem and placebo. This was evident on all three treatment days. This agrees with 
most previous research (Nicholson and Stone, 1983; Adam et al., 1984; Goldenberg,
1985) that loprazolam increases stage 2 sleep time. It is likely these studies found 
increases in stage 2 sleep because o f  the reduction in wake time and stage 1 sleep also 
foimd. However, this present study did not find reductions in wake and stage 1 sleep 
time. Instead, less SWS was foimd under loprazolam than placebo. This finding also 
occurred in other studies (Goldenberg, 1985). Interestingly, Nicholson and Stone (1983) 
found no change in SWS in ‘normal’ participants, but Smirne et al. (1983) noted 
decreases in SWS in insomniacs. Perhaps with respect to SWS the ‘mild sleep 
complaint’ tested here equates to ‘ insomnia’ . This confirms the poor sleep present in 
participants before drug administration.
There was no significant change noted in the amount o f REM time experienced, 
contrary to the findings o f  Goldenberg (1985), who noted a decrease in REM sleep. 
Similarly to the pattern noted with the amount o f  SWS, Krieger et al. (1983) and Smirne 
et al. (1983) suggested decreases in REM sleep duration are foimd in insomniacs, but 
not ‘normals’ . This study used healthy participants, but they had a mild sleep complaint, 
and no decrease in REM sleep time was noted. Changes in the amount o f REM sleep 
may therefore be a marker between ‘ insomniacs’ and those with a ‘mild sleep 
complaint’ . Participants included in this present study may have had insomnia with 
respect to changes in SWS, but not REM sleep.
The results o f this present study showed that REM latency was longer for 
loprazolam compared to zolpidem and zopiclone (but not placebo); longer on treatment 
day 1 under loprazolam compared to all other treatments (including placebo), and 
longer on the third treatment day for loprazolam compared to placebo. Loprazolam 
therefore lengthens REM latency compared to placebo on the first night o f  treatment. 
This increase in REM latency by loprazolam has also been noted in other studies 
(Smirne et al., 1983). Loprazolam was not found to change the amount o f REM time in 
this present study, but it was found to alter the distribution o f REM sleep.
There is a strong link between REM sleep and depression, in that depression can
result in decreases in REM latency and increases in REM sleep time (Berger et al.,
1982; Kupfer et al., 1985; Waller et al., 1989). This may account for the reduction in
LARS depression scores while imder loprazolam (compared to placebo). Alleviation o f
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depression has been noted using medication that increases latency to REM sleep (Vogel 
et al., 1990). It is possible that the REM delaying and redistributing properties o f 
loprazolam improved depressive feelings, as measured by LARS. Alternatively, the 
lower depression score may be related to the increased duration o f  sedation found in 
intermediate acting hypnotics. However, the LARS ‘ sedation’ component showed there 
was a higher sedation score on zolpidem than loprazolam, and also no significant 
differences between loprazolam and placebo, so this is unlikely.
5.6.1.2 Effects o f  Loprazolam on Morning Performance
On the first treatment day, the CFF threshold (Hz) under loprazolam was lower 
than under zopiclone, indicating loprazolam was more detrimental to cognitive 
functioning than zopiclone. Also, loprazolam treatment reduced delayed word recall in 
the mornings compared to placebo, showing selective hangover effects o f loprazolam. 
However, loprazolam did not impair immediate word recall, suggesting that detrimental 
hangover effects on memory are selective. Hindmarch and Clyde (1980) also found no 
effects o f loprazolam on morning tests o f  short term memory, but did not test long term 
memory.
In addition, the present study found loprazolam had no detrimental effect on 
CRT and DSST, which agrees with Hindmarch and Clyde (1980), who found no effects 
o f loprazolam 0.5mg, lmg, and 2mg on next day performance. However, with repeated 
doses o f  lmg, or an acute dose o f 2mg, participants complained o f increasing tiredness. 
Grobler et al (2000) also found no hangover effects, but did note participants were 
drowsier the morning after dose compared to placebo. Also, participants missed more 
responses on a hand-eye coordination test.
These results suggest there are negligible hangover effects associated with a 
lmg dose o f loprazolam. This is supported by the findings o f  the LSEQ, which showed 
no significant changes in subjective ratings o f ‘behaviour following awakening’ . Bayer 
et al. (1983) also found similar results in a study o f older adults, where loprazolam had 
no effect on early morning coordination or alertness after waking.
5.6.1.3 Discontinuation Effects o f  Loprazolam
Discontinuation o f loprazolam after just three nights o f  treatment led to
significant changes in sleep architecture. In particular, sleep latency was increased on
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both discontinuation nights compared to the treatment nights. Discontinuation o f 
loprazolam also decreased stage 2 sleep compared to placebo. In addition, an increase in 
SWS latency was also noted, and this was reflected in a reduction in the percentage o f 
SWS dining the second period o f the night under loprazolam compared to placebo. 
There was a general decrease in the amount o f  SWS on discontinuation day 1 compared 
to placebo. This change in the amount o f  SWS was also noted by Adam et al. (1984) 
after three nights on lmg o f  loprazolam. Also, compared to zopiclone, participants 
under loprazolam had a lower CFF threshold (Hz) on the first discontinuation day, 
indicating increased sedation, or poor information processing capacity, compared to 
zopiclone. However, this effect was not significantly different to placebo.
5.6.2 Zopiclone
5.6.2.1 Effects o f  Zopiclone on Sleep
On treatment days 1 and 3, zopiclone showed significantly shorter sleep latency 
(SL) than placebo, but no difference to the other drugs. Zopiclone therefore decreases 
SL. Previous research has found that subjective measures have shown a reduction in 
sleep latency under zopiclone (van der Kleijn, 1989; Rettig et al., 1990; Uchiumi et al., 
2000; Tsutsui et al., 2001), but this has not always been supported by objective 
measures (Mann et al., 1996; Hemmeter et al., 2000; Nakajima et al., 2000). The present 
study showed no effect on stage 1 time, contrary to Nicholson and Stone (1983), 
Billiard et al. (1989), and Yamadera et al. (1997) who found reductions, but only at high 
doses.
It was foimd that the amount o f  stage 2 sleep was increased under zopiclone
compared to placebo. On treatment days 1 and 3, zopiclone increased stage 2 sleep than
zolpidem and placebo (but less than loprazolam), and on treatment day 2 zopiclone
showed more stage 2 sleep than placebo. Other researchers have shown similar
increases in stage 2 sleep during treatment with zopiclone (Mamelak et al., 1982;
Nicholson and Stone, 1983; Warot et al., 1987; Aeschbach et al., 1994; Mann et al.,
1996; Yamadera et al., 1997; Hemmeter et al., 2000; Nakajima et al., 2000).
Although sleep latency was decreased and stage 2 time increased, TST remained
unchanged under zopiclone. This is in contrast to other studies, which showed increases
in TST (Mamelak et al. (1982), Maim et al. (1996), Yamadera et al. (1997), and
Hemmeter et al. (2000)). In addition, this present study foimd no changes in objective
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wake time under zopiclone, contrary to Billiard et al. (1989), Mann et al. (1996), 
Parrino et al. (1997), and Hemmeter et al. (2000), who noted reductions. Reasons for 
this are unclear’, and may be due to inter-individual variations (Grobler et al., 2000).
Latency to SWS was significantly less under zopiclone than placebo, notably on 
the first treatment day. SWS latency was therefore decreased under zopiclone. Latency 
to SWS is not commonly recorded, but has been shown here to significantly change 
under zopiclone, which is contrary to Nakajima et al. (2000). The distribution o f SWS 
was also altered, as there was less SWS in period 2 o f  the night under zopiclone 
compared to placebo. There was no effect on the amount o f  SWS time, contrary to 
Nicholson and Stone (1983) who found durations o f stage 2, 3 and 4 sleep were 
increased by 7.5mg and lOmg o f zopiclone. Jovanovic and Dreyfus (1983), Billiard et 
al. (1987/1989), Tiberge et al. (1988), Mouret et al. (1990), Yamadera et al. (1997), and 
Nakajima et al. (2000) all found increases in SWS.
On treatment day 1, the REM latency for zopiclone was longer than zolpidem 
and placebo. Therefore, an acute dose o f  zopiclone extends latency to REM sleep. Also 
on treatment day 1, the REM latency for zopiclone was shorter than that o f loprazolam, 
but there was no difference between the two on treatment day 3. This means any 
alteration in REM positioning in the night was resolved between the drugs by treatment 
night 3. It appeal’s the activity o f  zopiclone with respect to REM latency is comparable 
to loprazolam, but different to zolpidem and placebo. This agrees with Nicholson and 
Stone (1983) who foimd an increase in REM latency, but disagrees with other research 
(Hemmeter et al., 2000; Nakajima et al., 2000; Mann et al., 1996; Jovanovic and 
Dreyfus, 1983).
Zopiclone was found to have no significant effect on the amount o f REM time, 
and this is in agreement with other research (Mamelak et al, 1982; Jovanovic and 
Dreyfus, 1983; Hemmeter et al., 2000). In contrast, Nicholson and Stone (1983) 
observed a reduction in the amount o f REM with lOmg o f  zopiclone, but only during 
the first 6 hours o f the night’ s sleep. The present study, however, used only 7.5mg o f 
zopiclone which may account for the difference in findings.
5.6.2.2 Effects o f  Zopiclone on Morning Performance
In comparison with loprazolam, less morning impairment was observed with
evening doses o f  zopiclone. Whilst CFF threshold on treatment day 1 was decreased by
zopiclone, indicating a sedative effect, this reduction in CFF appeared to diminish as the
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treatment days continued, and by treatment day 3 there was no significant difference 
compared to placebo. These results are in agreement with other researchers who have 
also found no changes in CFF performance after the third treatment night (Harrison et 
al., 1985; Warot et al., 1987; Ponciano et al., 1990; Tafti et al., 1992).
Results showed zopiclone impaired delayed word recall more in the morning 
than during evening tests. Some effects o f  zopiclone on long term memory have been 
reported (Warot et al., 1987), but only at 2 hours post dose, and not the morning after. 
Hemmeter et al. (2000) tested 12 older adults (60-70 years old) with single doses o f  
7.5mg zopiclone, and found CRT was still impaired under zopiclone at 07:00, but not at 
09:00. No morning effects o f  CRT were found in this present study, but this was 
assessed at 10.5 hours post dose. Zopiclone had no significant effect on short term 
memoiy, DSST or immediate word recall, which is in agreement with other research 
(Lader and Demiey, 1982; Nicholson and Stone, 1983; Subhan and Hindmarch, 1984). 
In addition, no changes were observed in subjective ratings o f morning sleepiness or 
mood, again supporting other research in this area (van der Kleijn, 1989).
5.6.2.3 Discontinuation Effects o f  Zopiclone
Several withdrawal effects were observed after three nights administration of 
zopiclone. On discontinuation day 1, zopiclone showed a longer sleep latency (SL) than 
loprazolam and placebo. Also, under zopiclone, SL was longer and there was less stage 
2 sleep on the discontinuation days compared to all other days. In addition, on 
discontinuation day 1, zopiclone had a longer SWS latency compared to all other drugs, 
and SWS latency was longer on the discontinuation days than all other days. There was 
also an effect on REM latency, as this was significantly shorter on the discontinuation 
days than all other days. These findings are similar to those o f  Mann et al. (1996), who 
noted nonsignificant discontinuation trends towards reduced sleep time, and increased 
time spent awake and latency to sleep. Also, they found the amount o f  stage 2 sleep and 
SWS returned to baseline values, and there was a significant increase in the amount o f 
REM recorded.
In the present study, these withdrawal effects did not lead to impairments in 
daytime performance. A  positive discontinuation effect was shown in the CFF task, 
where improved cognitive functioning was seen on both discontinuation days under 
zopiclone compared to placebo. Indeed, results showed the second discontinuation day
showed less sedation on the CFF task than treatment day 2.
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Zolpidem showed a significantly shorter sleep latency (SL) than placebo, and 
this was apparent on treatment days 1 and 3. There was no difference between the SLs 
o f zolpidem and the other hypnotics, indicating a comparable effect. A  shorter SL under 
zolpidem is a well documented effect (Merlotti et al., 1989; Kryger et al., 1991; Scharf 
et al., 1991; Blois et al., 1993; Roehrs et al., 1994; Mendelson, 1995; Roth et al., 1995; 
Elie et al., 1999; Monti et al., 2000; Nakajima et al., 2000; Saletu-Zyhlarz et al., 2000). 
There was also no significant effect on sleep efficiency, which was also found by 
Kryger et al. (1991), Blois et al. (1993), Herrmann et al. (1993), Monti et al. (2000), and 
Saletu-Zyhlarz et al. (2000), and no effect on wake time, which agrees with the work o f  
Monti et al. (2000) and Nakajima et al. (2000). Total sleep time was also unaffected by 
zolpidem, which disagrees with Merlotti et al. (1989), Kryger et al. (1991), Scharf et al. 
(1991), Balkin et al. (1992), Roth et al. (1995), Elie et al. (1999), Monti et al. (2000), 
and Saletu-Zyhlarz et al. (2000).
There was also no effect on stage 1 sleep, supporting the work o f  Merlotti et al.
(1989), Kryger et al. (1991), Mendelson (1995), Nakajima et al. (2000). There was no 
effect o f zolpidem compared to placebo on the amount o f  stage 2 sleep, unlike 
loprazolam that significantly reduced stage 2 sleep on the first and third treatment days. 
The effects o f  zolpidem on stage 2 sleep remains controversial, with some researchers 
reporting an increase in stage 2 sleep (Kryger et al., 1991; Cluydts et al., 1995; Feinberg 
et al., 2000; Monti et al., 2000), whilst others foimd no increase (Blois et al., 1993; 
Kanno et al., 2000; Nakajima et al., 2000).
There was no effect o f zolpidem on stage 3 sleep, supporting Mendelson (1995) 
and Monti et al. (1996), and no effects on stage 4 sleep supporting Blois et al. (1993) 
and Mendelson (1995). Zolpidem increased the amount o f  SWS compared to 
loprazolam, but not compared to placebo. This is in agreement with other research 
(Merlotti et al., 1989; Mendelson, 1995; Monti et al., 2000), although this has been 
disputed (Kryger et al., 1991; Kanno et al., 2000) and does not follow the model o f 
Nakajima et al. (2000) previously outlined. Latency to SWS was reduced by zolpidem 
compared to placebo, but was not statistically different to zopiclone. In addition, there 
was more percentage SWS in the first period o f  the night on zolpidem compared to
5.6.3 Zolpidem
5.6.3.1 Effects o f  Zolpidem on Sleep
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placebo, which agrees with Kryger et al. (1991), Declerck et al. (1992), Herrmann et al. 
(1993), Kanno et al. (2000), Nakajima et al. (2000), and Saletu-Zyhlarz et al. (2000).
There was no effect o f zolpidem on the amount o f REM sleep. This is in 
agreement with other research including that o f  Merlotti et al. (1989), Kryger et al. 
(1991), Cluydts et al. (1995), Mendelson (1995), Monti et al. (1996), Kanno et al. 
(2000), Monti et al. (2000), and Nakajima et al. (2000). However, a reduction in REM 
sleep latency was found under zolpidem compared to placebo, although this disagrees 
with the research o f  Nakajima et al. (2000). This present study showed evidence for a 
lack o f  significant change in the amount o f  REM sleep under zolpidem compared to 
placebo, but the REM distribution had changed. This pattern was also seen in the effects 
on SWS.
Also, under zolpidem, there was more subjective depression than with
loprazolam (measured by the LARS depression scale). As before, it is possible that
these scales are related to the changes in REM sleep, in that a short REM latency is
associated with depression (Berger et al., 1982; Kupfer et al., 1985; Waller et al., 1989).
Indeed, depression scores for loprazolam were less than zolpidem, and also REM
latency was longer for loprazolam. Here, under zolpidem, depression scores were
higher, and REM latency was generally shorter than loprazolam. However, there was no
significant difference between the amount o f  REM during the first period o f  the night
with loprazolam and zolpidem. This suggests both zolpidem and loprazolam reduce
REM latency compared to placebo, and this may be linked to scores o f  depression, but
there is a lack o f significant difference between the two hypnotics.
In this present study, there were very few significant subjective effects.
Zolpidem showed more subjective sedation (measured by the LARS sedation scale)
compared to loprazolam, agreeing with Rush and Griffiths (1996), Greenblatt et al.
(1998), and Drover et al. (2000), although there was no significant difference compared
to placebo. This may seem unexpected because o f the shorter half-life o f  zolpidem
compared to loprazolam, therefore zolpidem should result in fewer residual effects.
However, the increases in sedation with zolpidem may have arisen from its lack o f
effect on sleep architecture. Zolpidem does not seem to change most sleep parameters,
and so may not improve the sleep o f sleep-disturbed participants as much as
loprazolam, hence the higher sedation scores, as sleep may not have been as refreshing.
Indeed, zolpidem was found to have no effect on the LSEQ ease o f  getting to sleep and
the quality o f sleep, although this is contrary to Bensimon et al. (1990), Kryger et al.
(1991), Scharf et al. (1991), Fairweather et al. (1992), Richens et al. (1993), Mendelson
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(1995), Dockhorn and Dockhorn (1996), Declerck and Smits (1999), Elie et al. (1999), 
Monti et al. (2000), and Tsutsui et al. (2001). Reasons for this are unclear. However, the 
differences between the findings in this study and other studies may be due to the timing 
o f  the dose. Loprazolam, zopiclone and zolpidem were taken two hours before lights 
out. The peak absorption o f  loprazolam and zopiclone is likely to have been after this 
time, but zolpidem is a rapidly absorbed drug, and lights out may have been after its 
peak effects. The maximum plasma concentration o f  zolpidem has been reported to be 
at approximately 1.6 hours after a lOmg dose (Holm and Goa, 2000).
5.6.3.2 Effects o f  Zolpidem on Morning Performance
Zolpidem had no significant effect compared to placebo on any o f  the 
psychometric tasks, indicating that it did not impair cognitive function or psychomotor 
performance. This is in agreement with other research (Fairweather et al., 1992; Berlin 
et al., 1993; Roehrs et al., 1994; Cluydts et al., 1995). This suggests zolpidem may be 
the drug o f choice where daytime performance needs to be optimum, and this may be 
particularly applicable to the elderly. This lack o f  residual effect is likely to be due to 
the short half life o f  zolpidem, which is supported by the observations that impairments 
are only found when tests are administered close to drug ingestion (Berlin et al., 1993; 
Dingemanse et al., 1995; Wilkinson, 1995; Mattila et al., 1998; Troy and Darwish, 
1999; Drover et al., 2000; Isawa et al., 2000). Indeed, Drover et al. (2000) found 
subjective sedation was impaired 1 hour post dose, but not at 8 hours post dose. Also, 
Mattila et al. (1998) found impairment o f DSST, CFF and body sway, but not after 5 
hours post dose.
5.6.3.3 Discontinuation Effects o f  Zolpidem
Discontinuation o f  zolpidem resulted in few significant effects. Impairments in
CFF were present on the second discontinuation day, where information processing was
worse after the discontinuation o f  zolpidem compared to the discontinuation o f
zopiclone (but not placebo). Sleep latency was longer on the discontinuation o f
zolpidem compared to nights on the treatment. Also, there was a significant lengthening
o f latency to SWS on discontinuation o f  zolpidem compared to placebo and the
discontinuation o f  loprazolam and zopiclone. The distribution o f  SWS therefore
changed on the discontinuation o f  zolpidem, as there was more SWS in the first period
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o f  the night on discontinuation day 1 compared to most other days, and more on 
discontinuation day 2 compared to all other days.
Other research also finds little evidence for rebound insomnia (Leppik et al., 
1997; Ware et al., 1997; Kanno et al., 2000; Monti et al., 2000). However, Nakajima et 
al. (2000) found an increase in stage 2 sleep on their third discontinuation night. This 
does not agree with this current study, but it does indicate that zolpidem may have 
minor rebound effects on sleep architecture. This, and the changes in sleep architecture 
found in the present study, needs further investigation.
5.6.4 Significant Effects Under Placebo
It is interesting that significant effects were noted at baseline. These were found 
in the sleep variables o f  the amount o f  stage 2 sleep, latency to SWS and latency to 
REM. Because all groups were talcing placebo on that day, there should have been no 
significant differences between the conditions. It may have been easily explainable had 
these variables have been mood or cognitive tests, perhaps by experimenter effects or 
unease at the start o f  the study, but the variables in question cannot be altered by 
participant behaviour. It is unlikely that this effect is due to chance in the statistical 
analysis. The most stringent ANOVA correction factor was used, along with a strict 
post-hoc test. This effect may therefore show support for the findings o f Grobler et al.
(2000), who noted sizable inter-individual variations. The standard deviation for the 
amount o f  stage 2 sleep on the placebo day is 29.4 around a mean o f  226.4 minutes, the 
standard deviation o f  SWS latency is 17.6 with mean 24.4 minutes, and the standard 
deviation o f  REM latency us 43.9 around a mean o f 97.0 minutes. It is possible that 
these variables show significant variation under normal condition to produce a 
significant effect on placebo. If so, it may be possible that the nonsignificant results 
found in the valerian study (chapter 4) may also have been affected by large inter­
individual variation.
Alternatively, this effect may be due to ‘placebo responders’ , as identified by 
Bayer et al. (1983). These authors suggest that there are a proportion o f  patients in eveiy 
clinical study that will improve with placebo treatment. It is unclear if this is due to 
hypochondriasis, or to suggestion, but Bayer et al. (1983) recommend a three night 
placebo treatment with patients being told they are taking ‘ something to help them sleep 
better’ to identify placebo responders. The authors then suggest removing them from 
participation in the trial.
Chapter 5
227
Chapter 5
5.6.5 Diurnal Effects
From the results, it was apparent there was a strong and recurrent effect between 
morning and evening tests, regardless o f  drug. This was true for CRT (motor, 
recognition and total reaction time), STM task, immediate and delayed recall, DSST and 
STAI. Under all conditions, participants always performed worse in the morning tests 
compared to the evening tests. In the STAI test, measuring anxiety levels, participants 
were found to have more anxiety in the morning than the evening. It appears that testing 
in the morning is associated with more performance pressure and poorer achievement 
compared to evening tests. This is probably due to normal sleepiness after waking, 
rather than any impairment caused by drug intake.
5.6.6 Effects o f  Discontinuation
All three active treatments showed effects o f discontinuation. Discontinuation 
effects o f  an impairing nature were found during LSEQ getting to sleep and quality o f 
sleep, sleep latency, TST, and sleep efficiency. Changes were also found in stage 2 
sleep time, stage 4 sleep time, REM sleep time, SWS and REM latency, and SWS and 
REM sleep in the first period o f  the night and SWS in the second period o f  the night. 
All the variables that showed a discontinuation effect were sleep-related variables, as 
there were no signs o f  detriment in the psychometric tests o f  CFF, STM, and delayed 
recall. This suggests that the discontinuation effect o f these hypnotics is to selectively 
impair or change sleep, and that these changes do not have a significant impact on 
daytime performance. Interestingly, immediate recall and DSST tasks showed an 
increase in correct scores on the discontinuation nights compared to other nights. This 
indicates any lingering impairing effects o f  the drugs were removed by the first 
discontinuation night. This shows loprazolam, zopiclone and zolpidem have half-lives 
short enough not to have an accumulation effect.
5.6.7 Comparison o f  Loprazolam. Zopiclone and Zolpidem
Loprazolam, zopiclone and zolpidem, although differing in structure and
mechanism, have all been found to aid sleep compared to placebo. To assess these
hypnotics, especially in relation to therapeutic assessment, they must be compared one
to another. Jonas et al. (1992) found no differences in clinical and pharmacologic
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activity between benzodiazepines (including loprazolam), and zopiclone and zolpidem. 
If these hypnotics are similar, then it is possible the types o f  hypnotics prescribed to the 
elderly are o f  no consequence.
Few results o f  this study showed a degree o f similarity between the three 
hypnotics. During the delayed recall task, loprazolam, zopiclone and zolpidem all 
produced more correct words in the evening task than placebo did. On treatment day 2, 
all three drugs differed from placebo, but not each other, in the amount o f stage 2 sleep 
recorded. Lastly, on the third treatment night, REM latency was shorter under placebo 
than the three hypnotics.
However, clear differences were also present. With respect to sleep variables, 
zopiclone showed a longer sleep latency than loprazolam and placebo on the first 
discontinuation night. Although loprazolam has a longer half-life (Nicholson and Stone, 
1983), accumulation effects were not considered likely (Wagner, 1967). Loprazolam did 
not differ to zopiclone in the amount o f  stage 2 sleep recorded, but this was significantly 
more than under zolpidem and placebo. This agrees with the idea that loprazolam and 
zopiclone are a more potent influence on sleep architecture (Nakajima et al., 2000). 
Indeed, loprazolam showed less SWS than zolpidem and placebo, but there was no 
difference in amount to zopiclone. The percentage SWS in the first period o f the night 
was less on loprazolam and zopiclone compared to placebo, but not zolpidem. Again, 
loprazolam and zopiclone show similarities in sleep architecture. Differences are found 
in SWS latency, where placebo differs from zolpidem and zopiclone, but not 
loprazolam. Also, REM latency was longer under loprazolam than zopiclone and 
zolpidem, and the percentage o f REM sleep in the first period o f the night was higher on 
placebo than loprazolam and zolpidem.
In terms o f psychometric testing, loprazolam decreased information processing 
capacity (measured by CFF) compared to zopiclone on treatment day 1 and 
discontinuation day 1, which indicates loprazolam is initially more CNS depressant than 
zopiclone on initiation o f  treatment and initial discontinuation o f  treatment. Also during 
the CFF task, zolpidem was found to be more sedative than zopiclone on 
discontinuation day 2. It is likely this is due to inter-individual variation as both o f  these 
drugs are suggested to have half-lives too short to sustain impairment o f CFF (Goa and 
Heel, 1991; Holm and Goa, 2000). During the morning delayed recall task, fewer words 
were remembered correctly under loprazolam compared to zolpidem. This shows 
greater morning impairment under loprazolam than zolpidem. However, less depression
and sedation (both measured by LARS) were noted under loprazolam than zolpidem.
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Despite the reported increased effect o f  loprazolam compared to zolpidem, loprazolam 
did not increase depressive or sedative effects.
Some support is found for Jones et al. (1992) in the similarity between 
loprazolam and zopiclone, as this has been found with respect to their effects on delayed 
recall, LARS, and the amount o f  stage 2 sleep and SWS. However, there is little 
evidence for a similarity between loprazolam and zolpidem. It is likely this similarity 
exists between loprazolam and zopiclone, but not zolpidem, due to their method and 
duration o f action. Zopiclone acts on both the benzodiazepine receptors omega-1 and 
omega-2, so has more in common with loprazolam, but is not identical because o f  the 
tendency o f zopiclone towards preference o f  the omega-1 receptor. Loprazolam binds to 
each receptor with a more equal preference. Zolpidem, however, hardly binds to the 
omega-2 receptor, so has much less in common with loprazolam than zopiclone. 
However, some similarities exist between zolpidem and zopiclone due to similarities 
between their mechanisms o f  action. This shows support for the theoiy o f  Nakajima et 
al. (2000) shown in figure 5.1, although zolpidem was not found to increase SWS, 
which contradicts the theoiy.
5.6.8 Adverse Events (AEs)
5.6.8.1 AEs on Loprazolam
Previous research has shown loprazolam to be well tolerated without 
haematological or biochemical changes, even in the elderly (Hugonot, 1980; Costa de 
Silva and Borges, 1983; Kesson et al., 1984). Botter (1983), Salkind and Silverstone 
(1983), and McAlpine et al. (1984) reported no o f  AEs in their studies. However, others 
did, including Clark et al. (1986), who found side effects (adverse events) o f headache, 
dizziness, ataxia, nightmares, dry mouth, depression, nausea and gastro-intestinal 
disturbances. Bourin and Malinge (1996) found one o f each o f the following AEs at a 
lmg dose: an ebrious (intoxicated) sensation, fantastic and unpleasant dreams, dryness 
o f mouth, post-prandial somnolence, fatigue, feeling clumsy, memoiy disorders, and 
nausea in the morning.
In this study, loprazolam lmg was found to have similar effects to those 
previously reported. Thirteen out o f  the 16 volunteers who participated in the study 
reported an AE, with a total o f  39 AEs reported which were related to the study drug to
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some degree. These were mainly drowsiness (7 reports), headache (4 reports), fatigue (4 
reports), dizziness (3 reports), and rashes (3 reports).
5.6.8.2 AEs on Zopiclone
Most previous research has shown that zopiclone is well tolerated and safe for 
the use in most patient populations. Lader and Denney (1982), Mamelak et al. (1982), 
van der Kleijn (1989), Rettig et al. (1990), and Stip et al. (1999) reported no AEs in 
their studies. However, Warot et al. (1987) found that 2 horns post dose (7.5mg), 
participants felt more drowsy, dizzy, clumsy and tired, less alert and energetic. Also, 
Hajak et al. (1994) studied 1315 insomniacs over 28 days, and recorded AEs of: 
dizziness (27.6%), headache (25.7%), nausea (24.8%), vertigo (23.9%), feelings o f 
weakness (21.1%), weakness in legs (14.1%), vomiting (8.8%), a bitter metallic taste 
(6.7%), speech disorder (5.6%), tiredness/exhaustion (2.5%), restlessness (1.3%), and 
dry mouth (1.1%).
In this present study, 15 out o f  the total 16 participants complained o f  a side 
effect, with 72 AEs in total being reported, the most out o f  all drugs tested. These were 
very similar to those reported under the other drugs, mainly drowsiness (9 reports) 
headache (7 reports), fatigue (7 reports), dizziness (6 reports) and taste distortion (6 
reports). The taste distortion experienced is likely to be due to the bitter metallic taste 
widely associated with zopiclone.
5.6.8.3 AEs on Zolvidem
Zolpidem is generally well tolerated (Roger et al., 1993; Leppik et al., 1997). 
Tsutsui et al. (1999) reported less AEs under zolpidem than zopiclone, and this pattern 
was also found in the present study. However, more AEs were reported under zolpidem 
than loprazolam. Emeriau et al. (1988) reported no AEs in their study, but Hajak and 
Bandelow (1998) found reports o f  nausea, dizziness, malaise, nightmares, agitation, 
headache, vomiting, somnolence, confusion, and paranoia. Ahrens (1993) found 629 
AEs at the lOmg, namely dizziness, hypotension, headache, and nausea. Tsutsui et al.
(2001) investigated the effects o f  lOmg o f zolpidem on 422 volunteers, and found 
occurrence o f  104 AEs, including: sleepiness, headache, nausea/vomiting,
lightheadedness, thirst, bitter taste, and malaise.
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In this present study, 14 out o f  the 16 participants reported an AE, and a total o f 
60 AEs were reported throughout the time spent taking zolpidem. These were also 
similar to those experienced under the other drugs, mainly dizziness (9 reports), 
abnormal coordination (8 reports), abnormal vision (7 reports), headache (5 reports), 
drowsiness and confusion (4 reports each).
5.6.8.4 AEs on Placebo
It is worth mentioning the types o f  AE reported under placebo, as this adds 
perspective to any AEs reported under active substances. Under placebo, 10 out o f  the 
16 participants reported an AE, and a total o f 27 AEs were reported. These were similar 
to those reported under the active drugs, mainly fatigue (3 reports), headache (3 
reports), an autonomic nervous system disorder, nightmares, diarrhoea, and rashes (2 
reports each). Comparing these AEs with those under loprazolam, zopiclone and 
zolpidem, it can be seen that all three active dings are well tolerated and safe to use.
5.7 Conclusions: Loprazolam, Zopiclone, Zolpidem and the Elderly
The aim o f this study was to assess and compare the sleep effects and 
psychometric profile o f  loprazolam, zopiclone and zolpidem, against each other, and 
against a placebo. Loprazolam, zopiclone and zolpidem reduced sleep latency, which 
indicates all three hypnotics have the ability to induce sleep. All three hypnotics have no 
significant effect on total sleep time, sleep efficiency, wake time, and the amount o f  
stage 1 time, which suggests these hypnotics do not differ in their abilities to improve 
sleep continuity in non-patient populations. Differences were seen between the drugs 
with respect to stage 2 sleep. Both loprazolam and zopiclone increased the amount o f 
stage 2 sleep time, but zolpidem did not. This is perhaps indicative o f  the more potent 
effects o f loprazolam and zopiclone, as suggested by their longer half lives (Nicholson 
and Stone, 1983; Nakajima et al., 2000). This may also be the case in the effects o f 
these hypnotics on the amount o f SWS, as loprazolam decreases SWS whilst the only 
effect o f  zopiclone and zolpidem is a redistribution o f SWS. Loprazolam, zopiclone and 
zolpidem all have no significant effect on the amount o f REM sleep, but loprazolam and 
zopiclone show redistribution o f REM sleep when zolpidem does not, as the two former 
hypnotics increase REM latency. Zolpidem has no effect on REM latency.
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With respect to morning after effects, there was no effect o f  zolpidem on any o f 
the measures, and zopiclone only showed impairment in CFF. Loprazolam, however, 
possibly due to its longer half-life than zopiclone and zolpidem (Swift et al., 1985), 
showed impairment o f  CFF, delayed recall, and LARS. However, loprazolam showed 
an improvement in LSEQ getting to sleep and quality o f  sleep whereas zopiclone and 
zolpidem did not. This is based on the assumption that the doses o f  the three hypnotics 
used were comparable.
Some discontinuation effects were seen with the withdrawal o f loprazolam, 
zopiclone and zolpidem. All three increased sleep latency, which is indicative o f  
rebound insomnia. Zolpidem had no effect on stage 2 sleep, but this was decreased by 
loprazolam and zopiclone. Loprazolam was the only hypnotic to have discontinuation 
effects on SWS, whereby it was reduced, but all three hypnotics increased the latency to 
SWS. Only zopiclone had a decreasing effect on the amount o f  REM sleep on 
withdrawal, but zopiclone and zolpidem both decreased REM latency indicating REM 
rebound effects. Loprazolam did not show these effects. This is possibly due to its 
longer half-life, and possible accumulation effects not shown in the first two nights o f  
withdrawal (Mclmies et al., 1985).
The results o f  this study therefore largely agree with previous literature on the 
effects o f  these hypnotics. The results in this study can be assessed in relation to older 
adults. Mouret et al. (1990) investigated the effects o f zopiclone for 15 days on 10 aged 
insomniac patients. They foimd zopiclone improved sleep parameters and increased 
SWS. They suggested these patterns were similar to patterns seen in young, healthy 
participants, and conclude it is likely the changes caused to elderly sleep by zopiclone 
are the same as changes caused to sleep in younger adults. Any experimental results are 
likely to be similar whether tested in the young or old. Problems in relating results may 
not be in age, but in sleep quality. Malpas et al. (1974) foimd insomniacs tended to 
suffer less hangover effects than normal healthy participants. Libman et al. (1997) foimd 
poor sleepers are less accurate in subjective reports o f  sleep than good sleepers. Using 
poor sleepers in a clinical trial may result in inaccurate reports o f effects. The 
participants in this study were healthy young people, but with a mild sleep disturbance. 
Hopefully this will adequately represent an older person with the sleep problems 
associated with old age.
Loprazolam has the longest elimination half-life, and subsequently has the most
impairment effect in the morning after dose. This was followed by zopiclone, and the
least number o f  impairments the next morning occurred under zolpidem. This agrees
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with Goa and Heel (1991). It is therefore suggested that the elderly avoid more 
impairing hypnotics like loprazolam, and use zopiclone or zolpidem instead. However, 
loprazolam produces changes in sleep architecture not seen in zolpidem. It may be that 
zolpidem may be the drug o f  choice, as it may interfere less with the deteriorating sleep 
EEG o f the elderly, or conversely, loprazolam may be the better choice to normalise the 
deterioration in sleep EEG. However, loprazolam has been foimd to reduce the amount 
o f  SWS during treatment and also on discontinuation. This may be detrimental to older 
adults, as amounts o f  stage 4 sleep have been found to decrease with normal ageing 
anyway (Kaye, 2002). Not enough is known about the relationships between sleep 
parameters and the quality or ‘ soundness’ o f  sleep (Hoch et al., 1994). Until this is 
researched and documented, it is difficult to indicate from this point o f view which 
hypnotic would suit the elderly best.
Age does become an important factor when discussing adverse events (AEs). 
AEs associated with these hypnotics tend to be dose-related, and are especially 
prevalent in the elderly (McEvoy, 1999). Greenblatt et al. (1977) suggested that the 
elderly are more susceptible to AEs. Older age increases sensitivity to mediations taken, 
especially hypnotics and other psychoactive substances (Hemmeter et al., 2000). It 
should therefore only follow that the elderly are also more sensitive to their side effects. 
However, the AEs noted in this study were typical o f  AEs seen under these three 
hypnotics (Warot et al., 1987; Bourin and Malinge, 1996; Tsutsui et al. 2001), and there 
was no noticeable difference between the types o f  AEs reported imder active treatment, 
and those under placebo. Therefore, with respect to side effects, all three o f  these 
hypnotics would be suitable for the elderly, but perhaps zolpidem more so than 
zopiclone or loprazolam. All three hypnotics show some mild discontinuation effect, 
again zolpidem less so than zopiclone and loprazolam. It is unlikely these are potent 
enough to cause distress, or encourage dependence. There was some concern in the 
literature regarding within-night rebound effects o f these short-acting hypnotics (Lader, 
1998). This would be a difficult problem to overcome in the elderly, as sleep 
maintenance is their most prevalent problem (Gislason et al., 1993; Mallon and Hetta, 
1997). However, there was no evidence here for any within-night rebound effects, for 
any o f  the three hypnotics.
In conclusion, any o f  these three hypnotics may be suitable for use in the
elderly, although if a problem with sleep maintenance persists under a short acting drug
like zolpidem, a longer acting drug like loprazolam may be needed to maintain sleep-
enhancing effects throughout the night. There may still be minimal residual effects in
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the morning, but is suggested to be safe to use. All these hypnotics show little effect on 
morning performance, but this study does not indicate exactly when the participants are 
free from effects. LSEQ, LARS and CFF were used as measures o f sedation, but future 
studies should also examine objective sedation using a technique such as the MSLT. 
The main concern with prescribing longer acting (or intermediate acting to some extent) 
hypnotics is the detrimental effect on performance if the user was to get up in the night. 
There is a great deal o f  concern that, although longer acting hypnotics may aid sleep all 
night long, they may also result in falls and accidents in the night due to their sedating 
effects during the night (Trewin et al., 1992). The type o f  hypnotic given to an elderly 
insomniac must therefore be chosen carefully to match the needs o f  the individual.
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6.1 Abstract
The use o f antidepressants as hypnotic treatment is increasing in prevalence 
(Anderson, 2001). Antidepressants can alleviate depression and associated sleep 
problems, so it is suggests antidepressants may be able to alleviate sleep problems in 
insomniac. This study tested two popular antidepressants, dothiepin (a TCA) and 
moclobemide (a RIM A) as hypnotics.
There were 14 healthy male participants, aged between 18 and 35 years old 
(mean age 25.3 years, sd 4.85), administered dothiepin 75mg, dothiepin 150mg, 
moclobemide 450mg, moclobemide 600mg or placebo for two nights, with a one week 
washout period between each treatment. Objective sleep was measured by overnight 
EEG and daytime functioning was measured using a battery o f psychometric tests, 
administered eveiy two hours from 09:00 until 19:00. Results showed characteristic 
REM suppression from both antidepressants, but no beneficial effects on sleep latency, 
sleep continuity or sleep efficiency. Moclobemide showed no effects on daytime 
functioning, but dothiepin showed some impairment o f  short-term memoiy. It is 
therefore suggested moclobemide and dothiepin are not useful hypnotic drugs, but may 
still benefit sleep disturbance in depression.
6.2 Introduction
The survey on the sleep o f  the elderly showed that antidepressants are often 
prescribed to the elderly as an aid to sleep. It was found that 8.2% o f those who used a 
prescription to aid sleep took an antidepressant, which was nearly 1% o f all the 5846 
older adults surveyed. This is a large proportion considering 6% o f the 5846 older adults 
used hypnotics. Also, 12.5% o f older adults who took more than one prescription 
medication for sleep used antidepressants as their secondary medication.
6.2.1 Associations Between Depressive Symptoms and Sleep Abnormalities
The link between sleep and depression has been well established (Mellinger et 
al., 1985; Ford and Kamerow, 1989). Sleep deprivation has been shown to alter mood in 
approximately 50% o f depressed patients (Pflug and Tolle, 1971; van den Burg and van
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den Hoofdakker, 1975; Post et al., 1976; Wu and Bunney, 1990). In addition, studies 
have shown that REM sleep deprivation specifically can also change mood in depressed 
patients (Vogel et al., 1975). Changes in sleep patterns are among diagnostic criteria for 
mood disorders such as major depression (DSM-IV). These changes seem to become 
more pronounced with increasing age (Ulrich et al., 1980, Gillin et al., 1981; Thase and 
Kupfer, 1987; Kerkhofs et al., 1988; Knowles and MacLean, 1990; Reynolds et al., 
1990; Lauer et al., 1991; Benca et al., 1992; Buysse and Kupfer, 1993; Cartwright,
1993). This may be because depression has been suggested to accelerate or exaggerate 
the normal physiological processes associated with ageing (Ulrich et al., 1980; Feinberg 
and Caro11, 1984; Thase and Kupfer, 1987). During major depression, up to 90% o f 
patients will show some sleep disruption (Reynolds and Kupfer, 1999), often with 
complaints o f a difficulty falling asleep, subjectively frequent awakenings, subjective 
early morning awakenings, a feeling o f nonrestorative sleep, and disturbing dreams 
(Benca, 1994). Conversely, some complaints during atypical depression or bipolar 
disorder are o f  extended sleep periods with a difficulty awakening, and excessive 
daytime sleepiness (Detre et al., 1972).
Subjective reports o f  sleep disturbance in depression are supported by objective 
changes in sleep architecture. These include a prolonged objective sleep latency, an 
increased amount o f  waking during sleep, early morning awakenings, sleep 
fragmentation and reduced sleep efficiency (Zung et al., 1964; Gresham et al., 1965). In 
addition, some studies have noted a reduction in the amount o f slow-wave sleep (SWS) 
(Berger et al., 1982; Borbely et al., 1984; Kupfer et al., 1985) or a change in the 
distribution o f  SWS (Kupfer et al., 1986), which did not appeal* to correlate with 
reductions in total sleep time or the disturbed sleep continuity (Kupfer et al., 1986). 
There also appears to be a decrease in the latency to REM sleep in depression (Akiskal 
et al., 1982; Berger et al., 1982; Akiskal et al., 1984; Jones et al., 1985; Kupfer et al., 
1985; Quitkin et al., 1985; Kupfer et al., 1989; Waller et al., 1989; Emslie et al, 
1990a/b), and in psychotic depression, sleep onset REM has been noted (Ulrich et al., 
1980; Thase et al., 1986). In addition, an increase in the first REM period duration is 
often observed (Berger et al., 1982; Feinberg et al., 1982b; Borbely et al., 1984), with 
increased REM density (Foster et al., 1976; Jones et al., 1985; Kupfer et al., 1985; 
Waller et al., 1989), and an increase in overall REM time during the night (Berger et al., 
1982; Waller etal., 1989).
Despite this strong association between depression and sleep disturbances, there 
is little evidence for associations between specific sleep changes and depressive
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subtypes (Giles et al., 1987; Goetz et al., 1987). However, changes in sleep patterns can 
distinguish patients with depressive symptoms from patients with other disorders, for 
example anxiety (Reynolds et al., 1983) and dementia (Reynolds et ah, 1988). In 
addition, studies have shown a lack o f association between clinical ratings o f  depression 
and sleep abnormalities (Berger et al., 1982; Feinberg et al., 1982a; Kumar et al., 1987). 
The presence o f  a sleep disorder does not indicate depression, and depressed mood 
alone does not produce polysomnographic abnormalities (Giles et al., 1990). However, 
evidence from family studies has shown the reduction in REM latency may be a trait 
marker for depression, if  not a reliable state marker (Giles et al., 1989, 1990). This 
demonstrates the difficulty in assessing sleep changes in depression. There is always a 
‘ chicken and egg’ problem when trying to decide whether sleep changes are a ‘ cause’ 
depression, or a ‘ symptom’ o f depression. Whichever is the case, there is strong 
evidence for a link between depression and sleep abnormalities.
6.2.2 Antidepressants as Sleep Aids
The next progression from the link between depression and sleep is the idea that 
antidepressants may make effective hypnotics or sleep aids. It is possible that the 
positive effect o f  some antidepressants on the sleep o f  depressed patients may improve 
the sleep o f  those without depression, or in cases where mood is low. It is therefore 
understandable that general practitioners may favour* the prescription o f antidepressants 
above hypnotics for their older patients. Mood has increasingly been found to be low in 
the elderly due to circumstances such as retirement and boredom, ill health, and poverty 
(Monk et al., 1991). It is suggested about 20-30% o f those over 60 year’s o f  age may be 
affected to the point that pharmacological intervention is required (Darcourt, 1984). 
Delle Chiaie et al. (1990) have suggested older adults may have a vulnerability to 
stressors via altered psychoneuroendocrine reactivity. Whatever the reason or reaction, 
antidepressant prescription in this age group may improve quality o f  life with respect to 
mood and sleep. However, despite many antidepressants being increasingly used as 
sleep aids, Kupfer and Reynolds (1997) and Wagner, Wagner and Hening (1998) 
suggest there is little evidence from controlled trials to show antidepressants improve 
sleep in patients with insomnia but no depressive symptoms.
There are many forms o f  antidepressant, and a by-product o f  their mechanism is 
thought to be changes in sleep architecture (Anderson, 2001). Most antidepressants act 
primarily by inhibiting reuptake in the monoaminergic system (Paes de Sousa and
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Tropa, 1986; Hobson et al., 1998). Vogel et al. (1990) reviewed 251 studies on 
antidepressants between 1962 and 1989, and found almost all antidepressants decrease 
REM sleep time, leading to REM rebound on discontinuation. The influence o f the 
antidepressant on the noradrenergic and serotonergic systems may lead to impeded 
REM sleep via anticholinergic mechanisms. However, this explanation is confused by 
an increase in REM sleep noted with antidepressants such as amfebutamone. The 
increase in REM is suggested to be due to the lack o f  inhibitory effect on serotonin 
reuptake (Seeman, 1993), but explanations as to why amfebutamone is still an effective 
antidepressant are unclear.
The effects o f antidepressants on NREM sleep are less consistent than the effects 
on REM sleep. Some studies have shown an increase slow-wave sleep (Ruigt et al., 
1990), a decrease SWS (Brezinova et al., 1977) or no changes (Taylor et al., 1995). 
TCAs and venlafaxine are thought to redistribute SWS to the first part o f the night, and 
it is postulated that serotonin has a role in the regulation o f SWS (Sharpley et al., 1994). 
It is unclear, however, as to how an effect on SWS relates to antidepressant efficacy 
(Staner et al., 1999), but Ehlers et al. (1996) foimd the redistribution o f SWS indicated 
clinical response. Indeed, changes in distribution may reflect normalisation o f  SWS in 
depression (Thase, 1998).
It is more widely thought that the amount o f REM suppression effected by the 
antidepressant is the key to predicting clinical response, despite the lack o f association 
between ratings o f  depression and sleep abnormalities (Gillin et al., 1978b; Kupfer et 
al., 1981; Hochli et al., 1986; Monti, 1989; Vogel et al., 1990). Thase et al. (1996, 1997) 
have suggested depressed patients with increased REM latency, reduced REM density 
and increased sleep efficiency may respond better to psychotherapy rather than 
psychopharmacology. However, many studies have found no relationship between 
decreased REM sleep and the alleviation o f  depression (Ware et al., 1989; Staner et al., 
1995; Van Bemmel et al., 1995).
6.2.2.1 Tricyclic Antideuressants (TCAs)
Whilst there are distinct differences between the different kinds o f  tricyclic 
antidepressants (TCAs), there are common mechanisms to all. Both serotonin and 
noradrenaline reuptake are blocked. The resulting increase in serotonin and 
noradrenaline alters sleep patterns and are thought to account for the antidepressant 
effect o f  these drugs (Hollister, 1987). In addition, TCAs are also antagonists o f  the
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anticholinergic-muscarinic system (Richelson and Nelson, 1984), which can lead to 
anticholinergic effects such as memory impairment, constipation, visual disturbances, 
and dry mouth; the ai-adrenergic system, which can lead to effects such as dizziness 
and falls; and the histaminergic system, which can lead to effects such as sleepiness, 
impaired psychomotor function and weight gain. All five mechanisms are thought to 
cause drowsiness, hence the use o f TCAs as hypnotics.
Any antidepressant effects o f  TCAs can take up to a fortnight to appear (Joint 
Formulary Committee, 2002). The main effect o f  most TCAs is the suppression o f  REM 
sleep (Kupfer et al., 1982). This means an increase in REM latency and a decrease in 
REM time and percentage. This occurs from the first night o f administration, and is 
followed by REM rebound on cessation (Herdman et al., 1993). TCAs increase sleep 
continuity (meaning fewer awakenings), and either increase slow-wave sleep (SWS) in 
healthy individuals (Feuillade et al., 1992) or not (Hartmann and Cravens, 1974). This 
inconsistency is also present in depressed individuals, as amitriptyline has been found to 
increase SWS in depressed patients (Gillin et al., 1978a) but not in healthy individuals 
(Hartmann and Cravens, 1974).
TCAs are associated with a high incidence o f poor compliance (Martin et al., 
1997), thought to be due to their sedating effects (Donoghue et al., 1996; Hale, 1997). 
Stanley et al. (1999) suggests dothiepin reduces activity in depressed patients, which 
contributes to this poor compliance. However, Barbui et al. (2001) found fewer 
dropouts on dothiepin than SSRIs. The authors found SSRIs can enhance anxiety, 
despite the use o f  some SSRIs as anxiolytics. SSRIs such as citalopram can increase 
anxiety before having an anxiolytic effect. TCAs include drugs such as dothiepin, 
imipramine, trimipramine, amitriptyline, doxepin, and clomipramine.
6.2.2.2 Monoamine Oxidase Inhibitors ('MAOIs)
Monoamine oxidase destroys noradrenaline, and so reduces the amount o f 
available noradrenaline. The main mechanism o f MAOIs is to inhibit monoamine 
oxidase, thereby increasing the amount o f  noradrenaline, which is thought to provide an 
antidepressant effect. MAOIs produce a similar effect to TCAs but via this alternative 
method (Staner et al., 1999). However, unlike the TCAs, the effects o f MAOIs are non- 
reversible, so do not stop their effects on cessation o f treatment. They are also non- 
selective, which can lead to many adverse events, such as sleep disturbances, dizziness, 
gastrointestinal disorders and headache (Fitton et al., 1992).
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The sleep effects o f  MAOIs are also very similar to TCAs, as there is little effect 
on SWS (Wyatt et al., 1971b; Kupfer and Bowers, 1972), an initial potent suppression 
o f  REM (Bowers and Kupfer, 1971; Wyatt et al., 1971a/b), with REM rebound on 
discontinuation (Staner et al., 1999). However, MAOIs tend to impair sleep continuity, 
leading to increased insomnia (Feighner and Cohn, 1985). This is problematic as an 
increase in insomnia may lead to poor patient compliance (Annitage, 1996). Also, it 
makes MAOIs unsuitable as a hypnotic. Poor patient compliance also occurs because o f  
the widely documented ‘ cheese reaction’ (Staner et al., 1999). Patients must adhere to a 
strict diet low in tyramine, which is found foods like mature cheese, and meat and yeast 
extracts. Tyramine increases noradrenaline, and in combination with MAOIs may 
increase noradrenaline causing dangerous levels o f  blood pressure (hypertension) 
(Staner et ah, 1999). MAOIs are therefore probably unsuitable for patients with 
insomnia, and are difficult to take because o f  dietary restrictions. MAOIs include drugs 
such as phenelzine, tranylcypromine and isocarboxazid.
6.2.2.3 Reversible Inhibitors o f  Monoamine Oxidase (R-MAOIs or RIMAs)
The alternatives to MAOIs are RIMAs. These are reversible MAOIs, so can 
withstand abrupt cessation. They have greater selectivity for the serotonin pathway, 
resulting in fewer adverse effects than MAOIs. Also, there is no ‘ cheese reaction’ 
associated with concomitant tyramine intake, so no strict diet is required with taking 
RIMAs (Staner et ah, 1999).
RIMAs also suppress REM to a lesser degree than MAOIs, and there is also less 
REM rebound on cessation (Monti et ah, 1990; Minot et ah, 1993). Again RIMAs do 
not affect SWS (Monti et ah, 1990; Minot et ah, 1993). RIMAs may make suitable 
hypnotics due to their enhancing effects on sleep continuity, as they can reduce the 
number o f  awakenings (Monti et ah, 1990). However, this is disputed by Minot et ah 
(1993), and more research is needed into the suitablility o f  RIMAs as sleep enhancers. 
RIMAs include drugs such as moclobemide, brofaromine, and cimoxatone.
6.2.2.4 Selective Serotonin Reuvtake Inhibitors (SSRIs) and Specific Serotonin and 
Noradrenaline Reuvtake Inhibitors (SNRIs)
These classes o f antidepressant are thought o f  as the newer antidepressants, and 
both selectively inhibit the reuptake o f  serotonin and/or noradrenaline. These
Chapter 6
241
antidepressants have the least affinity for the muscarinic, a-adrenergic and 
histaminergic receptors, so they are less likely to show the same types and severities o f 
adverse effects found with TCA use (Staner et al., 1999). SSRIs and SNRIs have been 
foimd to be as effective as TCAs in treating depression (Kupfer et al., 1991; Van 
Bemmel et al., 1993; Staner et al., 1995).
Studies have shown within-class differences in SSRIs and SNRIs with respect to 
their effects on sleep. SNRI mirtazapine increases sleep continuity and increases SWS 
in healthy subjects (Ruigt et al., 1990), whilst in depressed patients, SNRI venlafaxine 
impairs sleep continuity without affecting the amount o f  SWS, although there is 
evidence that SWS may be shifted to the beginning o f  the night (Luthringer et al., 
1996). In contrast, SSRIs are generally thought to have no effect on SWS in healthy 
(Nicholson and Pascoe, 1986; Saletu et al., 1991; Sharpley et al., 1996) or depressed 
individuals (Shipley et al., 1984; Kerkhofs et al., 1990; Kupfer et al., 1991; Van 
Bemmel et al., 1993; Staner et al., 1995). Similarly to TCAs, SSRIs and SNRIs suppress 
REM sleep by increasing REM latency and decreasing REM duration (Nicholson and 
Pascoe, 1986; Saletu et al., 1991; Luthringer et al., 1996). However, it is not likely that 
SSRIs and SNRIs would make effective hypnotic drugs. They can decrease total sleep 
time and sleep efficiency (Nicholson and Pascoe, 1986; Saletu et al., 1991; Sharpley et 
al., 1996), and can have a significant alerting effect. This may induce arousals in sleep, 
compromising the sleep continuity in both healthy and depressed individuals (Dechant 
and Clissold, 1991). SNRI drugs include venlafaxine, and mirtazapine, and SSRI drugs 
include citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
6.2.3 Antidepressant Use in Older Adults
As previously mentioned, the prescription o f  antidepressants to older adults with 
low mood and insomnia may aid both these problems (Rees and Risdall, 1976). It is also 
possible that the prescription o f  antidepressants to the older adult with insomnia, but 
without depressive symptoms, may be o f benefit. As with hypnotics, the prescription o f 
antidepressants to the elderly must be done with the same caution and considerations, as 
older adults seem to become more sensitive to the side effects o f  medication (Anderson, 
2001). As previously described, drugs such as TCAs are associated with many 
detrimental anticholinergic adverse events (Anderson, 2001), such as gastro-intestinal 
disturbances, visual disturbances, dizziness and drowsiness. These side effects may 
decrease quality o f  life and increase accident risk (Lader, 1997).
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It appears the antidepressant groups with the fewest adverse effects are the 
SSRIs and SNRIs, due to the reduced risk o f  anticholinergic effects and the greater 
serotonin selectivity (Ramaekers et al., 1995). However, it is suggested these 
antidepressants do not make useful hypnotics. Their alerting effects can decrease sleep 
continuity and increase wakefulness dining the sleep period (Wilson et al., 2000), 
making then generally unsuitable sleep aids. In addition, MAOIs may also provide poor 
sleep aid due to their disrupting effects on sleep continuity.
Despite the risk o f  detrimental side effects, TCAs are the most sedating o f 
antidepressants, and can improve sleep continuity. However, an alternative hypnotic 
may be available in RIMAs. These improve sleep continuity, but are not associated with 
as many adverse events as TCAs, and do not require the dietary restrictions o f MAOIs. 
It is therefore likely that TCAs and RIMAs are the antidepressants that will provide the 
best improvement in insomnia. Indeed, this seems to be in practice, as the survey o f  the 
elderly in chapter 3 revealed 5.0% o f prescription users for sleep problems used TCAs 
(0.5% o f all 5846 respondents), compared to only 0.3% using SSRIs (0.03% o f all 5846 
respondents). As an additional prescription medication for sleep problems, 6.2% o f 
additional users took TCAs, compared to no SSRIs being taken as secondaiy 
prescriptions. However, there were no reports o f  RIMAs being used as a sleep aid.
To assess antidepressants as sleep aids, a TCA (dothiepin) and a RIM A 
(moclobemide) will be compared to each other and placebo. This will investigate their 
effects on sleep, and will assess any detrimental adverse events which may occur. To 
avoid the confounding effects o f old age, young volunteers will again be used to 
ascertain the true effects o f  these antidepressants. In the same manner, healthy 
participants (as opposed to those with depression) will be used to assess these drugs. 
Healthy participants will be used to mimic the administration o f antidepressants to those 
with sleeping problems, and no depressive symptoms. Anderson (2001) found the level 
o f  depression o f participants used in patient studies could confound conclusions about 
the effects o f  antidepressants. Also, there are documented differences between the 
hypnotic-induced changes in sleep o f  insomniacs and normal volunteers (Kryger et al. 
(1991). This difference is also seen between the response o f  normal volunteers and 
depressives to antidepressants. However, this difference is not seen between normal 
volunteers and insomniacs with respect to antidepressants. Therefore, the use o f healthy 
normal volunteers in this study is justified because they are thought not to differ in 
response to antidepressants from insomniac patients, and also studying healthy
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participants helps to minimise the introduction o f other psychiatric illnesses, or co­
medication (Dingemanse et ah, 1998b).
6.2.4 Dothiepin
Dothiepin has been chosen for assessment because it was one o f the most 
popular TCAs used, according to the survey o f the elderly in chapter 3. Dothiepin was 
used by 1.7% o f prescription users (0.2% o f all 5846 respondents), and 3.1% o f 
secondary prescription users. Dothiepin has been available since 1969 (Donovan et al., 
1994), and Stephenson et al. (2000) and Wilson et al. (2000) both suggest dothiepin is 
the most commonly prescribed and used antidepressant in the U.K. For the treatment o f 
depression, dothiepin has been found as effective as fluoxetine (Mullin et al., 1988), 
mianserin (Paes de Sousa and Tropa, 1986; Blacker et al., 1988), amitriptyline, and 
trazodone (Blacker et al., 1988).
Dothiepin is a dibenzothiepine tricyclic antidepressant, with a recommended 
daily dose o f 75mg initially, increasing to 150mg after a week or so o f  treatment (due to 
initial adverse events) (Joint Formulary Committee, 2002). Doses can rise to 225mg 
under hospital conditions. Peak plasma concentration is achieved 2 to 4 hours after 
ingestion o f a single oral dose, and the elimination half-life has been found to be 
between 14.4 and 23.9 hours (Yu et al., 1986), which is greater than the half-life o f 
SSRIs (for example, the elimination half life o f  fluoxetine is only 1-3 hours (Farid et al.,
1986)). There is great inter-subject variation, but it is thought time to peak plasma 
concentration, distribution time and the elimination half-life are all increased in the 
elderly, as with most drugs (Ogura et al., 1983a). Again this is due to the decreased 
metabolic rate in older adults. The recommended daily dose for the elderly is 50-75mg, 
and increases are made with caution (Lancaster and Gonzales, 1989). Steady-state 
plasma concentration can take up to a fortnight to achieve in young adults (Ramaekers 
et al., 1995). It is unclear if  this coincides with the onset o f  therapeutic effect. 
Mendlewicz et al. (1980), in a study o f  32 uni- or bi-polar depressives, found 
improvements in the Hamilton Depression Rating Scale coincided with serum 
concentrations after 4 weeks dose o f  200mg. However, using 10 major depressives and 
the same scale, Maguire et al. (1982) found no association with therapeutic 
improvement and serum concentrations o f  150mg o f dothiepin over 4 weeks.
Dothiepin, like other TCAs, facilitates noradrenergic and serotonergic 
neurotransmitters, although the delay in therapeutic response may indicate the
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antidepressant effect may be due to secondary responses (Lancaster and Gonzales, 
1989). Dothiepin also shows the characteristic TCA antagonism o f muscarinic 
receptors, and histamine receptors (Lancaster and Gonzales, 1989).
6.2.4.1 Psychometric. Psychomotor and Cognitive Effects o f  Dothiepin
The main effect o f  dothiepin on performance is its sedating effect. Hindmarch et 
al. (1992) found sedation can carry over into the day after dosing, and can impair 
daytime performance. For example, at 1.5 hours post 50mg dose o f  dothiepin, 
Hindmarch (1987) found increases in sedation. However there is some disagreement as 
to whether this actually affects daytime performance. At 1.5 and 3 hours post dose, 
Allen et al. (1993) studied 12 healthy males on a single dose o f  20mg, and found 
dothiepin impaired attention, visual information processing and episodic memoiy, and 
an impairment o f  focused and divided attention was also foimd by Weinstein et al.
(1996) studying six healthy male volunteers on a dose o f lOOmg o f dothiepin.
As dothiepin is usually taken before bedtime, to make use o f  its sedating effects 
(Pearce and Linford Rees, 1974), a more useful study design is the examination o f  the 
effects o f  dothiepin the day after the evening ingestion. A study by Wilson et al. (2000) 
in 12 young males showed a single evening dose o f lOOmg dothiepin reduced quality o f  
sleep (as measured by the LSEQ), but there were no morning-after effects on saccadic 
eye movements, mood scales, visual attention, tracking, or short-term memoiy. In 
agreement, Ramaekers et al. (1995) foimd no effect o f  22 days o f  150mg dothiepin on 
actual driving performance, LSEQ or LARS, although there was a decrease in sustained 
attention on the first day. In 7 yoimg and 7 elderly patients, Ogura et al. (1983a/b) found 
a low dose (25mg) o f dothiepin did not alter CFF, whereas amitriptyline did show a 
decrement. Stille and Herberg (1989) administered 75mg o f dothiepin per day rising to 
150mg after one week, and found no psychometric effects on 48 healthy volunteers after 
19 days, except a slight concentration impairment. Fairweather et al. (1999) studied 63 
patients with major depression aged between 18 and 70 years o f age, on 6 weeks o f 
fluoxetine 20mg or dothiepin 75mg, rising to 150mg after one week. They found no 
significant next day effects o f  serial subtraction, Kim’s Game (a test o f  short-term visual 
memoiy), LSEQ getting to sleep and quality o f sleep, and MESS (Milford-Epworth 
Sleepiness Scale). However, some psychometric effects under dothiepin have been 
noted. Fairweather et al. (1999) also found alertness following sleep (using the LSEQ)
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was significantly impaired, again showing sedative effects, and that CFF was 
significantly reduced under dothiepin compared to fluoxetine. Rees and Risdall (1976) 
found 75mg o f dothiepin in 74 depressed patients improved mood over 4 weeks, but 
also found increases in anxiety and insomnia.
In summary, there seems to be strong evidence for a sedative effect o f dothiepin, 
although Lancaster and Gonzales (1989) suggest these effects are not excessive, and are 
similar to those o f mianserin and trazodone. It is unclear as to whether standard doses 
(75mg to 150mg) cause significant impairment o f performance the day after dosing. 
Table 6.1 shows a summary o f these effects.
6.2.4.2 Effects ofDothievin on Sleep
There are veiy few studies investigating the effects o f  dothiepin on sleep, in both 
healthy and depressed individuals (Wilson et al., 2000). This antidepressant needs 
further assessment in this respect. Dothiepin has been found to increase quality and 
duration o f  sleep (Akhtar et al., 1984). Blacker et al. (1988) studied 227 depressed 
patients for 6 weeks on trazodone 150mg, mianserin 30mg rising to 60mg after one 
week, amytriptyline and dothiepin 75mg rising to 150mg and lOOmg after one week, 
respectively. Blacker et al. (1988) foimd dothiepin was superior to mianserin in 
improving getting to sleep and quality o f sleep (as measured by LSEQ). Stephenson et 
al. (2000) gave dothiepin 75mg rising to 150mg after one week, and fluoxetine 20mg, to 
107 major depressives aged 22 to 70 years old for 6 weeks. They found improvements 
in getting to sleep and quality o f  sleep, although more patients reported drowsiness 
under dothiepin than fluoxetine.
In a comprehensive study completed by Wilson et al. (2000), 12 yoimg males 
were given single doses o f  dothiepin lOOmg and fluvoxamine lOOmg. The authors 
found REM suppression and an increase in REM latency, which is characteristic o f 
TCAs. However, there was less o f an increase in REM latency under dothiepin than 
fluvoxamine, which the authors attribute to differences in pharmacokinetics. Dothiepin 
was found to increase sleep continuity and increase total sleep time. Sleep efficiency 
was increased, sleep latency was reduced, and there was also a reduction in stage 1 
sleep. Increases in stage 2 were explained as a result o f participants in the dothiepin 
group going to bed earlier, and therefore achieving more sleep, and so more stage 2 
sleep. Wilson et al. (2000) also found an increase in SWS, and suggest TCAs may 
increase SWS due to their effects on serotonin. Sedative effects were again noted, as
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MSLTs (Multiple Sleep Latency Tests, where the daytime sleep latencies o f  participants 
are measured), revealed an increase in daytime sleepiness compared to placebo.
In summary, dothiepin seems to have useful effects on sleep, such as improving 
getting to sleep, the quality o f  sleep, sleep efficiency, total sleep time and reducing 
waking after sleep onset. Table 6.2 shows a summary o f  these effects.
6.2.4.3 Safety and Toler ability o f  Dothiepin
The major problem with prescribing dothiepin is the adverse events that can 
occur*. This is especially relevant to the elderly, as dothiepin has been found to be more 
poorly tolerated in the elderly than the young (Anderson, 2001). Dollery (1999) 
questions the safety o f dothiepin in the elderly, and Stephenson et al. (2000) 
recommends a reassessment o f  its use in this patient group. Indeed, it has been shown 
that accident risk is increased in the elderly on high doses o f  TCAs (Leveille et al.,
1994). In addition, dothiepin has been found to be toxic in overdose, causing 
convulsions, coma and respiratory depression (Lancaster and Gonzales, 1989). This 
toxicity profile is not seen in the newer antidepressants. However, less suicidal 
tendencies have been reported under TCAs, as agitation occurs more often with SSRIs 
(Anderson, 2001).
Lancaster and Gonzales (1989) pooled adverse event (AE) data from 12 studies, 
and foimd diy mouth was the most common AE (24%). Ogura et al. (1983a) foimd dry 
mouth was particularly troublesome in the elderly, due to a reduction in salivary flow 
rate. Other AEs noted by Lancaster and Gonzales (1989) included drowsiness (16.8%), 
gastrointestinal disorders (10.8%), dizziness (10.3%), tremor (8.5%), sweating and 
insomnia (5.7%), blurred vision (4.5%), weight gain (3.5%), palpitations (2.8%), and 
hypotension and headache (1.9%). Rees and Risdall (1976) found 75mg o f  dothiepin 
taken once a day over 4 weeks resulted in drowsiness (35%), diy mouth (32%), 
dizziness (18%), sweating (16%), tremor and visual disturbance (12%), bowel 
disturbance (9%), and micturation difficulty (1%). Ramaekers et al. (1995) found 
150mg o f  dothiepin led to dry mouth (33%), headache (27.8%), shakiness (22.2%), and 
fatigue, concentration problems, and difficulty waking up (16.7%). They also noted that 
AEs were no more frequent under 150mg dothiepin than 20mg fluoxetine. This was also 
foimd in the study by Fairweather et al. (1999), in a study o f 84 depressed patients aged 
18 to 70 years old, taking dothiepin 75mg and fluoxetine 20mg for 6 weeks. However, 
Stephenson et al. (2000) noted that dothiepin tended to be worse for diy mouth,
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constipation, dizziness, tremor, drowsiness, disturbed sleep, dyspepsia, vomiting, 
orthostatic hypotension, tachycardia, and fainting, whereas fluoxetine tended to elicit 
more anxiety, nausea, headache, sweating, and rashes. It may not be that dothiepin has 
‘more’ or ‘worse’ AEs, but that it is associated with different AEs to other classes o f  
antidepressant. Indeed, there are less AEs under dothiepin than mianserin (Paes de 
Sousa and Tropa, 1986), and a review by Donovan et al. (1994) concluded that AEs 
under dothiepin are inconvenient rather than serious.
In summary, dothiepin displays many anticholinergic AEs (such as 
gastrointestinal disorders, tachycardia and dizziness), but the biggest problem seems to 
be sedation. Dosing regime can help this, as Pearce and Linford Rees (1974) found a 
lower single dose was more effective as an antidepressant than a higher dose spread out 
over 3 doses during the day. These authors suggested taking dothiepin in the evening 
would aid sleep, and that detrimental sedative effects would be greatly reduced or 
absent by morning.
6.2.5 Moclobemide
Moclobemide, as a RIMA, may have potential to make a usefiil antidepressant 
and/or hypnotic, but it was not specified as being used by any o f  the 5846 older adults 
surveyed in chapter 3. This is probably due to the increase in use o f newer 
antidepressants like SSRIs. Nevertheless, moclobemide may be a useful hypnotic for the 
elderly, and requires investigation to that effect.
It has been suggested that monoamine oxidase (MAO) can inhibit neuronal and 
non-neuronal cells (Greenawalt, 1972), and the form MAO-A may play a role in 
depression. MAO-A can deaminate serotonin, noradrenaline and adrenaline, and can 
affect tyramine and dopamine (Strolin Benedetti and Dostert, 1987). It was found that 
an inhibitor o f  MAO-A made an effective antidepressant (Youdim and Finberg, 1983). 
Original monoamine oxidase inhibitors (MAOIs) showed similar effects to TCAs, with 
a reduction in REM sleep and an increase in REM latency, with REM rebound on 
discontinuation (Cohen et al., 1982). However, MAOIs are not practical due to their 
interaction with tyramine if  taken with tyramine rich foods, as previously described.
Moclobemide is a reversible-MAOI (RIMA), first launched in 1993 (Mackay et 
al., 1999). It still inhibits MAO-A, but can be removed easily on cessation, so can be 
stopped abruptly for surgery, for example (Fitton et al., 1992). No restrictive diet is 
necessary for moclobemide use, as it does not have the same interaction with tyramine.
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The recommended daily dose is 300-450mg, which is usually divided into 2 or 3 doses. 
It is suggested that the dosage does not need to be adjusted for the elderly, as Stoecktel 
et al. (1990) and Maguire et al. (1991) found no difference between intravenous and oral 
absoiption, distribution and elimination in healthy and depressed older adults, 
respectively. Peak plasma concentration occurs after 1 to 2 hours following a single oral 
dose o f  50-300mg in healthy individuals (Schoerlin et al., 1991), although an effect is 
seen with food whereby eating 30 minutes before ingestion can slow down the 
absoiption rate (Schoerlin et al., 1988). The elimination half-life is a short 3 hours 
(Dingemanse et al., 1998a), so the effects o f  moclobemide last for approximately 8 
hours (Blois and Galliard, 1990), and a steady-state plasma concentration is achieved 
after one week o f  standard administration (Schoerlin et al., 1987). Some researchers 
have suggested moclobemide is not an antidepressant, as they found no difference in 
efficacy compared to placebo (Larsen et al., 1989; Ose and Holm, 1992). However, 
Fairchild et al. (1986) suggest this is due to moclobemide being more effective for some 
types o f  depression than others. Other researchers have found moclobemide comparable 
to amitriptyline 125-250mg/day (Beckers et al., 1990), imipramine 75-150mg/day 
(Casacchia and Rossi, 1989), maprotiline 75-225mg/day (Burner, 1990), mianserin 75- 
150mg/day (De Vanna et al., 1990), and fluvoxamine 100-200mg/day (Bourgerol et al., 
1992), for the treatment o f  major depression.
6.2.5.1 Psychometric, Psvchomotor and Cognitive Effects o f  Moclobemide
Research into the cognitive and psychomotor effects o f  moclobemide has been 
favourable. Tiller (1990) and Berlin et al. (1990a/b) concluded there were no morning- 
after psychometric effects o f moclobemide. Berlin et al. (1990b) gave 12 healthy male 
volunteers 450mg per day for 8 days, and found no effects on CFF, DSST, CRT, short­
term or long-term memory, and LARS. Hindmarch and Kerr (1992) also found no 
detrimental next morning effects o f  200-400mg o f  moclobemide on CFF, CRT, 
tracking, and short-term memory. Ramaekers et al. (1994) found no effect o f  a large 
dose o f moclobemide (600mg in three divided doses) on the actual driving performance 
o f  34 healthy young volunteers, Puchler et al. (1997) gave 10 young volunteers single 
doses o f  150mg and 300mg, and found both doses had no effect on CRT, auditory 
evoked potentials, visual analogue scales o f performance, effort, wakefiilness and 
excitation, and saccadic eye movements. Wesnes et al. (1989a/b) did find a slight 
impairment in number vigilance, after elderly (aged 60 to 75 years old) volunteers took
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100-300mg o f moclobemide. However, the authors also noted an improvement in 
memory.
It appeal’s moclobemide has very little effect on cognitive and psychomotor 
function, and Allain et al. (1992) suggests moclobemide may actually have a positive 
effect. They studied 37 major depressed outpatients for 42 days, at a dose o f 450mg per 
day (split into three doses). Results showed an increase in Critical Flicker Fusion (CFF) 
(an increase in alertness), decreased reaction times, no effect on verbal recall, increased 
response to delayed verbal recall, no effect on semantic organisation, no effect on word 
recognition, increased face recognition, and improved quality o f  life. This has lead 
Allain et al. (1992) to suggest moclobemide may actually be a ‘ cognitive facilitator’ . 
Indeed, Berlin et al. (1990a) found that 400mg o f moclobemide can remove the 
depressive effects o f alcohol on CFF. Allain et al. (1992) suggest this is either due to the 
administration o f moclobemide as a split dose, and so habituation to the sedative effect, 
or it is due to later emerging secondary effects. This facilitation o f  cognitive effects 
would be very useful to the elderly, who may be suffering from a decline in cognitive 
function due to ageing. Administration o f  moclobemide may help mood, sleep, and 
daytime performance. In summary, moclobemide is suggested to have veiy little effect 
on cognitive and psychomotor function. This is shown in table 6.3.
6.2.5.2 Effects o f  Moclobemide on Sleep
Moclobemide is often taken in divided doses throughout the day. This is done to 
maintain the antidepressant effect, as the duration o f  action is quite short. It is suggested 
this is the reason why moclobemide seems to have varied effects on sleep (Fitton et al., 
1992). Steiger et al. (1994) tested 3 males aged between 23 and 29 years for 21 days on 
300mg o f moclobemide, divided into three doses. They found there was no effect on 
sleep continuity and NREM sleep, and the REM suppression seen in most 
antidepressants was not continuous. There was only a slight REM rebound on 
discontinuation. Fitton et al. (1992) concludes that a lack o f  REM effect is characteristic 
o f moclobemide. However, another RIMA brofaromine shows clear REM suppression 
(Hoff et al., 1986). It is unclear as to why moclobemide appeai-s to be different (Monti,
1989); although it may be that efficacy simply wears o ff (Fitton et al., 1992). Berlin et 
al. (1990b) studied 12 healthy males between the ages o f  20 and 29 year old, for 8 days 
on 450mg moclobemide (three divided doses). There was no effect noted on subjective
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total sleep time, sleep latency and the number o f  awakenings. This agrees with 
Ramaekers et al. (1994) who studied 34 young healthy volunteers for 8 days on 200mg, 
and found no effects on subjective sleep duration or subjective sleep quality. Indeed, 
Blois and Galliard (1990) studied 10 healthy males and females, aged between 20 and 
28 years. A  low dose o f  moclobemide (4mg/kg) over two nights showed no effect on 
total sleep time (TST), sleep latency (SL), subjective sleep duration, and percentage o f 
wake time. There was also no change in SWS. However, the amount o f stage 1 and 
stage 2 sleep was increased, and there was a decrease in the amount o f REM sleep. A 
higher dose o f  moclobemide (6mg/kg) decreased TST, increased stage 2 on the first 
night, had no effect on SL, had no effect on the percentage o f  wake, there was no 
change in SWS, decreased REM, and had no effect on REM latency. Both doses 
showed some REM rebound on discontinuation. These authors found no hypnotic 
effect, and concluded the sleep effects in moclobemide are veiy weak in comparison to 
other antidepressants (agreeing with Jovanovic, 1979).
There is some evidence for an effect o f  moclobemide on REM sleep. Monti et al.
(1990), in a study o f  8 depressed patients on 300mg for 4 weeks, found a decrease in 
REM sleep duration, agreeing with Blois and Gaillard (1990). Monti et al. (1990) found 
sleep continuity was improved and there was an increase in stage 2 sleep, also there was 
REM suppression, albeit mild compared to the effects o f  MAOIs. Hoff et al. (1986) 
gave 300mg o f moclobemide daily for one month to depressed patients. There was no 
change in sleep continuity, but there was evidence o f  minimal REM suppression. 
Campos et al. (1994) found moclobemide in depressed patients improved sleep quality, 
reduced subjective number o f  awakenings, but had no effect on subjective SL. Monti 
(1989) spent 4 weeks investigating the effects o f  150mg moclobemide, rising to 300mg 
after the first week, on 6 unipolar manic-depressives, 3 major depressives and one 
atypical depressive. He foimd a decrease in time spent awake, an increase in TST, an 
increase in NREM (an increase in stage 2), no change in SWS, an increase in the 
amount o f REM towards the latter stages o f  the night, and an increase in REM latency. 
There was also a small REM rebound on withdrawal. All these studies show that the 
subjective effects o f  moclobemide on sleep are less reliable than the objective effects. 
Subjective effects seem to be influenced by time o f dosing and the amount o f dose. 
Most doses seem to improve sleep quality and continuity. Objectively, moclobemide 
seems to provide a modest REM suppression effect, with increases in NREM sleep 
rather than SWS. Sleep time and continuity are also favourably affected. Table 6.4 
shows some effects.
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6.2.5.3 Safety and Toler ability o f Moclobemide
Chapter 6
Moclobemide is reported to be safe and generally well tolerated, and it is less 
dangerous in overdose than TCAs (Beaumont and Hetzel, 1992). Fitton et al. (1992) 
pooled the data o f studies o f  less than 12 weeks duration, o f  doses up to 600mg, and 
found moclobemide was almost as well tolerated as placebo, Stabl et al. (1989) tested 
285 patients and found only nausea was more frequent under moclobemide than 
placebo. Other AEs found by Stabl et al. (1989) under moclobemide included: dry 
mouth (13%), headache and dizziness (10%), insomnia (7%), constipation and anxiety 
(5%), agitation, epigastric discomfort and fatigue (4%), tachicardia, tremor, diarrhoea 
and blurred vision (3%), and orthostatic hypotension (2%). Baumhackl et al. (1989) 
suggest the adverse event (AE) rate is less than non-reversible MAOIs, much better than 
imipramine (a TCA) because o f fewer anticholinergic effects (n=164, Versiani et al.,
1989), and is better than fluvoxamine (Bourgerol et al., 1992) and maprotiline (Burner,
1990). However, De Vanna et al. (1990) found that in the elderly, the AE rate for 
moclobemide and maprotiline are similar.
The AEs o f moclobemide are suggested to be well tolerated in the elderly, 
without much difference to younger adults (Versiani et al., 1990; Angst and Stabl, 1992; 
Amrien et al, 1997). However, Anderson (2001) in a review, suggested tolerance was 
lower in the elderly. In contrast, the results o f  the effects o f  moclobemide on cognitive 
functions in a study by Allain et al. (1992) suggested moclobemide could be beneficial 
to the elderly as a cognitive facilitator. This is supported by Pancheri et al. (1994), who 
also suggest moclobemide is a cognitive enhancer, due to increases in noradrenaline and 
dopaminergic activities (Zametkin et al., 1985).
Thiene (1986) and Breuel and Zimmer (1988) found moclobemide to be mildly 
sedative at 400-600mg, but sedation was not a common AE. Jouvent et al. (1998) 
studied 65 patients for 4 weeks on 450mg daily, and noted reports o f increased anxiety 
(12%), diy mouth (13%) and agitation (8%). It is thought some dropouts on 
moclobemide may be due to increases in anxiety. Monti (1989) studied 10 volunteers on 
moclobemide 300mg, and they reported a metallic taste in mouth, mild stomatitis, 
blurred vision, anxiety, constipation, headache, oedema o f the lower extremities, and 
changes in urinary frequency, Dingemanse et al. (1998b) foimd 600mg o f moclobemide 
was too large a dose with respect to AEs, and some volunteers nearly left the trials 
because o f  it. Also, Dingemanse et al. (1998b) found as many AEs on placebo as
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moclobemide, and these were similar in nature. There is little evidence to suggest that 
more detrimental AEs are foimd on moclobemide compared to placebo.
6.3 Aims
Fairweather and Hindmarch (1995) suggest there is little difference between the 
clinical efficacies o f  antidepressants, but there is great difference between their effects 
on cognitive functioning and psychomotor performance. Dothiepin is suggested to be 
sedative, and when taken in the evening, can improve sleep continuity, total sleep time, 
and sleep quality. The AEs are not serious, although troublesome effects do occur, and 
there is little evidence to suggest significant performance impairment the next day. It is 
suggested that moclobemide may have fewer AEs than dothiepin, and does not require 
the dietary restrictions o f  the MAOIs. Moclobemide also improves sleep continuity and 
quality, but with less REM suppression. There is very little evidence for daytime 
impairment. Both are considered to be adequately tolerated in the elderly, with perhaps 
a cognitive enhancing effect o f moclobemide. Either o f  these drugs may make suitable 
hypnotics in the elderly, whether or not depression is present. However, there is little 
research on the effects o f  dothiepin on sleep, especially in normal volunteers (Wilson et 
al., 2000), and little research about the possible sleep enhancing effects o f  
moclobemide. This study will investigate the suitability o f  these two antidepressants as 
sleep aids, with reference to sleep in the elderly. Also, assessing subjects the day after 
dosing is “clinically relevant” (p.379), as in practice most patients use antidepressants at 
bed time to take full advantage o f  any sedative or sleep enhancing effects (Wilson et al., 
2000). The next day effects o f  dothiepin and moclobemide are also very important. As 
with hypnotics, a measure o f their suitability are their effects the morning after dose. 
This is particularly relevant to the elderly, as they are sensitive to these effects. 
According to Wilson et al. (2000), taking antidepressants will affect daytime 
performance for two reasons: firstly, due to the effect o f  the drug, and secondly, due to 
the sort o f night’ s sleep the drug creates. Indeed, Stepanski et al. (1984) showed that 
fragmenting sleep by deliberate arousals lead to a daytime cognitive deficit. This study 
will investigate both o f  these aspects, and also will assess the suitability o f  these 
antidepressants with respect to adverse events.
Chapter 6
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6.4.1 Design
This study was a single centre, randomised, double blind, placebo controlled, 
five way crossover study using 15 normal healthy male volunteers. The use o f male 
volunteers was a prerequisite from the sponsoring pharmaceutical company. The 
independent variable is the medication under investigation, either moclobemide (450mg 
or 600mg), dothiepin (75mg or 150mg), or matched placebo. In accordance with a 
within-subject design, each volunteer received all o f  the test doses during different 
periods throughout the study. The dependent variables are the objective measures o f 
sleep EEG, subjective reports, and psychometric tests (see Procedure). Each treatment 
period was separated by a week washout period. The schedule o f  assessment is shown 
in table 6.5.
6.4 Methods
Test Period Pre-Screening Screening Treatm ent Days Post
Study
A lcohol screen X
Consent X (X ) .(X ) (X )
M edical examination X X
Laboratory screens 
(haematology and 
biochemistry)
X X
Sleep adaptation X
Adverse events, 
concurrent illness/ 
medication
X X X
Test training X
Drug administration X
Psychometric testing X
Sleep EEG X
Table 6.5 -  Scheduling o f  Assessments
To avoid any bias in the results, controls were placed over variables within the 
study. All participants slept in identical bedrooms, and a strict study schedule was 
adhered to. All adverse events (AEs) and concomitant medications were documented in 
the Case Report Forms (CRFs), for reference during data analysis. Participants gave full 
medical histories, which were corroborated by their general practitioners (GPs), and 
consent to participation in the study was obtained from the volunteers and their GPs. 
Participants in this study underwent a medical examination, and were screened for 
abnormal ECG, laboratory, biochemical or haematological values. All psychometric 
tests and mood scales were standardised, as were instructions for completion.
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Participants were practised on all psychometric tests until they reached a learning 
plateau, to remove any possibility o f  practise effects confounding results. In addition, a 
double-blind technique was implemented to avoid bias in the results via volunteers or 
experimenters. The test medication was in capsule form, and the placebo was matched 
to the active medications. All foods provided on the study nights were standardised and 
low in fat, and caffeine and alcohol was not permitted during test periods, or within 24 
hours before the study. This criterion was used to avoid any alerting effects o f caffeine 
which may confound the treatment effects. However, it is possible that withdrawal o f 
caffeine may have adverse effects, such as headache and sedation (Greden et al., 1980). 
The use o f medication other than oral contraceptives and non-steroidal painkillers 
throughout the duration o f  the study was forbidden. However, as mentioned in chapter 
4, some research shows some non-steroidal treatments can produce feelings o f sedation 
(Zacny et al., 1996), so more research is necessary into the implications o f  allowing this 
concomitant medication in these trials. The author o f this thesis contributed towards the 
implementation o f  the study and analysed all data.
6.4.2 Participants
The participants were all volunteers aged between 18 and 35 years old (mean 
age 25.3 years, sd 4.85), selected via their medical examinations from responses to the 
mailings o f  the HPRU Medical Research Centre volunteer database. There were 14 
healthy male volunteers in total. Volunteers were assigned a study number that 
randomly allocated them to a test pattern group, determining the order in which the test 
medication was administered.
Strict inclusion and exclusion criteria were used to select participants in this study, 
shown in table 6.6.
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• Males aged between 1 8 -3 5  years inclusive.
• A  body mass index greater than or equal to 18 and less than or equal to 30.
• In good health as determined by a medical histoiy, ECG, haematology, b lood  and urine biochemistry,
and physical examination by the doctor.
• Able and willing to give informed consent.
• Having the consent o f  the volunteer’s general practitioner.
The exclusion criteria were as follows:
• Current and past (in the last six months) use o f  tobacco or products containing nicotine.
• Current participation in another clinical trial, or participation in a clinical trial within the last 90 days.
• Concomitant psychotropic medication.
• Significant histoiy o f  mental illness, significant drug allergy, malignancy or chronic drug abuse 
(including alcohol).
• Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological or 
haematological disease or abnormality.
• Marked laboratory, biochemical, or haematological abnormalities not including isolated abnormalities 
which are considered to be clinically insignificant by the medical supervisor.
• Abnormal or unstageable EEG.
• A  sleep/wake cycle (e.g. shiftwork), liable to prejudice the results o f  the study.
• Any subject that the physician or investigator judges to be unsuitable. _______________________
Table 6 .6 : Inclusion and Exclusion Criteria
6.4.3 Materials and Measures
The inclusion criteria were as follows:
Materials used included psychometric software and computers, all 
questionnaires, Case Report Forms (CRFs), breath alcohol tester, height measure and 
weighing scales, ECG and medical examination equipment, EEG electrodes and 
application materials (tape measure, chinograph pencil, collodian glue, acetone, and 
chlorhexidine as a de-greaser), Nicolet Ultrasom digital EEG sleep recording 
equipment, and test medication (see Dosing).
Objective EEG was recorded with 4 EEG (C4-A1, C3-A2, 02-A1, 01-A2), 2 
EOG (electroocculograph) and 4 submental EMG (electromyograph) leads and 
Ag/AgCl electrodes on to a Nicolet Ultrasom digital EEG machine. Sleep stages were 
visually scored by one experienced rater according to the criteria o f  Rechtshaffen and 
Kales (1968).
Subjective and psychometric assessments were achieved using Critical Flicker 
Fusion (CFF), Choice Reaction Time (CRT), Sternberg Memoiy Test, Line Analogue 
Rating Scale (LARS), Leeds Sleep Evaluation Questionnaire (LSEQ), and the Milford- 
Epworth Sleepiness Scale (MESS).
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6.4.4 Dosing
Each test period lasted 2 nights, and volunteers received each o f  the five test 
doses, each period separated by a one week washout period. Each o f the doses were 
taken orally as a capsule with 100 ml o f  water, and were placebo matched. Volunteers 
received one treatment at 09:00 and one at 21:00 (matching the evening dose time in 
chapter 5). The doses used were moclobemide 450mg, moclobemide 600mg, dothiepin 
75mg and 150mg. Roche Products PTY Ltd. supplied all medication.
6.2.5 Procedure
Before the start o f  the study, all participants were required to attend the Unit for 
a one-night adaptation period. This period serves parts o f  a screening procedure, to 
check for anomalies in the participants trace, but also to familiarise the participants with 
the instrumentation used, and also the sleep bedrooms. Within a week o f  the adaptation 
night, the treatment phases began. Baseline nights were also recorded, one before the 
study and one after the study, to ensure EEG remained unchanged at the end o f  the 
study period.
For each study period, the following assessments were made: Sleep 
Electroencephalograph (EEG), Critical Flicker Fusion (CFF), Choice Reaction Time 
(CRT), Short Term Memory Test (SMT), Line Analogue Rating Scales (LARS), Leeds 
Sleep Evaluation Questionnaire (LSEQ), and the Milford-Epworth Sleepiness Scale 
(MESS).
On Day 1, participants arrived at the hospital at 08:00, were breathalysed, and 
underwent the baseline psychometric tests. Assessment o f  AEs and concomitant 
medication was made through the test period. Drugs were administered at 09:00, and 
psychometric tests were carried out throughout the day, at 2 hourly intervals (e.g. 11:00, 
13:00, 15:00, 17:00, and 19:00). At 21:00, a second dose was given. During the 
evening, participants had EEG electrodes attached to their face and scalp for the 
overnight EEG sleep recording, in accordance with the 10-20 electrode placement 
system (Jasper, 1958). Lights out was at 23:00, and the EEG recordings ran from 23:00 
to 07:00 the next morning.
On Day 2, participants were awoken at 07:00, and baseline psychometric tests 
were completed. Drug administration was again at 09:00, and again psychometric tests
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were completed at 2 hourly intervals throughout the day. The second dose was at 21:00, 
and a second night’ s sleep EEG was recorded at 23:00 imtil 07:00 the next morning.
On Day 3, participants were again awoken at 07:00, and baseline psychometric 
tests were completed. Drugs were administered at 09:00, and psychometric tests were 
completed throughout the day at 2 hourly intervals, until 19:00 when subjects left the 
hospital. The study timetable is shown in table 6.7.
Chapter 6
D ay Real Tim e Event
1 08:00 Participants arrive and are breathalysed. Baseline psychometric tests completed.
09:00 First drug administration o f  the day.
11:00-19:00 Psychometric testing at 2 hourly intervals.
21:00 Second drug administration o f  the day.
23:00 Lights out
2 07:00 Participants awoken, and baseline psychometric tests completed.
09:00 First drug administration o f  the day.
11:00-19:00 Psychometric testing at 2 hourly intervals.
21:00 Second drug administration o f  the day.
23:00 Lights out
3 07:00 Participants awoken, and baseline psychometric tests completed.
09:00 First drug administration o f  the day.
11:00-19:00 Psychometric testing at 2 hourly intervals.
20:00 Participants leave.
Table 6.7 -  Study Timetable for Each Treatment Period
6.5 Results
6.5.1 Statistical Analyses
Although there were 14 participants included in this study, not all could be used 
in analyses due to missing data points. Missing data points were either due to 
withdrawal from the study, or test failure. For all variables, a two-way repeated 
measures ANOVA analysis was used, chosen because o f  the within-subjects design and 
ratio level data. An epsilon correction (Greenhouse and Geisser, 1959) was enforced 
with these ANOVAs. This correction factor works to reduce the degrees o f freedom, 
introducing more stringent criteria for significance. This was done because o f  the large 
amount o f data for analysis, as a guard against inclusion o f spurious significant effects.
Tukey’s (HSD) test was used with more than two data sets, when a significant 
factor in the ANOVA analysis had two or more levels. Tukey’s is thought to be a 
conservative method o f  analysis, and can sometimes reject true effects. However, it is a 
thorough test and reduces in conservatism with large numbers o f  data groups, or data 
sets. As the amount o f  data in this study is large, it is thought to be the most appropriate
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test, to avoid inclusion o f  spurious significant effects. When Tukey’s found no 
significant effects, t-tests were then used to demonstrate significance.
All analyses were computerised, using CLR ANOVA 2,0 (Clear Lake Research 
Inc.) on an Apple Macintosh. Unfortunately, due to missing data points via computer 
and experimenter error, the numbers o f  volunteers included in some analyses fell to half 
the number actually tested. This decreases the power o f the analyses used, but can be 
restored if  the data is re-created using special statistical techniques, which do not alter 
the overall means. This technique was not employed in these analyses due to time 
constraints.
6.5.2 Psychometric Analyses
6.5.2.1 Choice Reaction Time (CRT) Recognition Reaction Time (RRT)
There were 14 participants included in this analysis, and only a significant effect 
o f  Time was noted (F(6.8, 88.4)=7.805, p<0.01). There was no significant effect o f 
Drug, meaning there was no significant difference between moclobemide and dothiepin, 
and placebo. These effects can be seen in graph 6.1, where error bars show one standard 
deviation above and below the mean. Post-hoc analysis using orthogonal t-tests revealed 
significant difference (p<0.05) between test point 1 and 8, 9, 10, 11, 18, 20, 21, test 
point 2 and 8, 10, 17, 18, 19, 20, 21, test point 3 and 18, 19, 20, 21, test point 4 and 8, 
10, 18, 19, 20, 21, test point 5 and 8, 10, 18, 20, 21, test point 6 and 7, 17, 18, 19, 20, 
21, test point 7 and 8, 10, 11, 18, 19, 20, 21, test point 8 and 9, 12, 14, 15, 17, 18, 19, 
20, 21, test point 9 and 17, 18, 19, 20, 21, test point 10 and 12, 13, 14, 15, 17, 18, 19, 
20, 21, test point 11 and 17, 18, 19, 20, 21, test point 12 and 18, 19, 20, 21, test point 13 
and 15, 17, 18, 19, 20, 21, test point 14 and 17, 18, 19, 20, 21, test point 15 and 18, 19, 
20, 21, test point 16 and 17, 18, 19, 20, 21, test point 17 and 21, test point 19 and 21, 
and test point 20 and 21. Means show recognition reaction time with drug collapsed 
follows a pattern o f  reaction time which is longer on the second day o f  testing than the 
first, and which is shorter on the last day o f  testing than the other days. Andreas (1972) 
suggests that in all tests, participants have a ‘warm-up’ , which is initial enthusiasm for 
the task, and an ‘ end spurt’ , which is a last attempt before the end o f  testing. It is 
possible, because the participants knew when their last day o f  testing was, that more 
initial and final efforts were made. Graph 6.7 shows this pattern. Although an
Chapter 6
261
interesting effect, this is not relevant to the drug analysis, and will not be investigated 
further here.
6.5.2.2 Choice Reaction Time (CRT) Motor Reaction Time (MRT)
There were 14 participants included in this analysis. The two-way repeated 
measures ANOVA with epsilon correction showed a significant effect o f Drug (F(2.72, 
35.36)=2.846, p<0.05) and Time (F(6.4, 83.2)=4.884, p<0.01), but no interaction. Post- 
hoc analysis using t-tests showed significant difference (p<0.01) between dothiepin 
150mg and moclobemide 450mg (motor reaction time was greater for moclobemide 
450mg than dothiepin 150mg). There was also significant difference (p<0.05) between 
dothiepin 150mg and dothiepin 75mg (motor reaction time was greater under the 75mg 
dose) and also between moclobemide 600mg and moclobemide 450mg (motor reaction 
time was greater under the 450mg dose). There was no significant difference between 
placebo and any test drug or dose. Graph 6.2 shows these results.
Post-hoc analysis using orthogonal t-tests showed significant differences 
(p<0.05) between test point 1 and 15, 21, test point 2 and 6, 7, 8, 15, 18, 19, 20, 21, test 
point 3 and 6, 7, 15, 21, test point 4 and 6, 7, 15, 21, test point 5 and 7, 9, 10, 11,17, 21, 
test point 6 and 9, 10, 11, 17, test point 7 and 8, 9, 10, 11, 12, 13, 14, 17, test point 8 and 
9, 10, 11, 17, 21, test point 9 and 14, 15, 18, 19, 20, 21, test point 10 and 13, 15, 16, 18, 
19, 20, 21, test point 11 and 13, 14, 15, 16, 18, 19, 20, 21, test point 12 and 15, 20, 21, 
test point 13 and 15, 17, 21, test point 14 and 15, 17, 21, test point 15 and 16, 17, test 
point 16 and 17, 21, and test point 17 and 18, 19, 20, and 21. Means show motor 
reaction time with drug collapsed follows a pattern o f  reaction time that is longer 
towards the end o f  the first day o f  testing, is longer on the second day o f testing, and 
which is shorter on the last day o f  testing compared to the other days. Graph 6.8 shows 
this pattern. Although an interesting effect, this is again not relevant to the drug 
analysis, and will not be investigated further here.
6.5.2.3 Choice Reaction Time (CRT) Total Reaction Time (TRT)
There were 14 participants included in this analysis, and a significant effect was 
only found for Time (F(6.8, 88.4)=9.402, p<0.01). There was no significant difference 
between moclobemide and dothiepin, and placebo. Graph 6.3 shows these results. Post- 
hoc analysis using orthogonal t-tests revealed significant difference (p<0.05) between
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test point 1 and 8, 9, 10, 11, 18, 20, 21, test point 2 and 8, 10, 17, 18, 19, 20, 21, test 
point 3 and 18, 19, 20, 21, test point 4 and 8, 10, 18, 19, 20, 21, test point 5 and 8, 10,
18, 20, 21, test point 6 and 7, 17, 18, 19, 20, 21, test point 7 and 8, 10, 11, 18, 19, 20, 
21, test point 8 and 9, 12, 14, 15, 17, 18, 19, 20, 21, test point 9 and 17, 18, 19, 20, 21, 
test point 10 and 12, 13, 14, 15, 17, 18, 19, 20, 21, test point 11 and 17, 18, 19, 20, 21, 
test point 12 and 18, 19, 20, 21, test point 13 and 15, 17, 18,19, 20, 21, test point 14 and 
17, 18, 19, 20, 21, test point 15 and 18, 19, 20, 21, test point 16 and 17, 18, 19, 20, 21, 
test point 17 and 21, test point 19 and 21, and test point 20 and 21. Means show total 
reaction time with drug collapsed follows a pattern o f reaction time which is longer on 
the second day o f  testing compared to the first, and which is shorter on the last day o f  
testing compared to the other days. Graph 6.9 shows this pattern. Although an 
interesting effect, this is again not relevant to the drug analysis, and will not be 
investigated further here.
6.5.2.4 Sternberg Memory Test (STM)
There were 13 participants included in this analysis. Significant effects were 
noted for Drug (F(2.72, 32.62)=11.535, pO .O l) and Time (F(4.4, 52.8)=3.724, p<0.01). 
Post-hoc analysis using Tukey’ s HSD showed significant differences (pO.Ol) between 
dothiepin 150mg and moclobemide 450mg, dothiepin 75mg, and placebo. Here, 
reaction times for memory were slower under dothiepin 150mg than moclobemide 
450mg, dothiepin 75mg, and placebo. Significant differences were also noted between 
moclobemide 600mg and moclobemide 450mg (pO.Ol) and dothiepin 75mg (p<0.05). 
Here, reaction times for memory were slower under moclobemide 600mg and 
moclobemide 450mg and dothiepin 75mg. The only significant difference from placebo 
was with dothiepin 150mg. Graph 6.4 shows these results. Post-hoc analysis o f  Time 
using orthogonal t-tests shows significant difference (p<0.05) between test point 1 and 
2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 18, 19, 20, 21, test point 2 and 7, 15, 16, 19, 20, 
21, test point 3 and 7, 10, 12, 13, 15, 16, 19, 20, 21, test point 4 and 15, 19, 20, 21, test 
point 5 and 6, 15, 19, 20, 21, test point 6 and 21, test point 7 and 21, test point 8 and 15,
19, 20, 21, test point 9 and 15, 19, 20, 21, test point 10 and 19, 21, test point 11 and 15, 
19, 21, test point 12 and 21, test point 13 and 19, 21, test point 14 and 21, test point 15 
and 21, test point 16 and 19, 21, test point 17 and 18, 19, 20, 21, test point 19 and 21. 
Means show memory test reaction times with drug collapsed follows a pattern o f 
reaction time that is longer towards the end o f  the first day o f  testing, is longer on the
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second day o f testing, and which is shorter on the last day o f  testing compared to the 
other days. Graph 6.10 shows this pattern. Although an interesting effect, this is again 
not relevant to the drug analysis, and will not be investigated further here.
6.5.2.5 Leeds Sleep Evaluation Questionnaire (LSEQ) Getting to Sleep (GTS)
There were 14 participants in this analysis. A  significant effect was found for 
Drug (F(3.08, 40.04)=4.790, p<0.01). Post-hoc Tukey’s test showed significant 
difference between dothiepin 75mg and: moclobemide 450mg (p<0.05) and 
moclobemide 600mg and (p<0.01). Inspection o f  the means shows higher scoring o f 
‘ getting to sleep’ under both doses o f  moclobemide compared to 75mg dothiepin, so 
getting to sleep was reported to be harder under moclobemide than dothiepin 75mg. 
There was no difference between placebo and any other drug or dose. Graph 6.5 shows 
these results.
6.5.2.6 Milford-Epworth Sleepiness Scale (MESS)
There were 13 participants included in this analysis. There was no significant 
effect o f drug, so there were no differences between active treatments and placebo. 
However there was a significant effect o f  Time (F(1.24, 14.88)=4.792, p<0.05). Tukey’ s 
post-hoc analysis revealed significant difference between the mornings after nights 3 
and 1 (p<0.05), and 3 and 2 (p<0.05). Inspection o f  the means shows MESS scores for 
sleepiness were higher on the morning after night 3, compared to both nights 1 and 2.
6.5.2.7 Critical Flicker Fusion (CFF). Line Analogue Rating Scale for Sedation (LARS). Leeds 
Sleep Evaluation Questionnaire (LSEQ) Quality o f Sleep (QOS), and Leeds Sleep Evaluation 
Questionnaire (LSEQ) Alertness Following Sleep (AFS)
After two-way ANOVA analyses, there were no significant effects o f CFF (13 
participants), LARS (14 participants), LSEQ (QOS) (14 participants) shown in graph 
6.6, and LSEQ (AFS) (14 participants).
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Choice Reaction Time (CRT) Recognition Reaction Time (RRT)
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450
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Condition
Graph 6.1: Shows the effects o f  dothiepin and moclobemide on recognition reaction time. There are no 
significant differences between dothiepin. moclobemide and placebo, but the recognition reaction time is 
quicker on the third test day compared to the first and second. Error bars denote one standard deviation.
Choice Reaction Time (CRT) Motor Reaction Time (MRT)
300
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Condition
Graph 6.2: Shows the effects o f  dothiepin and moclobemide on motor reaction time. Reaction time is 
significantly slower under dothiepin 75mg compared to 150mg. Also, reaction time was significantly 
slower under m oclobemide 450mg compared to dothiepin I50mg and moclobeinide 600mg. Error bars 
denote one standard deviation.
Choice Reaction Time (CRT) Total Reaction Time (TRT)
800
<j> 700 t  T  T  T  "
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.3: Shows the effects o f dothiepin and moclobemide on total reaction time. There is no significant
difference between dothiepin. moclobemide. and placebo, but total reaction time is significantly faster on
the third test day compared to the first and second. Error bars denote one standard deviation.
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Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.4: Shows the effects o f  dothiepin and moclobemide on short-term memory. The worst memory 
deficit occurred under dothiepin 150mg. Error bars denote one standard deviation.
LSEQ - Getting To Sleep
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.5: Shows the effects o f  dothiepin and moclobemide on LSEQ getting to sleep. There are no 
significant differences to placebo, but ‘ getting to sleep’ is significantly worse under both doses o f  
moclobemide than dothiepin 75mg. Error bars denote one standard deviation.
LSEQ - Quality of Sleep
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Treatment Conditions
Graph 6.6: Shows the effects o f  dothiepin and moclobemide on LSEQ quality o f  sleep. There are no 
significant differences between conditions, but non-significantly better quality o f  sleep is seen under 
m oclobemide. Error bars denote one standard deviation.
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I Placebo □  Dothiepin 75mg ^Dothiepin 150mg □Moclobemide 450mg 0  Moclobemide 600mg
550
9 10 11 12 13 14 15 16
Test Points
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Graph 6.7: Showing the pattern o f  the speed o f  recognition reaction time during the choice reaction time 
task at each test point for each drug. Test points 1-8 are on dav 1. test points 9-16 are on dav 2 and test 
points 17-21 are on day 3. Reaction times are longer on day 2. and by day 3. reaction times are shorter 
overall for all test medication. There was no significant interaction between test point and drug. Error bars 
denote one standard deviation.
Choice Reaction Time (CRT) Motor Reaction Time (MRT)
I Placebo □  Dothiepin 75mg H Dothiepin 150mg □  Moclobemide 450mg H Moclobemide 600mg
400
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Graph 6.8: Showing the pattern o f  the speed o f  motor reaction time during the choice reaction time task at 
each test point for each drug. Test points 1-8 are on dav 1. test points 9-16 are on dav 2 and test points 17- 
21 are on day 3. By day 3. reaction times are shorter overall for all test medication. There was no 
significant interaction between test point and drug. Error bars denote one standard deviation.
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Graph 6.9: Showing the pattern o f  the speed o f  motor reaction time during the choice reaction time task at 
each test point for each drug. Test points 1-8 are on dav 1. test points 9-16 are on day 2 and test points 17- 
21 are on day 3. Reaction times are longer on day 2. but by day 3. reaction times are shorter overall for all 
test medication. There was no significant interaction between test point and drug. Error bars denote one 
standard deviation.
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Graph 6.10: Showing the pattern o f  the speed o f  short-term memory at each test point for each drug. Test 
points 1-8 are on day 1, test points 9-16 are on day 2 and test points 17-21 are on dav 3. Bv day 3. 
reaction times are shorter overall for all test medication. There was no significant interaction between test 
point and drug. Error bars denote one standard deviation.
I Placebo □  Dothiepin 75mg ■  Dothiepin 150mg □  Moclobemide 450mg 0  Moclobemide 600mg
I Placebo □  Dothiepin 75mg 0 Dothiepin 150mg □  Moclobemide 450mg 0 Moclobemide 600mg
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6.5.3.1 Total Sleep Time (TST)
There were 10 participants included in this analysis. Results showed a 
significant effect o f  Drug (F(2.44, 21.6)=5.745, p<0.05). Post-hoc analysis using 
Tukey’s HSD showed significant difference between dothiepin 75mg and moclobemide 
450mg (p<0.01) and moclobemide 600mg (p<0.01). There was also significant 
difference between dothiepin 150mg and moclobemide 450mg (p<0.05) and 
moclobemide 600mg (p<0.05). Inspection o f  the means shows total sleep time was 
greater under dothiepin 75mg than both moclobemide doses, and also greater imder 
dothiepin 150mg than both moclobemide doses, but no significant effect between the 
doses o f  the same drug. There is no significant difference between placebo and any drug 
or dose. Graph 6.11 shows the pattern o f  results.
6.5.3.2 Sleep Latency (SL)
There were 13 participants included in this analysis. A significant effect o f Drug 
was noted (F(1.76, 21.12)=7.674, p<0.01) and post-hoc analysis using Tukey’ s showed 
significant effect between dothiepin 150mg and moclobemide 450mg and 600mg (both 
p<0.01). Also, there was significant difference between dothiepin 75mg and 
moclobemide 450mg (p<0.01) and 600mg (p<0.05). Inspection o f  the means shows 
sleep latency was significantly longer under both doses o f  moclobemide than 150mg o f 
dothiepin, and 75mg o f dothiepin. There was no significant effect between placebo and 
any drug or dose. Graph 6.12 shows the pattern o f these results.
6.5.3.3 Sleep Efficiency (SE)
There were 10 participants included in this analysis, and a significant effect o f 
Drug was found (F(2.12, 19.08)=6.938, p<0.01). Post-hoc analysis using Tukey’ s test 
showed significant difference between dothiepin 75mg and both moclobemide doses 
(p<0.01), between dothiepin 150mg and both moclobemide doses (p<0.05), and 
between moclobemide 450mg and placebo (p<0.05). Inspection o f  the means shows 
sleep efficiency was higher under dothiepin 75mg and dothiepin 150mg than both
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moclobemide doses, and that the sleep efficiency under moclobemide 450mg was 
significantly lower than sleep efficiency under placebo. Graph 6.13 shows these results.
6.5.3.4 Amount o f  Stage 1 Sleep
There were 10 participants in this analysis. There was no significant effect o f 
Drug, but there was a significant effect o f  Night (F(l, 9)=9.214, p<0.05). Inspection o f 
the means shows there was significantly more stage 1 sleep on the second night o f 
analysis compared to the first night. This is regardless o f  drug taken.
6.5.3.5 Amount o f  Stage 4 Sleep
There were 10 participants included in this analysis, and a significant effect o f 
Drug was found (F(2.36, 21.24)=3.901, p<0.05). Post-hoc analysis using Tukey’ s HSD 
showed a significant difference between dothiepin 150mg and moclobemide 450mg. 
Inspection o f  the means shows there is significantly more stage 4 sleep under dothiepin 
150mg than moclobemide 450mg. There was no difference between placebo and any 
drugs or doses.
6.5.3.6 Amount o f  SWS in First Period o f  the Night
There were 8 participants in this analysis, and there was a significant effect o f 
Drug (F(2.76, 19.32)=6.703, p<0.01). Post-hoc analysis using Tukey’ s showed a 
significant difference between moclobemide 450mg and both doses o f dothiepin 
(p<0.01). There was also significant difference between moclobemide 600mg and 
dothiepin 150mg (p<0.05). Inspection o f  the means shows there was a longer amount o f  
SWS in the first period o f  the night under both doses o f  dothiepin compared to 
moclobemide 450mg, and also more SWS in the first period o f  the night under 
dothiepin 150mg than moclobemide 600mg. There was no significant difference 
between placebo and any drug or dose.
6.5.3.7 REM Sleep Latency
There were 10 participants included in this analysis, and there was a significant 
effect o f  Drug (F(2.52, 22.68)=11.259, p<0.01). Post-hoc Tukey analysis showed
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significant difference between dothiepin 150mg and all other drugs and doses including 
placebo (p<0.01), plus a significant difference between moclobemide 600mg and 
placebo (p<0.05). Inspection o f  the means shows REM latency is significantly longer 
under dothiepin 150mg than all other conditions including placebo, and significantly 
longer under moclobemide 600mg than placebo. Graph 6.16 shows these results.
6.5.3.8 Amount o f  REM Sleep
There were 10 participants in this analysis, and significant effects were found by 
the two-way repeated measures ANOVA o f Drug (F(3.32, 29.88)=19.280, p<0.01) and 
Night (F(l, 9)=9.224, p<0.05). Post-hoc analysis o f the Drug effect using Tukey’ s HSD 
revealed significant differences between placebo and all other conditions (p<0.01), and 
between dothiepin 150mg and dothiepin 75mg (p<0.01) and moclobemide 450mg 
(p<0.01). There was no significant difference between dothiepin 150mg and 
moclobemide 600mg. Inspection o f  the means showed there was more REM time under 
placebo than all other conditions, and there was less REM time under dothiepin 150mg 
than dothiepin 75mg and moclobemide 450mg. Graph 6.15 shows these results.
Inspection o f  the mean REM time on the two nights o f testing showed there was 
significantly more REM time on the second night compared to the first night. There was 
no Drug x Time interaction.
6.5.3.9 Amount o f  REM Sleep in First Period o f  the Night
There were 8 participants included in this analysis. A  significant effect o f  Drug 
was found (F(2.88, 20.16)=11.342, p<0.01),and post-hoc analysis by Tukey’ s revealed a 
significant difference between placebo and all other conditions (placebo vs. 
moclobemide 450mg (p<0.05), and placebo vs. moclobemide 600mg, dothiepin 75mg 
and dothiepin 150mg (p<0.01)). The means for each condition show there was 
significantly more REM sleep in the first period o f the night under placebo than all 
other conditions. There was no significant difference between the active drugs and 
doses.
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Total Sleep Time (TST)
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.11: Shows the effects o f  dothiepin and m oclobemide on total sleep time. This shows total sleep 
time is greater under both doses o f  dothiepin compared to both doses o f  moclobemide. There is no 
significant difference to placebo. Error bars denote one standard deviation.
Sleep Latency (SL)
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Graph 6.12: Shows the effects o f  dothiepin and m oclobemide on sleep latency. This shows sleep latency 
longer under both doses o f  moclobemide compared to both doses o f  dothiepin. There is no significant 
difference to placebo. Error bars denote one standard deviation.
Sleep Efficiency (SE)
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.13: Shows the effects o f dothiepin and moclobemide on sleep efficiency (SE). Sleep efficiency is
significantly lower on moclobemide 450mg than placebo, and the efficiency on moclobemide is lower
than on dothiepin (a small but significant difference). Error bars denote one standard deviation.
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■  Night 1 
□  Night 2
Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
-r 450mg 600mgTreatment Conditions
Graph 6.14: Shows the effects o f  dothiepin and moclobemide on the amount o f  SWS. This shows no 
significant difference between the amount o f  SW S under dothiepin. moclobemide and placebo. Error bars 
denote one standard deviation.
Amount of REM Time
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Treatment Conditions
Graph 6.15: Shows the effects o f  dothiepin and m oclobemide on the amount o f  REM sleep. This shows 
there was significantly more REM on the second night o f  testing. Error bars denote one standard 
deviation.
Latency to REM Sleep
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Placebo Dothiepin 75mg Dothiepin Moclobemide Moclobemide
150mg 450mg 600mg
Treatment Conditions
Graph 6.16: Shows the effects of dothiepin and moclobemide on the latency to REM sleep. REM latency
was significantly longer under dothiepin 150mg and moclobemide 600mg than placebo. REM latency
was the longest under dothiepin 150mg. Error bars denote one standard deviation.
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6.5.3.10 Amount of REM Sleep in Second Period of the Night
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There were 8 participants included in this analysis. There was a significant effect 
o f Drug (F(2.2, 15.4)=8.260, p<0.01) found. Tukey’s post-hoc analysis showed 
significant difference between dothiepin 150mg and all other conditions, including 
placebo (p<0.01). Inspection o f  the means showed the percent o f  REM sleep in the 
second period o f  the night was significantly lower imder dothiepin 150mg than under all 
other conditions.
6.5.3.11 Wake Time. Number o f  Wakes Less Than and More Than One Minute. Amount 
o f  Stage 2 Sleep. Amount o f  Stage 3 Sleep, Amount o f  Slow-Wave Sleep (SWS), Amount 
o f  Slow-Wave Sleep in the Second and Third Periods o f  the Night, and Amount o f  REM 
Sleep in the Third Period o f  the Night
After two-way ANOVA analysis, there was no significant effect o f wake time 
(10 participants), the number o f  wakes less than or more than one minute in duration (10 
participants), amount o f  stage 2 sleep (10 participants), amount o f  stage 3 sleep (10 
participants), amount o f  SWS (10 participants) (shown in graph 6.14), amount o f  SWS 
in the second and third periods o f  the night (8 participants), and the amount o f  REM 
sleep in the third period o f  the night.
6.5.4 Adverse Events CAEs')
Table 6.8 shows the adverse events reported during treatment with placebo, 
dothiepin 75mg and 150mg, and moclobemide 450mg and 600mg. The largest number 
o f  adverse events were reported under placebo, but this was a very similar amount to 
both dothiepin 150mg and moclobemide 600mg. Dothiepin 75mg elicited the next 
largest amount o f  AEs, and the fewest were reported under moclobemide 450mg. The 
most frequent AEs reported under placebo were: tiredness, headache, and dizziness; 
under dothiepin 75mg were: tiredness, drowsiness, nausea and dizziness; under 
dothiepin 150mg were: drowsiness, headache, rashes, and vomiting, under
moclobemide 450mg were: drowsiness and headache; and under moclobemide 600mg 
were: headache, dizziness, dry mouth and visual disturbance. There is very little 
difference in the amount or types o f AEs reported in each condition, including placebo.
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Adverse Event Placebo Dothiepin 
75 mg
Dothiepin
150mg
M oclobem ide
450mg
M oclobem ide
600mg
N o. o f  Participants with AEs 9 5 8 6 6
Dehydrated 1
Depersonalisation 1
Depressed M ood 1
Dizziness 4 2 1 2
Drowsiness 2 4 3
Dry Mouth 2
Gastrointestinal Disorder 1 1
Headache 5 2 2 6
Lethargy 2 1 1
Irritable 1
Nausea 1 2 1 1
Rash 2
Tremor 1
Stomach Pain
Tiredness 8 2 1 1 1
Visual Disturbance 1 2
Vomiting 1 2
Total N o. o f  AEs Reported 20 9 18 7 17
Table 6.8 - Number o f  participants with at least one incidence o f  adverse event, possibly, probably or 
definitely related to treatment drug.
6.6 Discussion
In the survey o f  the elderly, 1.7% o f elderly prescription users took dothiepin, 
and none took moclobemide. The aim o f this study was to investigate the effects o f 
these two types o f  antidepressant on sleep, and morning-after cognition and 
psychomotor performance. The tolerability o f  each drug was also important, due to the 
increased sensitivity o f the older adult to side effects (Anderson, 2001). This study 
aimed to assess the use o f  dothiepin and moclobemide as hypnotic drugs, and to assess 
their suitablility for use in older adults. Only males were used in this trial, but other 
studies have shown no gender differences with respect to antidepressant effect (for 
example, Blois and Galliard, 1990; and Fairweather et al., 1999). It is therefore assumed 
that the effects seen in the current study would also be suggested to occur in females.
Due to financial and time constraints, there was no withdrawal phase o f  this 
study. However, it is important to assess discontinuation effects o f  drugs, as this can 
have profound effects on quality o f  life and may lead to AEs (Trewin et al., 1992), and 
may encourage dependence to avoid withdrawal effects (Petursson and Lader, 1984). 
Future studies o f antidepressants as hypnotics should include a placebo withdrawal 
phase to assess any adverse discontinuation or residual effects, or drug accumulation.
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Both antidepressants were well tolerated, with AEs occurring at a similar rate to 
placebo, which agrees with the reports by Stabl et al. (1989) and Fitton et al. (1992). 
There were 27 adverse events (AEs) under dothiepin, principally drowsiness (6 reports 
-  22.2% o f dothiepin AEs), dizziness, lethargy, nausea and tiredness (each reported 3 
times -  11.1% o f dothiepin AEs). There were no reports o f  a diy mouth, as suggested to 
be most common by Lancaster and Gonzales (1989) in a review, and by Ramaekers et 
al. (1995). As participants had free access to water, this AE may simply have not been 
noticeable. In agreement with the current study, Ramaekers et al. (1995) found 
drowsiness was frequently reported (16.8%), and dizziness was reported by 10.3%. 
Rees and Risdall (1976) foimd drowsiness to be the most reported AE (35%), followed 
by dry mouth (32%), dizziness (18%), and sweating (16%).
There were a total o f  24 AEs reported under moclobemide, principally headache 
(8 reports -  33.3% o f moclobemide AEs), drowsiness (3 reports - 12.5% o f 
moclobemide AEs), diy mouth, dizziness and tiredness (2 reports each -  8.3% o f 
moclobemide AEs). Stabl et al. (1989) fomid a similar rate o f dry mouth reports (13%), 
but this was their most commonly reported AE. They found headache and dizziness 
were also frequently reported (10% each), which agrees with the current study. 
However, in contradiction, Stabl et al. (1989) also found no reports o f drowsiness. 
Dingemanse et al. (1998a), on moclobemide 450mg, noted reports o f headache (5), 
insomnia (4), fatigue (3), diy mouth, dizziness and lethargy (2), and nausea (1). These 
AEs and rates are veiy similar to those found in the current study, with the exception o f 
insomnia. A subjectively detrimental effect o f  moclobemide on sleep was not found. 
Overall, there were no serious adverse events, and the AEs found are the types o f  AEs 
expected under most psychoactive medication. For example, they are similar to those 
found with hypnotic use in chapter 5.
It is likely from this data that both moclobemide and dothiepin would be suitable 
to prescribe to older adults. However, Anderson (2001) suggests dothiepin is more 
poorly tolerated in the elderly than the young, and Leveille et al. (1994) found high 
doses o f TCAs can lead to more accidents in the elderly. The use o f  dothiepin should be 
monitored in the elderly, and lower doses should be used. Moclobemide, however, has 
been found to be as well tolerated in the elderly as in the young (Versiani et al., 1990; 
Angst and Stabl, 1992; Amrien et al., 1997). Also, Maguire et al. (1991) concluded 
there was no need to alter the dose for the elderly. However, some caution may be
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advisable, as De Vanna et al. (1990) found the AE rate o f  moclobemide in the elderly 
was similar to that o f  TCA maprotiline.
6.6.2 The Effect o f  Dothiepin on Cognitive Function and Psychomotor Performance
There was no significant difference found between dothiepin 75mg and placebo 
for CFF, CRT (recognition, motor, and total reaction times), and the Sternberg memory 
test, on the morning after dose. Also, there was no difference between dothiepin 150mg 
and placebo for CFF, and CRT (recognition, motor, and total reaction times). However, 
there was significant difference between dothiepin 150mg and placebo on the Sternberg 
memoiy task. This shows speed o f  short-term memory is significantly worse under 
dothiepin 150mg compared to placebo. This agrees with the finding o f  Allen et al.
(1993), who found dothiepin impaired attention, visual information processing and 
episodic memoiy. Many researchers have concluded there are little or no effects o f 
dothiepin on performance, even as soon as 1.5 hours post 50mg dose (Hindmarch, 1987; 
Stille and Herberg, 1989; Ramaekers et al., 1995; Fairweather et al., 1999; Wilson et al., 
2000). The current study agrees with these findings, although some decrement is seen 
under the 150mg dose.
6.6.3 The Effect o f  Dothiepin on Sleep EEG and Sleepiness
There was no significant difference found between dothiepin 75mg and 150mg 
and placebo for LARS for sedation, LSEQ getting to sleep, quality o f sleep and 
alertness following sleep, and also MESS. This shows there is no difference in 
subjective sedation and feelings o f  sleepiness between dothiepin 75mg and 150mg, and 
placebo, despite AEs o f  drowsiness, lethargy and tiredness. This is contrary to the 
reported sedative effects (based on pain threshold, LSEQ alertness following sleep, 
CFF, and MSLTs) o f  dothiepin by Hindmarch (1987), Hindmarch et al. (1992), Coquoz 
et al. (1993), Fairweather et al. (1999), Stephenson et al. (2000) and Wilson et al. 
(2000). It is not clear* as to why no sedative effects were shown in this current study. It 
may be due to strong placebo-effects seen in antidepressant trials (Vida and Looper, 
1999). Alternatively, it may be that the most sedative effects have worn o ff before the 
participants went to sleep, as drug administration was 2 hours before lights out. Or, it 
may be that dothiepin is not as sedative as an evening drug as was previously thought.
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It is also unclear as to whether dothiepin improves quality o f sleep. In this 
current study, no effect o f  dothiepin on LSEQ quality o f  sleep was noted. However, 
Wilson et al. (2000) found an impairment o f LSEQ quality o f  sleep (lOOmg), but Akhtar 
et al. (1984) fomid an increase in quality o f  sleep. These are three conflicting findings, 
and further research is therefore necessary to ascertain the effects o f dothiepin on 
quality o f sleep. This study also found no effects on LSEQ getting to sleep, which is 
contrary to the findings o f  Wilson et al. (2000), who found improved ratings o f  getting 
to sleep. Again, this may need further research.
There was no significant difference between dothiepin 75mg and 150mg and 
placebo for total sleep time (TST), sleep latency (SL), sleep efficiency (SE), the amount 
o f  stage 1, stage 2, stage 3, stage 4, and slow-wave sleep (SWS). There was also no 
significant difference between dothiepin 75mg and 150mg and placebo for the amount 
o f  SWS in the first, second and third periods o f  the night, the amount o f  REM in the 
third period o f  the night, the amount o f  wake time, and the number o f  awakenings less 
than and more than one minute in duration. Both doses o f  dothiepin therefore have no 
effect on sleep continuity. For use in the elderly, it may have been beneficial for 
dothiepin to increase amounts o f  SWS, as the amount o f  SWS this has been found to 
decline in some older adults (Reynolds et al., 1985a). However, this is not the case.
There were fewer effects on sleep EEG noted in this current study, compared to 
previous research. Akhtar et al. (1984), Stephenson et al. (2000) and Wilson et al. 
(2000) found an increase in the duration o f  sleep, and Stephenson et al. (2000) and 
Wilson et al. (2000) found a decrease in sleep latency. Wilson et al. (2000) also found 
an increase in SE, sleep continuity, SWS and stage 2 sleep, and a decrease in stage 1 
sleep. This is contrary to the current findings, as none o f  these effects were found to be 
significant. However, Wilson et al. (2000) does suggest their increase in stage 2 sleep 
was perhaps due to the general increased sleep time o f  the participants on dothiepin. It 
may be these differences are due to differences in study designs, perhaps techniques o f  
scoring sleep. For example, in the current study, all records were visually staged by an 
experienced sleep stager, and in the study by Wilson et al. (2000), records were staged 
by computer with visual amendments only.
However, there were significant placebo differences with respect to REM 
latency, the amount o f  REM sleep, and the percentage o f  REM sleep in the first and 
second periods o f  the night. On dothiepin 75mg, there was no placebo difference in 
REM latency, but REM latency was significantly longer under dothiepin 150mg than 
placebo. The amount o f  REM was significantly less under dothiepin 75mg and 150mg
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than placebo. Lastly, there was less REM sleep in the first period o f  the night under both 
doses o f  dothiepin than placebo, and significantly less REM sleep in the second period 
o f  the night under dothiepin 150mg than placebo. Here, there was no significant 
difference between dothiepin 75mg and placebo. The decrease in REM and an increase 
in REM latency agree with the work o f  Wilson et al. (2000). This confirms the 
characteristic REM suppression effects noted with the use o f antidepressants. The 
current study also shows these effects to be dose-dependent. The suppression o f  REM 
under the 150mg dose continued to the second period o f  the night, but this was not 
noted under the 75mg dose.
In summary, dothiepin did not have sedative effects, and did not affect quality o f 
sleep, total sleep time (TST), the amount o f  wake time and the number o f awakenings, 
sleep latency (SL), sleep efficiency (SE), the amount o f  stage 1, stage 2, stage 3, stage 4, 
and slow-wave sleep (SWS). Dothiepin did suppress REM, by decreasing the amount o f 
REM and increasing REM latency. The higher dose maintained this effect longer than 
the lower dose.
6.6.4 The Effect o f  Moclobemide on Cognitive Function and Psvchomotor Performance
There were no significant differences between both doses o f  moclobemide and 
placebo for CFF, CRT (recognition, motor, and total reaction times), and the Sternberg 
memory test. Therefore there is no difference in cognitive function on either dose o f 
moclobemide compared to placebo. This is supported by the work o f Berlin et al. 
(1990a/b), Tiller (1990), Hindmarch and Ken* (1992), Ramaekers et al. (1994) and 
Puchler et al. (1997), who found no effects o f  moclobemide on CFF, DSST, CRT, short- 
and long-term memory, LARS, actual driving performance, auditory evoked potentials, 
and saccadic eye movements.
Other researchers have found positive effects o f moclobemide. Although 
Wesnes et al. (1989a/b) foimd a slight impairment in number vigilance, they also noted 
an improvement in memoiy. Allain et al. (1992) found moclobemide increased CFF 
(increased alertness), decreased reaction times, had no effect on verbal recall, increased 
response to delayed verbal recall, had no effect on semantic organisation, no effect on 
word recognition, increased face recognition, and improved quality o f  life. Also, Berlin 
et al. (1990a) found that 400mg o f moclobemide could remove the depressive effects o f 
alcohol on CFF. This lead Allain et al. (1992) to suggest that moclobemide may be a 
‘ cognitive facilitator’ , which would be beneficial to the elderly due to possible
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decrements in cognitive function due to ageing (Hohagen et al., 1994). However, a lack 
o f  positive effects found in this current study means there is no evidence here to support 
this suggestion.
6.6.5 The Effect o f  Moclobemide on Sleep EEG and Sleepiness
There were no significant differences between both doses o f  moclobemide and 
placebo for LARS sedation, LSEQ getting to sleep, quality o f  sleep, alertness following 
sleep, and also MESS. This shows a lack o f  sedating effect when taking moclobemide, 
despite AEs o f drowsiness and tiredness. There was also a lack o f  positive subjective 
effects on sleep. Past research supports this, in the lack o f  effects found on cognitive 
and psychomotor function (see above). Also, Ramaekers et al. (1994) found no effect o f 
moclobemide on sleep quality, although this has been disputed by Campos et al. (1994).
There were no significant differences between moclobemide and placebo for 
TST, SL, the amount o f  stage 1, stage 2, stage 3, stage 4 sleep, and SWS, the amount o f 
SWS in all three periods o f the night, the amount o f  REM sleep in the second and third 
periods o f  the night, the amount o f  wake time, and the number o f  awakenings less than 
and more than one minute in duration. This is supported by a number o f  studies. Berlin 
et al. (1990b), and Blois and Galliard (1990) found no effect o f moclobemide on TST, 
and these authors plus Campos et al. (1994) found no effect on SL. Blois and Galliard 
(1990) and Ramaekers et al. (1994) found no effect o f moclobemide on subjective sleep 
duration, and no effect was found on the amount o f  NREM sleep (Steiger et al., 1994) 
and SWS (Monti, 1989; Blois and Galliard, 1990). There was also no effect o f 
moclobemide on sleep continuity (Hoff et al., 1986; Steiger et al., 1994) or the number 
o f awakenings (Berlin et al., 1990b; Blois and Galliard, 1990).
In contrast, Monti (1989) found increases in TST, and increases in stage 1 and 
stage 2 sleep were found by Monti (1989), Blois and Galliard (1990), and Monti et al. 
(1990). Monti (1989) and Monti et al. (1990) found sleep continuity to be improved by 
moclobemide, and Monti (1989) and Campos et al. (1994) found reductions in 
subjective and objective amounts o f  wake time respectively. These differences in 
findings may have been due to the timing o f dose in the study designs. In this study, the 
doses were taken 2 hours before sleep onset, matching the dosing time used in chapter 
5. Peak plasma time o f  moclobemide may have coincided with sleep onset, so the 
moclobemide may have worn off, showing no effects on sleep continuity and wake 
time.
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In this current study, there were significant differences compared to placebo 
with respect to sleep efficiency, REM latency, the amount o f  REM sleep, and the 
amount o f REM sleep in the first period o f the night. The sleep efficiency is 
significantly lower than placebo under moclobemide 450mg. This is contrary to most 
research, as there has been findings o f  a lack o f effect or an increase in sleep continuity 
(see above), but not a reduction. The number o f  awakenings or the amount o f wake time 
in this study was not significantly different under moclobemide. Therefore sleep 
efficiency may not be a measure o f  sleep continuity.
REM latency is significantly longer under moclobemide 600mg than placebo, 
but there is no significant difference between moclobemide 450mg and placebo. There 
is significantly less REM sleep than placebo on both doses o f moclobemide, and this is 
also significantly less for both doses than placebo in the first period o f the night 
particularly. This shows evidence for REM suppression under moclobemide, but 
increased REM latency occurs only at the higher dose. Therefore this shows REM 
suppression is also dose-dependent on moclobemide. Previous research has been 
contradictory. Fitton et al. (1992) and Steiger et al. (1994) found no evidence for REM 
suppression, whereas REM suppression has been shown by Hoff et al. (1986), Monti
(1989) and Monti et al. (1990). Blois and Galliard (1990) have found a reduction in 
REM time, but found no REM latency (as with the lower dose in the current study), and 
Monti (1989) did find increased REM latency on moclobemide.
There are a great number o f contradictions within the previous research into the 
effects o f  moclobemide on sleep. It is possible this has happened due to different study 
designs. For example, it seems the effects o f  moclobemide on REM sleep may be dose- 
dependent, so different doses may interfere with study comparisons. Reviewing 
previous research indicates that sleep effects are more likely to be found in depressed 
trial participants than healthy trial participants (for example, in Monti (1989) and Blois 
and Galliard (1990)). Moclobemide may have more o f  an effect on sleep in depressed 
individuals. Healthy participants were used in the current study, so this may go some 
way to explaining the lack o f  effect found.
6.6.6 Comparison o f  Cognitive Function and Psychomotor Performance Under 
Different Doses o f Dothiepin and Moclobemide
Although there are veiy few effects o f  both dothiepin and moclobemide that are 
significantly different to placebo, there are many significant differences between the
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doses o f  dothiepin compared to the doses o f  moclobemide. There are no differences 
between both drugs and doses for CFF, and CRT recognition and total reaction times, 
but CRT motor reaction time was significantly slower under moclobemide 450mg 
compared to both dothiepin 150mg and moclobemide 600mg. Also, dothiepin 75mg 
slowed motor reaction time significantly more than dothiepin 150mg. This means the 
lower doses o f both drugs had a significant effect o f slowing psychomotor performance 
more than higher doses. Reasons for this are unclear. On the Sternberg memory task, 
reaction time performances were worse under dothiepin 150mg than both moclobemide 
450mg and dothiepin 75mg. Also, the Sternberg task was worse under moclobemide 
600mg than both dothiepin 75mg and moclobemide 450mg. It seems the low doses o f 
both drugs slowed motor performance, and the high doses o f  both drugs impaired the 
memoiy task, but there was no effect between the drugs on CNS arousal as measured by 
CFF.
6.6.7 Comparison o f  Sleep EEG and Sleepiness Under Different Doses o f Dothiepin and 
Moclobemide
There were no differences between the drugs and doses with respect to LARS 
sedation and MESS, showing dothiepin, moclobemide and placebo are as sedative as 
each other. There was also no difference between LSEQ quality o f  sleep and alertness 
following sleep, but scores on LSEQ getting to sleep were significantly higher on 
moclobemide 450mg and 600mg compared to dothiepin 75mg (but not dothiepin 
150mg). This shows the low dose o f  dothiepin was rated as better for getting to sleep 
compared to both doses o f  moclobemide.
Both doses o f  dothiepin resulted in a longer total sleep time, a shorter sleep 
latency and a higher sleep efficiency than both doses o f  moclobemide. This indicates a 
superiority o f dothiepin over moclobemide as a sleep aid. There were no differences 
between the two drags and doses for the amount o f SWS, stage 1, 2, and stage 3 sleep, 
however there was significantly more stage 4 sleep under dothiepin 150mg than 
moclobemide 450mg. There was more SWS in the first period o f  the night under 
dothiepin 75mg than moclobemide 450mg, and more SWS in the first period o f the 
night under both doses o f  dothiepin compared to both doses o f moclobemide. This 
shows there may be greater changes in SWS distribution under dothiepin compared to 
moclobemide. According to Sharpley et al. (1994), these changes in SWS may show a 
greater effect o f  dothiepin on serotonin compared to moclobemide. There was no
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significant differences between the two drugs and doses with respect to the amount o f  
SWS in the second and third periods o f  the night, the amount o f  wake time, and the 
number o f wakes less than and more than one minute in duration. Therefore there was 
no difference in sleep continuity between the two drugs.
There was also no significant difference between the two drugs and doses with 
respect to the amount o f REM sleep in the first and third periods o f  the night. However, 
latency to REM sleep was significantly longer under dothiepin 150mg than dothiepin 
75mg and both doses o f  moclobemide. Also, there was significantly less REM sleep 
under dothiepin 150mg compared to dothiepin 75mg and moclobemide 450mg, but was 
not significantly different to moclobemide 600mg. There was also significantly more 
REM sleep in the second period o f the night under dothiepin 150mg compared to 
dothiepin 75mg and both doses o f moclobemide. This shows there is significantly more 
REM suppression under dothiepin than moclobemide, and the higher dose o f 150mg o f 
dothiepin can retain its REM suppressant effects for longer than the 75mg dose, and 
longer than both doses o f  moclobemide. To conclude, results show dothiepin 150mg is 
similar in effect to moclobemide 600mg, and dothiepin 75mg is similar in effect to 
450mg moclobemide.
6.7 Conclusions
Dothiepin was found to only have an impairment in speed o f  short-term memoiy 
when compared to placebo, and when compared to moclobemide, the low dose o f  both 
drugs impaired motor performance and the high dose o f  both drugs impaired memory. 
No sedative effects were found compared to placebo, nor were effects on quality o f 
sleep, total sleep time (TST), the amount o f  wake time and the number o f  awakenings, 
sleep latency (SL), sleep efficiency (SE), the amount o f stage 1, stage 2, stage 3, stage 4, 
and slow-wave sleep (SWS). However, dothiepin 75mg was found to be better for 
getting to sleep than moclobemide. There was evidence for a REM suppression effect, 
and this was maintained for a longer duration in the night on the higher dose compared 
to the lower dose. When compared to moclobemide, both doses o f  dothiepin resulted in 
a longer TST, a shorter SL, increased SE, and an increased amount o f  SWS. There was 
evidence that changes in SWS distribution were significantly more evident under 
dothiepin than moclobemide, indicating dothiepin may have more effect on serotonin 
levels than moclobemide (Sharpley et al., 1994). Dothiepin also shows a greater REM 
suppression than moclobemide, which is maintained for a longer period in the night.
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Moclobemide itself has no effects on cognitive function and psychomotor performance 
the day after dosing compared to placebo, but reduces SE compared to placebo. It also 
shows some REM suppressing effects, but decreasing REM sleep time and increasing 
REM latency, compared to placebo.
In depression, there are reports o f  difficulty initiating and maintaining sleep, o f 
early morning awakenings, nonrestorative sleep, disturbing dreams, decreases in SWS 
and in sleep efficiency, and an increase in REM sleep, especially in the first period o f 
the night (Gillin et al., 1979; Akislcal et al., 1982; Berger et al., 1982; Feinberg et al, 
1982b; Lahmeyer et al., 1983; Akiskal et al., 1984; Borbely et al., 1984; Jones et al., 
1985; Kupfer et al., 1985; Quitkin et al., 1985; Kupfer et al., 1989; Waller et al., 1989; 
Ernslie et al., 1990a/b; Benca, 1994). From the above results, it seems dothiepin and 
moclobemide can help these problems in the same way, and that is by suppressing 
REM. Neither drug improved sleep time, sleep efficiency or the number o f  awakenings 
compared to placebo, although compared to moclobemide, dothiepin seems more 
preferable in this respect. These are results from testing healthy participants, and as 
Anderson (2001) suggests depressed individuals may respond better than healthy 
individuals, sleep-enhancing effects o f  these antidepressants may be seen when using 
depressed participants.
This study considers the use o f  dothiepin and moclobemide as hypnotic drugs in 
non-depressed individuals. Kupfer and Reynolds (1997) and Wagner, Wagner and 
Hening (1998) suggest that there is little evidence that antidepressants can improve 
sleep in patients without depression, and the results o f  the current study tend to agree. 
Dothiepin and moclobemide, compared to placebo, do not enhance sedation, improve 
the quality o f sleep and getting to sleep, decrease sleep latency and the amount o f  wake 
time, nor increase sleep efficiency. This indicates that dothiepin and moclobemide are 
not suitable hypnotic drugs. Stephenson et al. (2000) and Wilson et al. (2000) have 
found that dothiepin is the most commonly prescribed antidepressant, and this is not 
surprising as it does have potent REM suppressing effects, even on the first dose. Like 
moclobemide, dothiepin is also well tolerated, and with a decreased dose, is a safe drug 
for the elderly. Dothiepin and moclobemide may make useful antidepressants for the 
elderly to use, and may improve sleep in depressed elderly individuals, but there is no 
evidence here that dothiepin and moclobemide will help sleep problems for individuals 
without depression.
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Chapter 7
7.1 Abstract
This chapter outlines the aims o f  the thesis, and summaries each o f  the study 
chapters. The sleep o f  older adults was suggested to decline with age, and treatments 
used included prescription medication, over-the-counter preparations, herbal remedies, 
hot milky drinks and alcohol. Results o f  the trials o f some o f these treatments showed 
valerian, dothiepin and moclobemide were not suggested to be useful hypnotics, but 
loprazolam, zopiclone and zolpidem may help improve sleep problems. These findings 
are related to improving sleep in an older population, and suggestions are made for 
future research.
7.2 Conclusions
7.2.1 The Aims o f This Thesis
The aim o f this thesis was to gather information about sleep in the elderly 
population, and to elucidate whether sleep complaints are common in old age, how they 
occur, and whether these complaints are problematic for older adults.
It is widely believed that sleep worsens with increasing age (Webb, 1982a; Braz 
et al., 1990; Habte-Gabr et al., 1991; Bliwise et al., 1992; Hoch et al., 1994; Foley et al., 
1995; Mallon and Hetta, 1997). However, recent research by Seppala et al. (1997) has 
disputed this view by showing 80% o f older adults actually have good sleep, as only 
20% o f  older adults complained o f  a sleep problem. Therefore, it is unclear if sleep 
problems in the elderly should be a concern or not. The second aim was to collect 
information about how the elderly are currently dealing with their sleep problems, such 
as uses o f  prescriptions, over-the-counter preparations, herbal remedies and behavioural 
manipulations. There is very little data available on the solutions to sleep problems 
sought by the elderly (Sproule et al., 1999), so it is difficult to know if  health authorities 
are addressing sleep problems in older adults properly. The third aim o f this thesis was 
to assess, via sleep EEG and psychometric tests, some o f these treatments for disrupted 
sleep, to assess their efficacy as sleep aids, and to evaluate their appropriateness for use 
in an elderly population. The elderly have been found to have a greater sensitivity to 
hypnotic and other psychotropic medications (Morgan, 1990), which can lead to
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increased adverse events, compared to younger users (Greenblatt et al., 1982; Greenblatt 
et al., 1991). Information was needed regarding the adverse events associated with sleep 
medications the elderly are taking, in order to assess their safety for use in the elderly 
population.
These aims were achieved by four studies regarding the sleep o f older adults, the 
use o f  sleep aids in older adults, and the effects o f  some o f  the medications that older 
adults use. Chapter 3 involved a survey o f the sleep habits and medication use o f  a 
sample o f 5846 older adults, aged 50-98 years (mean 69 ±  8.5 years), collected via 
responses to a magazine article. This survey showed older adults used three main types 
o f sleep aids, namely over-the-counter or herbal remedies, hypnotics and 
antidepressants. The next experimental chapters were designed to investigate these aids. 
Chapter 4 looked at the effects o f  a herbal remedy, a preparation o f valerian, on the 
EEG sleep and performance o f  16 volunteers aged 50 to 64 years (mean age 56 ± 4.7 
years). These volunteers had a mild sleep complaint, so provided a realistic situation in 
which the elderly may use valerian. Chapter 5 studied the effects o f  three hypnotics, 
loprazolam, zopiclone and zolpidem, on EEG sleep variables and next day performance 
o f  16 young sleep-disturbed volunteers, aged between 20 and 39 years (mean age 28 ±
6.1 years). Younger adults were used in this study to test the hypnotics without 
interaction with the confounds associated with ageing, such as waking up in the night 
because o f  pain or needing the toilet. Chapter 6 studied two antidepressants prescribed 
to aid sleep from the perspective o f  hypnotics. Fourteen young healthy volunteers aged 
18 to 35 years (mean age 25 ±  4.9 years) were given either moclobemide or dothiepin. 
Young healthy participants were again used, to avoid any drug/disease interactions 
associated with depression, and also to avoid any interfering factors o f  old age. Sleep 
EEG and next day performance were analysed to investigate the suitablility o f 
antidepressants as sleep enhancers.
7.2.2 Sleep Problems and Their Causes in the Elderly Population
The question o f  the prevalence, severity and causes o f  sleep problems in the 
elderly was addressed by chapter 3. Here, one o f  the largest and most comprehensive 
surveys was completed, using 5846 respondents. The responses were thought reliable 
because o f  two reasons. Firstly, the respondents were not volunteering for a trial 
regarding sleep, as they responded to an article regarded a trial on ginkgo biloba and not 
sleep. Secondly, there were a large number o f respondents, and Kryger et al. (1991)
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suggests a large number o f  participants increases the reliability o f  findings. However, 
certain problems with the methodology must be mentioned. Firstly, there have been 
suggestions o f  inaccuracies within self reports, as good sleepers report their sleep more 
accurately than poor sleepers (Adam et al., 1986; Liljenberg et al., 1988; Morin and 
Gramling, 1989), or perhaps the reports o f  poor sleepers are less well correlated to EEG 
sleep. It has also been suggested that females report their sleep more accurately than 
males (Hoch et al., 1987), or report sleep that correlates better to EEG sleep than males. 
Self reports may also be subject to dishonesty (Uiponen et al., 1988), especially when 
answering embarrassing questions, for example, about toilet use. The findings o f self 
reports are correlational only, and camiot show cause and effect. Although the 
questionnaire asked about sleep experienced in the last month, some respondents 
answered the questionnaire either with their sleep habits taking hypnotics, or not taking 
hypnotics. It is therefore difficult to be sure which circumstance they are describing. 
Lastly, when the respondents were categorised into age groups, there was an unbalanced 
number o f participants in each age group. There were fewest respondents in the 85+ 
year old age group (n = 128 out o f  5846), compared to 299 in the 50-54 year age group, 
479 in the 55-59 year age group, 779 in the 60-64 year age group, 1171 in the 65-69 age 
group, 1217 in the 70-74 age group, 1025 in the 75-79 age group, and 364 in the 80-84 
age group. This imbalance in participant numbers is due to all respondents over 50 years 
old being surveyed, regardless o f  exact age. This may have influenced the results, so 
future research should include an even amount o f  participants in each age group.
This survey showed older adults do have sleep problems, and these can increase 
in number with age, agreeing with Karacan et al. (1976), Mellinger et al. (1985) and 
Morgan et al. (1988), for example. However, this is a complicated issue, as not all 
aspects o f  sleep decline with age, and not all decrements o f  sleep are problematic. There 
are also differences between sleep and ageing for males and females.
Those over the age o f  60 years more frequently reported not getting enough 
sleep, there was an increase in napping with increasing age, and the reports o f  daytime 
effects o f  poor sleep increased over the age o f 74 years (compared to younger 
respondents). However, an increase in prescription hypnotic use occurred with 
increasing age only for females. Males may have feel that they have better sleep than 
females as ageing advances, because males report less severe early morning awakenings 
(EMAs) and less severe sleep complaints. Despite this, there is also evidence for 
improvement o f some aspects o f  sleep with age. For example, feeling tired on 
awakening decreases with increasing age, perhaps due to the removal o f  pressures such
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as working. Overall, it was shown that 87.6% o f the older adults surveyed slept for 5 to 
8 hours per night, 77.7% said their sleep did not affect their daytime activities, and 
57.8% o f older adults in this survey did not report a sleep problem. Also, the prevalence 
o f  other sleep complaints did not increase with age. It is therefore hard to generalise 
these results, and confidently suggest sleep becomes worse with age, because 
‘ insomnia’ can encompass so many complaints, and have different meanings to many 
people.
Because o f  this, conclusions can be drawn by breaking down insomnia into its 
constituent parts, o f  difficulty initiating sleep (DIS), difficulty maintaining sleep (DMS) 
and early morning awakenings (EMA). The survey showed there were no increases in 
DMS and EMA with increasing age, and only females suffer increasing DIS with 
increasing age. This is thought to be mild DIS, whereas males tend to suffer more 
moderate DIS. Therefore, males may have less DIS than females, but to a greater 
severity. More females than males reported worse and more frequent DMS than males. 
It was suggested by Libman et al. (1997) that the greater amount o f DIS and DMS 
experienced by females might be due to increased anxiety. This may prevent sleep 
occurring, and may prevent regaining sleep once woken in the night. In agreement, this 
survey showed more females (19.6%) associated anxiety (for example, thoughts running 
through the mind and vivid dreaming) with sleep problems than males (11.7%). 
Depression is also thought to be associated with poor sleep (Mellinger et al., 1985; Ford 
and Kamerow, 1989), and it has been suggested that there is a higher prevalence o f 
depression amongst females (Kronholm and Hyyppa, 1985; Habte-Gabr et al., 1991), 
although more older males have been found to commit suicide than older females 
(Pearson, 2002). There were no reports o f  depressive symptoms in this survey, but the 
use o f  antidepressants was approximately even between the genders. This may imply 
depression in old age has a similar prevalence between the genders.
Indeed, reports made about the types o f sleep complaints experienced showed 
primary insomnia does not play a major role in sleep problems in the elderly. In addition 
to psychological interference, physical factors can also disrupt sleep. The most 
disruptive effect on sleep was the need to use the toilet in the night (29.4%), most 
significantly seen in those over the age o f  65, and especially in males over the age o f 75 
years. Middelkoop et al. (1996) suggested this was due to a decrease in nocturnal anti­
diuretic hormone found commonly in ageing males. In addition, pain was found to 
disrupt DMS more than other types o f insomnia. Females were found to have more 
health complaints than males, and females were prescribed more medication. This
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increase in health problems may also partly explain why females appeal* to have worse 
sleep.
Another important aspect o f  assessing sleep involves the number o f hours slept 
each night, to assess sleep fragmentation. The survey enquired about nocturnal sleep 
hours separately from daytime sleep (meaning napping). On average, females reported 
less nocturnal sleep compared to males, with a decrease in sleep duration with age. 
Interestingly, despite shorter sleep hours, females tended to nap for shorter durations 
than males, which Asplund (1996) and Newman et al. (1997) suggest is due to increased 
incidence o f  sleep apnoea, snoring and respiratory problems in the older male. In 
agreement, this survey also showed a higher number o f complaints o f  these problems in 
males. Most older adults have been found to nap (57.1%). Daytime performance does 
not decline with increasing age, but this could be due to the increase amount o f 
compensatory napping. Indeed, females complaint o f  decrements to daytime 
performance more than males, perhaps associated with their lack o f napping.
In summary, most older adults appear to have good sleep, with 57.8% not 
reporting a problem, and 77.7% having no daytime effects. However, the number o f 
sleep problems reported does increase with increasing age. Whilst DIS and DMS was 
only foimd to increase for females, EMA was not shown to increase with increasing age. 
In general, females reported more sleep problems than males, however, this may be due 
to females being more willing to discuss their problems (Briscoe, 1978; Hoch et al., 
1987; Blay and Mari, 1990). There is evidence to suggest that poorer health amongst 
females and a lack o f  compensatory napping may also contribute to the perception o f 
increased sleep problems. Napping increases, particularly in elderly males, and those 
over the age o f  60 years increasingly feel like they do not get enough sleep. It is clear 
sleep does change with ageing, but whether this becomes a problem depends on how the 
individual reacts to these changes, views their sleep, how and what they perceive 
insomnia to be, and how active they are during the day (for example, napping may not 
be a problem if the individual is retired). Although most older adults have good sleep, 
the 42.2% reporting sleep complaints presents a concern.
7.2.3 Solutions to Sleep Problems
The question o f  how older adults deal with their sleep problems was also 
addressed in chapter 3. It was found that older adults either use certain activities to
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enhance sleep, use alcohol or other beverages, and take prescription medication, over- 
the-counter (OTC) preparations, and lastly, herbal remedies.
Females were found to use more activities to aid sleep than males (11.0% vs. 
6.1%), but the number using activities did not increase with increasing age for males or 
females. The most popular activity was reading at bedtime, followed by aromatherapy, 
special bed/bedding, heat, meditation/breathing, listening to the radio, eating, and 
exercising. There were no reports o f  behavioural techniques, such as stimulus control or 
sleep restriction, but the elderly may benefit from learning these techniques. The 
activities listed are all (with the exception o f  exercising) showing the elderly are not 
likely to be suffering poor sleep because o f  their bedtime behaviours. Also, milk-based 
hot drinks were also very popular to use at bedtime (31.3%), particularly Horlicks and 
hot chocolate. This may be due to L-tryptophan in the milk, which may have a role in 
sleep onset (Moran et al., 1988). More females than males tend to use non-alcoholic 
beverages at nighttime, but there is no age-related increase. However, the survey also 
showed the elderly aided sleep onset with the use o f alcohol, most commonly whisky, 
followed by wine. Although alcohol can reduce sleep latency, it also has a tendency to 
disrupt REM sleep in the latter pail o f  the night, which is detrimental to sleep (Moran et 
al., 1988). More males than females use alcohol, but there is no increase in the numbers 
consuming alcohol with increasing age.
The prevalence o f prescription use is 10.8%, and more females are users than 
males (12.4% vs. 8.0%). The use o f  prescriptions does increase with increasing age, but 
this was only for females and not males. Specifically, the prevalence o f  use o f  hypnotics 
is 6.4%, which is 59.5% o f the medications used. Hypnotic use also increases with 
increasing age, but only over the age o f  65 years old. The most popular hypnotic for 
both males and females is temazepam (29.4% o f prescriptions taken), followed by 
nitrazepam, zopiclone, lormetazepam and loprazolam. However, this means 40.5% o f 
prescriptions taken to aid sleep are not hypnotics. Other medication reported to be used 
for sleep problems included analgesics (13.6% o f prescriptions used), probably used to 
control pain in the night, and also antidepressants (8.2% o f prescriptions used). The 
prevalence o f  use o f  antidepressants as sleep aids is similar between genders, with males 
in general being prescribed amitriptyline, whilst females primarily being prescribed 
dothiepin. The reason for this is not clear. Overall, the most commonly prescribed 
antidepressants are amitriptyline, dothiepin and paroxetine (despite alerting and sleep 
disrupting effects o f  the latter), but there is no increase in antidepressant prescription 
with increasing age.
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The prescription o f hypnotics to the elderly must be done with caution. The use 
o f  hypnotics can lead to health risks in the elderly (Lader, 1997); for example, 
respiratory problems can be exacerbated (Swift and Shapiro, 1993). If an individual 
presents to their general practitioner (G. P.) with disturbed sleep, hypnotics may be 
prescribed even though the cause o f  the poor sleep may be apnoea. This is true for all 
underlying health complaints. For example, pain or restless legs will not be improved 
with the use o f  hypnotics, so the prescription may be unnecessary. It appears some 
hypnotics may be unsuitable for use by elderly individuals (Cook, 1986). Those with a 
longer duration o f  action may cause residual sedation in the morning after a nighttime 
dose (Massoud, 1984). More falls could occur due to daytime sedation, or even middle- 
of-the-night sedation if  the individual gets up in the night. In this survey, it was foimd 
those using hypnotics were twice as likely to feel tired in the morning as those not using 
hypnotics (12.3% vs. 5.3%). It was suggested shorter half-life hypnotics might be more 
suitable for the elderly, due to a lack o f  effect the next morning, and also a lack o f  effect 
in the middle o f  the night, hi this survey, only 7.6% o f prescription users used 
zopiclone, and 0.7% used zolpidem. These are relatively low percentages o f  use, despite 
their suggested appropriateness in the elderly. This may be for two reasons. Firstly, 
individuals suffering from DMS may need a longer lasting hypnotic to help them sleep 
all night, and secondly, these newer hypnotics are much more expensive than the older 
types (Joint Formulary Committee, 2002).
The prevalence o f  OTC and herbal use is 17.7%, which is higher than 
prescription use (10.8%). There were no differences between the number o f  each gender 
that uses OTCs and herbals, but females were more likely to use more than one 
preparation. There was no difference in prevalence with increasing age, and no 
difference in the types o f  preparations used with increasing age. The most popular OTC 
preparation was Nytol (diphenhydramine) (14.6% o f OTC/herbals), which is an 
antihistamine. Another antihistamine reportedly used as a sleep aid was Sominex 
(promethazine) (1.0% o f  OTC/herbals). These have been suggested to leave a residual 
sedation the next day (Caranasos, 1987), but the survey fomid that most (70.6%) 
individuals using antihistamines did not have decrements in daytime performance the 
next day. Analgesics were also popular* OTC preparations to take (11.9%), again for 
health complaints and pain. The most popular herbal remedy was camomile tea (13.2% 
o f OTC/herbals), followed by other herbal o f  fruit teas (10.7%). Valerian alone totalled 
5.3% o f OTCs or herbals used, but herbal remedies containing valerian were taken by 
23.5% o f OTC/herbal users. Passiflora was the next most popular herb, totalling 0.6%
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o f OTC/herbal users, rising to 9.8% when all products containing passiflora are counted. 
Despite their common use, this survey found those using OTC or herbal preparations 
were twice as likely to have a sleep problem than not have a sleep problem. This casts 
doubt as to whether these remedies are really helpful in solving sleep problems. 
Valerian is the most popular herb, but despite this, 55.7% o f valerian users still suffer 
DIS, 74.3% suffer DMS, and 62.9% still suffer EMA.
In summary, older adults tend to read and use aromatherapy to aid their sleep, 
and drink whisky, wine, Horlicks and hot chocolate. A  tenth o f  the older adults 
surveyed use a prescribed sleep aid, commonly temazepam or nitrazepam, but they also 
use antidepressants. The use o f  OTC preparations and herbal remedies is also common, 
especially the use o f  Nytol, camomile and other teas, and valerian products.
7.2.4 The Suitability and Appropriateness o f  Sleep Medication Use in the Elderly
To assess the suitability o f  some sleep aids commonly used by older adults, 
chapters 4, 5 and 6 investigated various preparations for their use as sleep aids. Valerian 
was chosen as a subject because it is a herbal remedy used by the older adults surveyed 
in chapter 3. Loprazolam is an established hypnotic, which older adults also reported 
using. It has an intermediate half-life, and this was used as a comparison to newer 
shorter acting hypnotics, namely zopiclone and zolpidem. Lastly, two antidepressants 
were assessed for their suitability to improve sleep, as this was also reported to be a 
category o f prescriptions used by older adults as sleep aids. For this, a TCA (tricyclic 
antidepressant) and a RIMA (reversible inhibitor o f  monoamine oxidase-A) were used. 
TCAs have been found to be sedating (Donoghue et al, 1996; Hale, 1997), so are taken 
in the evening to aid sleep onset. RIMAs have been found to be less sedating (Monti et 
al., 1990), so a RIMA was used as a comparison to the effects o f  the TCA.
7.2.4.1 Valerian
There was no acute effect o f  valerian on nighttime sleep, daytime cognitive 
function or daytime psychomotor performance. This suggests there is no advantage in 
taking this preparation o f  valerian as a single dose, however, a lack o f daytime effect 
also suggests there is little harm in taking it. There may have been reasons as to why 
this preparation showed no efficacy. It is likely that effects o f valerian need a longer 
duration o f administration. Kuhlmann et al. (1999) showed effects after a fortnight, and
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this is thought to be the minimum length o f time to dose with valerian (Houghton, 
1999). However, Donath et al. (2000) did show effects on sleep architecture after only 
one night with the 600mg dose, justifying the single dose design o f  the study. 
Alternatively, a higher dose may be needed, as only low (300mg) and medium (600mg) 
doses were administered in this study. It is possible there were too few participants. A 
power calculation was completed to assess the number o f  participants needed, but as 
most previous studies on valerian differ greatly, this calculation may not have been 
reliable. Lastly, the inclusion criteria may not have been stringent enough. Participants 
were required to have a mild sleep complaint, but this meant many things, including 
DIS, DMS, and/or EMA. If valerian only aids initiation o f sleep, for example, 
participants who did not have DIS may have not shown this effect. There are also other 
variables within the valerian preparation, such as a difference in batches with respect to 
constituents, quality, contamination and time o f harvest (O’Hara et al., 1998). Despite 
this, there was a non-significant trend towards an increase in sedation, and the most 
common adverse event (AE) was drowsiness. This indicates a trend towards the efficacy 
o f  valerian, which would perhaps be elucidated with changes to the study design. To 
conclude, this preparation was found to have no advantageous effects for sleep- 
disturbed older adults, but there was also no evidence for any detrimental effects.
7.2.4.2 Loprazolam, Zopiclone and Zolpidem
Loprazolam was found to be the biggest suppressor o f  REM (rapid eye 
movement) sleep, having a longer REM sleep latency and more REM redistribution 
than both zopiclone and zolpidem. Although loprazolam is not an antidepressant, REM 
suppression is an effect o f  antidepressants, and accordingly, loprazolam also showed the 
lowest scores o f  LARS depression. REM redistribution was significantly different to 
placebo under loprazolam and zolpidem, and zopiclone was found to show the same 
effects as loprazolam, although these were not significant. Loprazolam was also found 
to have the most apparent effects on sleep architecture. There was more stage 2 sleep 
under loprazolam than zopiclone, and both o f  these hypnotics had more stage 2 sleep 
than zolpidem and placebo. There was a greater reduction in slow wave sleep (SWS) 
loprazolam than zopiclone, and again both o f  these had less SWS than zolpidem and 
placebo. All three hypnotics changed the distribution o f SWS in the night, by reducing 
latency to SWS, so brought forward SWS in the night. All three hypnotics also delayed 
REM sleep. All three reduced sleep latency (SL) in comparison to placebo, but there
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were no differences between them. Loprazolam, zopiclone and zolpidem had no effects 
on the amount o f  wake time, total sleep time (TST), sleep efficiency, and the amount o f 
stage 1, 3 and 4 sleep, compared to placebo.
In terms o f  objective hypnotic efficacy, loprazolam, zopiclone and zolpidem 
were very similar*, all three reducing the time to sleep onset, and changing the 
distribution o f  SWS and REM sleep. This effect was strongest in loprazolam, followed 
by zopiclone. These are all advantageous, as ‘normal’ sleep patterns show delayed REM 
and shorter sleep latencies, compared to disrupted sleep patterns. Sleep in old age is 
generally thought to involve an increase in wake time (Monk et al., 1991), a decrease in 
TST (Habte-Gabr et al., 1991), a decrease in sleep efficiency (Hoch et al., 1994), a 
decrease in REM sleep (Webb, 1982a), a decrease in SWS (Hoch et al., 1997), and a 
decrease in light sleep (stages 1 and 2) (Hohagen et al., 1994). In relation to sleep in old 
age, loprazolam, zopiclone and zolpidem have not been found to improve sleep 
efficiency, TST, or wake time, and may decrease SWS further. However, sleep latency, 
the amount o f light sleep and REM distribution may be improved. With respect to sleep 
architecture alone, these hypnotics do not show evidence for efficacy in the elderly.
It is commonly thought that the subjective opinion o f  sleep is more important 
than objective measures (Karacan et al., 1976). However, loprazolam, zopiclone and 
zolpidem were found to have no effects on LSEQ scores o f getting to sleep and quality 
o f sleep compared to placebo. Sedation (measured by LARS) was greater under 
zolpidem than loprazolam, but this was not significant compared to placebo. Next day 
performance was generally unimpaired by all the hypnotics. There was a slight decrease 
in CFF threshold (indicating increased sedation or decreased information processing 
capacity) with loprazolam than zolpidem, but not compared to placebo. There was a 
decrease in CFF with zopiclone compared to placebo, showing sedative effects o f 
zopiclone. Memoiy effects were shown under loprazolam compared to placebo, as there 
was a decrement in delayed recall. There were no other detrimental effects on daytime 
performance noted.
An aspect o f  hypnotic prescription is the adverse effects that may be suffered 
during withdrawal from the drug. Abrupt withdrawal effects o f  loprazolam included an 
increase in SL, a decrease in stage 2 sleep, an increase in SWS latency, a decrease in 
SWS, and a decrease in CFF threshold (indicating sedation). There was no drug-specific 
REM rebound. As the elderly tend to have less stage 2 sleep, less SWS and a longer SL, 
withdrawal o f  loprazolam may result in sleep problems similar to those already 
experienced in old age. Withdrawal effects o f  zopiclone include increased SL, reduced
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stage 2 sleep, increased SWS latency and decreased REM latency. Withdrawal o f 
zopiclone may only share similarities in sleep problems in the elderly with respect to a 
longer SL and less stage 2 sleep. Withdrawal o f zolpidem resulted in decreased CFF 
threshold (indicating sedation) compared to zopiclone, and increased SL and increased 
SWS latency compared to placebo, so zolpidem may only affect discontinuation sleep in 
the elderly by increasing the time taken to get to sleep.
The final aspect to consider is the adverse events (AEs) that may result from the 
use o f  the hypnotics. There were very few AEs found with all three hypnotics. Under 
loprazolam, there were reports o f  drowsiness, headache, fatigue, dizziness and rashes, 
which agree with studies by Clark et al. (1986) and Bourin and Malinge (1996). Under 
zopiclone, there were reports o f  drowsiness, headache, fatigue dizziness and taste 
distortion, which are similar to reports foimd by Warot et al. (1987) and Hajak (1994). 
Under zolpidem, there were reports o f  dizziness, abnormal coordination, abnormal 
vision, headache, drowsiness and confusion, but these are similar to reports found by 
Hajak and Bandelow (1998) and Tsutsui et al. (2001). To show these AEs in 
perspective, AEs found under placebo included fatigue, headache, autonomic nervous 
disorder, nightmares, diarrhoea and rashes. Overall, these three hypnotics seem to be 
well tolerated, and safe for use. This is probably also true in older adults, even though 
they maybe more sensitive to these effects (Bayer and Pathy, 1986). Mouret et al. 
(1990) suggests the effects o f  zopiclone are the same whether tested in young or older 
volunteers. However, the elderly are prescribed 3.75mg o f zopiclone, whereas younger 
adults are prescribed 7.5mg (Joint Formulary Committee, 2002).
To conclude, the effects o f  these hypnotics are rather similar, despite the 
differences in their mechanisms o f  effect and their elimination half-lives. Loprazolam 
appeai-s to have the most hangover effects, and the most initial discontinuation effects, 
also loprazolam and zopiclone appear to have the greatest effects on sleep architecture. 
This is all in agreement with the theory o f  their mechanisms presented by Nakajima et 
al. (2000), shown in figure 5.1, chapter 5. The results o f  this study suggest loprazolam 
and zopiclone are suitable for use in the elderly, but zolpidem may be better due to 
marginally less hangover effect and less change to sleep architecture. This is all based 
on the assumption that the doses used are equivalent, because they are the recommended 
doses (Joint Formulary Committee, 2002).
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Chapter 7
The assessment o f  antidepressants as sleep aids was achieved using a TCA and a 
RIMA, namely dothiepin and moclobemide. Both drugs were well tolerated, and AEs 
reported were similar to those reported under placebo. On dothiepin, there were reports 
o f  drowsiness, dizziness, lethargy, nausea and tiredness, similar to those found by Rees 
and Risdall (1976), and on moclobemide there were reports o f  headache, drowsiness, 
dry mouth, dizziness and tiredness, similar to those found by Stabl et al. (1989). In 
terms o f daytime performance, there were no effects under moclobemide, but there were 
detrimental memory effects under the higher (150mg) dose o f  dothiepin. Overall, it was 
likely that both dothiepin and moclobemide were suitable for use in the elderly, due to 
few daytime effects, but the use o f  dothiepin may need closer monitoring, due to 
increased severity o f  AEs and memory impairments. Moclobemide, however, is much 
less o f a concern, as Maguire et al. (1991) found there was no need to alter doses for the 
use in the elderly.
There was little evidence for next day sedative effects o f  the nocturnal use o f 
dothiepin compared to placebo. There was no effect on LARS sedation, and there were 
no subjective sleep effects (measured by LSEQ). However, drowsiness was the most 
commonly reported AE. This may have been due to strong placebo effects found in 
antidepressant studies (Vida and Looper, 1999), or perhaps the time delay between 
dosing (21:00) and testing (07:00) was too great so show sedative effects on the tests. 
Moclobemide also showed no sedative effects or effects on subjective sleep measures. 
With respect to subjective perspective o f  sleep, these antidepressants were not found to 
be efficacious hypnotics. However, this may not be a problem, as the hypnotics tested 
were also ineffective on subjective measures.
Comparisons between dothiepin and moclobemide o f  their effects on sleep 
variables showed there was no difference between them with respect to sedation and 
LSEQ quality o f sleep. However, dothiepin was more advantageous than moclobemide 
with respect to LSEQ scores o f getting to sleep. In addition, dothiepin is more effective 
with respect to increasing TST, increasing sleep efficiency and decreasing SL than 
moclobemide, perhaps indicating dothiepin is preferable to moclobemide in terms o f 
aiding sleep. However, there was no difference in the effects on sleep continuity. 
Greater effects on SWS were found under dothiepin than moclobemide, perhaps 
reflecting a greater effect on the serotonin system (Sharpley et al., 1994).
7.2.4.3 Dothiepin and Moclobemide
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Compared to placebo, both dothiepin and moclobemide had no effect on TST, 
SL, the amount o f  stage 1, 2, 3, and 4 sleep, SWS, SWS distribution, the amount o f 
wake time, and the number o f  awakenings. Dothiepin had no effect on sleep efficiency, 
but moclobemide actually significantly decreased sleep efficiency. The main effect o f 
these drugs was to alter REM sleep, as do most antidepressants (Vogel et al., 1990). 
Compared to placebo, both dothiepin and moclobemide increased REM latency and 
reduced the amount o f REM sleep time, in a dose-dependent maimer (more REM 
suppression with higher doses). These effects were also seen in the hypnotics, which 
could mean these antidepressants work in a similar way to the hypnotics. However, the 
hypnotics reduced SL, which is important when suffering from insomnia, but these 
antidepressants did not. It is possible that antidepressants may affect sleep variables like 
SL, but perhaps only in sleep-disturbed individuals, and improvements may not be seen 
in participants who already have a ‘normal’ sleep latency and sleep efficiency because 
there is nothing to improve.
To conclude, the AEs and daytime performance effects o f  dothiepin and 
moclobemide suggest these antidepressants would be relatively safe for use in older 
adults. However, there is question as to whether these drugs would make efficacious 
hypnotics. Both dothiepin and moclobemide have veiy little effect on sleep variables, 
except REM suppression, and have no effect on subjective measures o f  sleep. Wagner et 
al. (1998) and Kupfer and Reynolds (1997) suggest there is little evidence for 
antidepressant use as a sleep aid to non-depressives, and the results o f this study tend to 
agree. These antidepressants are safe for use (moclobemide more so than dothiepin), but 
perhaps would only help the sleep problems o f  depressed older adults, and not non­
depressed older adults. There was no evidence in this study that dothiepin and 
moclobemide would make useful hypnotics.
7.3 Summary and Future Research
To summarise, sleep in older adults has been found to change with age, but these 
changes only become problematic when the individual reacts adversely to these 
changes. To alleviate these sleep disturbances, older adults primarily consume hot milky 
drinks at bedtime, but also drink alcohol, use prescription medication, and use OTC and 
herbal remedies. Hypnotics are the most common prescription medication used to 
improve sleep, but analgesics and anti depressants are also used. Valerian, loprazolam, 
zopiclone, zolpidem, dothiepin and moclobemide were all assessed as sleep aids. All
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were considered safe for use in the elderly, but only the hypnotics loprazolam, 
zopiclone and zolpidem were found to improve sleep.
These studies have provided scope for future research. Firstly it is clear that 
further research is needed into the sleep habits and perceptions o f  sleep o f older adults. 
As Habte-Gabr et al. (1991) suggested, research into this area is limited. Although many 
authors have described some effects o f  poor sleep on quality o f  life, it is uncommon to 
use specifically designed quality o f  life questionnaires in surveys. Future surveys should 
incorporate scales such as the SF36. Also, studies are completed in many different 
countries and cultures, with most past research having been completed in the U. S. (for 
example, Karacan et al., 1976), and most recent research completed in Finland (for 
example, Habte-Gabr et al., 1991). More British research, such as studies by Morgan et 
al. (1988) and Beaman (1989) are necessary to specify findings to our own 
circumstances. The perception o f sleep appeal's to be most important when studying 
sleep in older adults, as ‘ insomnia’ to different individuals may mean DIS, DMS, or 
EMA, or a combination o f  these. Studies must concentrate on older adults who feel their 
sleep is poor, rather than those who have a long sleep latency, for example, which may 
not be a problem to the individual. The subjective opinion in this circumstance appears 
to be more important to investigate than objective variables o f  sleep.
To ensure reliability o f  sleep surveys, a repeat survey should be administered to 
the same volunteers, to assess the differences in their perception o f  their sleep, from one 
month to another. This test-retest approach would show any differences in sleep that 
were experienced, as sleep may change within a short period o f  time. This is particularly 
important with respect to time o f year. The time when surveys are administered is veiy 
influential on the answers collected. For example, the survey in chapter 3 was 
administered over winter. This biased the responses accordingly; for example, heat was 
listed as a method o f improving sleep, which may not have been listed in a summer 
survey. Future sleep surveys should test-retest in different seasons, and the common 
responses within them should be assumed to be a stable method o f  improving sleep.
Although the sample in chapter 3 was not biased because they were not self- 
selecting for a trial on sleep disturbance, there was a bias in that they were all readers o f 
SAGA magazine. This may have attracted more affluent, better educated, and more 
active older adults, than those who do not read SAGA. Therefore, future studies should 
attempt to recruit volunteers with diversity o f  background and personality in mind. 
Also, There should be equal numbers o f  males and females recruited, and also an equal 
amount in each age group studied. This will help ensure the reliability o f  findings. Also,
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responders were volunteering for a trial o f  ginkgo biloba, which was suggested in the 
advertising article to improve memory. Therefore, responders may have had cognitive 
deficits, as only those with poor memoiy may have replied to the advertisement. Good 
and poor sleepers without other specific complaints should complete future surveys.
This survey asked respondents to answer questions about their sleep in the last 
few months. However, Martikainen et al. (1992) and Ohayon and Caulet (1996) found 
that many different answers could be elicited by asking about sleep over different time 
scales. Repeat tests should survey similar time frames. Also, a better picture o f sleep 
habits in the elderly would be achieved using longitudinal trials. This would show how 
the sleep o f  individuals changes with increasing age, and would provide great insight in 
to the process. However, this would be veiy time consuming and costly to perform, and 
it is always difficult to follow volunteers over a long length o f  time.
It is very difficult for individuals to judge their own sleep latency, total sleep 
time and number o f  awakenings (et cetera) accurately, as it is difficult to know the 
precise moment o f  sleep onset, for example. To assess this with greater accuracy, future 
studies should require concurrent completion o f  sleep diaries with surveys, as 
implemented by Gislason et al. (1993). This would give a better picture o f  sleep habits 
in the elderly, and also daytime activities. However, this may introduce the problem o f 
back-filling, where participants forget to fill in their diaries, and then ‘guess’ entries at a 
later date. Ideally, o f  course, sleep EEG could be used concurrently to assess these 
objective variables o f  sleep in old age, but on such a high number o f volunteers, over 
several nights, this would prove a difficult, time consuming and an extremely costly 
event.
Also with respect to daytime performance, the survey in chapter 3 could be 
expanded in future surveys to include more questions regarding any impairments in 
daytime functioning experienced in older adults, either from poor sleep or the use o f  
sleep medication. The distinction between the two should be made on the survey. Future 
surveys should focus on the nature o f any daytime effects suffered. This will enable the 
investigation o f  perhaps the different sorts o f decrements suffered with certain types o f 
sleep problem.
There was scope for future improvement o f  chapter 4, the study regarding 
valerian. There were many possible reasons as to why no effects were found, and future 
studies should incorporate these to avoid missing significant effects. The main concern 
was that the study was not o f  sufficient duration to show effects. Although Donath et al. 
(2000) found sleep EEG effects after one night o f  dosing, it is generally thought at least
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a fortnight o f  dosing is necessary (Houghton, 1999). Longer clinical studies are 
therefore needed into the effects o f  valerian, or if  this proves too costly, then perhaps 
longitudinal survey investigations into the use o f valerian may show any beneficial 
effects. It is possible that the doses studied were not high enough, so future studies 
should include more doses. Also, tests become more sensitive with an increased number 
o f  participants, so if possible, a greater number o f  volunteers should be used in these 
EEG trials, because the effect o f  valerian does not appear to be prominent. Different 
preparations o f  valerian require more research, as it is suggested different types can 
have differing effects (Bos et al., 1998b). In connection with this, Houghton (1999) also 
calls for more research into the constituents o f valerian, as even small parts o f valerian 
are thought to have influence on sleep. Also, studies are necessary into preparations 
where valerian is combined with other sleep-enhancing herbals. For example, an 
increased hangover effect is thought to occur when valerian is taken with hops 
(Leathwood and Chauffard, 1983). There are many other types o f  herbs thought to 
improve sleep, such as passiflora and lettuce. These herbs should also be assessed via 
clinical trial.
Separate studies investigating the effects o f  valerian on different participants are 
also necessary. A  comparison study o f young and older participants would show in 
which age valerian is most potent. Significant effects were seen using younger 
volunteers in the studies o f  the hypnotics and antidepressants, so perhaps valerian may 
also have an effect in a younger population. Also, it may be the case that valerian has 
effects specifically on certain types o f insomnia. For example, valerian may improve the 
sleep o f  those suffering DMS, but not DIS. Future studies should separate their 
participants into different subtypes o f insomnia, and also include healthy participants as 
a comparison. This is because research into both patient and non-patient populations is 
necessary when testing sleep aids. Including insomniacs in studies provides a more 
realistic treatment scenario, as it is insomniacs who will receive hypnotic medications. 
However, there are many types o f  insomnia, and these may require different sorts o f 
treatment. Therefore, categories o f  insomnia must be used in studies, but as explained in 
chapter 1, the classification o f  insomnia in itself is problematic. Using non-patients in 
studies can eliminate these inter-participant variations, but then the realistic treatment 
scenario is lost. However, the effects o f  sleep medication can then be seen without the 
confounds o f  sleep problems. Also, as insomnia and health problems are closely linked 
(Kripke et al. 1991; Janson et al., 1995), using healthy normal participants will remove 
any concurrent illnesses, plus any associated medication. Therefore, testing both
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insomniac and healthy volunteers and comparing the results enables further 
understanding o f  the treatment and the circumstances where medication may be 
efficacious.
The study o f  the three hypnotics was also completed over a short duration o f  
three days on each drug. After extended use (three or four weeks), Declerck and Smits 
(1999) found secondary effects can occur, so there may be changes in sleep architecture 
under those conditions. If the elderly are more sensitive to the effects o f psychotropic 
medication (Hemmeter et al., 2000), then they may suffer secondary effects after the 
initial effects o f  the medication. This study should be repeated with the use o f  both 
younger and older participants to provide a direct comparison. These hypnotics appear 
safe for use in the elderly, but more research in elderly participants is required to 
examine the effects o f  these hypnotics directly on old age. However, this may prove 
difficult. Any older adults used in this research must be assessed for physical disorders, 
as only healthy participants should be used, to eliminate any disturbed sleep because o f  
health complaints. This includes the exclusion criteria o f  sleep apnoea and restless legs, 
for example. Also, those with nocturia should be excluded, as this may prejudice results. 
Before this can happen, it is necessary to research nocturnal toilet use, to understand 
how many visits to the toilet in the night is normal, and when nocturnal toilet use 
becomes a physical sleep problem. In addition, trials o f  these hypnotics should be 
repeated using young healthy individuals without sleep complaints, to show any effects 
o f  these drugs without alteration from the disturbed sleep o f the participants. Smirne et 
al. (1983) showed there was more REM sleep found in healthy participants compared to 
insomniacs.
It would also be interesting to add a test o f depression into this study. It was 
foimd both the hypnotics and antidepressants had a similar effect on REM sleep. In 
reverse, it would be interesting to investigate whether hypnotics have antidepressant 
qualities, in addition to the antidepressants having hypnotic qualities.
There was a lack o f  effect o f  loprazolam, zopiclone and zolpidem during the 
morning after dose; however, there was no assessment o f  middle-of-the-night effects, to 
reveal when the effects o f  these hypnotics were no longer present. These hypnotics have 
been suggested to be safe for use in the elderly, in respect to hangover effects. However, 
it is not clear if these hypnotics would be safe to use if  the individual wanted to get up 
in the night, for example to use the toilet (as is common in older adults). EEG can show 
many o f the effects o f  hypnotics on objective sleep, but not the subjective. Future 
experiments should wake elderly participants in the night to assess how long into the
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night’ s sleep the subjective effect o f the hypnotics last. This leads to the idea o f  middle- 
of-the-night dosing. It is possible that shorter acting hypnotics may be taken in the 
middle o f  the night, because when the user wakes, they may have worn o ff sufficiently 
for the individual to function normally in the morning (Danjou et al., 1999). This idea 
needs more research, and o f  course, other hypnotics need more research for their use in 
older adults.
It was concluded that dothiepin and moclobemide are not sleep aids. However, 
research has shown these antidepressants may improve sleep if  depressive symptoms 
are also present. Blois and Gaillard (1990) suggested that sleep effects were more likely 
to be shown by antidepressants used in depressed participants than healthy participants. 
Antidepressants may affect sleep differently in healthy participants than in depressed 
participants. Therefore, dothiepin and moclobemide should be assessed for their sleep 
enhancing effects in depressed individuals, and results compared to this study. As this 
study was completed on healthy participants, the participants also did not have a sleep 
problem. It is possible that, as perhaps hypnotics do, sleep is only improved by 
antidepressants if  there is an initial sleep disturbance to improve. Dothiepin and 
moclobemide should therefore also be tested for their sleep effects on sleep-disturbed 
individuals, results again compared to the study in chapter 6. As the most commonly 
prescribed antidepressant as a sleep aid to the elderly was amitriptyline, then this and 
other antidepressants mentioned in the survey in chapter 3 should also be tested as 
hypnotics.
Also, only males were used in this study, and future research should include 
females. Many researchers have found that psychological problems are reported to keep 
females awake more than males (for example, Middelkoop et al., 1996; Mallon and 
Hetta, 1997), so it is possible antidepressants may be beneficial to the female population 
with sleep problems. In addition, a placebo withdrawal period should be used in future 
research, as was shown in chapter 5. This would show the effects o f  dothiepin and 
moclobemide after cessation, and would assess any rebound or withdrawal effects that 
may be detrimental to the elderly.
It is possible that the time o f  dosing, 2 hours before lights out, was too long. 
Dothiepin has a longer elimination half life than moclobemide, but the action o f 
moclobemide is very short lived. It is possible that the effects o f  moclobemide may 
have worn o ff before sleep onset. Therefore, future studies should investigate more 
appropriate time schedules for this drug. Antidepressants as sleep enhancers should be 
administered at various times o f  the day, to assess if, and when, there is an optimum
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time for dosing. Lastly, this was also a short study o f two nights per dose. Longer 
studies are required to assess any secondary effects o f dothiepin and moclobemide, and 
also any habituation effects.
This thesis has shown that sleep in the elderly does change with increasing age, 
and not all medication that effects sleep is appropriate for use as sleep aids for older 
adults. Much more research is needed into the effect o f ageing on sleep, the problems 
that this brings, and why these changes are problems to certain individuals. Indeed, 
some work has been completed on the personality factors involved with having sleep 
complaints in later life (Fichten et al., 1995). This becomes a more pressing concern, as 
the population o f older adults already outnumbers the population o f younger adults, and 
the population o f  elderly people is burgeoning. By 2020, it is predicted that there will be
25.2 million people in the UK aged over 50 years o f  age, compared with 19.3 million in 
1999 (ONS, 1999). By assessing why changes become problems, it will then be possible 
to know when to administer sleep medication, and when to use behavioural and 
cognitive approaches to improving sleep. This thesis adds to the body o f literature 
attempting to assess sleep in older adults, in an attempt to improve the sleep problems 
and treatments in the elderly population.
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Appendices
Questionnaire designed to assess sleep problems in older adults, and methods 
used to alleviate these problems.
APPENDICES
Appendix 1
Sleep Questionnaire
This questionnaire is designed to assess your sleep patterns 
over the last few  months.
Please answer the questions by putting a cross in the appropriate boxes, 
fo r example [x] I f  you mark a box in error, please shade it in and put 
your cross in the correct box.
Identification (Office use only)
r + Y P t w p w w " rjesntc * • •. '.up*:I • m i - . 'T T : • • -  5 i1'
Q3 b) How much o f  a problem is this for 
you?
Mild r
Moderate
Severe
The following questions refer to sleep problems commonly experienced 
by most people at some stage in their lives.
Q3 c) How often does this occur?
Less than 1 night per month i-i
1-2 nights per month
3-4 nights per month
1-3 nights per week
4-7 nights per week
y
Q4 b) How much o f  a problem is this for
you?
Mild
Moderate
Severe —
Q _
Q4 c) How often does this occur?
Less than 1 night per month
1-2 nights per month
3-4 nights per month
1-3 nights per week
4-7 nights per week
Survey: 4 P a g e : 1
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Q5 b) How much o f  a problem is this for
you?
Mild —
Moderate
Severe
V
Q5 c) How often does this occur?
Less than 1 night per month 
1 -2 nights per month
3-4 nights per month 
1-3 nights per week
4-7 nights per week
Q6 b) How much o f  a problem is this for
you?
Mild
Moderate
Severe -
X- y
Q6 c) How often does this occur?
Less than 1 night per month 
1-2 nights per month
3-4 nights per month 
1-3 nights per week
4-7 nights per week
Q7 b) How much o f  a problem is this for
you?
Mild —
Moderate
Severe —
V
Q7 c) How often does this occur?
Less than 1 night per month 
1-2 nights per month
3-4 nights per month 
1-3 nights per week
4-7 nights per week
^ 8  b ) Please specify
Q8 c) How much o f  a problem is this for
you?
Mild —
Moderate
Severe
v J
Q8 d) How often does this occur?
Less than 1 night per month
1-2 nights per month
3-4 nights per month
1-3 nights per week
4-7 nights per week
I j
Survey : 4 Page : 2
mill mill
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If you answered 'yes' to any of the questions regarding sleep problems (Q3- Q8), please answer 
Q9a. If you answered 'no' to all these questions, please go to QlOa.
Q9 b) How much o f  a problem is this for
you?
Mild —
Moderate
Severe
>
Q9 c) How often does this occur? ' ^
Less than 1 night per month —
1-2 nights per month
3-4 nights per month
1-3 nights per week
4-7 nights per week
ft-
The following questions relate to products which you may use TO HELP 
YOU SLEEP. Please put a cross in ail relevant boxes and give more details, 
where applicable.
/Q l  1 b ) Please specify:
(§12  b ) Please specify:
Survey: 4 P a g e :3
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^ 1 3  b ) Please specify:
¥>14 b ) Please specify:
'QlSbj Please specify:
HfciC r r, /loollSilfe
f ^ j 6 b )  Please specify:
Thank you very much for completing this questionnaire.
Please ensure that you have answered all the questions, and that if there is 
more than one of you in your household taking part in this survey, that you 
have completed the form that was addressed to you.
Survey: 4 P age: 4
HPRU University o f Surrey
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